
<!DOCTYPE html>
<html>
<head>
<!-- Required meta tags -->
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<!-- Check Browser, as well as Hostname and set JS, CSS, Favicon path based on that-->

<!-- Favicon --><!-- cpcommit -->
<!-- <link rel="shortcut icon" type="image/x-icon" href="https://www.sec.gov/favicon.ico"> -->

<script>
	(function() {
		var hostName = window.location.hostname;

		var browserAccepted = function() {

			var ua = window.navigator.userAgent;
			var trident = ua.indexOf('Trident/'); //IE 11;
			var msie = ua.indexOf('MSIE '); // IE 10 or older
			if (msie > 0) {
				return false;
			}
			return true;
		}();

		var pathToLibs = 'https://www.sec.gov/js';
		var pathToError = '/';
		if (hostName === 'www-test.sec.gov' || hostName === 'www.sec.gov') {
			pathToLibs = 'https://www.sec.gov/ixviewer/js';
			pathToError = '/ixviewer/';
		}
		if (browserAccepted) {

			// css
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/custom-bootstrap.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/lib/fontawesome/css/all.min.css>');
			document
					.write('<link rel="stylesheet" href=' + pathToLibs + '/css/app.css>');

			// js
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/jquery-3.3.1.slim.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/popper.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/bootstrap.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/moment.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/vanilla-picker.min.js"><\/script>');
			document
					.write('<script type="text/javascript" src="' + pathToLibs + '/lib/he.js"><\/script>');

			var date = new Date();
			var todaysDate = date.getDate() + '-' + (date.getMonth() + 1) + '-'
					+ date.getFullYear();
			document.write('<script type = "text/javascript" defer=true src="'
					+ pathToLibs + '/production.min.js?d=' + todaysDate
					+ '"><\/script>');
		} else {
			// user us on a browser that we do not support
			var currentUrl = window.location.href.split('?')[0];
			var browserError = currentUrl.substring(0, currentUrl
					.lastIndexOf('/'));
			browserError += pathToError + 'browser-error.html?url='
					+ encodeURIComponent(window.location.href);
			window.location.href = browserError;
		}
	})();
</script><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/custom-bootstrap.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/lib/fontawesome/css/all.min.css"><link rel="stylesheet" href="https://www.sec.gov/ixviewer/js/css/app.css"><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/jquery-3.3.1.slim.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/popper.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/bootstrap.min.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/moment.js"></script><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/vanilla-picker.min.js"></script><style>.picker_wrapper.no_alpha .picker_alpha{display:none}.picker_wrapper.no_editor .picker_editor{position:absolute;z-index:-1;opacity:0}.picker_wrapper.no_cancel .picker_cancel{display:none}.layout_default.picker_wrapper{display:-webkit-box;display:flex;-webkit-box-orient:horizontal;-webkit-box-direction:normal;flex-flow:row wrap;-webkit-box-pack:justify;justify-content:space-between;-webkit-box-align:stretch;align-items:stretch;font-size:10px;width:25em;padding:.5em}.layout_default.picker_wrapper input,.layout_default.picker_wrapper button{font-size:1rem}.layout_default.picker_wrapper>*{margin:.5em}.layout_default.picker_wrapper::before{content:'';display:block;width:100%;height:0;-webkit-box-ordinal-group:2;order:1}.layout_default .picker_slider,.layout_default .picker_selector{padding:1em}.layout_default .picker_hue{width:100%}.layout_default .picker_sl{-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_sl::before{content:'';display:block;padding-bottom:100%}.layout_default .picker_editor{-webkit-box-ordinal-group:2;order:1;width:6.5rem}.layout_default .picker_editor input{width:100%;height:100%}.layout_default .picker_sample{-webkit-box-ordinal-group:2;order:1;-webkit-box-flex:1;flex:1 1 auto}.layout_default .picker_done,.layout_default .picker_cancel{-webkit-box-ordinal-group:2;order:1}.picker_wrapper{box-sizing:border-box;background:#f2f2f2;box-shadow:0 0 0 1px silver;cursor:default;font-family:sans-serif;color:#444;pointer-events:auto}.picker_wrapper:focus{outline:none}.picker_wrapper button,.picker_wrapper input{box-sizing:border-box;border:none;box-shadow:0 0 0 1px silver;outline:none}.picker_wrapper button:focus,.picker_wrapper button:active,.picker_wrapper input:focus,.picker_wrapper input:active{box-shadow:0 0 2px 1px dodgerblue}.picker_wrapper button{padding:.4em .6em;cursor:pointer;background-color:whitesmoke;background-image:-webkit-gradient(linear, left bottom, left top, from(gainsboro), to(transparent));background-image:-webkit-linear-gradient(bottom, gainsboro, transparent);background-image:linear-gradient(0deg, gainsboro, transparent)}.picker_wrapper button:active{background-image:-webkit-gradient(linear, left bottom, left top, from(transparent), to(gainsboro));background-image:-webkit-linear-gradient(bottom, transparent, gainsboro);background-image:linear-gradient(0deg, transparent, gainsboro)}.picker_wrapper button:hover{background-color:white}.picker_selector{position:absolute;z-index:1;display:block;-webkit-transform:translate(-50%, -50%);transform:translate(-50%, -50%);border:2px solid white;border-radius:100%;box-shadow:0 0 3px 1px #67b9ff;background:currentColor;cursor:pointer}.picker_slider .picker_selector{border-radius:2px}.picker_hue{position:relative;background-image:-webkit-gradient(linear, left top, right top, from(red), color-stop(yellow), color-stop(lime), color-stop(cyan), color-stop(blue), color-stop(magenta), to(red));background-image:-webkit-linear-gradient(left, red, yellow, lime, cyan, blue, magenta, red);background-image:linear-gradient(90deg, red, yellow, lime, cyan, blue, magenta, red);box-shadow:0 0 0 1px silver}.picker_sl{position:relative;box-shadow:0 0 0 1px silver;background-image:-webkit-gradient(linear, left top, left bottom, from(white), color-stop(50%, rgba(255,255,255,0))),-webkit-gradient(linear, left bottom, left top, from(black), color-stop(50%, rgba(0,0,0,0))),-webkit-gradient(linear, left top, right top, from(gray), to(rgba(128,128,128,0)));background-image:-webkit-linear-gradient(top, white, rgba(255,255,255,0) 50%),-webkit-linear-gradient(bottom, black, rgba(0,0,0,0) 50%),-webkit-linear-gradient(left, gray, rgba(128,128,128,0));background-image:linear-gradient(180deg, white, rgba(255,255,255,0) 50%),linear-gradient(0deg, black, rgba(0,0,0,0) 50%),linear-gradient(90deg, gray, rgba(128,128,128,0))}.picker_alpha,.picker_sample{position:relative;background:url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='2' height='2'%3E%3Cpath d='M1,0H0V1H2V2H1' fill='lightgrey'/%3E%3C/svg%3E") left top/contain white;box-shadow:0 0 0 1px silver}.picker_alpha .picker_selector,.picker_sample .picker_selector{background:none}.picker_editor input{font-family:monospace;padding:.2em .4em}.picker_sample::before{content:'';position:absolute;display:block;width:100%;height:100%;background:currentColor}.picker_arrow{position:absolute;z-index:-1}.picker_wrapper.popup{position:absolute;z-index:2;margin:1.5em}.picker_wrapper.popup,.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{background:#f2f2f2;box-shadow:0 0 10px 1px rgba(0,0,0,0.4)}.picker_wrapper.popup .picker_arrow{width:3em;height:3em;margin:0}.picker_wrapper.popup .picker_arrow::before,.picker_wrapper.popup .picker_arrow::after{content:"";display:block;position:absolute;top:0;left:0;z-index:-99}.picker_wrapper.popup .picker_arrow::before{width:100%;height:100%;-webkit-transform:skew(45deg);transform:skew(45deg);-webkit-transform-origin:0 100%;transform-origin:0 100%}.picker_wrapper.popup .picker_arrow::after{width:150%;height:150%;box-shadow:none}.popup.popup_top{bottom:100%;left:0}.popup.popup_top .picker_arrow{bottom:0;left:0;-webkit-transform:rotate(-90deg);transform:rotate(-90deg)}.popup.popup_bottom{top:100%;left:0}.popup.popup_bottom .picker_arrow{top:0;left:0;-webkit-transform:rotate(90deg) scale(1, -1);transform:rotate(90deg) scale(1, -1)}.popup.popup_left{top:0;right:100%}.popup.popup_left .picker_arrow{top:0;right:0;-webkit-transform:scale(-1, 1);transform:scale(-1, 1)}.popup.popup_right{top:0;left:100%}.popup.popup_right .picker_arrow{top:0;left:0}</style><script type="text/javascript" src="https://www.sec.gov/ixviewer/js/lib/he.js"></script><script type="text/javascript" defer="true" src="https://www.sec.gov/ixviewer/js/production.min.js?d=20-4-2022"></script>
<title>Inline XBRL Viewer</title>
<style type="text/css" id="customized-styles"> #dynamic-xbrl-form [enabled-taxonomy="true"][continued-taxonomy="false"]{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;display:inline;} #dynamic-xbrl-form [enabled-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;} #dynamic-xbrl-form [enabled-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #FF6600, 2px 0px 0px 0px #FF6600;border-top:none;border-bottom:none;} #dynamic-xbrl-form [highlight-taxonomy="true"]{background-color:#FFD700 !important;} #dynamic-xbrl-form [highlight-taxonomy="true"] > *{background-color:#FFD700 !important;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-main-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][text-block-taxonomy="true"]{box-shadow:-2px 0px 0px 0px #003768, 2px 0px 0px 0px #003768;} #dynamic-xbrl-form [selected-taxonomy="true"][continued-taxonomy="false"]{border:3px solid #003768 !important;display:inline;} #dynamic-xbrl-form [hover-taxonomy="true"]{background-color:rgba(255,0,0,0.3);} .tagged-data-example-1{border-top:2px solid #FF6600;border-bottom:2px solid #FF6600;} .search-results-example-1{background-color:#FFD700;} .tag-shading-exmple-1:hover{background-color:rgba(255,0,0,0.3);} .selected-fact-example-1{border:3px solid #003768 !important;}</style></head>
<body style="overflow:auto">
<!--?xml version="1.0" encoding="ASCII"?-->
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 31 05:30:22 UTC 2022 -->

     <title> </title>

<meta content="text/html" http-equiv="Content-Type">

<div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, D.C. 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonnumeric contextref="c0" name="dei:DocumentType">10-K</ix:nonnumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:DocumentAnnualReport"><span style="font-family: Times New Roman, Times, Serif"><b>☒</b></span></ix:nonnumeric><b>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the fiscal year ended <ix:nonnumeric contextref="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonnumeric contextref="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonnumeric>, <ix:nonnumeric contextref="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonnumeric></ix:nonnumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport"><span style="font-family: Times New Roman, Times, Serif"><b>☐</b></span></ix:nonnumeric><b>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FOR THE TRANSITION PERIOD FROM __________ TO
________</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>COMMISSION FILE NUMBER <ix:nonnumeric contextref="c0" name="dei:EntityFileNumber">001-39384</ix:nonnumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonnumeric contextref="c0" name="dei:EntityRegistrantName"><span style="font-size: 14pt"><b>VICARIOUS
SURGICAL INC.</b></span></ix:nonnumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Exact name of registrant as specified in its
charter)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt"><b>&nbsp;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonnumeric contextref="c0" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode"><span style="font-size: 10pt"><b>Delaware</b></span></ix:nonnumeric></td> <td style="text-align: center; width: 2%">&nbsp;</td> <td style="border-bottom: black 1.5pt solid; width: 49%; text-align: center"><ix:nonnumeric contextref="c0" name="dei:EntityTaxIdentificationNumber"><span style="font-size: 10pt"><b>87-2678169</b></span></ix:nonnumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of<br>
incorporation or organization)</b></span></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>(I.R.S. Employer<br>
Identification Number)</b></span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 8pt">&nbsp;</span></td> <td style="text-align: center"><span style="font-size: 8pt">&nbsp;</span></td> <td style="text-align: center"><span style="font-size: 8pt">&nbsp;</span></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><ix:nonnumeric contextref="c0" name="dei:EntityAddressAddressLine1"><span style="font-size: 10pt"><b>78 Fourth Avenue</b></span></ix:nonnumeric></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center">&nbsp;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b><ix:nonnumeric contextref="c0" name="dei:EntityAddressCityOrTown">Waltham</ix:nonnumeric>, <ix:nonnumeric contextref="c0" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Massachusetts</ix:nonnumeric></b></span></td> <td style="text-align: center">&nbsp;</td> <td style="border-bottom: black 1.5pt solid; text-align: center"><ix:nonnumeric contextref="c0" name="dei:EntityAddressPostalZipCode"><span style="font-size: 10pt"><b>02451</b></span></ix:nonnumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr> </tbody></table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant’s telephone
number, including area code: <span><ix:nonnumeric contextref="c0" name="dei:CityAreaCode">(617)</ix:nonnumeric> <ix:nonnumeric contextref="c0" name="dei:LocalPhoneNumber">868-1700</ix:nonnumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 7pt; ">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered pursuant to Section 12(b)
of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="white-space: nowrap; width: 2%; text-align: center">&nbsp;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Trading Symbols</b></span></td> <td style="white-space: nowrap; width: 2%; text-align: center">&nbsp;</td> <td style="border-bottom: black 1.5pt solid; white-space: nowrap; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Name of each exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center"><ix:nonnumeric contextref="c0" name="dei:Security12bTitle"><span style="font-size: 10pt"><b>Class A common stock, $0.0001 par value per share</b></span></ix:nonnumeric></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><ix:nonnumeric contextref="c0" name="dei:TradingSymbol"><span style="font-size: 10pt"><b>RBOT</b></span></ix:nonnumeric></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><ix:nonnumeric contextref="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-size: 10pt"><b>The New York Stock Exchange</b></span></ix:nonnumeric></td></tr> <tr style="vertical-align: top; "> <td style="text-align: center"><span style="font-size: 10pt"><b>Warrants to purchase one share of Class A common stock, each at an exercise price of $11.50 per share</b></span></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>RBOT WS</b></span></td> <td style="text-align: center">&nbsp;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>The New York Stock Exchange</b></span></td></tr> </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered pursuant to Section 12(g)
of the Act: None</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark if the registrant is a
well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">☐</span>
<ix:nonnumeric contextref="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonnumeric> <span style="font-family: Times New Roman, Times, Serif">☒</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark if the registrant is not
required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes <span style="font-family: Times New Roman, Times, Serif">☐</span>
<ix:nonnumeric contextref="c0" name="dei:EntityVoluntaryFilers">No</ix:nonnumeric> <span style="font-family: Times New Roman, Times, Serif">☒</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
(1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding
12&nbsp;months (or for such shorter period that the registrant was required to file such reports) and (2)&nbsp;has been subject to such
filing requirements for the past 90&nbsp;days. <ix:nonnumeric contextref="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonnumeric> <span style="font-family: Times New Roman, Times, Serif">☒</span> No <span style="font-family: Times New Roman, Times, Serif">☐</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
(1) has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T
during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to file such reports) and has been subject
to such filing requirements for the past 90 days. <ix:nonnumeric contextref="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonnumeric> <span style="font-family: Times New Roman, Times, Serif">☒</span> No <span style="font-family: Times New Roman, Times, Serif">☐</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”
and “emerging growth company” in Rule&nbsp;12b-2 of the Exchange Act. (Check one):</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr> <td style="width: 25%; text-align: left"><span style="font-size: 10pt">Large accelerated filer <span style="font-family: Times New Roman, Times, Serif">☐</span></span></td> <td style="width: 25%; text-align: left"><span style="font-size: 10pt">Accelerated filer <span style="font-family: Times New Roman, Times, Serif">☐</span></span></td> <td style="width: 25%; text-align: left"><span style="font-size: 10pt"><ix:nonnumeric contextref="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonnumeric> <span style="font-family: Times New Roman, Times, Serif">☒</span></span></td> <td style="text-align: left; width: 25%"><span style="font-size: 10pt">Smaller reporting company <ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif">☒</span></ix:nonnumeric></span></td></tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td><span style="font-size: 10pt">Emerging growth company <ix:nonnumeric contextref="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif">☒</span></ix:nonnumeric></span></td></tr> </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod"><span style="font-family: Times New Roman, Times, Serif">☐</span></ix:nonnumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. <ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag"><span style="font-family: Times New Roman, Times, Serif">☐</span></ix:nonnumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Indicate by check mark whether the registrant
is a shell company (as defined in Rule&nbsp;12b-2 of the Act). Yes <span style="font-family: Times New Roman, Times, Serif">☐</span>
No <ix:nonnumeric contextref="c0" format="ixt:fixed-false" name="dei:EntityShellCompany"><span style="font-family: Times New Roman, Times, Serif">☒</span></ix:nonnumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">The aggregate market value
of the registrant’s voting and non-voting equity held by non-affiliates of the registrant (without admitting that any person whose
securities are not included in such calculation is an affiliate) computed by reference to the price at which the Class A common stock
was last sold as of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, was
approximately $<span style="-sec-ix-hidden: hidden-fact-0">337.6</span> million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">As of March 9, 2022, the
registrant had <ix:nonfraction contextref="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitref="shares">100,639,359</ix:nonfraction>&nbsp;shares of Class A common stock outstanding and&nbsp;<ix:nonfraction contextref="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitref="shares">19,789,860</ix:nonfraction>&nbsp;shares of Class B common stock outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-size: 7pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 22.5pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 22.5pt"><span style="font-size: 7pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>TABLE OF CONTENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top; width: 90%"><span style="font-size: 10pt"><a href="#a_001">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></span></td>
    <td style="vertical-align: top; width: 1%">&nbsp;</td>
    <td style="vertical-align: bottom; width: 9%; text-align: center">ii</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_002"><span style="font-size: 10pt">PART I</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_003"><span style="font-size: 10pt">ITEM 1. BUSINESS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">1</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_004"><span style="font-size: 10pt">ITEM 1A. RISK FACTORS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">21</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_005"><span style="font-size: 10pt">ITEM IB. UNRESOLVED STAFF COMMENTS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">58</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_006"><span style="font-size: 10pt">ITEM 2. PROPERTIES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">58</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_007"><span style="font-size: 10pt">ITEM 3. LEGAL PROCEEDINGS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">58</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_008"><span style="font-size: 10pt">ITEM 4. MINE SAFETY DISCLOSURES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">58</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_009"><span style="font-size: 10pt">PART II</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_010"><span style="font-size: 10pt">ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">59</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_011"><span style="font-size: 10pt">ITEM 6. [RESERVED]</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">59</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_012"><span style="font-size: 10pt">ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">59</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_013"><span style="font-size: 10pt">ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_014"><span style="font-size: 10pt">ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">65</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_015"><span style="font-size: 10pt">ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_016"><span style="font-size: 10pt">ITEM 9A. CONTROLS AND PROCEDURES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_017"><span style="font-size: 10pt">ITEM 9B. OTHER INFORMATION.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_018"><span style="font-size: 10pt">ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">66</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_019"><span style="font-size: 10pt">PART III</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_020"><span style="font-size: 10pt">ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">67</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_021"><span style="font-size: 10pt">ITEM 11. EXECUTIVE COMPENSATION.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">72</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_022"><span style="font-size: 10pt">ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">79</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_023"><span style="font-size: 10pt">ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">82</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_024"><span style="font-size: 10pt">ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">86</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_025"><span style="font-size: 10pt">PART IV</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_026"><span style="font-size: 10pt">ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">88</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_027"><span style="font-size: 10pt">ITEM 16. FORM 10-K SUMMARY.</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">89</td></tr>
  <tr>
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top">&nbsp;</td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">&nbsp;</td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; vertical-align: top"><a href="#a_028"><span style="font-size: 10pt">SIGNATURES</span></a></td>
    <td style="vertical-align: top">&nbsp;</td>
    <td style="vertical-align: bottom; text-align: center">90</td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXPLANATORY NOTE</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In this Annual Report on Form 10-K, the terms “we,”
“us,” “our,” the “Company” and “Vicarious Surgical” mean Vicarious Surgical Inc. (formerly
D8 Holdings Corp.) and our subsidiaries. On September 17, 2021 (the “Closing Date”), D8 Holdings Corp., a Delaware corporation
that was previously a Cayman Islands exempted company (“D8” and after the Business Combination described herein, the “Company”)
that migrated to and domesticated (the “Domestication”), consummated the previously announced business combination (the “Business
Combination”) pursuant to the terms of the Agreement and Plan of Merger, dated as of April 15, 2021 (the “Business Combination
Agreement”), by and among D8, Snowball Merger Sub, Inc., a Delaware corporation (“Merger Sub”), and Vicarious Surgical
Inc., a Delaware corporation (“Legacy Vicarious”). Immediately upon the consummation of the Business Combination, the Domestication
and the other transactions contemplated by the Business Combination Agreement (collectively, the “Transactions”, and such
completion, the “Closing”), Merger Sub merged with and into Legacy Vicarious, with Legacy Vicarious surviving the Business
Combination as a wholly-owned subsidiary of D8 (the “Merger”). In connection with the Transactions, D8 changed its name to
“Vicarious Surgical Inc.” and Legacy Vicarious changed its name to “Vicarious Surgical US Inc.”</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="text-transform: uppercase"><b>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS </b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">This Annual Report on Form 10-K includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events, our future operations or financial
performance, or our plans, strategies and prospects. These statements are based on the beliefs and assumptions of our management team.
Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable,
we cannot assure that we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject
to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning possible
or assumed future actions, business strategies, events or performance, are forward-looking statements. These statements may be preceded
by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,”
“may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates”
or “intends” <span>or the negative of these terms, or other comparable terminology intended
to identify statements about the future, although not all forward-looking statements contain these identifying words</span>. The forward-looking
statements are based on projections prepared by, and are the responsibility of, our management team. Forward-looking statements contained
in this Annual Report on Form 10-K include, but are not limited to, statements about:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to recognize the
anticipated benefits of the Business Combination, which may be affected by, among other things, competition and our ability to grow and
manage growth profitably and retain our key employees;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to maintain the
listing of our Class A common stock on the New York Stock Exchange (the “NYSE”);</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">the success, cost and timing
of our product and service development activities;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">the commercialization and adoption
of our initial products and the success of the Vicarious System and any of our future product and service offerings;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">the potential attributes and
benefits of the Vicarious System and any of our other product and service offerings once commercialized;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to obtain and maintain
regulatory approval for the Vicarious System and our product and service offerings, and any related restrictions and limitations of any
approved product or service offering;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 3; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our business is subject to
a variety of U.S. and foreign laws, which are subject to change and could adversely affect our business;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to identify, in-license
or acquire additional technology;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to maintain our
existing license agreements and manufacturing arrangements;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to compete with
other companies currently marketing or engaged in the development of products and services for ventral hernia repair and additional surgical
applications, many of which have greater financial and marketing resources than us;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">the size and growth potential
of the markets for the Vicarious System and any of our future product and service offerings, and the ability of each to serve those markets
once commercialized, either alone or in partnership with others;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our estimates regarding expenses,
future revenue, capital requirements and needs for additional financing;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our ability to raise financing
in the future;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our financial performance;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">our intellectual property rights
and how failure to protect or enforce these rights could harm our business, results of operations and financial condition;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">economic downturns and political
and market conditions beyond our control and their potential to adversely affect our business, financial condition and results of operations;</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">the anticipated continued impact
of the COVID-19 pandemic on our business; and</span></td>
</tr></tbody></table><div>
</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">●</span></td><td style="text-align: left"><span style="font-size: 10pt">other factors detailed under
the section titled “<i>Risk Factors</i>.”</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">These forward-looking statements are based on information available
as of the date of this report, and current expectations, forecasts and assumptions, and involve a number of judgments, risks and uncertainties.
Important factors could cause actual results, performance or achievements to differ materially from those indicated or implied by forward-looking
statements such as those described under the caption “Risk Factors” in Item 1A of Part I of this Annual Report on Form 10-K
and in other filings that we make with the Securities and Exchange Commission. The risks described under the heading “Risk Factors”
are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess
the impact of all such risk factors on our business or the extent to which any factor or combination of factors may cause actual results
to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance.
You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable
to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing cautionary statements. We undertake no
obligations to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SUMMARY OF RISK FACTORS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The risk factors described below are a summary of the principal risk
factors associated with an investment in us. These are not the only risks we face. You should carefully consider these risk factors, together
with the risk factors set forth under the caption “Risk Factors” in Item 1A of Part I of this Annual Report on Form 10-K and
the other reports and documents filed by us with the Securities Exchange Commission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We have a limited operating history on which to assess the
prospects for our business, we have not generated any revenue from sales of our products, and have incurred losses since inception. We
anticipate that we will continue to incur significant losses for at least the next several&nbsp;years as we develop and commercializes
our products and applications.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We may need to raise additional funding to develop and commercialize
the Vicarious System and to expand our research and development efforts. This additional financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization
or development efforts or other operations.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We are a development stage company with a limited history
of operations and no products with marketing authorization in any jurisdiction, and we cannot assure you that we will ever have a commercialized
product.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">Our success depends upon market acceptance of our products,
our ability to develop and commercialize our products and additional applications and generate revenues, and our ability to identify
new markets for our technology.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We are highly dependent upon the continued contributions
of our key personnel. The loss of their services could harm our business, and if we are unable to attract, recruit, train, retain, motivate
and integrate key personnel, we may not achieve our goals.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We have no experience in marketing and selling our products
and if we are unable to successfully commercialize our products, our business and operating results will be adversely affected.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We expect to generate an increasing portion of our revenue
internationally in the future and may become subject to various additional risks relating to our international activities, which could
adversely affect our business, operating results and financial condition.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We rely on limited or sole suppliers for some of the materials
and components used in our products, and we may not be able to find replacements or immediately transition to alternative suppliers,
which could have a material adverse effect on our business, financial condition, results of operations and reputation.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">If we do not successfully develop, optimize and operate our
sales and distribution channels or we do not effectively expand and update infrastructure, our operating results and customer experience
may be negatively impacted.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">If we are unable to establish and maintain adequate sales
and marketing capabilities or enter into and maintain arrangements with third parties to sell and market our products, our business may
be harmed.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">The COVID-19 pandemic has and could continue to negatively
affect various aspects of our business, which could have a material adverse effect on our business, financial condition, results of operations,
or cash flows.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We have identified a material weakness in our internal control
over financial reporting. If we are unable to successfully remediate this material weakness in our internal control over financial reporting,
we may not be able to report our financial condition or results of operations accurately or in a timely manner, which may adversely affect
investor confidence in us and, as a result, materially and adversely affect our business and the value of our Class A common stock.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We are subject to extensive government regulation, which
could restrict the development, marketing, sale and distribution of our products and technologies and could cause us to incur significant
costs.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">There is no guarantee that the FDA will grant marketing authorization
for our current products or any of our future products and technologies, and failure to obtain necessary marketing authorization for
our current products and our future products and technologies would adversely affect our ability to grow our business.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">If we are unable to protect our intellectual property, our
ability to maintain any technological or competitive advantage over our competitors and potential competitors would be adversely impacted,
and our business may be harmed.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We may need or may choose to obtain licenses from third parties
to advance our research or allow commercialization of our current or future products and technologies, and we cannot provide any assurances
that we would be able to obtain such licenses.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">We and our partners may be sued for infringing the intellectual
property rights of third parties. If that happens, such litigation would be costly and time consuming, and an unfavorable outcome in
any such litigation could have a material adverse effect on our business.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">In addition to IP litigation risks (referenced above), we
face the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><div><a id="a_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
I</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1. BUSINESS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>The following discussion reflects the business
of Vicarious Surgical, as currently embodied by Vicarious Surgical. Unless the context otherwise requires, all references in this section
to the “Company”, “we,” “us” and “our” generally refer to Vicarious Surgical in the present
tense or Vicarious Surgical from and after the Business Combination.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Prior to the Domestication and the Closing, we were
a blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, capital stock
exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. On September&nbsp;16,
2021, we incorporated as a Delaware corporation in connection with the Domestication. On September&nbsp;17, 2021, we completed the Business
Combination pursuant to the Business Combination Agreement dated April&nbsp;15, 2021 that we entered into with Legacy Vicarious. In connection
with the transactions contemplated by the Business Combination, we changed our name to “Vicarious Surgical Inc.” and the business
of Legacy Vicarious became our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are combining advanced miniaturized robotics,
computer science and 3D visualization to build an intelligent and affordable, single-incision surgical robot, called the Vicarious System,
that virtually transports surgeons inside the patient to perform minimally invasive surgery, or MIS.&nbsp;With our disruptive next-generation
robotics technology, we are seeking to increase the efficiency of surgical procedures, improve patient outcomes and reduce healthcare
costs. Led by a visionary team of engineers from the Massachusetts Institute of Technology, or MIT, we intend to deliver the next generation
in robotic-assisted surgery, designed to solve the shortcomings of open surgery, and current laparoscopic and robot-assisted MIS.&nbsp;We
have developed multiple prototypes, and had pre-submission meetings with the FDA to align on our regulatory strategy and plan to file
a de novo application with the FDA for ventral hernia procedures as our first indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Vicarious System is uniquely designed to overcome
the deficiencies that have limited broad adoption of robot-assisted MIS to date. By fundamentally engineering a better solution, we believe
we have created a more capable surgical robot than those currently available on the market, and if approved by the FDA, the Vicarious
System will offer surgeons the ability to perform surgical procedures with greater dexterity and greater access to the entire abdomen,
with better visibility and sensor-based feedback, through a small single incision in the abdomen. The Vicarious System features proprietary
“de-coupled” actuators, which are intended to enable a cascade of benefits, including improved robotic mobility, reduced size,
improved functionality and lower materials costs. The Vicarious System is designed to enable surgeons to perform procedures, if approved
by the FDA, inside the abdomen with human-equivalent motion, with a full nine degrees of freedom per robotic arm, providing an experience
that is more natural, and more akin to the surgeon’s own upper body movements. In surgical procedures conducted on cadavers, the
Vicarious System provides exceptional reach within the abdomen, and if approved by the FDA, it will enable the surgeon to enter the abdomen
from nearly any angle and work in nearly any direction, without having to triangulate to the surgical area from multiple incisions or
to operate only within the limited area directly in front of a single incision. The Vicarious System is designed to provide exceptional
visualization, with a high-performance, stereoscopic camera that rotates in three degrees of freedom (yaw, pitch, and roll) to provide
the surgeon with stereoscopic imaging of nearly every surface in the abdomen. The Vicarious System also contains 28 sensors per instrument
arm, which allows the system to provide real-time feedback to the surgeon on force, motion and other key data that are intended to enhance
surgical procedures and patient outcomes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Vicarious System is being developed to provide
attractive advantages to hospitals and ambulatory surgical centers, or ASCs, which we believe will drive rapid and widespread adoption.
Unlike the large footprints of legacy surgical robotic systems that require a construction build-out and a dedicated operating room, the
Vicarious System is much smaller and could be easily moved to any operating room throughout a medical facility. We anticipate that, if
approved by the FDA, the smaller size and advanced engineering of the Vicarious System and related disposable instruments will be offered
at a cost-effective price point compared to existing legacy robotic systems. Hospitals and ASCs would not be required to dedicate permanent
space and would reduce expenses relating to sterilization and operating room turnover. We believe that, if approved by the FDA, adoption
of the Vicarious System could be facilitated by a streamlined training regimen, where surgeons will be able to develop proficiency much
more quickly than for legacy robotic systems. This is due to the design features of the Vicarious System, such as the ease of use and
more natural, human-equivalent motion of the Vicarious System, the reduced surgeon burden during setup, and the fact that the Vicarious
System would not be confined to a dedicated operating suite and therefore could have more availability for training purposes. In addition,
with its increased capability and dexterity, the Vicarious System is designed to enable many procedures to be performed faster and more
effectively, with less injury and risk to the patient, significantly reducing overall healthcare costs. Because the Vicarious System had
not yet been approved by the FDA or commercialized, the intended advantages of the Vicarious System have not yet been realized and are
dependent upon the successful development of the Vicarious System and a timely approval by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We estimate that there are 39&nbsp;million soft
tissue abdominal and gynecological surgical procedures performed annually worldwide that could be addressed with the Vicarious System,
including ventral hernia, other types of hernia, hysterectomy, cholecystectomy (gall bladder) and certain other gastrointestinal procedures.
We intend for ventral hernia procedures to be the first clinical application for the Vicarious System, of which there are estimated to
be 4.1&nbsp;million cases worldwide and 0.9&nbsp;million in the U.S.&nbsp;We then intend to seek FDA approval to enable the expansion
into the other applications addressable by the Vicarious System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Industry Background</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Despite the advancements in manual and robot-assisted
MIS over the last 40&nbsp;years, of the estimated 39&nbsp;million procedures addressable by the Vicarious System, it is estimated that
more than 50% are currently performed by open surgery and less than 5% are performed by existing robot-assisted MIS technologies today.
The large incisions required for open surgery, while allowing the surgeon to see with their own eyes and operate with their own hands,
create significant trauma to the patient, resulting in long hospitalization and recovery times, high hospitalization costs, as well as
significant pain and suffering. Due to the significant trauma to the patient associated with open surgery, 15% to 20% of such surgeries
result in tissue or internal organs pushing through the muscle into the abdomen, or incisional hernias, caused by the operation, requiring
additional complex surgery to correct. Although there have been significant improvements in MIS procedures over open surgery, the following
limitations associated with MIS still exist:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">Laparoscopic surgery results in improved patient outcomes,
but it presents significant challenges for surgeons, primarily associated with using long, rigid instruments through multiple incisions
across the abdominal wall, which introduces the “fulcrum effect” requiring the surgeon to adjust for the inversion and scaling
of movements. These laparoscopic instruments are difficult to manipulate, have limited degrees of freedom, limited reach and reduced
depth-perception and visibility, which requires significant coordination among the surgical team to perform the procedure.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">Multi-port robotic systems introduced in the early 2000s
have managed to overcome some of the challenges associated with laparoscopy, but they require multiple incisions. While the wristed robotic
instruments provide more dexterity than the long, rigid instruments used in laparoscopy, these robotic systems still require multiple
systems and require the surgeon to define the workspace and kinematic motion profile of the robotic system for every procedure, based
on where they create the incisions and where they intend to operate. Additionally, these systems are expensive and require a difficult
learning-curve for surgeons. In addition, these systems are often underutilized because they have large footprints, limited portability
and require extensive setup and longer operating room turnover time.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">More recently, single-port surgical robots have been developed,
but these systems are limited in that they rely on legacy robotic architecture, and thus require a much larger incision than multi-port
robotic systems, have limited motion, strength, and visualization, and can only operate in a small procedural area. Given the relatively
large size of the trocar incision required to be made by the surgeon to accommodate existing single-port robotic systems, among other
limitations, these existing single-port robots have unfortunately resulted in significantly higher rates of complications with higher
levels of injury to the patient, with less capability for the surgeon. For all these reasons, legacy single-port robotic solutions, much
like multi-port manual and robotic MIS, have received limited adoption to date.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe the slow adoption of robot-assisted surgery,
estimated to be less than 5% of the estimated 39&nbsp;million addressable abdominal soft-tissue surgical procedures performed worldwide
annually, has occurred because of several factors, including the following:</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Significant Capital Investment. </i></b>Legacy
robotic systems require high upfront acquisition costs and burdensome annual service contracts that are often prohibitively expensive,
especially in outpatient settings. We estimate these capital costs to be up to $2.0&nbsp;million or more per system upfront, plus an
additional 10% to 20% annually for maintenance and service contracts.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Low Utilization. </i></b>In addition to the significant acquisition costs, existing robotic
                                                                                       systems create inefficiencies and increase costs to medical facilities considering adoption. Due to their large size and limited
                                                                                       portability, existing robotic systems require the construction of a dedicated operating room, occupying valuable real estate within
                                                                                       the hospital. Once in place, these robotic systems require extensive set-up and operating room turnover times, which limits the
                                                                                       number of procedures that can be performed with the robotic system.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Limited Capabilities. </i></b>Existing
robotic systems have limited capabilities and are ill-suited for many outpatient procedures. Due to their limited degrees of freedom
inside the abdomen, they depend on significant, complicated, robotic motion outside the body, and they have limited ability to operate
in multiple quadrants, difficulty operating on the “ceiling” of the abdomen, create collisions inside and outside of the
patient’s abdomen, and restrict overall access of the operating team to the patient.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Difficult to Use. </i></b>Existing robotic systems
require the surgeon to develop an extensive procedure plan in advance to determine appropriate incision sites and angles for each procedure,
in order to avoid collisions inside and outside of the patient’s abdomen. Surgeons must develop this plan with fewer degrees of
freedom than they would employ using open surgery, restricting their natural movements. To become proficient at manipulating these legacy
robotic systems to perform the procedures they otherwise were trained to perform via open surgery requires extensive training and several
dozen procedures on live patients. As these systems are maintained in dedicated, expensive, operating rooms, obtaining access to train
on the system becomes a significant impediment to adoption, resulting in more open surgeries.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>The Vicarious System</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The single-port Vicarious System with advanced,
miniaturized robotics and exceptional visualization is designed to address the significant limitations of open surgery and existing single-
and multi-port robotic surgical approaches to improve patient outcomes and enhance adoption by hospitals and other medical facilities.
The Vicarious System is designed with a fundamentally different architecture, and proprietary “de-coupled actuators,” to overcome
many of the limitations of open surgery or existing robot-assisted surgical procedures with a minimally invasive and more capable robotic
system. This architecture enables unprecedented dexterity inside the abdomen through an ultra-thin support tube, providing significant
improvement over existing legacy robotic systems and minimizing the complications and trauma associated with open surgery. The Vicarious
System has not yet been approved by the FDA.&nbsp;We have had pre-submission meetings with the FDA to align on our regulatory strategy
and plan to file a de novo application with the FDA for ventral hernia procedures as our first indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>


</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><img alt="" data-src="https://www.sec.gov/Archives/edgar/data/1812173/000121390022016785/image_001.jpg" src="https://www.sec.gov/Archives/edgar/data/1812173/000121390022016785/image_001.jpg"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">The Vicarious System is capable of incision sizes as low as
1.2cm. Current disposables require 1.8cm incisions. We are developing and expect to launch disposables requiring 1.5cm incisions.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The Vicarious System consists of the following components:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Camera and Instrument Arms. </i></b>The Vicarious System
has a high performance stereoscopic camera that, when combined with robotic motion, provides full 360-degree viewing capability and is
being developed to continuously map the depth of the patient’s body. The camera moves in any direction and, together with the instrument
arms, based on cadaver studies, the Vicarious System is capable of operating in nearly every direction within the abdomen, including
rotating back and operating around the trocar incision point, unlike any robotic system on the market today. The Vicarious System’s
surgical instrument arms each have nine degrees of movement, completely mimicking the degrees of freedom in the surgeon’s own wrists,
elbows and shoulders, providing for a more complete and more natural range of motion for the surgeon. While existing robotic systems
are limited to operating in a small section directly in front of the rigid instrument, the Vicarious System’s unique ability to
operate in nearly every direction is designed to provide significantly more capability to the surgeon, while minimizing the injury and
trauma to the patient. The camera and both instrument arms are being developed to enter the abdomen through a single, 1.8 centimeter
trocar, which is anticipated to be reduced to a 1.5 centimeter trocar as development continues, that is within the size of conventional
MIS trocars. Due to the smaller size of the Vicarious System, it will be able to provide significantly more sensing capability than existing
systems, if the Vicarious System receives FDA approval. The Vicarious System features 28 sensors per arm, to provide valuable feedback
to the surgeon in real-time, and the sensors will also be capable of providing robust intraoperative data to continually enhance our
AI capabilities and enhance surgeon capabilities over the long-term.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: left; text-indent: -0.25in"><b><i>&nbsp;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left"><b><i>●</i></b></td><td style="text-align: left"><b><i>Surgeon Console. </i></b>The Vicarious System surgeon
console is designed to provide all the systems necessary for the surgeon to have an effective, immersive experience, visualizing the
surgical field and controlling all the motions of the robot, and if approved by the FDA, enabling performance and patient outcomes that
are not available on other existing systems. When the surgeon wants to simultaneously engage and react to other activities within the
operating room as well as what is going on inside the abdomen, he or she can utilize the 3D surgical screen powered by proprietary software.
In addition, visualization can be deeply immersive using a head mounted display that responds to the motion of the surgeon’s own
head and allows the surgeon to feel as if he or she is “inside” the patient. Currently, the initial launch of the Vicarious
System will not have the ability to utilize a head mounted display for visualization, but we anticipate providing surgeons with this
ability as development continues.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Patient Cart. </i></b>The Vicarious System patient
cart is designed to be only 34 inches wide, which could easily pass through the doorways of hospitals, outpatient clinics, ambulatory
surgical centers, and any standard doorway, alleviating the equipment maneuverability concerns experienced by healthcare providers with
competitor surgical robotics systems. Unlike existing robotic systems, the Vicarious System, if approved by the FDA, would not require
a dedicated operating room and could be wheeled into or out of any room, or stored in the hall, as the hospital does with other medical
devices, significantly expanding accessibility to the system. Further, as most of the robotic motion occurs inside the abdomen in a single
port, the Vicarious System does not have multiple, expensive, high-performance robotic arms outside the body, pivoting around the incision
point to make small movements inside the body. We believe that these factors, together with the ability to utilize more advanced, sometimes
less expensive manufacturing processes, will enable the Vicarious System to be significantly less expensive to build than competitive
robotic systems, based on their publicly available data.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Vicarious System Advantages</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We believe that to overcome the issues that have
limited broad adoption of robot-assisted MIS procedures to date: cost, size, capability, ease of use, fast setup, high throughput, streamlined
training, and improved patient outcomes, it is imperative to provide a solution that addresses all these concerns. The Vicarious System,
with its advanced engineering and “de-coupled actuators,” which enable a revolutionary approach to the development of surgical
robotics, is designed to be uniquely able to significantly improve upon each of these factors. Because of its proprietary engineering
advantage, the Vicarious System is designed to offer more degrees of freedom and dexterity with which the surgeon can more naturally operate,
and to provide greater visibility, sensing and functionality to the surgeon, all through a small, single port that is designed to offer
more capability and fewer challenges than any single or multi-port surgical modality available. Because the Vicarious System had not yet
been approved by the FDA or commercialized, the intended advantages of the Vicarious System have not yet been realized and are dependent
upon the successful development of the Vicarious System and a timely approval by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Decoupled Actuators. </i></b>Robotic arms are controlled
by actuators at each joint. Traditionally, these actuators are “coupled,” meaning that movement of one joint causes movement
at each subsequent or prior joint. This coupled motion can be corrected by legacy robots via complicated software to coordinate and eliminate
the unwanted motion between these joints that would otherwise be created. However, the software cannot eliminate the exponential buildup
of force across these joints caused by this coupled action. This exponential force buildup requires stronger cables and pulleys and other
expensive and larger components, which adds significant size, cost, and limits the available mobility of legacy robotic systems. By fundamentally
engineering a better solution, we have decoupled the motion between these actuators, reducing cost and integrating components and materials
that enable enhanced visibility, flexibility and strength, which in turn are intended to provide significant benefits for surgeons, hospitals,
ASCs and patients.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify"><b><i>Surgeon Experience</i></b></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><b><i>&nbsp;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b><i>●</i></b></td><td style="text-align: left"><b><i>Human Equivalent Motion&nbsp;—&nbsp;Nine Degrees
of Freedom. </i></b>The Vicarious System is the only robotic system, compared to all legacy single- or multi-port solutions, to offer
the same nine full degrees of freedom that exist in the natural motion of the surgeon’s own wrists, elbows and shoulders, providing
unprecedented dexterity in a robot-assisted MIS.&nbsp;While other legacy robotic systems require the surgeon to conform and limit their
movements to what the robot will enable, in cadaver studies, the Vicarious System offers the nearly full range of motion of the surgeon’s
own upper body, providing an experience that is more natural, and more akin to what they know best, open surgery, except miniaturized
and transformed inside the body.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><b><i>&nbsp;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b><i>●</i></b></td><td style="text-align: left"><b><i>Expanded Reach Inside the Abdomen. </i></b>With the
full nine degrees of freedom provided by the Vicarious System, as shown in cadaver studies, the surgeon can enter the abdomen from nearly
any angle and work in nearly any direction, with more freedom, all through a small single incision. Legacy robotic systems and manual
MIS require the surgeon to triangulate to the surgical area and limit the surgeon to performing only in a small section directly in front
of the incision. The Vicarious System’s unprecedented reach is designed to enable the surgeon to pivot in nearly any direction
during surgery and the surgeon can even pivot backwards and operate near the incision&nbsp;site.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Sensing, Visualization and AI. </i></b>The surgeon can
utilize the 3D screen on the console and eventually the surgeon will have the ability to utilize a head mounted display for visualization.
The Vicarious System’s high-performance, stereoscopic camera can rotate in nearly every direction, following the natural motion
of the surgeon’s head, and is being developed to provide full 3D mapping. The Vicarious System contains more than two dozen sensors
per arm, designed to provide unmatched sensing capability that is being developed to deliver valuable feedback on force, motion and other
key data, to the surgeon in real-time. These sensors also will be used to feed our rapidly expanding need for data and AI development,
which will be utilized to further enhance surgical procedures and provide a significant link and insight between pre- and peri-operative
data and patient outcomes.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Hospital and Ambulatory Surgical Center (ASC) Advantages</i></b></td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>System Size. </i></b>Unlike legacy systems that require
a construction build-out simply to fit their system into a dedicated operating room, the Vicarious System is designed to be small enough
to fit through a single door. This is intended to enable faster set-up and break-down times, allowing the Vicarious System to be used
anywhere within the facility.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Training. </i></b>Because of the more natural motion
of the Vicarious System, together with the fact that it is not confined to a dedicated operating suite like most legacy robotic systems,
the Vicarious System can be more available for surgeons to practice, and it is expected that surgeons would be able to develop proficiency
more quickly and easily than with legacy systems, which could improve surgeon adoption and enhance hospital and ASC return on investment.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Economics/System Cost. </i></b>If approved by the FDA,
we intend to offer the Vicarious System, maintenance and service support at more attractive pricing to existing legacy systems. With
its increased capability and dexterity, it is expected that many procedures could be performed faster and more effectively, which could
greatly reduce overall hospital costs.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Disposability. </i></b>Our instruments and accessories
have been designed and will be offered at a price that enables them to be used once and then disposed. Hospitals and ASCs will no longer
need to dedicate space and expense to ensure these items are properly sterilized and available for re-use.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify"><b><i>Patient Outcomes</i></b></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b><i>Enhanced Capability. </i></b>The Vicarious System will
be designed to provide increased visualization and capability to the surgeon, and if the FDA approves the Vicarious System, it is intended
to allow the surgeon to more easily perform advanced techniques that are proven in existing clinical use to provide for better patient
outcomes.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in"><b><i>&nbsp;</i></b></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.5in"></td><td style="width: 0.25in; text-align: left"><b><i>●</i></b></td><td style="text-align: left"><b><i>Smaller Trocar&nbsp;—&nbsp;Fewer Complications.
</i></b>In open surgery, due to the large size of the incision, the incision fails to heal properly&nbsp;15-20% of the time, a complication
requiring additional surgery to fix. Multi-port manual and robot-assisted MIS, while significantly less capable than the Vicarious System
is designed to be, utilize small trocars (<i>i.e.</i>, 8mm to 12mm), which greatly reduces this risk to approximately 1%. Existing single-port
robots utilize at least a 25mm trocar size, which have a failure rate of nearly 10%, beginning to approach the failure rate of open surgery.
The Vicarious System, like multi-port MIS, is designed to utilize a small trocar, which could enable superior results with the lowest
overall risk. Currently, the Vicarious System utilizes an 18mm trocar, which is anticipated to be reduced to a 15mm trocar as development
continues.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Our Strategy</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">With revolutionary advancements in design, we seek
to democratize surgery through widespread access to a more capable and more affordable surgical robotic platform. Our objective is to
become the leading provider of surgical robotic platforms for soft tissue surgery. To achieve this objective, we are pursuing the following
business strategies, all of which are dependent upon the receipt of FDA clearance:</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Drive adoption of the Vicarious System initially in the
ventral hernia market. </b>We plan to initially focus our marketing efforts on surgeons and hospitals performing surgical procedures
in general surgery, gynecology and other procedures that will benefit from our single incision platform. We believe our innovative system
will deliver clinical and economic value that will address the unmet need in today’s surgical operating rooms. Our strategy is
to work with key thought leaders in general surgery, gynecology and other specialties who can help provide feedback that will help guide
our product roadmap and surgical techniques.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Expand indications. </b>The ability to have universal
access to the abdomen with the Vicarious System also presents opportunities of other procedures that we plan to target in the near future.
Some of the future indications that are being targeted are inguinal and hiatal hernias, hysterectomy, cholecystectomy (gallbladder),
colorectal and other gastrointestinal procedures. We estimate that 39&nbsp;million of these procedures are performed annually today.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Generate recurring revenue. </b>After the initial installation
of the Vicarious System, our goal is to increase the utilization of the Vicarious System by demonstrating the procedural and workflow
efficiency of the System. Faster set up and procedure times with the Vicarious System can enable hospitals and ASCs to potentially schedule
more procedures, which would in turn drive volume sales of single use components, including the robotic arms, camera and instrument tips.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Demonstrate clinical and financial value proposition.
</b>Over 50% of ventral hernia procedures are performed as open surgical procedures in the hospital. We aim to capitalize on the trend
of moving procedures from hospitals to ASCs. Additionally, we believe that the Vicarious System can accelerate the ability to perform
complex hernia surgeries with an MIS procedure in an ASC as opposed to a hospital. However, ASCs typically do not have significant capital
budgets to justify large capital purchases, nor do they have infrastructure budgets to undertake the construction of a dedicated operating
suite. The Vicarious System’s value proposition is designed to appeal to these ASCs.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Expand product offerings. </b>We believe that technologies
such as virtual reality and AI have the potential to further enhance a surgeon’s capabilities. We plan to develop advanced AI features,
such as 3D depth mapping, and automated suturing, to be incorporated into future generations of the Vicarious System.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left"><b>Commercialization outside U.S.</b> If the FDA clears the
Vicarious System for commercialization in the U.S., we intend to seek applicable regulatory clearances or approvals in Asia, Europe and
the rest of the world to commercialize the Vicarious System worldwide.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Historical Development of the Vicarious System and Regulatory Pathway</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The technology for our robot was developed by Legacy
Vicarious founders Adam Sachs, Sammy Khalifa, and Barry Greene between 2009 and 2015. After considerable prototyping and experimentation,
the team discovered and patented a cable pathway through the robotic arm to fully de-couple the motion of the robotic device. This series
of innovations enabled the first successful prototype of a complete robotic arm that resembles the motion of the surgeon’s body.
The founding team went on to take this design and create a full prototype of the device, machining the parts themselves and funding the
project out of pocket. After the first fully functioning robotic arm was created, integrated with software designed by the Legacy Vicarious
founders, as well as a surgeon input tracking system, the founding team was able to raise outside capital and successfully grow the team
in order to continue to drive development and growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have conducted, and continue to conduct, several
cadaver studies with the prototype Vicarious System. The goal of each study was to refine the performance of the Vicarious System. In
these cadaver studies, the Vicarious System prototype was used to perform several ventral hernia repair procedures, hysterectomy procedures
and cholecystectomy procedures. In addition, in these cadaver studies surgeons have used the Vicarious System prototype to perform various
techniques for ventral hernia repair, including robotic transabdominal preperitoneal, or rTAPP, retrorectus, and intraperitoneal onlay
mesh repair (IPOM) plus. These studies were used to gather insights regarding:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The length of the robotic instruments needed to perform ventral
hernia repair;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Field and depth of view of the robotic camera;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">User interface elements, such as the clutch pedal, navigation
pedals and digital interface elements;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Quality of robotic end-effector motion in response to surgeon
hand motion;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Insertion and extraction workflow; and</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Reliability of the robotic instruments and camera.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In November&nbsp;2019, we received FDA Breakthrough
Device designation for a prior version of the Vicarious System with a proposed indication for use of ventral hernia repair. The Vicarious
System is considered a Class&nbsp;II medical device. We have had pre-submission meetings with the FDA to align on our regulatory strategy
and plan to file a de novo application with the FDA for ventral hernia procedures as our first indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A preliminary meeting with the FDA was conducted
in December 2021 to discuss with the FDA our decision to make two technology changes to the Vicarious System design that was granted Breakthrough
Device designation in November 2019. Based on these changes, the FDA has determined that the current Vicarious System design that is planned
for the initial limited launch and was submitted to the FDA in the November 2021 FDA pre-submission meeting request is different from
the device that was granted Breakthrough Device designation for the device design filed in November 2019. The FDA stated that the Breakthrough
Device designation remains active for the prior device design granted Breakthrough Device designation in November 2019. In the future,
we may attempt to reincorporate the technologies from such prior device design to leverage the previously granted Breakthrough Device
designation. The process of medical device development is inherently uncertain and there is no guarantee that a Breakthrough Device designation
will be granted to a different device design, and if it were granted, there is no guarantee that such designation will accelerate the
timeline for approval or make it more likely that the Vicarious System will be approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In February 2022 a pre-submission meeting was held
with the FDA to gain alignment on the current Vicarious System. Feedback provided by the FDA indicated that each robotic-assisted surgical
system has distinctive kinetics, connections, data transmission and interfaces, including interfaces for the user, patient and environment,
the combination of which composes a unique and multifaceted system. Additionally, the FDA indicated that each robotic-assisted surgical
system has unique inputs and outputs and must account for uncertainty and instability in different ways. Taken together, these different
technological characteristics raise different questions of safety or effectiveness that are not applicable to a predicate device and may
pose a significant safety or effectiveness concern for the Vicarious System. For example, the way that a robotic-assisted surgical system
is constructed and implemented will have a direct bearing on the safety and effectiveness profile of the device and different robotic-assisted
surgical systems are not sufficiently similar to allow for meaningful comparison between the Vicarious System and predicate robotic-assisted
surgical systems. The FDA indicated that the evaluation of the complex Vicarious System requires a holistic approach of the performance
testing, such as software, bench, animal, human factors and usability, and clinical data to determine how each element establishes the
Vicarious System’s integration approach to the intended use and more specifically the indicated procedures. Therefore, each robotic-assisted
surgical system carries new or different risks and an evaluation of these risks will require an independent evaluation of the safety and
effectiveness of the Vicarious System due to the technology and the implementation into the clinical care. Based on this feedback, the
FDA has determined that a 510(k) submission would likely be found not substantially equivalent to a predicate robotic-assisted surgical
system. In accordance with this FDA feedback, we have revised our regulatory roadmap for market clearance, as discussed below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Regulatory Roadmap for&nbsp;Market Clearance</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Based on the outcome of the pre-submission meeting
with the FDA in February 2022, the FDA has determined that there is no legally marketed&nbsp;predicate device. Therefore, we will plan
to file a de novo classification request for the proposed initial indication of ventral hernia repair as a regulatory pathway to classify
the Vicarious System. Devices that are classified into Class I or Class II through a de novo classification request may be marketed and
used as predicates for future premarket notification 510(k) submissions, when applicable. Accordingly, we believe that 510(k) filings
will be available as a regulatory pathway for the Vicarious System with respect to future indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We will conduct a prospective human pivotal clinical
investigation under a FDA Investigational Device Exemption (IDE) to evaluate the safety, effectiveness, and performance of the Vicarious
System to obtain U.S. market clearance for the proposed indication of ventral hernia repair. In addition to conducting a human pivotal
clinical investigation, we will conduct non-clinical testing activities to verify and validate the safety, performance, effectiveness,
functionality, usability and reliability characteristics of the Vicarious System with respect to the intended use and defined requirements.
A verification and validation process is expected to provide the necessary data to submit to the FDA for IDE approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Non-clinical verification and validation testing
will be conducted to verify and validate that the Vicarious System meets all design specifications for its intended use. These tests will
include in-vitro, simulated clinical bench testing and cadaver studies, as well as animal studies to support and demonstrate the safety,
performance, effectiveness, functionality, usability, and reliability characteristics of the Vicarious System with respect to the intended
use and defined requirements. Cadaver studies, representing realistic dimensions and contours of the human abdominal space, will be used
primarily to verify and validate system functionality, performance, and safety relevant to patient anatomy and contexts of use with respect
to insertion, access and movement within the abdominal cavity, visualization, manipulating tissue, cutting, and suturing as needed during
a simulated ventral hernia repair. Animal studies will be used primarily to demonstrate performance, safety, efficacy, and usability of
the system as relevant to a live model with respect to insertion, access and movement within the abdominal cavity, visualization, manipulating
tissue, cutting, coagulating, and suturing, during a simulated ventral hernia repair. This testing may also be used to demonstrate that
applicable risk mitigation features, including software alarms, alerts, extraction of multi-jointed instrumentation in case of system
failure, misuse, or other errors are adequate and perform to specifications. Summative usability testing will be conducted by surgeons,
nurses and technicians in a simulated operating room environment to provide objective evidence that the Vicarious System can be used safely
and effectively by end users for its intended uses, the device functions as expected and intended, and all risk mitigations implemented
are safe and effective. In addition, we will conduct simulated bench-top testing on transparent anatomical models to evaluate, among other
things, how the Vicarious System performs in “worst case” scenarios to verify and validate safe anatomical access, instrument/camera
angulation and movement at the extremes of various surgical procedures with respect to patient anatomy and dimensions that cannot be readily
controlled for when using live animal and human cadaver models.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Future Indications</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We plan to expand upon our claims and/or indication
for use to address additional unmet clinical needs in different anatomical areas as well as therapeutic procedures. Following the initial
clearance for ventral hernia repair under a de novo classification, if obtained by the FDA, we plan to submit additional 510(k)&nbsp;filings
for other indications for use, using the Vicarious System’s first de novo authorization&nbsp;as a predicate, along with other predicate
devices with similar cleared indications for use. We have identified several potential future indications and procedures that align well
with the Vicarious System’s ability to access and visualize the abdominal cavity. Possible future indications may include but not
be limited to inguinal and hiatal hernias, hysterectomy, cholecystectomy (gallbladder), colorectal and other gastrointestinal procedures.
We will perform an assessment to determine the appropriate regulatory strategy required to expand claims and obtain applicable regulatory
approvals in the United&nbsp;States and in other global markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We strive to protect and enhance the proprietary
technology, inventions and improvements that are important to our business by seeking, maintaining and defending our intellectual property,
all of which has been developed internally and not in-licensed from third parties. We also rely on trade secrets, know-how, continuing
technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary position in the field of surgical
robotics. Additionally, we intend to rely on regulatory protection afforded through data exclusivity and market exclusivity as well as
patent term extensions, where available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We currently do not rely heavily on technologies
from third parties. However, in the future, we may need to rely or be dependent on patented or proprietary technologies that we may license
from third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We maintain a patent portfolio that includes issued
U.S.&nbsp;and foreign patents as well as pending U.S.&nbsp;and foreign patent applications, which include claims directed towards our
proprietary technology. We intend to pursue additional intellectual property protection to the extent we believe it would be beneficial
and cost-effective. As of March 1, 2022, we owned approximately six (6)&nbsp;issued U.S.&nbsp;patents, approximately two (2)&nbsp;issued
patents in foreign jurisdictions including one (1)&nbsp;in China and one (1)&nbsp;in Japan, and approximately 40 pending patent applications
in the U.S.&nbsp;and foreign jurisdictions, including in Canada, China, Europe, Japan and India. These issued patents and pending patent
applications (if they were to issue as patents) are all utility patents and have expected expiration dates ranging between 2035 and 2042.
Our patents and patent applications are directed to, among other things, our core technology. This includes the surgical robotic and camera
system; sensing capabilities, controls and visualization interfaces; the surgical tools suite; and related technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The term of individual patents may vary based on
the countries in which they are obtained. Generally, patents issued for applications filed in the United&nbsp;States are effective for
20&nbsp;years from the earliest effective non-provisional filing date. In addition, in certain instances, a patent term can be extended
to recapture a portion of the term effectively lost as a result of the FDA regulatory review period. The restoration period cannot be
longer than five&nbsp;years and the total patent term, including the restoration period, must not exceed 14&nbsp;years following FDA approval.
The duration of patents outside of the United&nbsp;States varies in accordance with provisions of applicable local law, but typically
is also 20&nbsp;years from the earliest effective filing date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In addition to patents and patent applications,
we rely on trade secrets and know-how to develop and maintain our competitive position. However, trade secrets can be difficult to protect.
We seek to protect our proprietary technology and processes, and obtain and maintain ownership of certain technologies, in part, through
confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors, contractors and commercial
partners. We also seek to preserve the integrity and confidentiality of our data, trade secrets and know-how, including by implementing
measures intended to maintain the physical security of our premises and the physical and electronic security of our information technology
systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our future commercial success depends, in part,
on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how
related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing
the valid enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling,
offering to sell or importing our products will depend on the extent to which we have rights under valid and enforceable patents or trade
secrets that cover these activities. Moreover, we may be unable to obtain patent protection for the Vicarious System generally, as well
as with respect to certain surgical indications. See the section entitled “<i>Risk Factors&nbsp;—&nbsp;Risks Related to Our
Intellectual Property</i>” for a more comprehensive description of risks related to our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Research and Development</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of March&nbsp;1, 2022, our research and development programs are generally pursued by our </span>89 <span style="font-family: Times New Roman, Times, Serif">engineering,
scientific and technical personnel employed by us in our offices in Massachusetts and California on a full-time basis or as consultants,
or through partnerships with industry leaders in manufacturing and design and with researchers in academia. We are also working with subcontractors
in developing specific components of our technologies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The primary objectives of our research and development
efforts are to continue to introduce incremental enhancements to the capabilities of the Vicarious System and to advance development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">For the fiscal year ended December&nbsp;31, 2021,
we incurred research and development expenses of approximately $22.1 million compared to research and development expenses of approximately
$9.8 million for the fiscal year ended December&nbsp;31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Manufacturing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are expanding our manufacturing capabilities
with the development of a manufacturing facility, including a clean room, within our new headquarters in Waltham, Massachusetts, and has
hired key manufacturing personnel. We currently rely, and expect to continue to rely, on third parties for the manufacturing of certain
products for preclinical and clinical testing, as well as for commercial manufacturing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We purchase both custom and off-the-shelf components
from a large number of suppliers and subjects them to stringent quality specifications and processes. Some of the components necessary
for the assembly of the Vicarious System are currently provided to us by sole-sourced suppliers or single-sourced suppliers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Competition</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We face competition in the forms of existing open
surgery, conventional MIS, drug therapies, radiation treatment, and emerging interventional surgical approaches. Our success depends on
continued clinical and technical innovation, quality and reliability, as well as educating hospitals, surgeons, and patients on the results
associated with robotic-assisted surgery using the Vicarious System and our value proposition relative to other techniques. We also face
competition from several companies that have introduced or are developing new approaches and products for the MIS market. We believe that
the entrance or emergence of competition validates robotic-assisted surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We face competition from larger and well-established
companies. The companies that have introduced products in the field of robotic-assisted surgery or have made explicit statements about
their efforts to enter the field, include, but are not limited to: Intuitive Surgical, Inc.; Johnson&nbsp;&amp; Johnson (including their
wholly-owned subsidiaries Ethicon Endo-Surgery, Inc., Auris Health, Inc. and Verb Surgical Inc.); Medtronic plc (including their wholly-owned
subsidiary Covidien LP); Virtual Incision Corporation; Titan Medical Inc.; Stryker Corporation; and CMR&nbsp;Surgical Ltd. Other companies
with substantial experience in industrial robotics could potentially expand into the field of surgical robotics and become a competitor.
In addition, research efforts utilizing computers and robotics in surgery are underway at various companies and research institutions.
Our ability to generate future revenue may be adversely impacted as competitors announce their intent to enter these markets and as our
potential customers anticipate the availability of competing products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Commercialization</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have not yet established a sales or product distribution
infrastructure for the Vicarious System. We plan to access the U.S.&nbsp;market with the Vicarious System through strategic partnerships
and will also develop our own focused, specialized sales force or distribution channels once we have commercialized the Vicarious System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Government Regulation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our operations are subject to comprehensive federal,
state, and local laws and regulations in the jurisdictions in which we or our research and development partners or affiliates do business.
The laws and regulations governing our business and interpretations of those laws and regulations and are subject to frequent change.
Our ability to operate profitably will depend in part upon our ability, and that of our research and development partners and affiliates,
to operate in compliance with applicable laws and regulations. The laws and regulations relating to medical products and healthcare services
that apply to our business and that of our partners and affiliates continue to evolve, and we must, therefore, devote significant resources
to monitoring developments in legislation, enforcement, and regulation in such areas. As the applicable laws and regulations change, we
are likely to make conforming modifications in our business processes from time to time. We cannot provide assurance that a review of
our business by courts or regulatory authorities will not result in determinations that could adversely affect our operations or that
the regulatory environment will not change in a way that restricts our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>FDA Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Medical devices are strictly regulated by the FDA,
in the United&nbsp;States. Under the Federal Food, Drug, and Cosmetic Act, or the FDCA, a medical device is defined as “an instrument,
apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including a component, part
or accessory which is, among other things: intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation,
treatment, or prevention of disease, in man or other animals; or intended to affect the structure or any function of the body of man or
other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other
animals and which is not dependent upon being metabolized for the achievement of any of its primary intended purposes.” This definition
provides a clear distinction between a medical device and other FDA regulated products such as drugs. If the primary intended use of a
medical product is achieved through chemical action or by being metabolized by the body, the product is usually a drug or biologic. If
not, it is generally a medical device.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We are currently developing a robotic-assisted surgical
system, which is regulated by the FDA as a medical device under the FDCA, as implemented and enforced by the FDA.&nbsp;The FDA regulates
the development, testing, manufacturing, labeling, packaging, storage, installation, servicing, advertising, promotion, marketing, distribution,
import, export, and post-market surveillance of our medical devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Device Premarket Regulatory Requirements</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Before being introduced into the U.S.&nbsp;market,
each medical device must obtain marketing clearance or approval from the FDA through the premarket notification (or 510(k)) process, the
de novo classification process, or the premarket approval, or PMA, process, unless they are determined to be Class&nbsp;I devices or to
otherwise qualify for an exemption from one of these available forms of premarket review and authorization by the FDA.&nbsp;Under the
FDCA, medical devices are classified into one of three classes&nbsp;—&nbsp;Class&nbsp;I, Class&nbsp;II or Class&nbsp;III&nbsp;—&nbsp;depending
on the degree of risk associated with each medical device and the extent of control needed to provide reasonable assurance of safety and
effectiveness. Classification of a device is important because the class to which a device is assigned determines, among other things,
the necessity and type of FDA review required prior to marketing the device. Class&nbsp;I devices are those for which reasonable assurance
of safety and effectiveness can be maintained through adherence to general controls that include compliance with the applicable portions
of the FDA’s Quality System Regulation, or the QSR, as well as regulations requiring facility registration and product listing,
reporting of adverse medical events, and appropriate, truthful and non-misleading labeling, advertising, and promotional materials. The
Class&nbsp;I designation also applies to devices for which there is insufficient information to determine that general controls are sufficient
to provide reasonable assurance of the safety and effectiveness of the device or to establish special controls to provide such assurance,
but that are not life-supporting or life-sustaining or for a use which is of substantial importance in preventing impairment of human
health, and that do not present a potential, unreasonable risk of illness or injury.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Class&nbsp;II devices are those for which general
controls alone are insufficient to provide reasonable assurance of safety and effectiveness and there is sufficient information to establish
“special controls.” These special controls can include performance standards, post-market surveillance requirements, patient
registries and FDA guidance documents describing device-specific special controls. While most Class&nbsp;I devices are exempt from the
premarket notification requirement, most Class&nbsp;II devices require a premarket notification prior to commercialization in the United&nbsp;States;
however, the FDA has the authority to exempt Class&nbsp;II devices from the premarket notification requirement under certain circumstances.
As a result, manufacturers of most Class&nbsp;II devices must submit premarket notifications to the FDA under Section&nbsp;510(k)&nbsp;of
the FDCA (21 U.S.C. § 360(k)) in order to obtain the necessary clearance to market or commercially distribute such devices. To obtain
510(k)&nbsp;clearance, manufacturers must submit to the FDA adequate information demonstrating that the proposed device is “substantially
equivalent” to a “predicate device” that is already on the market. A predicate device is a legally marketed device that
is not subject to PMA, meaning, (i)&nbsp;a device that was legally marketed prior to May&nbsp;28, 1976 (“preamendments device”)
and for which a PMA is not required, (ii)&nbsp;a device that has been reclassified from Class&nbsp;III to Class&nbsp;II or&nbsp;I, or
(iii)&nbsp;a device that was found substantially equivalent through the 510(k)&nbsp;process. If the FDA agrees that the device is substantially
equivalent to the predicate device identified by the applicant in a premarket notification submission, the FDA will grant 510(k)&nbsp;clearance
for the new device, permitting the applicant to commercialize the device. Premarket notifications are subject to user fees, unless a specific
exemption applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">If there is no adequate predicate to which a manufacturer
can compare its proposed device, the proposed device is automatically classified as a Class&nbsp;III device. In such cases, a device manufacturer
must then fulfill the more rigorous PMA requirements or can request a risk-based classification determination for its device in accordance
with the de novo classification process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Devices that are intended to be life sustaining
or life supporting, devices that are implantable, devices that present a potential unreasonable risk of harm or are of substantial importance
in preventing impairment of health, and devices that are not substantially equivalent to a predicate device and for which safety and effectiveness
cannot be assured solely by the general controls and special controls are placed in Class&nbsp;III.&nbsp;Such devices generally require
FDA approval through the PMA process, unless the device is a preamendments device not yet subject to a regulation requiring premarket
approval. The PMA process is more demanding than the 510(k)&nbsp;process. For a PMA, the manufacturer must demonstrate through extensive
data, including data from preclinical studies and one or more clinical trials, that the device is safe and effective for its proposed
indication. The PMA must also contain a full description of the device and its components, a full description of the methods, facilities
and controls used for manufacturing, and proposed labeling. Following receipt of a PMA submission, the FDA determines whether the application
is sufficiently complete to permit a substantive review. If the FDA accepts the application for review, it has 180&nbsp;days under the
FDCA to complete its review and determine whether the proposed device can be approved for commercialization, although in practice, PMA
reviews often take significantly longer, and it can take up to several&nbsp;years for the FDA to issue a final decision. Before approving
a PMA, the FDA generally also performs an on-site inspection of manufacturing facilities for the product to ensure compliance with the
QSR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The de novo classification process allows a manufacturer
whose novel device is automatically classified into Class&nbsp;III to request down-classification of its device to Class&nbsp;I or Class&nbsp;II,
on the basis that the device presents low or moderate risk, as an alternative to following the typical Class&nbsp;III device pathway requiring
the submission and approval of a PMA application. Under the Food and Drug Administration Safety and Innovation Act&nbsp;of&nbsp;2012,
the FDA is required to classify a device within 120&nbsp;days following receipt of the de novo classification request from an applicant;
however, the most recent FDA premarket review goals state that in fiscal year 2021, FDA will attempt to issue a decision within 150&nbsp;days
of receipt on 65% of all de novo classification requests received during the year and on 70% of de novo requests received during fiscal
year 2022. If the manufacturer seeks reclassification into Class&nbsp;II, the classification request must include a draft proposal for
special controls that are necessary to provide a reasonable assurance of the safety and effectiveness of the medical device. The FDA may
reject the classification request if it identifies a legally marketed predicate device that would be appropriate for a 510(k)&nbsp;notification
or determines that the device is not low to moderate risk or that general controls would be inadequate to control the risks and special
controls cannot be developed. De novo classification requests are subject to user fees, unless a specific exemption applies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Clinical trials are almost always required to support
PMAs and are sometimes required to support 510(k)&nbsp;and de novo classification submissions. All clinical investigations of devices
to determine safety and effectiveness must be conducted in accordance with the FDA’s investigational device exemption, or IDE, regulations
that govern investigational device labeling, prohibit promotion of investigational devices, and specify recordkeeping, reporting and monitoring
responsibilities of study sponsors and study investigators. If the device presents a “significant risk,” as defined by the
FDA, the FDA requires the device sponsor to submit an IDE application to the FDA, which must become effective prior to commencing human
clinical trials. The IDE will automatically become effective 30&nbsp;days after receipt by the FDA, unless the FDA denies the application
or notifies us that the investigation is on hold and may not begin until the sponsor provides supplemental information about the investigation
that satisfies the FDA’s concerns. If the FDA determines that there are deficiencies or other concerns with an IDE that require
modification of the study, the FDA may permit a clinical trial to proceed under a conditional approval. In addition, the study must be
approved by, and conducted under the oversight of, an institutional review board, or IRB, for each clinical site. If the device presents
a non-significant risk to the patient according to criteria established by the FDA as part of the IDE regulations, a sponsor may begin
the clinical trial after obtaining approval for the trial by one or more IRBs without separate authorization from the FDA, but must still
comply with abbreviated IDE requirements, such as monitoring the investigation, ensuring that the investigators obtain informed consent,
and labeling and record-keeping requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Post-Marketing Restrictions and Enforcement</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">After a device is placed on the market, numerous
regulatory requirements apply. These include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">submitting and updating establishment registration and device
listings with the FDA;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">compliance with the QSR, which requires manufacturers to
follow stringent design, testing, control, documentation, record maintenance, including maintenance of complaint and related investigation
files, and other quality assurance controls during the manufacturing process;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">unannounced routine or for-cause device facility inspections
by the FDA, which may include our suppliers’ facilities; and</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">labeling regulations, which prohibit the promotion of products
for uncleared or unapproved (or “off-label”) uses and impose other restrictions relating to promotional activities;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">corrections and removal reporting regulations, which require
that manufacturers report to the FDA field corrections or removals if undertaken to reduce a risk to health posed by a device or to remedy
a violation of the FDCA that may present a risk to health; and</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">post-market surveillance regulations, which apply to certain
Class&nbsp;II or&nbsp;III devices when necessary to protect the public health or to provide additional safety and effectiveness data
for the device.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In addition, under the FDA medical device reporting,
or MDR, regulations, medical device manufacturers are required to report to the FDA information that a device has or may have caused or
contributed to a death or serious injury or has malfunctioned in a way that would likely cause or contribute to death or serious injury
if the malfunction of the device or a similar device of such manufacturer were to recur. The decision to file an MDR involves a judgment
by the manufacturer. If the FDA disagrees with the manufacturer’s determination, the FDA can take enforcement action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The medical device reporting requirements also extend
to health care facilities that use medical devices in providing care to patients, or “device user facilities,” which include
hospitals, ambulatory surgical facilities, nursing homes, outpatient diagnostic facilities, or outpatient treatment facilities, but not
physician offices. A device user facility must report any device-related death to both the FDA and the device manufacturer, or any device-related
serious injury to the manufacturer (or, if the manufacturer is unknown, to the FDA) within 10&nbsp;days of the event. Device user facilities
are not required to report device malfunctions that would likely cause or contribute to death or serious injury if the malfunction were
to recur but may voluntarily report such malfunctions through MedWatch, the FDA’s Safety Information and Adverse Event Reporting
Program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The FDA also has the authority to require the recall
of commercialized medical device products in the event of material deficiencies or defects in design or manufacture. The authority to
require a recall must be based on an FDA finding that there is a reasonable probability that the device would cause serious adverse health
consequences or death. Manufacturers may, under their own initiative, recall a product if any distributed devices fail to meet established
specifications, are otherwise misbranded or adulterated under the FDCA, or if any other material deficiency is found. The FDA requires
that certain classifications of recalls be reported to the FDA within ten working&nbsp;days after the recall is initiated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The failure to comply with applicable regulatory
requirements can result in enforcement action by the FDA, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">warning letters, fines, injunctions or civil penalties;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">recalls, detentions or seizures of products;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">operating restrictions;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">delays in the introduction of products into the market;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">total or partial suspension of production;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">delay or refusal of the FDA or other regulators to grant
510(k)&nbsp;clearance, PMA approvals, or other marketing authorization to new products;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">withdrawals of marketing authorizations; or</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">in the most serious cases, criminal prosecution.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To ensure compliance with regulatory requirements,
medical device manufacturers are subject to market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA, and
these inspections may include the manufacturing facilities of subcontractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Breakthrough Device Designation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The 21<sup>st</sup> Century Cures Act, which was
signed into law on December&nbsp;13, 2016, established and directed FDA to implement the Breakthrough Devices Program. Under the program,
device manufacturers may voluntarily request breakthrough designation for devices that provide for more effective treatment or diagnosis
of life-threatening or irreversibly debilitating human disease or conditions over currently available technology and that meet at least
one of the following criteria:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The device represents breakthrough technology;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">There are no approved or cleared alternatives for the device;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">The device offers significant advantages over existing approved
or cleared alternatives; or</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Availability of the device is in the best interest of patients.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The goal of the Breakthrough Devices Program is
to accelerate the timeline to market for novel devices that will likely provide a benefit to terminally or critically ill patients. A
Breakthrough Device designation offers multiple benefits to the device manufacturer, including priority review of the pre-market submission
for the device, opportunities to interact directly with FDA’s experts throughout the process, and engagement of FDA senior management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In November 2019, we received FDA Breakthrough Device
designation for a prior version of the Vicarious System with a proposed indication for use of ventral hernia repair. The Vicarious System
is considered a Class II medical device. We have had pre-submission meetings with the FDA to align on our regulatory strategy and plan
to file a de novo application with the FDA for ventral hernia procedures as our first indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A preliminary meeting with the FDA was conducted
in December 2021 to discuss with the FDA our decision to make two technology changes to the Vicarious System design that was granted Breakthrough
Device designation in November 2019. Based on these changes, the FDA has determined that the current Vicarious System design that is planned
for the initial limited launch and was submitted to the FDA in the November 2021 FDA pre-submission meeting request is different from
the device that was granted Breakthrough Device designation for the device design filed in November 2019. The FDA stated that the Breakthrough
Device designation remains active for the prior device design granted Breakthrough Device designation in November 2019. In the future,
we may attempt to reincorporate the technologies from such prior device design to leverage the previously granted Breakthrough Device
designation. The process of medical device development is inherently uncertain and there is no guarantee that a Breakthrough Device designation
will be granted to a different device design, and if it were granted, there is no guarantee that such designation will accelerate the
timeline for approval or make it more likely that the Vicarious System will be approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Federal Trade Commission Regulatory Oversight</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our advertising for our products and services is
subject to federal truth-in-advertising laws enforced by the Federal Trade Commission, or the FTC, as well as comparable state consumer
protection laws. Under the Federal Trade Commission Act, or FTC Act, the FTC is empowered, among other things, to (a)&nbsp;prevent unfair
methods of competition and unfair or deceptive acts or practices in or affecting commerce; (b)&nbsp;seek monetary redress and other relief
for conduct injurious to consumers; and (c)&nbsp;gather and compile information and conduct investigations relating to the organization,
business, practices, and management of entities engaged in commerce. The FTC has very broad enforcement authority, and failure to abide
by the substantive requirements of the FTC Act and other consumer protection laws can result in administrative or judicial penalties,
including civil penalties, injunctions affecting the manner in which we would be able to market services or products in the future, or
criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Healthcare Law and Regulation</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">If the Vicarious System or our other product candidates
are approved in the United&nbsp;States, we will have to comply with various U.S.&nbsp;federal and state laws, rules and regulations pertaining
to healthcare fraud and abuse, including anti-kickback laws and physician self-referral laws, rules and regulations. Violations of the
fraud and abuse laws are punishable by criminal and civil sanctions, including, in some instances, exclusion from participation in federal
and state healthcare programs, including Medicare and Medicaid. These laws include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the federal Anti-Kickback Statute prohibits, among other
things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash
or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the federal False Claims Act imposes civil penalties, and
provides for civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented,
to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease or conceal
an obligation to pay money to the federal government;</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the federal Health Insurance Portability and Accountability
Act&nbsp;of&nbsp;1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program
or making false statements relating to healthcare matters;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act and its implementing regulations, also imposes obligations, including mandatory contractual terms, with
respect to safeguarding the privacy, security and transmission of individually identifiable health information;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the federal false statements statute prohibits knowingly
and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery
of or payment for healthcare benefits, items or services;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the federal transparency requirements under the Physician
Payments Sunshine Act require manufacturers of FDA-approved drugs, devices, biologics and medical supplies covered by Medicare or Medicaid
to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of
value to physicians, teaching hospitals, and certain advanced non-physician health care practitioners and physician ownership and investment
interests; and</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">analogous state and foreign laws and regulations, such as
state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services
reimbursed by nongovernmental third-party payors, including private insurers.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Some state laws require pharmaceutical or medical
device companies to comply with the relevant industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated
by the federal government in addition to requiring drug and device manufacturers to report information related to payments to physicians
and other health care providers or marketing expenditures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">State and foreign laws also govern the privacy and
security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted
by HIPAA, thus complicating compliance efforts. We also may be subject to, or may in the future become subject to, U.S.&nbsp;federal and
state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information.
Our actual or perceived failure to comply with such obligations could result in liability or reputational harm and could harm our business.
Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base and thereby decrease our future
revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Third-Party Coverage and Reimbursement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the United&nbsp;States, third-party payors, including
government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations, are responsible for
hospital and surgeon reimbursement for covered surgical procedures. Third-party payors generally reimburse hospitals and physicians for
surgery when the procedure is considered medically necessary. The Centers for Medicare and Medicaid Services, or CMS, manages the Medicare
program and administers the Medicaid program in conjunction with applicable state governments. Many commercial health insurers model their
reimbursement methodologies after the Medicare program. As the single largest payor, the Medicare program has a significant impact on
other third-party payors’ payment systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Generally, reimbursement for professional services
performed at a facility by physicians is reported under billing codes issued by the American Medical Association, or AMA, known as Current
Procedural Terminology, or CPT, codes. Physician reimbursement under Medicare generally is based on a fee schedule and determined by the
relative value of the professional service rendered. In addition, CMS and the National Center for Health Statistics are jointly responsible
for overseeing changes and modifications to billing codes used by hospitals to report inpatient procedures, known as ICD-10-PCS codes.
Under the Medicare program, CMS generally reimburses hospitals for services provided during an inpatient stay based on a prospective payment
system that is determined by a classification system known as Medicare-Severity Diagnostic Related Groupings, or MS-DRGs. MS-DRGs are
assigned using a number of factors, including the principal diagnosis, major procedures, discharged status, patient age, and complicating
secondary diagnoses, among other things. Hospital outpatient services, reported by CPT codes, are assigned to clinically relevant Ambulatory
Payment Classifications used to determine the payment amount for services provided.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Since October&nbsp;1, 2015, a new family of ICD-10-PCS
codes can be used, in conjunction with other applicable procedure codes, to describe various robotic-assisted procedures. An inpatient
surgical procedure, completed with or without robotic assistance, continues to be assigned to the clinically relevant MS-DRG.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Third-party payors carefully review and increasingly
challenge the prices charged for medical products and surgical services. Reimbursement rates from commercial health insurers vary depending
on the procedure performed, the specific payor’s reimbursement policies, contract terms, and other factors. Because both hospitals
and physicians may receive the same reimbursement for a surgical procedure, whether it is performed with robotic assistance or not and
regardless of actual costs incurred in furnishing the patient care, including for the specific medical products or supplies used during
that procedure, hospitals and physicians may decide not to use our products if reimbursement amounts are insufficient to cover any additional
costs incurred when purchasing and using our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">For procedures that would involve assistance from
our robotic-assisted surgical system, U.S.&nbsp;health care institutions typically bill various third-party payors, such as government
health programs (e.g., Medicare and Medicaid) and commercial health insurance plans, for the primary surgical procedure only. If our robotic-assisted
surgical system receives marketing authorization from the FDA, coverage and reimbursement by third-party payors will generally be determined
by the medical necessity of the primary surgical procedure. Government health programs and other third-party payors may also consider
additional factors when determining coverage and reimbursement, including the designation of the surgical procedure as a covered benefit,
the appropriateness of the procedure for the specific patient, guidelines for the procedure established by the relevant professional college
or medical society, and a payor determination that the procedure is neither experimental nor investigational. We believe that the procedures
we intend to pursue as indications for use for our robotic-assisted surgical system are established surgical procedures that are generally
already reimbursable by government health programs, commercial health insurers, and managed care organizations for appropriately selected
patients. If hospitals do not obtain sufficient reimbursement from third-party payors for procedures performed with our products, or if
government and commercial payors’ policies do not cover surgical procedures performed using our products, we may not be able to
generate the revenues necessary to support our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In the United&nbsp;States, there have been, and
continue to be, a number of legislative initiatives to contain healthcare costs. In March&nbsp;2010, the Patient Protection and Affordable
Care Act, as amended by the Health Care and Education Reconciliation Act (collectively, the “ACA”), was enacted. The ACA made
changes that have significantly impacted healthcare providers, insurers, and manufacturers of pharmaceuticals and medical devices. For
example, the ACA included a number of provisions designed to generate the revenues necessary to fund health insurance coverage expansion,
including, but not limited to, fees or taxes on certain health-related industries, including medical device manufacturers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>
</div><p style="margin: 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">There remain judicial and Congressional challenges
to certain aspects of the ACA, and as a result certain of its sections have not been fully implemented or effectively repealed. In particular,
in December of 2018, a Texas U.S.&nbsp;District Court Judge ruled that the ACA is unconstitutional in its entirety because the individual
mandate was repealed by Congress as part of the Tax Cuts and Jobs Act, effective January&nbsp;1, 2019. In December&nbsp;2019, the Fifth
Circuit Court of Appeals upheld the district court’s ruling that the individual mandate in the ACA was unconstitutional but remanded
the case to the district court to determine whether other reforms enacted as part of the ACA but not specifically related to the individual
mandate or health insurance could be severed from the rest of the ACA so as not to have the law declared invalid in its entirety. On March&nbsp;2,
2020, the U.S.&nbsp;Supreme Court granted the petitions for writs of certiorari to review this case and allocated one hour for oral arguments,
which occurred on November&nbsp;10, 2020. On February 10, 2021, the Department of Justice sent a letter to the U.S. Supreme Court that
stated the new administration believes the individual mandate and its tax penalty are constitutional, and if the Court determines that
they are not, the provision can be severed from the remainder of the act. With this letter, the Biden administration reversed the Trump
administration position that was presented to the Court. The Trump administration had claimed that the tax provision is unconstitutional
and could not be separated from the ACA, making the entire ACA unconstitutional as a result. The U.S. Supreme Court held in a 7–2
opinion that the states and individuals that brought the lawsuit challenging the ACA’s individual mandate do not have standing to
challenge the law. The U.S. Supreme Court did not reach the merits of the challenge, but the decision ends the case. It is unclear how
potential litigation and other efforts to repeal and replace the ACA will affect the implementation of that law, the pharmaceutical and
medical device industries more generally, and our business. Additionally, the 2020 federal spending package permanently eliminated, effective
January&nbsp;1, 2020, the ACA-mandated “Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax
and, effective January&nbsp;1, 2021, also eliminates the health insurer tax. In addition, CMS published a final rule that would give states
greater flexibility, effective January&nbsp;1, 2020, in setting benchmarks for insurers in the individual and small group marketplaces,
which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces. We
continue to evaluate the potential impact of the ACA and its possible repeal or replacement on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In addition, other legislative changes have been
proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to
2% per fiscal year pursuant to the Budget Control Act&nbsp;of&nbsp;2011, which began in 2013 and will remain in effect through 2030 unless
additional Congressional action is taken. However, the Medicare sequester reductions under the Budget Control Act&nbsp;of&nbsp;2011 was
suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the COVID-19 pandemic, pursuant to provisions of the Coronavirus
Aid, Relief, and Economic Security Act, or the CARES Act, which also extended the sequester by one year, through 2030, in order to offset
the added expense of the 2020 cancellation. The 2021 Consolidated Appropriations Act was subsequently signed into law on December&nbsp;27,
2020 and extends the CARES Act suspension period to March&nbsp;31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">On January&nbsp;2, 2013, the American Taxpayer Relief
Act&nbsp;of&nbsp;2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals, imaging centers, and cancer treatment centers. The Medicare Access and CHIP Reauthorization Act&nbsp;of&nbsp;2015,
enacted on April&nbsp;16, 2015 (“MACRA”), repealed the formula by which Medicare made annual payment adjustments to physicians
and replaced the former formula with fixed annual updates and a new system of incentive payments that began in 2019 and are based on various
performance measures and physicians’ participation in alternative payment models, such as accountable care organizations. Individual
states in the U.S.&nbsp;have also become increasingly aggressive in passing legislation and implementing regulations designed to control
medical product pricing, including price or patient reimbursement constraints and discounts, and require marketing cost disclosure and
transparency measures. Most recently, the Biden Administration has indicated that lowering healthcare costs and ensuring equitable patient
access to medical care is a priority, but we do not yet know what steps the administration will take or whether such steps will be successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We cannot predict the likelihood, nature or extent
of government regulation that may arise from future legislation or administrative or executive action, either in the United&nbsp;States
or abroad. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit
the amounts that federal and state governments will pay for health care products and services. Moreover, if we are slow or unable to adapt
to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance,
our medical devices may lose any marketing authorization that may have been obtained and we may not achieve or sustain profitability,
which would adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Human Capital</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We take pride in our work and value unique backgrounds
and experiences. We aim to be inclusive, so that everyone can be their true, authentic self at work every day. To attract and retain top
talent, we offer strong compensation and benefits packages that are evolving to meet the changing needs of our employees. Compensation
and benefits are paired with talent development programs to retain and develop our team.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of March 1, 2022, we had </span>165 <span style="font-family: Times New Roman, Times, Serif">employees, </span>89 <span style="font-family: Times New Roman, Times, Serif">of
whom were engaged directly in research, development, regulatory and clinical activities, </span>31 <span style="font-family: Times New Roman, Times, Serif">in
manufacturing and quality assurance and </span>45 <span style="font-family: Times New Roman, Times, Serif">in marketing, sales, and administrative
activities. None of our employee are covered by collective bargaining agreements, and we believe that our relationship with our employees
is good.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Safety and Wellness</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The safety and wellness of our employees is a top
priority for the organization, which we will continue to invest in. In light of COVID-19, we have put in place conservative safety protocols
to keep our employees and anyone entering our facility safe, in addition to offering work from home arrangements. To protect employees
and guests, our efforts include providing personal protective equipment (“PPE”), instituting mandatory screening before accessing
buildings, and maximizing workspaces. In addition, we have invested heavily in overall employee wellness, and will continue to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Physical, mental, and financial wellness are front
and center of our benefits. We provide access to external experts who can assist employees and their families who are going through challenging
times. Additionally, we offer multiple incentives and rewards to encourage healthy behaviors. Financially, we provide access to a financial
advisory service, access to an online financial wellness assessment and education service, free webinars, and offers a company 401(k)&nbsp;match.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legal Proceedings</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As of March&nbsp;1, 2022, we were not a party to
any material legal proceedings. From time to time, we may become involved in legal proceedings arising in the ordinary course of our business.
Regardless of the outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources,
negative publicity and reputational harm and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Facilities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our principal executive offices are currently located
at 78 Fourth Avenue, Waltham, Massachusetts 02451, consisting of approximately 42,000 square feet. On October 14, 2021, we entered into
a lease amendment pursuant to which we agreed to lease additional space consisting of approximately 30,000 square feet located at 62 Fourth
Avenue Waltham, MA 02451. Pursuant to the lease amendment, we also extended the term of the original lease for an additional period of
three years and one month. Both leased spaces will expire conterminously on March 31, 2032, with an option to renew for an additional
five years until March 31, 2037.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Information Available on the Internet</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our internet address is <i>https://www.vicarioussurgical.com</i>, to
which we regularly post copies of our press releases as well as additional information about us. We also maintain an Investor Relations
website as a routine channel for distribution of important information, including news releases, presentations, and financial statements
(<i>https://investor.vicarioussurgical.com</i>). We intend to use our Investor Relations website as a means of complying with our disclosure
obligations under Regulation FD. Accordingly, investors should monitor our Investor Relations website in addition to press releases, Securities
and Exchange Commission (the “SEC”) filings, and public conference calls and webcasts. Our annual reports on Form&nbsp;10-K,
quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K, and all amendments to those reports, will be available to you free
of charge through the Investor Relations section of our website as soon as reasonably practicable after such materials have been electronically
filed with, or furnished to, the SEC. The SEC maintains an internet site (<i>http://www.sec.gov</i>) that contains reports, proxy and
information statements, and other information regarding issuers that file electronically with the SEC. We include our web site address
in this Annual Report on Form 10-K only as an inactive textual reference. Information contained in our website does not constitute a part
of this report or our other filings with the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 1A. RISK FACTORS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Careful consideration should be given to the following risk factors,
in addition to the other information set forth in this Annual Report on Form 10-K, including the section of titled “Management’s
Discussion and Analysis of Financial Condition and Results of Operations” and our consolidated financial statements and related
notes, and in other documents that we file with the SEC, in evaluating our company and our business. Investing in our securities involves
a high degree of risk. If any of the events described in the following risk factors actually occur, our business, financial condition,
results of operations and future growth prospects could be materially and adversely affected and the trading price of our securities could
decline. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that
are described below and elsewhere in this Annual Report on Form 10-K.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Unless the context otherwise requires, references in this section
to “we,” “us,” “our” and the “Company” refer to Vicarious Surgical Inc. and its subsidiaries
following the Business Combination, or to Legacy Vicarious or D8 prior to the Business Combination, as the case may be.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Financial Condition and Capital Requirements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have a limited operating history on which to assess the prospects
for our business, we have not generated any revenue from sales of the Vicarious System, and have incurred losses since inception. We anticipate
that we will continue to incur significant losses for at least the next several years as we develop and commercializes the Vicarious System
for ventral hernia repair and future indications.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since inception, we have devoted substantially all of our financial
resources to developing our surgical robot. We have financed our operations primarily through the issuance of equity securities. We have
not generated revenue from the sale of the Vicarious System to date and have incurred significant losses. The amount of our future net
losses will depend, in part, on future sales and on-going development of the Vicarious System, the rate of our future expenditures and
our ability to obtain funding through the issuance of our securities, strategic collaborations or grants. We expect to continue to incur
significant losses for at least the next several years as we commercialize the Vicarious System for ventral hernia repair and seeks to
develop and commercialize new surgical applications for the Vicarious System, such as gynecological, urological or other general surgical
applications. We anticipate that our expenses will increase substantially if and as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">continue to build our sales, marketing and distribution infrastructure to commercialize our Vicarious System for ventral hernia repair;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">continue to develop the Vicarious System;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">seek to identify, assess, acquire, license and/or develop other products and technologies or components thereof and subsequent generations of our current products and technologies;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">seek to maintain, protect and expand our intellectual property portfolio;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">seek to attract and retain skilled personnel; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">support our operations as a public company.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our ability to generate future revenue from the Vicarious System sales
depends heavily on our success in many areas, including but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">launching and commercializing current and future uses for the Vicarious System, either directly or in conjunction with one or more collaborators or distributors;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">obtaining and maintaining regulatory authorization with respect to each application for the Vicarious System and maintaining regulatory compliance throughout relevant jurisdictions;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">maintaining clinical and economical value for end-users and customers in changing environments;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">addressing any competing technological and market developments;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">establishing and maintaining distribution relationships with third-parties that can provide adequate (in amount and quality) infrastructure to support market demand for the Vicarious System; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have incurred significant losses since inception. As such,
you cannot rely upon our historical operating performance to make an investment or voting decision regarding us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Since inception, we have engaged in research and development activities.
We have financed our operations primarily through the issuance of equity securities, and have incurred net losses of $35.2 million and
$12.9 million in the years ended December 31, 2021 and 2020, respectively. Our accumulated deficit as of December 31, 2021 was $66.8 million.
We do not know whether or when we will become profitable. Our ability to generate revenue and achieve profitability depends upon our ability
to accelerate the commercialization of the Vicarious System in line with the demand from new partnerships and our aggressive business
strategy. We may be unable to achieve any or all of these goals.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may need to raise additional funding to develop and commercialize
the Vicarious System and to expand our research and development efforts. This additional financing may not be available on acceptable
terms, or at all. Failure to obtain this necessary capital when needed may force us to delay, limit or terminate our product commercialization
or development efforts or other operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our operations have consumed substantial amounts of cash since inception.
We expect to expend substantial additional amounts to commercialize the Vicarious System for ventral hernia repair and to develop new
surgical applications for the Vicarious System. We expect to use the funds received in connection with the Business Combination to scale
our operations, develop and commercialize the Vicarious System for ventral hernia repair, develop new surgical applications for the Vicarious
System, such as gynecological, urological or other general surgical applications, expand internationally, and for working capital and
general corporate purposes. We will require additional capital to develop and commercialize the Vicarious System for abdominal surgeries
and to develop the Vicarious System for new surgical applications. In addition, our operating plans may change as a result of many factors
that may currently be unknown to us, and we may need to seek additional funds sooner than planned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any future financing may adversely affect the holdings or the
rights of our stockholders and the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance,
may cause the market price of our common stock to decline. The incurrence of indebtedness could result in increased fixed payment obligations,
and we may be required to agree to certain restrictive covenants, such as limitations on our ability to incur additional debt, limitations
on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our
ability to conduct our business. We could also be required to seek funds through arrangements with collaborative partners or otherwise
at an earlier stage than otherwise would be desirable, and we may be required to relinquish rights to some of our technologies or otherwise
agree to terms that are unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.
In addition, raising additional capital through the issuance of equity or convertible debt securities would cause dilution to holders
of our equity securities, and may affect the rights of then-existing holders of our equity securities. Even if we believe that we have
sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or if we
have specific strategic considerations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Business and Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are a development stage company with a limited history of
operations and no products with marketing authorization in any jurisdiction, and we cannot assure you that we will ever have a commercialized
product.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are a development stage medical device company with a limited operating
history, and we currently do not have any products authorized for commercialization in any country or jurisdiction or any source of revenue.
We have been engaged in research and product development since our inception in 2014 and have invested all of our time and resources in
developing our technology and the Vicarious System, which we intend to commercialize initially for ventral hernia repair, followed by
subsequent indications. The future success of our business will depend on our ability to obtain regulatory authorization to market our
Vicarious System, drive adoption, successfully introduce new surgical applications for the Vicarious System, establish our sales force
and distribution network, and control costs, all of which we may be unable to do. We have a limited history of operations upon which you
can evaluate our business and our operating expenses are increasing. Our lack of a significant operating history also limits your ability
to make a comparative evaluation of us, the Vicarious System and our prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we do not successfully manage the development and launch of
the Vicarious System, we will not meet the long term forecasts we presented to D8 Holdings and our business, operating and financial results
and condition could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We aim to launch the Vicarious System initially for use in ventral
hernia repair, but to later expand the product to other abdominal surgical applications, including gynecological, urological and general
surgery uses. We face risks associated with developing and launching the Vicarious System for the first indication specific use and other
surgical applications. We are in the process of developing the Vicarious System, and will need to complete beta testing, verification
and validation prior to filing for FDA clearance, which is expected to occur in 2023. If we encounter development or manufacturing challenges
or discovers errors during our development cycle, the launch dates of the initial and new surgical applications may be delayed, which
will cause delays in our ability to achieve our forecasted results. The expenses or losses associated with unsuccessful product development
or launch activities or lack of market acceptance of the Vicarious System could adversely affect our business or financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The market for the Vicarious System and the use of robotic-assisted
surgical technology is rapidly evolving, and increasingly competitive, as the healthcare industry is undergoing significant structural
change, which makes it difficult to forecast demand for our products and technologies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market for the Vicarious System and the use of robotic-assisted
surgical technology is rapidly evolving, and it is uncertain whether we will achieve and sustain high levels of demand and market adoption.
Our future financial performance will depend in part on growth in this market and on our ability to adapt to the changing demands of customers.
It is difficult to predict the future growth rate and size of our target market. As a result, the addressable market projections provided
to D8 Holdings for purposes of considering the Business Combination may not be achieved. Negative publicity concerning the Vicarious System
could limit market acceptance of the Vicarious System. If our customers do not perceive the benefits of the Vicarious System, when or
if it is authorized for marketing, or if the Vicarious System does not attract new customers, then our market may not develop at all,
or it may develop more slowly than we expect. Our success will depend to a substantial extent on the willingness of healthcare organizations
to increase their use of our technology and our ability to demonstrate the value of our technology relative to competing products to existing
and potential customers. If healthcare organizations do not recognize or acknowledge the benefits of the Vicarious System or if we are
unable to reduce healthcare costs or drive positive health outcomes, then the market for our solutions might not develop at all, or it
might develop more slowly than we expect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Because our markets are highly competitive, customers may choose
to purchase our competitors’ products or services or may not accept the Vicarious System for ventral hernia repair, which would
result in a reduced ability to generate future revenue.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Robotic-assisted surgery using the Vicarious System is a technology
that competes with established and emerging treatment options in both disease management and reconstructive medical procedures. These
competitive treatment options include conventional open surgery and minimally invasive approaches. Some of these procedures are widely
accepted in the medical community and, in many cases, have a long history of use. Studies could be published that show that other treatment
options are more beneficial and/or cost-effective than robotic-assisted surgery. We cannot be certain that physicians will use our products
to replace or supplement established treatments or that our products will be competitive with current or future technologies, when or
if those products are authorized for marketing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, we face or expect to face competition from companies
that develop or have developed robotic-assisted surgical systems and products. Companies have introduced products in the field of robotic
surgery or have made explicit statements about their efforts to enter the field including, but not limited to, the following companies:
Intuitive Surgical, Inc.; Johnson &amp; Johnson (including their wholly-owned subsidiaries Ethicon Endo-Surgery, Inc., Auris Health, Inc.
and Verb Surgical Inc.); Medtronic plc (including their wholly-owned subsidiary Covidien LP); Virtual Incision Corporation; Titan Medical
Inc.; CMR Surgical Ltd.; and Stryker Corporation. Other companies with substantial experience in industrial robotics could potentially
expand into the field of surgical robotics and become competitors. Our ability to generate future revenue may be reduced due to pricing
pressure if our competitors develop and market products that are more effective or less expensive than our future commercial products.
If we are unable to compete successfully, our ability to generate future revenue will suffer, which could have a material adverse effect
on our business, financial condition, result of operations, or cash flows.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our success depends upon market acceptance of the Vicarious System
for ventral hernia repair, our ability to develop and commercialize the Vicarious System for ventral hernia repair and additional surgical
applications and generate revenues, and our ability to identify new markets for our technology.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have developed and are engaged in the development of the Vicarious
System initially for ventral hernia repair. Achieving physician, patient, and third-party payor acceptance of robotic-assisted surgery
as a preferred method of performing surgery is crucial to our success. Our success will depend on the acceptance of the Vicarious System
in the United States and global health care markets, when or if it is authorized for marketing in those jurisdictions. We are faced with
the risk that the marketplace will not be receptive to the Vicarious System over competing products, including traditional and existing
robotic-assisted surgical procedures used in hospitals and ambulatory surgical centers, or ASCs, and that we will be unable to compete
effectively. Factors that could affect our ability to successfully commercialize the Vicarious System for ventral hernia repair and to
commercialize any potential future products and technologies include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">challenges of developing or acquiring externally-developed technology solutions that are adequate and competitive in meeting the requirements of next-generation design challenges; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">dependence upon hospitals, ASCs, surgeons and other healthcare practitioners’ acceptance of the Vicarious System.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if we can prove the safety and effectiveness of the Vicarious
System and they receive marketing authorization, hospitals, ASCs, or surgeons may elect not to use it. In addition, hospitals, ASCs and
surgeons may be slow to adopt the Vicarious System because of the perceived liability risks arising from the use of new products and the
uncertainty of reimbursement from third-party payors, particularly in light of ongoing healthcare reform initiatives and the evolving
healthcare environment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Broad use of the Vicarious System will require training of surgical
teams. We expect that there will be a learning process involved for surgical teams to become proficient in the use of the Vicarious System.
Market acceptance could be delayed due to the time required to complete this training. We may not be able to rapidly train surgical teams
in numbers sufficient to generate adequate demand for our products. We cannot assure investors that the Vicarious System or any future
products and technologies will gain broad market acceptance. If the market for the Vicarious System or any future products and technologies
fail to develop or develops more slowly than expected, or do not achieve or sustain market acceptance, our business and operating results
would be materially and adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Surgeons, hospitals, ASCs and distributors may have existing
relationships with other medical device companies that make it difficult for us to establish new relationships with them, and as a result,
we may not be able to sell and market the Vicarious System effectively.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe that to sell and market the Vicarious System effectively,
when or if the product receives marketing authorization, we must establish relationships with key surgeons, hospitals and ASCs in the
field of abdominal surgery. Many of these key surgeons, hospitals and ASCs already have long-standing relationships with large, well-known
companies that dominate the medical device industry through collaborative research programs and other relationships. Because of these
existing relationships, some of which may be contractually enforced, surgeons, hospitals and ASCs may be reluctant to adopt the Vicarious
System, particularly if it competes with or has the potential to compete with products and technologies supported by these existing relationships
or through their own collaborative research programs. Even if these surgeons, hospitals and ASCs purchase the Vicarious System, they may
be unwilling to enter into collaborative relationships with us to promote joint marketing programs or to provide us with clinical and
financial data.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Any failure in our efforts to train surgeons, hospital or ASC
staff could result in lower than expected product sales and potential liabilities.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A critical component of our future sales and marketing efforts is the
training of a sufficient number of surgeons and hospital staff to properly use the Vicarious System, when or if it is authorized for marketing.
We rely on surgeons and hospital staff to devote adequate time to learn to use our future products and technologies. Convincing surgeons,
hospital and ASC staff to dedicate the time and resources necessary for adequate training in the use of the Vicarious System will be challenging,
and we cannot assure you we will be successful in these efforts. If surgeons, hospital or ASC staff are not properly trained, they may
misuse or ineffectively use the Vicarious System. If nurses or other members of the hospital or ASC staff are not adequately trained to
assist in using the Vicarious System, surgeons may be unable to use the Vicarious System. Insufficient training may result in unsatisfactory
patient outcomes, patient injury and related liability or negative publicity, which could have an adverse effect on our product sales
or create substantial potential liabilities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Robotic-assisted surgical device development is costly and involves
continual technological change, which may render the Vicarious System obsolete.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The market for robotic-assisted surgical devices is characterized by
rapid technological change, medical advances and evolving industry standards. Any one of these factors could reduce the demand for the
Vicarious System, when or if it is authorized for marketing, or require substantial resources and expenditures for research, design and
development to avoid technological or market obsolescence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success will depend on our ability to enhance our current technology,
services and systems and develop or acquire and market new technologies to keep pace with technological developments and evolving industry
standards, while responding to changes in customer needs. A failure to adequately develop or acquire device enhancements or new devices
that will address changing technologies and customer requirements adequately, or to introduce such devices on a timely basis, may have
a material adverse effect on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We might have insufficient financial resources to improve existing
devices, advance technologies and develop new devices at competitive prices. Technological advances by one or more competitors or future
entrants into the field may result in the Vicarious System becoming non-competitive or obsolete, which may decrease revenues and profits
and adversely affect our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may encounter significant competition across our existing and future
planned products and technologies and in each market in which we sell or plan to sell the Vicarious System from various companies, many
of which have greater financial and marketing resources than us. Our primary competitors include Intuitive Surgical, Johnson &amp; Johnson
(including their wholly-owned subsidiaries Ethicon Endo-Surgery, Inc., Auris Health, Inc. and Verb Surgical Inc.), and Medtronic, which
are currently the top manufacturers of robotic-assisted surgical devices.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, our primary competitors, which are well-established medical
device manufacturers with significant resources, may engage in aggressive marketing tactics. Competitors may also possess the ability
to commercialize additional lines of products, bundle products or offer higher discounts and incentives to customers in order to gain
a competitive advantage. If the prices of competing products are lowered as a result, we may not be able to compete effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are highly dependent upon the continued contributions of our
co-founder, Chief Executive Officer and President, Adam Sachs, our co-founder and Chief Technology Officer, Sammy Khalifa. The loss of
their services could harm our business, and if we are unable to attract, recruit, train, retain, motivate and integrate key personnel,
we may not achieve our goals.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our future success depends on our ability to attract, recruit, train,
retain, motivate and integrate key personnel, including our co-founder, Chief Executive Officer and President, Adam Sachs, our co-founder
and Chief Technology Officer, Sammy Khalifa, as well as our recently expanded management team and our research and development, manufacturing,
sales and marketing personnel. Our future business and results of operations depend in significant part upon the continued contributions
of Messrs. Sachs and Khalifa. If we were to lose their services or if they fail to perform in their current positions, or if we are not
able to attract and retain skilled employees in addition to Messrs. Sachs and Khalifa, this could adversely affect the development and
implementation of our business plan and substantially harm our business. Competition for qualified personnel is intense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we rely upon technical and scientific employees or third-party
contractors to effectively establish, manage and grow our business. Consequently, we believe that our future viability will depend largely
on our ability to attract and retain highly skilled robotics engineers, artificial intelligence engineers, software engineers, hardware
engineers and optical engineers, as well as other managerial, sales, scientific and technical personnel. In order to effectively recruit
these personnel, we may need to pay higher compensation or fees to our employees or consultants than we currently expect, and such higher
compensation payments may have a negative effect on our operating results. Competition for experienced, high-quality personnel is intense,
and we cannot assure investors that we will be able to recruit and retain such personnel. Our growth depends, in particular, on attracting
and retaining highly-trained sales personnel with the necessary technical background and ability to understand the Vicarious System at
a technical level to effectively identify and sell to potential new customers and develop new uses for the Vicarious System. Because of
the technical and complex nature of the Vicarious System and the dynamic market in which we compete in, any failure to attract, recruit,
train, retain, motivate and integrate qualified personnel could materially delay development of the Vicarious System and harm our operating
results and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We will need to expand our organization, and we may experience
difficulties in recruiting needed additional employees and consultants, which could disrupt our operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As our development and commercialization plans and strategies develop,
we will need additional managerial, operational, sales, marketing, financial, legal and other resources. The competition for qualified
personnel in the medical device industry is intense. Due to this intense competition, we may be unable to attract and retain the qualified
personnel necessary for the development of our business or to recruit suitable replacement personnel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our management may need to divert a disproportionate amount of our
attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not
be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes,
loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require
significant capital expenditures and may divert financial resources from other projects, such as the development of additional surgical
applications for the Vicarious System. If our management is unable to effectively manage our growth, our expenses may increase more than
expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our
future financial performance and our ability to commercialize the Vicarious System and compete effectively will depend, in part, on our
ability to effectively manage any future growth.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have no experience in marketing and selling the Vicarious
System and if we are unable to successfully commercialize the Vicarious System, our business and operating results will be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have no experience marketing and selling the Vicarious System, should
we receive marketing authorization from the FDA and other regulatory authorities. We currently intend to sell the Vicarious System to
hospitals and ASCs. Future sales of the Vicarious System will depend in large part on our ability to effectively market and sell the Vicarious
System, successfully manage and expand our sales force, and increase the scope of our marketing efforts. We may also enter into distribution
arrangements in the future. Because we have limited experience in marketing and selling the Vicarious System, our ability to forecast
demand, the infrastructure required to support such demand and the sales cycle to customers is unproven. If we do not build an efficient
and effective marketing and sales force, our business and operating results will be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We expect to generate an increasing portion of our revenue internationally
in the future and may become subject to various additional risks relating to our international activities, which could adversely affect
our business, operating results and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We intend to generate revenues from international sources as we expand
our sales and marketing opportunities internationally. We have limited experience operating internationally and engaging in international
business involves a number of difficulties and risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the challenges associated with building local brand awareness, obtaining local key opinion leader support and clinical support, implementing reimbursement strategies and building local marketing and sales teams;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">required compliance with foreign regulatory requirements and laws, including regulations and laws relating to patient data and medical devices;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">trade relations among the United States and those foreign countries in which our future customers, distributors, manufacturers and suppliers have operations, including protectionist measures such as tariffs and import or export licensing requirements, whether imposed by the United States or such foreign countries;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">difficulties and costs of staffing and managing foreign operations;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">difficulties protecting, procuring or enforcing intellectual property rights internationally;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">required compliance with anti-bribery laws, such as the U.S. Foreign Corrupt Practices Act, data privacy requirements, labor laws and anti-competition regulations;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">laws and business practices that may favor local companies;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">longer payment cycles and difficulties in enforcing agreements and collecting receivables through certain foreign legal systems;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">political and economic instability and war or other military conflict, including the ongoing conflict occurring in Ukraine, which could have a material adverse impact on our sales in Europe and elsewhere; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">potentially adverse tax consequences, tariffs, customs charges, bureaucratic requirements and other trade barriers.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We dedicate significant resources to our international operations and
are unable to manage these risks effectively, our business, operating results and financial condition may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we experience decreasing prices for our products and technologies
and are unable to reduce our expenses, including the per unit cost of producing our products and technologies, there may be a material
adverse effect on our business, results of operations, financial condition and cash flows.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may experience decreasing prices for the Vicarious System upon regulatory
authorization due to pricing pressure from managed care organizations and other third-party payors and suppliers, increased market power
of our payors as the medical device industry consolidates, and increased competition among suppliers, including manufacturing services
providers. If the prices for the Vicarious System decrease and we are unable to reduce our expenses, including the cost of sourcing materials,
logistics and the cost to manufacture the Vicarious System, our business, results of operations, financial condition and cash flows may
be adversely affected. To the extent that we engage in sales to large hospital networks, we may be subject to procurement discounts, which
could have a negative impact on the prices of our products and technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may experience manufacturing problems or delays that could
limit the growth of our revenue or increase our losses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may encounter unforeseen situations that would result in delays
or shortfalls in our production as well as delays or shortfalls caused by our outsourced manufacturing suppliers and by other third-party
suppliers who manufacture components for the Vicarious System. The FDA has established comprehensive and prescriptive regulations for
manufacturers of finished medical devices and device components, which require them to establish and maintain processes and procedures
to adequately control device manufacturing operations and environmental conditions that could adversely affect product quality and impact
patient safety. Clean room standards are an example of these requirements. Failure of us or our third-party component manufacturers or
suppliers to comply with applicable standards and regulatory requirements could delay the production of the Vicarious System.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We or our third-party component manufacturers or suppliers may encounter
difficulties in scaling up or maintaining production relating to the Vicarious System, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">problems involving production yields;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">quality control and assurance;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">component or material supply shortages;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">import or export restrictions on components, materials or technology;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">shortages of qualified personnel; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">compliance with state and federal regulations.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we are unable to keep up with demand for the Vicarious System, our
future revenue could be impaired, market acceptance for the Vicarious System could be adversely affected and our customers might instead
purchase our competitors’ products. Our inability to successfully manufacture the Vicarious System would have a material adverse
effect on our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We rely on limited or sole suppliers for some of the materials
and components used in the Vicarious System, and may not be able to find replacements or immediately transition to alternative suppliers,
which could require us to redesign aspects of the Vicarious System and which would have a material adverse effect on our business, financial
condition, results of operations and reputation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on limited or sole suppliers for certain materials and components
that are used in the Vicarious System. While we periodically forecast our needs for such materials and enters into standard purchase orders
with them, we do not have long-term contracts with some of these suppliers. If we were to lose such suppliers, or if such suppliers were
unable to fulfill our orders or to meet our manufacturing specifications, there can be no assurance that we will be able to identify or
enter into agreements with alternative suppliers on a timely basis or on acceptable terms, if at all. Furthermore, if we are required
to change the manufacturer of a key component of the Vicarious System, we would be required to verify that the new manufacturer maintains
facilities and procedures that comply with quality standards and with all applicable regulations and guidelines, and we may be required
to redesign aspects of the Vicarious System to accommodate the new component, which would result in significant delays and additional
costs. An interruption in our operations could occur if we encounter delays or difficulties in redesigning the Vicarious System, or securing
these materials and components, or if the quality of the materials and components supplied do not meet our requirements, or if we cannot
then obtain an acceptable substitute. The time and effort required to redesign the Vicarious System, or to qualify a new supplier and
ensure that the new materials and components provide the same or better quality results could result in significant additional costs.
Any such interruption could significantly affect our business, financial condition, results of operations and reputation. While we believe
that our supplies of components and materials are currently sufficient for us to continue the development of our products and technologies
without a disruption to our business, in the event that we must replace one of our suppliers, there can be no assurance that we can maintain
this level of inventory in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Acquisitions, joint ventures or strategic alliances could disrupt
our business, cause dilution to our stockholders and otherwise harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may acquire other businesses or products and technologies, as well
as pursue strategic alliances, joint ventures, technology licenses or investments in complementary businesses. We have not engaged in
any of these strategic transactions to date, and our ability to do so successfully is unproven. Any of these strategic transactions could
be material to our financial condition and operating results and expose us to many risks, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">disruption in our relationships with customers, distributors, manufacturers or suppliers as a result of such a transaction;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">unanticipated liabilities related to acquired companies;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">difficulties integrating acquired personnel, technologies and operations into our existing business;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">diversion of management’s time and focus away from operating our business to acquisition integration challenges;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">increases in our expenses and reductions in our cash available for operations and other uses; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">possible write-offs or impairment charges relating to acquired businesses.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foreign acquisitions involve unique risks in addition to those mentioned
above, including those related to the integration of operations across different cultures and languages, currency risks and the particular
economic, political and regulatory risks associated with specific countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the anticipated benefit of any acquisition may not materialize.
Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent
liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the
number, timing or size of future joint ventures, strategic alliances or acquisitions, if any, or the effect that any such transactions
might have on our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we do not successfully develop, optimize and operate our sales
and distribution channels or we do not effectively expand and update infrastructure, our operating results and customer experience may
be negatively impacted.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we do not adequately predict market demand or otherwise develop,
optimize and operate our sales and distribution channels successfully, it could result in excess or insufficient inventory or fulfillment
capacity, increased costs, or immediate shortages in product or component supply, or harm our business in other ways. In addition, if
we do not maintain adequate infrastructure to enable us to, among other things, manage our purchasing and inventory, it could negatively
impact our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we are unable to continue the development of an adequate sales
and marketing organization and/or if our direct sales organization is not successful, we may have difficulty achieving market awareness
and selling our product and technologies in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We must develop and grow our sales and marketing organization and enter
into partnerships or other arrangements to market and sell our products and technologies and/or collaborate with third parties, including
distributors and others, to market and sell our products and technologies to develop and maintain the commercial success of the Vicarious
System, when or if we are authorized for marketing, and to achieve commercial success for any of our future products and technologies.
Developing and managing a direct sales organization is a difficult, expensive and time-consuming process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To develop our sales and marketing organization to successfully achieve
market awareness and sell our products and technologies after they receive appropriate marketing authorization, we must:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">continue to recruit and retain adequate numbers of effective and experienced sales and marketing personnel;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">effectively train our sales and marketing personnel in the benefits and risks of the Vicarious System;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">establish and maintain successful sales, marketing, training and education programs that educate health care professionals so they can appropriately inform their patients about the Vicarious System;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">manage geographically dispersed sales and marketing operations; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">effectively train our sales and marketing personnel on the applicable fraud and abuse laws that govern interactions with health care practitioners as well as current and prospective patients and maintain active oversight and auditing measures to ensure continued compliance.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may not be able to successfully manage our sales force or increase
our product sales at acceptable rates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we are unable to establish and maintain adequate sales and
marketing capabilities or enter into and maintain arrangements with third parties to sell and market the Vicarious System, our business
may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot guarantee that we will be able to establish and maintain
an adequate volume of sales in the future. A substantial reduction in sales could have a material adverse effect on our operating performance.
To the extent that we enter into additional arrangements with third parties to perform sales or marketing services in the United States,
Europe or other countries, our product margins could be lower than if we directly marketed and sold the Vicarious System. To the extent
that we enter into co-promotion or other marketing and sales arrangements with other companies, any revenue received will depend on the
skills and efforts of others, and we cannot predict whether these efforts will be successful. In addition, the growth of market acceptance
of the Vicarious System by healthcare practitioners outside of the United States will largely depend on our ability to continue to demonstrate
the relative safety, effectiveness, reliability, cost-effectiveness and ease of use of the Vicarious System. If we are unable to do so,
we may not be able to increase product revenue from our sales efforts in other countries. If we are unable to establish and maintain adequate
sales, marketing and distribution capabilities, independently or with others, our future revenue may be reduced and our business may be
harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Quality problems could lead to recalls or safety alerts and/or
reputational harm and could have a material adverse effect on our business, results of operations, financial condition and cash flows.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Quality of our product and technologies and future commercial products
and technologies is very important to us and our customers due to the serious and costly consequences of product failure. Our success
depends on the quality and reliability of the Vicarious System. Our business exposes us to potential product liability risks that are
inherent in the design, manufacture, and marketing of medical devices. While we take measures to ensure that components, products and
technologies are manufactured to stringent quality specifications, The Vicarious System incorporates mechanical parts, electrical components,
optical components, packaging and computer software, any of which may contain errors or exhibit failures, especially when the finished
system is first introduced. In addition, new products or modifications may contain undetected errors or performance problems that, despite
testing, are discovered only after marketing authorization and commercial shipment. Because the Vicarious System is being designed to
perform complex surgical procedures, due to the serious and costly consequences of product failure, we and our future customers have an
increased sensitivity to such defects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although the Vicarious System is subject to stringent quality processes
and controls, we cannot provide assurance that our system will not experience component aging, errors, performance problems, manufacturing
nonconformities, or design defects or that unexpected risks to users or patients will not be discovered during commercial use. If we experience
product flaws or performance problems, any or all of the following could occur:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">delays in shipments;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">loss of revenue;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">delay in market acceptance;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">diversion of resources;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">damage to reputation;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">product recalls;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">regulatory actions;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">increased service or warranty costs; or</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">product liability claims.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, the manufacture and production of the Vicarious System
requires a highly controlled and clean environment to minimize particles and other yield- and quality-limiting contaminants. Weaknesses
in process control or minute impurities in materials may result in defective products. If we are not able to maintain stringent quality
controls, or if contamination problems arise, we may experience delays in development and commercialization efforts and may be subject
to regulatory enforcement actions, which would harm our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we or our third-party component manufacturers or suppliers fail
to meet any applicable product quality standards and the Vicarious System is the subject of recalls, safety alerts or other regulatory
enforcement actions, our reputation could be damaged, we could lose customers, and our revenue and results of operations could decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we are not able to develop and release new surgical applications
for the Vicarious System, or successful enhancements, new features and modifications to the Vicarious System or to achieve adequate clinical
utility, our business, financial condition and results of operations could be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The markets in which we operate are characterized by rapid technological
change, frequent new product and service introductions and enhancements, changing customer demands, and evolving industry standards. The
introduction of products embodying new technologies can quickly make existing products obsolete and unmarketable. Additionally, changes
in laws and regulations could impact the usefulness of the Vicarious System and could necessitate changes or modifications to the Vicarious
System to accommodate such changes. We invest substantial resources in researching and developing new developments to the Vicarious System
and enhancing the Vicarious System by incorporating additional features, improving functionality, and adding other improvements to meet
customers’ evolving needs. The success of any enhancements, improvements or any new features to the Vicarious System, when or if
authorized for marketing by the FDA, depends on several factors, including timely completion, competitive pricing, adequate quality testing,
integration with new and existing technologies and third-party partners’ technologies and overall market acceptance. We may not
succeed in developing, marketing and delivering on a timely and cost-effective basis enhancements or improvements to the Vicarious System
or any new products and technologies that respond to continued changes in market demands or new customer requirements, and any enhancements
or improvements to the Vicarious System or any new solutions may not achieve market acceptance or authorization. Since developing the
Vicarious System is complex, the timetable for the release of new enhancements is difficult to predict, and we may not offer new updates
as rapidly as our customers require or expect. Any new products and technologies that we develop may not be introduced in a timely or
cost-effective manner, may contain errors or defects, or may not achieve the broad market acceptance necessary to generate sufficient
revenue. Moreover, even if we introduce new products and technologies, we may experience a decline in revenue from the Vicarious System
that is not offset by revenue from the new products and technologies. For example, customers may delay making purchases of new products
and technologies to permit them to make a more thorough evaluation of these products and technologies or until industry and marketplace
reviews become widely available. Customers may also delay purchasing a new product because their existing Vicarious System or other devices
continues to meet their needs. Some customers may hesitate to migrate to a new product due to concerns regarding the performance of the
new product. In addition, we may lose existing customers who choose a competitor’s products. This could result in a temporary or
permanent revenue shortfall and adversely affect our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The introduction of new products and solutions by competitors, the
development of entirely new technologies to replace existing offerings or shifts in healthcare benefits trends could make our future commercial
products and technologies obsolete or adversely affect our business, financial condition and results of operations. We may experience
difficulties with industry standards, design or marketing that could delay or prevent our development, introduction or implementation
of new products and technologies, enhancements, additional features or capabilities. If customers do not widely purchase and adopt our
future products and technologies, we may not be able to realize a return on our investment. If we do not accurately anticipate customer
demand or if we are unable to develop, license or acquire new features and capabilities on a timely and cost-effective basis, or if such
enhancements do not achieve market acceptance, it could result in adverse publicity, loss of revenue or market acceptance or claims by
customers brought against us, each of which could have a material and adverse effect on our reputation, business, results of operations
and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The COVID-19 pandemic has and could continue to negatively affect
various aspects of our business, which could have a material adverse effect on our business, financial condition, results of operations,
or cash flows.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In December 2019, a novel strain of coronavirus was reported to have
surfaced in Wuhan, China, and it has since spread throughout other parts of the world, including the United States. Any outbreak of contagious
diseases, or other adverse public health developments, could have a material adverse effect on our business operations. These impacts
to our operations have included, and could again in the future include, disruptions or restrictions on the ability of our employees’
and customers’ to travel or the ability of us to pursue collaborations and other business transactions, oversee the activities of
our third-party manufacturers and suppliers and make shipments of materials. We may also be impacted by the temporary closure of the facilities
of suppliers, manufacturers or customers. The COVID-19 pandemic may also continue to have an impact on potential customers, as elective
surgeries are increasingly postponed and there is greater focus on areas of care with lower profitability, leading, as a consequence,
to lower expenditures on new products and devices by health care institutions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In an effort to halt the outbreak of COVID-19, a number of countries,
including the United States, have placed significant restrictions on travel and many businesses have announced extended closures. These
travel restrictions and business closures have and may in the future adversely impact our operations locally and worldwide, including
our ability to manufacture, market, sell or distribute the Vicarious System, when or if we are authorized by the FDA or other regulatory
authorities for marketing, and such restrictions and closure have caused or may cause temporary closures of facilities of suppliers, manufacturers
or customers. Any disruption in the operations of our employees, suppliers, customers, manufacturers or access to customers would likely
impact our future sales and operating results. In addition, travel restrictions could make it more difficult for us to monitor the quality
of our third party manufacturing operations if we are unable to conduct in-person quality audits of those facilities. We are continuing
to monitor and assess the effects of the COVID-19 pandemic on our operations. However, we cannot at this time accurately predict what
effects these conditions will ultimately have on our operations due to uncertainties relating to the ultimate geographic spread of the
virus, the severity of the disease, the duration of the outbreak, and the length of the travel restrictions and business closures imposed
by the governments of impacted countries. In addition, a significant outbreak of contagious diseases in the human population could result
in a widespread health crisis that could adversely affect the economies and financial markets of many countries, resulting in an economic
downturn that could affect demand for the Vicarious System and likely impact our operating results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unfavorable global economic conditions could adversely affect
our business, financial condition or results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our results of operations could be adversely affected by general conditions
in the global economy and in the global financial markets, including changes in inflation, interest rates and overall economic conditions
and uncertainties. To the extent inflation or other factors increase our business costs, it may not be feasible to offset higher costs
through manufacturing efficiencies. An economic downturn could result in a variety of risks to our business, including weakened demand
for our future products and technologies and our inability to raise additional capital when needed on acceptable terms, if at all. A weak
or declining economy could also result in further constraints on our third-party component manufacturers and suppliers or cause future
customers to delay making payments for our products and technologies. Any of the foregoing could harm our business and we cannot anticipate
all of the ways in which the current economic climate and financial market conditions could adversely affect our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The requirements of being a public company may strain our resources
and divert management’s attention, which could adversely affect our business, results of operations, and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have incurred and will continue to incur significant legal, accounting
and other expenses that we did not incur as a private company, including costs associated with public company reporting requirements.
We will also continue to incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley
Act, as well as rules implemented by the SEC and the NYSE. We expect that the requirements of these rules and regulations will continue
to increase our legal, accounting, and financial compliance costs, make some activities more difficult, time-consuming, and costly, and
place significant strain on our personnel, systems, and resources. For example, our management team will need to devote substantial time
regarding operations as a public company and compliance with applicable laws and regulations. As a result of the complexity involved in
complying with the rules and regulations applicable to public companies, our management’s attention may be diverted from other business
concerns, which could harm our business, results of operations, and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We have identified a material weakness in our internal control
over financial reporting. If we are unable to successfully remediate this material weakness in our internal control over financial reporting,
we may not be able to report our financial condition or results of operations accurately or in a timely manner, which may adversely affect
investor confidence in us and, as a result, materially and adversely affect our business and the value of our Class A common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have identified material weaknesses in our internal control over
financial reporting for the years ended December 31, 2021 and 2020. The material weaknesses we identified were as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we did not maintain an effective control environment as we did not maintain a sufficient complement of accounting and financial reporting resources commensurate with our financial reporting requirements.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we did not maintain an effective risk assessment process, which led to improperly designed controls.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we did not maintain appropriate control activities to support the appropriate segregation of duties over the review of account reconciliations and manual journal entries, and safeguarding of assets.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we did not design and implement control related to information technology, including access and change management.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we did not document, thoroughly communicate and monitor controls processes and relevant accounting policies and procedures.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These material weaknesses could result in a misstatement of account
balances or disclosures that would result in a material misstatement to our annual or interim financial statements that would not be prevented
or detected. Had we performed an evaluation of our internal control over financial reporting in accordance with Section 404, additional
control deficiencies may have been identified by management, and those control deficiencies could have also represented one or more material
weaknesses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In an effort to remediate the material weaknesses, we have retained
an accounting consulting firm to provide additional depth and breadth in our technical accounting and financial reporting capabilities.
We have also hired additional qualified accounting and finance personnel to provide needed levels of expertise in our internal accounting
function and maintain appropriate segregation of duties. We intend to complete an appropriate risk assessment to identify relevant risks
and specify needed objectives. We intend to formalize and communicate our policies and procedures surrounding our financial close, financial
reporting and other accounting processes. We intend to further develop and document necessary policies and procedures regarding our internal
control over financial reporting, such that we are able to perform a Section 404 analysis of our internal control over financial reporting
when and as required following the completion of the Merger. We cannot assure you that these measures will significantly improve or remediate
the material weaknesses described above. We also cannot assure you that we have identified all or that we will not have additional material
weaknesses in the future. Accordingly, a material weakness may still exist when we report on the effectiveness of our internal control
over financial reporting for purposes of our attestation when required by reporting requirements under the Exchange Act or Section 404
after the Merger. Further, while we remain an emerging growth company, we will not be required to include an attestation report on internal
control over financial reporting issued by our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect to incur additional costs to remediate these control deficiencies,
though there can be no assurance that our efforts will be successful or avoid potential future material weaknesses. If we are unable to
successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or if we identify
any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to
maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange
listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could
become subject to investigations by NYSE, the SEC or other regulatory authorities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The enactment of legislation implementing changes in the U.S.
taxation of international business activities, the adoption of other tax reform policies or changes in tax legislation or policies in
jurisdictions outside of the United States could materially impact our results of operations and financial condition.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will be subject to income tax in the numerous international jurisdictions
in which we intend to operate. Reforming the taxation of international businesses has been a priority for politicians, and a wide variety
of potential changes have been proposed. Some proposals, several of which have been enacted, impose incremental taxes on gross revenue,
regardless of profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our ability to use net operating losses to offset future income
may be subject to certain limitations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December 31, 2021, we had federal net operating loss carry forwards
(“NOLs”) to offset future taxable income of approximately $67.3 million, of which approximately $2.8 million will expire at
various dates from 2034 through December 31, 2037, if not utilized. A lack of future taxable income would adversely affect our ability
to utilize these NOLs. In addition, under Section 382 of the Code, a corporation that undergoes an “ownership change” is subject
to limitations on its ability to utilize its pre-change NOLs and other pre-change tax attributes (such as research tax credits) to offset
post-change taxable income. For these purposes, an ownership change generally occurs where the equity ownership of one or more stockholders
or groups of stockholders who owns at least 5% of a corporation’s stock increases its ownership by more than 50 percentage points
over its lowest ownership percentage within a three-year period (calculated on a rolling basis). Our existing NOLs may be subject to limitations
arising out of previous ownership changes and we may be limited as to the amount that can be utilized each year as a result of such previous
ownership changes. In addition, future changes in our stock ownership, including future offerings, as well as other changes that may be
outside of our control, could result in additional ownership changes under Section 382 of the Code. Our NOLs may also be impaired under
similar provisions of state law. We have not conducted a study to assess whether an ownership change has occurred, whether there have
been multiple ownership changes since inception or whether there has been an ownership change as the result of the Business Combination
due to the significant complexity and costs associated with such a study. We have recorded a full valuation allowance related to our NOLs
and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to the limitations discussed above under Sections 382 of
the Code, the utilization of NOLs incurred in taxable years beginning after December 31, 2017, are subject to limitations, as modified
by the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). In general, NOLs generated in taxable years beginning
after December 31, 2017 may offset no more than 80 percent of such year’s taxable income and there is no ability for such NOLs to
be carried back to a prior taxable year. The CARES Act modifies this limitation on the deduction of NOLs and provides that NOLs arising
in taxable years beginning after December 31, 2017 and before January 1, 2021, may be carried back to each of the five taxable years preceding
the tax year of such loss, but NOLs arising in taxable years beginning after December 31, 2020 may not be carried back. In addition, the
CARES Act eliminates the limitation on the deduction of NOLs to 80 percent of current year taxable income for taxable years beginning
before January 1, 2021. As a result of such limitation, we may be required to pay federal income tax in some future year notwithstanding
that we have a net loss for all years in the aggregate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>U.S. taxation of international business activities or the adoption
of tax reform policies could materially impact our future financial position and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Limitations on the ability of taxpayers to claim and utilize foreign
tax credits and the deferral of certain tax deductions until earnings outside of the United States are repatriated to the United States,
as well as changes to U.S. tax laws that may be enacted in the future, could impact the tax treatment of future foreign earnings. Should
the scale of our international business activities expand, any changes in the U.S. taxation of such activities could increase our worldwide
effective tax rate and harm our future financial position and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We could be adversely affected by violations of the U.S. Foreign
Corrupt Practices Act and other worldwide anti-bribery laws by us or our agents.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are subject to the U.S. Foreign Corrupt Practices Act (the “FCPA”),
which prohibits companies and their intermediaries from making payments in violation of law to non-U.S. government officials for the purpose
of obtaining or retaining business or securing any other improper advantage. Our possible future reliance on independent distributors
or strategic partners to sell the Vicarious System internationally demands a high degree of vigilance in enforcing our policy against
participation in corrupt activity, because these distributors or strategic partners could be deemed to be our agents, and we could be
held responsible for their actions. Other U.S. companies in the medical device and pharmaceutical fields have faced criminal penalties
under the FCPA for allowing their agents to deviate from appropriate practices in doing business with such non-U.S. government officials.
We are also subject to similar anti-bribery laws in the jurisdictions in which we plan to operate, including the United Kingdom’s
Bribery Act of 2010, which also prohibits commercial bribery and makes it a crime for companies to fail to prevent bribery. We have limited
experience in complying with these laws and in developing procedures to monitor compliance with these laws by our agents. These laws are
complex and far-reaching in nature, and, as a result, we cannot assure investors that we would not be required in the future to alter
one or more of our practices to be in compliance with these laws or any changes in these laws or the interpretation thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any violations of these laws, or allegations of such violations, could
disrupt our operations, involve significant management distraction, involve significant costs and expenses, including legal fees, and
could result in a material adverse effect on our business, prospects, financial condition, or results of operations. We could also incur
severe penalties, including criminal and civil penalties, disgorgement, and other remedial measures.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Health Care Industry Shifts and Changing Regulations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are subject to extensive government regulation, which could
restrict the development, marketing, sale and distribution of our products and technologies and could cause us to incur significant costs.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We and the Vicarious System are subject to extensive pre-market and
post-market regulation by the FDA and various other federal, state, local and foreign government authorities. Government regulation of
medical devices is meant to assure their safety and effectiveness, and includes requirements for, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">design, development and manufacturing processes;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">labeling, content and language of instructions for use and storage;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">product testing, pre-clinical studies and clinical trials (if applicable);</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">regulatory authorization, including but not limited to pre-market clearance or pre-market approval;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">establishment registration, device listing and ongoing compliance with the QSR requirements;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">advertising and promotion;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">marketing, sales and distribution;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">conformity assessment procedures;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">product traceability and record-keeping procedures;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">review of product complaints, complaint reporting, recalls and field safety corrective actions;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">post-market studies (if applicable); and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">product import and export.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The laws and regulations to which we and our products, technologies
and future commercial products will be subject are complex and subject to periodic changes. Regulatory changes could result in restrictions
on our ability to carry on or expand our operations, and may result in higher than anticipated costs or lower than anticipated sales.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Before a new medical device, or a significant modification of a medical
device, including a new use of, or claim for, an existing product, can be marketed in the United States, it must first receive either
510(k) clearance or premarket approval (“PMA”) from the FDA, unless an exemption applies. In the 510(k) clearance process,
the FDA must determine that a proposed device is “substantially equivalent” to a device legally on the market, known as a
“predicate” device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed
device for marketing. Clinical data is sometimes required to support substantial equivalence.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Obtaining marketing authorization for Class II or III medical devices
through the 510(k) premarket notification process, the PMA process, or the de novo classification process can be expensive and time-consuming,
and entails significant user fees to the FDA, unless an exemption is available. The FDA’s review of premarket notifications for
510(k) clearance usually takes 90 to 180 days and review of de novo classification applications usually takes 120 to 280 days, but both
review processes can last longer. In addition, after a device is cleared or authorized under a reclassification order, any modification
that could significantly affect the device’s safety or effectiveness, or that would constitute a major change in its intended use,
will require a new clearance, or possibly a PMA, depending on the extent of the modification and the associated risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the PMA approval process, the FDA must determine that a proposed
device is safe and effective for its intended use based, in part, on extensive data, including but not limited to, technical, pre-clinical,
clinical trial, manufacturing and labeling data. The process for obtaining a PMA is more costly and uncertain and approval can take anywhere
from 180 days to, in some cases, more than one year from the time the application is initially filed with the FDA. Modifications to devices
that are approved through a PMA application generally require FDA approval of a supplemental PMA application. The Vicarious System and
some of our future products and technologies may require PMA approval. In addition, the FDA may require that we obtain a PMA prior to
marketing future changes of the Vicarious System. Further, we may not be able to obtain additional 510(k) clearances or PMAs for new products
and technologies or for modifications to, or additional indications for, the Vicarious System in a timely fashion or at all. Delays in
obtaining future clearances or approvals could adversely affect our ability to introduce new or enhanced products and technologies in
a timely manner, which in turn could harm our revenue and future profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order to conduct a clinical investigation involving human subjects
for the purpose of demonstrating the safety and effectiveness of a medical device, if necessary, for a PMA application, 510(k) premarket
notification or de novo classification request, a company must, among other things, apply for and obtain institutional review board, or
IRB, approval of the proposed investigation. In addition, if the clinical study involves a “significant risk” (as defined
by the FDA) to human health, the sponsor of the investigation must also submit and obtain FDA approval of an investigational device exemption,
or IDE, application and follow applicable IDE regulations. Unless IDE-exempt, nonsignificant risk devices are still subject to certain
abbreviated IDE requirements; however, an IDE application is not required if such abbreviated requirements are met. We may not be able
to obtain any necessary FDA and/or IRB approval to undertake clinical trials in the United States for future devices we develop and intend
to market in the United States. If we do obtain such approvals, the FDA may find that our studies do not comply with the IDE or other
regulations governing clinical investigations or the data from any such trials may not support marketing authorization of the investigational
device. Moreover, certainty that clinical trials will meet desired endpoints, produce meaningful or useful data and be free of unexpected
adverse effects, or that the FDA will accept the validity of foreign clinical study data (if applicable) cannot be assured, and such uncertainty
could preclude or delay marketing authorization resulting in significant financial costs and reduced revenue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To ensure compliance with regulatory requirements, medical device manufacturers
are subject to post-market surveillance and periodic, pre-scheduled and unannounced inspections by the FDA or other regulatory authorities,
and these inspections may include the manufacturing facilities of our subcontractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, as well as our third-party manufacturers or suppliers that are
regulated by the FDA, is also subject to numerous post-marketing regulatory requirements, which include quality system regulations related
to the manufacture of the Vicarious System, labeling regulations and medical device reporting (“MDR”) regulations. The last
of these regulations requires us to report to the FDA if our commercial devices cause or contribute to a death or serious injury, or malfunction
in a way that would likely cause or contribute to a death or serious injury if the malfunction recurred. The failure to comply with applicable
regulatory requirements can result in enforcement actions by the FDA, which may include any of the following sanctions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">customer notifications, or orders for repair, replacement or refunds;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">voluntary or mandatory recalls, detentions or seizures of products;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">operating restrictions, including total or partial suspension of production;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">delays in the introduction of products into the market;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">delay or refusal of for the FDA to grant 510(k) clearances, PMA approvals or de novo classification orders for new products or new intended uses or modifications to authorized products;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">rescission of 510(k) clearance or suspension or withdrawal of PMAs that have already been granted; or</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">in the most serious cases, criminal prosecution.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The occurrence of any of these events may have a material adverse effect
on our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>There is no guarantee that the FDA will grant marketing authorization
for the Vicarious System or any of our future products and technologies, and failure to obtain necessary marketing authorization for the
Vicarious System and our future products and technologies would adversely affect our ability to grow our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Vicarious System and our new or modified products and technologies
will require FDA marketing authorization before they may be marketed in the United States. The FDA may refuse our requests for pre-market
review of new products and technologies or may not grant marketing authorization for these products and technologies for the indications
that are necessary or desirable for successful commercialization. Early stage review may also result in delays or other issues. For example,
the FDA has issued guidance intended to explain the procedures and criteria used in assessing whether pre-market review submissions may
be accepted for substantive review. Under the “Refuse to Accept” guidance, the FDA conducts an early review against specific
acceptance criteria to notify applicants whether a pre-market submission for a device is administratively complete, and if not, such notification
will identify the missing element(s). Applicants are given the opportunity to provide the FDA with any information identified as missing.
If the information is not provided within a specified time, the submission will not be accepted for FDA review and will be considered
abandoned. The FDA may also change its marketing authorization policies, adopt additional regulations or revise existing regulations,
or take other actions that may prevent or delay authorization of our products and technologies under development or impact our ability
to obtain marketing authorization for modifications to our authorized products in a timely manner. Significant delays in receiving or
failure to receive FDA marketing authorization for our new products and technologies would have an adverse effect on our ability to expand
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Unsuccessful animal studies, clinical trials or procedures relating
to products and technologies under development could have a material adverse effect on our prospects.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The regulatory approval process for new device products, technologies
and new indications for existing device products and technologies requires extensive data and procedures, including the development of
regulatory and quality standards and, potentially, studies involving animals or human subjects. Based on pre-submission communications
with the FDA, we intend to file a de novo classification request for the Vicarious System with respect to ventral hernia procedures, which
would require human clinical studies to ensure that the product candidate is safe and effective. Unfavorable or inconsistent data from
future animal studies, clinical trials or other studies conducted by us or third parties, or perceptions regarding such data, could adversely
affect our ability to obtain necessary device regulatory authorization and the market’s view of our future prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Failure to successfully complete any required studies in a timely and
cost-effective manner could have a material adverse effect on our prospects with respect to the Vicarious System or other products and
technologies. Because animal studies, clinical trials and other types of scientific studies are inherently uncertain, there can be no
assurance that these trials or studies will be completed in a timely or cost-effective manner, be suitable to support marketing authorization
or result in a commercially viable product. Clinical trials or other studies may experience significant setbacks even if earlier preclinical
or animal studies have shown promising results. Furthermore, preliminary results from animal studies or clinical trials may be contradicted
by subsequent clinical analysis. Results from animal studies or clinical trials may also not be supported by actual long-term studies
or clinical experience. If preliminary study results are later contradicted, or if initial results cannot be supported by actual long-term
studies or clinical experience, our business could be adversely affected. Clinical trials also may be suspended or terminated by us, the
FDA, the responsible IRB or other regulatory authorities at any time if it is believed that the trial participants face unacceptable health
risks. The FDA may disagree with our interpretation of the data from the animal studies or clinical trials, or may find the design, conduct
or results of such studies or trials inadequate to demonstrate safety and effectiveness of the product candidate. The FDA may also require
additional pre-clinical studies or clinical trials for ventral hernia or other indications, which could further delay approval of our
products and technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Recent initiatives by the FDA to enhance and modernize various
regulatory pathways for device products and technologies and its overall approach to safety and innovation in the medical technology industry
creates the possibility of changing product development costs, requirements, and other factors and additional uncertainty for our products,
technologies and business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regulatory requirements may change in the future in a way that adversely
affects us. Any change in the laws or regulations that govern pre-market authorization processes or the post-market compliance requirements
relating to our current and future product candidates could make it more difficult and costly to obtain marketing authorization for new
product candidates, or to produce, market and distribute existing product candidates that receive such authorization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For example, the FDA and other government agencies have been focusing
on the cybersecurity risks associated with certain medical devices and encouraging device manufacturers to take a more proactive approach
to assessing the cybersecurity risks of their devices both during development and on a periodic basis after the devices are in commercial
distribution. These regulatory efforts could lead to new FDA requirements in the future or additional product liability or other litigation
risks if the Vicarious System is considered to be susceptible to third-party tampering. In December 2016, Congress passed the 21st Century
Cures Act, which made multiple changes to the FDA’s rules for medical devices as well as for clinical trials, and in August 2017,
Congress passed the most recent iteration of the five-year medical device user fee reauthorization package, which affects medical device
regulation both pre- and post-approval and could have certain impacts on our business. Since that time, the FDA has announced a series
of efforts to modernize and streamline the 510(k) notification and regulatory review process and monitoring post-market safety, and issued
a Proposed Rule to formalize the de novo classification process to provide clarity to innovative device developers. Changes in the FDA
510(k) process could make clearance more difficult to obtain, increase delay, add uncertainty and have other significant adverse effects
on our ability to obtain and maintain clearance for our product candidates. The negotiation process for the next cycle of medical device
user fee programs began in 2020, as those programs must be reauthorized by Congress in mid-2022, and additional regulatory changes or
new agency programs may be implemented as a result.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">It is unclear at this time whether and how various activities initiated
or announced by the FDA to modernize the U.S. medical device regulatory system could affect our business, as some of the FDA’s new
medical device safety and innovation initiatives have not been formalized and remain subject to change. For example, a 2018 Medical Device
Safety Action Plan included a particular focus on post-market surveillance and how to respond when new safety concerns emerge once a product
is on the market. The increased attention that the medical technology industry is receiving from regulators, lawmakers, and other stakeholders
creates the possibility of unanticipated regulatory and other potential changes to the Vicarious System and our overall business. In response
to the COVID-19 public health emergency, for example, the FDA’s device center leadership has exercised a significant amount of enforcement
discretion to meet the medical community’s and patients’ needs for remote monitoring and other innovative solutions that involve
digital health products and product candidates. The FDA has signaled that some of its policy changes adopted during the COVID-19 pandemic
could remain in place after the public health emergency subsides, but it is unclear which policies will be retained or how those policies
could impact the medical device industry in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we fail to obtain regulatory authorizations in other countries
for existing product candidates or product candidates under development, we will not be able to commercialize these products and technologies
in those countries.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In order for us to market the Vicarious System in countries outside
of the United States, we must comply with extensive safety and quality regulations in other countries regarding the quality, safety and
efficacy of the Vicarious System. These regulations, such as the requirements for obtaining marketing authorization, including CE mark
grant in the European Union, as well as regulatory authorization in the Asia-Pacific region and the time required for regulatory review,
vary from country to country. Failure to obtain marketing authorization in any foreign country in which we plan to market the Vicarious
System may harm our ability to generate revenue and harm our business. Marketing authorization requirements and processes vary between
countries and can involve additional product testing and additional administrative review periods. The time required to obtain marketing
authorization in other countries might differ from that required to obtain FDA authorization. The pre-market review and authorization
process in other countries may include all of the risks detailed above regarding FDA clearance in the United States, as well as other
potential risks relating to delays, refusals, or uncertainties in the application preparation, submission, and review procedures specific
to the regulatory processes in such countries. Regulatory authorization of a product in one country does not ensure regulatory authorization
in another, but a failure or delay in obtaining marketing authorization in one country may negatively impact the regulatory process in
others. Failure to obtain regulatory authorization in other countries or any delay or setback in obtaining such authorization could have
the same adverse effects described above regarding FDA authorization in the United States.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we, our contract manufacturers or our component suppliers
are unable to manufacture the Vicarious System in sufficient quantities, on a timely basis, at acceptable costs and in compliance with
regulatory and quality requirements, the manufacturing and distribution of our devices could be interrupted, and our product sales and
operating results could suffer.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We, our contract manufacturers and our component suppliers are required
to comply with the QSR, which is a complex regulatory framework that covers the procedures and documentation of the design, testing, production,
control, quality assurance, labeling, packaging, sterilization, storage, distribution and servicing of our devices. We and our contract
manufacturers and regulated component suppliers will be subject to periodic unannounced inspections by the FDA and other regulatory authorities
to monitor and ensure compliance with post-market regulatory requirements. We cannot assure investors that the FDA or other regulatory
authorities will not discover evidence of noncompliance at our facilities or the facilities of our third-party manufacturers or suppliers
during a future quality system inspection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Accordingly, assuming we receive marketing authorization for one or
more products, we and our contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance,
including manufacturing, production, product surveillance, and quality control. Failure of us or our third-party manufacturers and component
suppliers to adhere to QSR requirements or take adequate and timely corrective action in response to an adverse regulatory inspection
finding could delay production of the Vicarious System and lead to fines, difficulties in obtaining regulatory authorizations recalls,
enforcement actions, including injunctive relief or consent decrees, or other consequences, which could have a material adverse effect
on our financial condition or results of operations. Any such failure, including the failure of our contract manufacturers, to achieve
and maintain the required high manufacturing standards could result in delays or failures in product testing or delivery, cost overruns,
increased warranty costs or other problems that could harm our business and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our current or future products and technologies may be subject
to product recalls even after receiving marketing authorization from the FDA. A recall of the Vicarious System, either voluntarily or
at the direction of the FDA, or the discovery of serious safety issues with our future products, could have a significant adverse impact
on us.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA and similar governmental bodies in other countries have the
authority to require the recall of the Vicarious System and any accessory devices if we or our third-party manufacturers fail to comply
with relevant regulations pertaining to, among other things, manufacturing practices, labeling or if new information is obtained concerning
deficiencies in the safety or efficacy of the Vicarious System. For example, under the FDA’s MDR regulations, we are required to
report to the FDA any incident in which the Vicarious System may have caused or contributed to a death or serious injury or in which the
Vicarious System malfunctioned in a manner likely to cause or contribute to death or serious injury if that malfunction were to recur.
Repeated incidents of the same or similar adverse events or product malfunctions may result in a voluntary or mandatory product recall,
or administrative or judicial seizure or injunction, when warranted. A government-mandated recall may be ordered if the FDA finds that
there is a reasonable probability that the device would cause serious, adverse health consequences or death. A voluntary recall by us
could occur as a result of a discovery of any material deficiency in a device, such as manufacturing defects, labeling deficiencies, packaging
defects or other failures to comply with applicable regulations. It is possible that the FDA could disagree with our initial classification
for a voluntary recall. The FDA requires that reports of corrections or removals of any device be submitted to the FDA within 10 working
days after the correction or removal is initiated; however, any recall initiated due to a discovery that a device violates the FDCA must
be reported to FDA immediately. If a change to a device addresses a violation of the FDCA, that change would generally constitute a medical
device recall and require submission of a recall report to the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Recalls of the Vicarious System would divert managerial and financial
resources and have an adverse effect on our reputation, results of operations and financial condition, which could impair our ability
to produce the Vicarious System in a cost-effective and timely manner in order to meet our customers’ demands. We may also be subject
to product liability claims, be required to bear other costs, or be required to take other actions that may have a negative impact on
our future sales and our ability to generate profits. Companies are required to maintain certain records of product withdrawals or removals,
even if they are not reportable to the FDA. We may initiate voluntary field actions involving the Vicarious System in the future that
we determine do not require notification to the FDA. If the FDA disagrees with our determinations, the FDA could require us to report
those actions as recalls. A future recall, withdrawal, or seizure of any product could materially and adversely affect consumer confidence
in our brand, lead to decreased demand for the Vicarious System and negatively affect our sales. In addition, the FDA could take enforcement
action for failing to report recalls when they were conducted by us or one of our agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be subject to enforcement action if we engage in improper
or off-label marketing or promotion of the Vicarious System, including fines, penalties and injunctions.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The FDA regulates the promotional labeling for our products to ensure
that the claims we make are consistent with the relevant marketing authorizations, that there is scientific data to substantiate the claims
and that our promotion and advertising is neither false nor misleading. The off-label marketing or false advertising of our products may
harm our image in the marketplace, result in injuries that lead to product liability suits, which could be costly to our business, or
result in costly investigations and sanctions from the FDA and other regulatory bodies if we are deemed to have engaged in off-label promotion
or false advertising. In addition to the FDA, depending on the form of marketing authorization that the Vicarious System and future products
and technologies receive, the Federal Trade Commission (“FTC”) may have overlapping authority to oversee the advertising of
our products and any related services offered by us. The FTC’s focus would be on ensuring such advertising is truthful and not deceptive
under the FTC Act rather than enforcing any of the regulatory requirements in the FDCA and FDA’s implementing regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In September 2020 the FDA issued a proposed rule to revise its regulation
governing the types of evidence relevant to determining the “intended use” of a drug or device under the FDCA, which once
finalized will have implications for when a manufacturer or distributor has engaged in off-label marketing. Public comments have been
solicited, and FDA is expected to publish in the near future a final regulation and justify any additional revisions it may make to this
regulatory language.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are subject to federal, state and foreign laws prohibiting
“kickbacks” and false or fraudulent claims, and other fraud and abuse laws, transparency laws, and other health care laws
and regulations, which, if violated, could subject us to substantial penalties. Additionally, any challenge to or investigation into our
practices under these laws could cause adverse publicity and be costly to respond to, and thus could harm our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we obtain FDA marketing authorization for our Vicarious System,
we will be subject to broadly applicable fraud and abuse and other health care laws and regulations that may constrain the business or
financial arrangements and relationships through which we market, sell and distribute any products for which we obtain marketing authorization.
Restrictions under applicable federal and state health care laws and regulations include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal health care program such as Medicare and Medicaid;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment by a federal government program, or making a false statement or record that is material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the federal false statements statute prohibits knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for health care benefits, items or services;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the federal transparency requirements under the Physician Payments Sunshine Act require manufacturers of FDA-authorized drugs, devices, biologics and medical supplies covered by Medicare or Medicaid to report, on an annual basis, to the Department of Health and Human Services information related to payments and other transfers of value to physicians, teaching hospitals and certain advanced non-physician health care practitioners and physician ownership and investment interests; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">analogous state laws and regulations such as state anti-kickback and false claims laws and analogous non-U.S. fraud and abuse laws and regulations, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers, and some state laws require medical device companies to comply with the device industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring device manufacturers to report information related to payments to physicians and other healthcare providers or marketing expenditures. State and non-U.S. laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Efforts to ensure that our business arrangements with third parties
comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will
conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud
and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other
governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages,
fines, imprisonment, exclusion of products from government funded health care programs, such as Medicare and Medicaid, and the curtailment
or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business
is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions
from government funded health care programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Health care policy and payment changes may have a material adverse
effect on our financial condition and results of operations.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot predict the likelihood, nature or extent of government regulation
that may arise from future legislation or administrative or executive action, either in the United States or abroad. In the United States
and in some other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health
care system that could prevent or delay marketing authorization of our products and technologies or any of our potential future products
and technologies, restrict or regulate post-authorization activities, or affect our ability to profitably sell any products and technologies
for which we obtain marketing authorization. Increased scrutiny by the U.S. Congress of the FDA’s medical device authorization process
may significantly delay or prevent marketing authorization, as well as subject us to more stringent product labeling and post-marketing
testing and other requirements. Congress also must reauthorize the FDA’s user fee programs every five years and often makes changes
to those programs, in addition to policy or procedural changes that may be negotiated between the FDA and industry stakeholders as part
of this periodic reauthorization process. The negotiation process for the next cycle of medical device user fee programs began in 2020
as those programs must be reauthorized by Congress in mid-2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2010, Congress passed the ACA, which substantially changed
the way health care is financed by both the government and private insurers, and significantly impacts the United States medical device
industry. As another example, the 2021 Consolidated Appropriations Act signed into law on December 27, 2020 incorporated extensive health
care provisions and amendments to existing laws.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There remain judicial and Congressional challenges to certain aspects
of the ACA, and as a result certain sections of the ACA have not been fully implemented or effectively repealed. In particular, in December
of 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the individual mandate was repealed
by Congress as part of the Tax Cuts and Jobs Act, effective January 1, 2019. In December 2019, the Fifth Circuit Court of Appeals upheld
the district court’s ruling that the individual mandate in the ACA was unconstitutional, but remanded the case to the district court
to determine whether other reforms enacted as part of the ACA, but not specifically related to the individual mandate or health insurance
could be severed from the rest of the ACA so as not to have the law declared invalid in its entirety. On March 2, 2020, the U.S. Supreme
Court granted the petitions for writs of certiorari to review this case and allocated one hour for oral arguments, which occurred on November
10, 2020. On February 10, 2021, the Department of Justice sent a letter to the U.S. Supreme Court that stated the new administration believes
the individual mandate and its tax penalty are constitutional, and if the Court determines that they are not, the provision can be severed
from the remainder of the act. With this letter, the Biden administration reversed the Trump administration position that was presented
to the Court. The Trump administration had claimed that the tax provision is unconstitutional and could not be separated from the ACA,
making the entire ACA unconstitutional as a result. The U.S. Supreme Court held in a 7–2 opinion that the states and individuals
that brought the lawsuit challenging the ACA’s individual mandate do not have standing to challenge the law. The U.S. Supreme Court
did not reach the merits of the challenge, but the decision ends the case. It is unclear how potential litigation and other efforts to
repeal and replace the ACA will affect the implementation of that law, the pharmaceutical and medical device industries more generally,
and our business. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the ACA-mandated
“Cadillac” tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also
eliminates the health insurer tax. In addition, CMS published a final rule that would give states greater flexibility, effective January
1, 2020, in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the
essential health benefits required under the ACA for plans sold through such marketplaces. We continue to evaluate the potential impact
of the ACA and its possible repeal or replacement on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The uncertainty around the future of the ACA, and in particular the
impact to reimbursement levels, may lead to uncertainty or delay in the purchasing decisions of our future customers, which may in turn
negatively impact product sales. If there are not adequate reimbursement levels, our business and results of operations could be adversely
affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, other legislative changes have been proposed and adopted
since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year pursuant
to the Budget Control Act of 2011, which began in 2013 and will remain in effect through 2030 unless additional Congressional action is
taken. However, the Medicare sequester reductions under the Budget Control Act of 2011 were suspended from May 1, 2020 through December
31, 2020 due to the COVID-19 pandemic, pursuant to provisions of the Coronavirus Aid, Relief, and Economic Security Act, or the CARES
Act, which also extended the sequester by one year, through 2030, in order to offset the added expense of the 2020 cancellation. The 2021
Consolidated Appropriations Act was subsequently signed into law on December 27, 2020 and extended the CARES Act suspension period to
March 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot predict whether future health care initiatives will be implemented
at the federal or state level or in countries outside of the United States in which we may do business in the future, or the effect any
future legislation or regulation will have on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Inadequate funding for the FDA and other government agencies
could hinder their ability to hire and retain key leadership and other personnel, prevent new products and technologies from being developed
or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation
of our business may rely, which could negatively impact our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The ability of the FDA to review and approve or clear new medical device
products and technologies can be affected by a variety of factors, including government budget and funding levels, ability to hire and
retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the FDA
have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations
may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid
and unpredictable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disruptions at the FDA and other agencies may also increase the time
necessary for new products and technologies to be reviewed and/or authorized by necessary government agencies, which would adversely affect
our business. For example, over the last several years, the U.S. government has shut down several times, and certain regulatory agencies,
such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19
pandemic, in March 2020, the FDA announced its intention to temporarily postpone most inspections of foreign manufacturing facilities
and products and technologies, as well as to temporarily postpone routine surveillance inspections of domestic manufacturing facilities.
Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities
subject to a risk-based prioritization system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of January 29, 2021, the FDA noted it was continuing to ensure timely
reviews of applications for medical products and technologies during the COVID-19 pandemic in line with its user fee performance goals
and conducting “mission-critical” domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA
quality standards. Utilizing a rating system to assist in determining when and where it is safest to conduct such inspections based on
data about the trajectory of SARS-CoV-2 infections in a given state and locality and the rules and guidelines that are put in place by
state and local governments, the FDA is either continuing to, on a case-by-case basis, conduct only “mission-critical” inspections,
or, where possible to do so safely, resuming prioritized domestic inspections, which generally include pre-approval inspections. Foreign
pre-approval inspections that are not deemed mission-critical remain postponed, while those deemed mission-critical will be considered
for inspection on a case-by-case basis. The FDA will use similar data to inform resumption of prioritized operations abroad as it becomes
feasible and advisable to do so, and it has recently resumed inspections in China and plans to also resume such activities in India as
soon as possible. The FDA’s assessment of whether an inspection is mission-critical considers many factors related to the public
health benefit of U.S. patients having access to the product subject to inspection, including whether the products and technologies are
used to diagnose, treat, or prevent a serious disease or medical condition for which there is no other appropriate substitute. Both for-cause
and pre-approval inspections can be deemed mission-critical. The FDA may not be able to maintain this pace and delays or setbacks are
possible in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, regulatory authorities outside the United States may
adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown or slowdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections
or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process regulatory submissions,
which could have a material adverse effect on our future business. Further, following the completion of the Business Combination and in
our operations as a public company, future government shutdowns could impact our ability to access the public markets and obtain necessary
capital in order to properly capitalize and continue our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Intellectual Property</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If we are unable to protect our intellectual property, our ability
to maintain any technological or competitive advantage over our competitors and potential competitors would be adversely impacted, and
our business may be harmed.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We rely on patent protection as well as trademark, copyright, trade
secret and other intellectual property rights protection and contractual restrictions to protect our proprietary technologies, all of
which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. If
we fail to obtain, maintain, and protect our intellectual property, third parties may be able to compete more effectively against us,
and we may lose our technological or competitive advantage. We may also incur substantial litigation costs in our attempts to defend,
enforce recover or restrict the use of our intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot assure investors that any of our currently pending or future
patent applications will result in granted patents, and we cannot predict how long it will take for such patents to be granted or whether
the scope of such patents, if granted, will adequately protect the Vicarious System from competitors. It is possible that, for any of
our patents that have been granted or that may be granted in the future, other parties will design alternatives that do not infringe our
patents. Further, we cannot assure investors that other parties will not challenge any patents granted to us or that courts or regulatory
agencies will hold our patents to be valid or enforceable. We cannot guarantee investors that we will be successful in defending challenges
made against our patents. Any successful third-party challenge to our patents could result in the unenforceability or invalidity of such
patents, or to such patents being interpreted narrowly or otherwise in a manner adverse to our interests. Our ability to establish or
maintain a technological or competitive advantage over our competitors may be diminished because of these uncertainties. For these and
other reasons, our intellectual property may not provide us with any competitive advantage. For example:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we or our licensors (should we in-license IP in the future) might not have been the first to make the inventions covered by our pending patent applications or granted patents;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we or our licensors might not have been the first to file patent applications for our inventions. To determine the priority of these inventions, we may have to participate in interference proceedings or derivation proceedings declared by the U.S. Patent and Trademark Office (“USPTO”) that could result in substantial cost to us and may be unsuccessful. No assurance can be given that our patent applications or granted patents (or those of our licensors) will have priority over any other patent or patent application involved in such a proceeding;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">other parties may independently develop similar or alternative products and technologies or duplicate any of our products and technologies;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">it is possible that our owned or licensed pending patent applications will not result in granted patents in the United States or foreign jurisdictions, and even if such pending patent applications grant as patents, they may not provide a basis for intellectual property protection of commercially viable products and technologies, may not provide us with any competitive advantages, or may be challenged and invalidated by third parties;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may not develop additional proprietary products and technologies and technologies that are patentable;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the patents of other parties may block us from practicing our technology and thereby have an adverse effect on our business; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">while we apply for patents covering our products and technologies and uses thereof, as we deem appropriate, we may fail to apply for or obtain patents on important products and technologies and uses thereof in a timely fashion or at all, or we may fail to apply for or obtain patents in potentially relevant jurisdictions.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The strength of patents involves complex legal questions and
can be uncertain. Even if one or more patents do successfully issue, third parties may challenge the validity, enforceability, inventorship
or scope thereof. Such a challenge may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength
of protection provided by our patents is threatened, it could dissuade companies from collaborating with us to develop, and threaten
our ability to commercialize, our technology. Further, if we encounter delays in clinical trials, the period of time during which we
could market our products under patent protection would be reduced. Since patent applications in the United States and most other countries
are confidential for a period of time after filing, we cannot be certain that we are the first to file any patent application related
to our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Even if our patent applications issue as patents, they may not issue
in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with
any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative technologies or
products in a non-infringing manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our patents
may be challenged in the courts or patent offices in the United States and abroad. For example, we may become involved in opposition,
interference, derivation, inter partes review or other proceedings challenging our patent rights, and the outcome of any proceedings are
highly uncertain. Such challenges may result in the patent claims of our patents being narrowed, invalidated or held unenforceable, which
could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and products,
or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development,
testing and regulatory review of new technology, patents protecting such technology might expire before or shortly after such technology
is commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to our products or otherwise provide us with a competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To the extent our intellectual property offers inadequate protection,
or is found to be invalid or unenforceable, we would be exposed to a greater risk of direct competition. If our intellectual property
does not provide adequate coverage over our products and technologies and protection against our competitors’ products and technologies,
our competitive position could be adversely affected, as could our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The measures that we use to protect the security of our intellectual
property and other proprietary rights may not be adequate, which could result in the loss of legal protection for, and thereby diminish
the value of, such intellectual property and other rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The patenting process is expensive and time-consuming, and we may not
be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. In addition,
we may not pursue or obtain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects
of our research and development output before it is too late to obtain patent protection. Our pending and future patent applications may
not result in issued patents that protect our technology or products, in whole or in part. In addition, our existing patents and any future
patents we obtain may not be sufficiently broad to prevent others from using our technology or from developing competing products and
technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we delay in filing a patent application, and a competitor files
a patent application on the same or a similar technology before we do, we may face a limited ability to secure patent rights. We may not
be able to patent the technology at all. Even if we can patent the technology, we may be able to patent only a limited scope of the technology,
and the limited scope may be inadequate to protect our products, or to block competitor products that are similar or adjacent to ours.
Our earliest patent filings have been published. A competitor may review our published patents and arrive at the same or similar technology
advances for our products as we developed. If the competitor files a patent application on such an advance before we do, then we may no
longer be able to protect the technology. We may require a license from the competitor, and if the license is not available on commercially-viable
terms, then we may not be able to launch our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to pursuing patents on our technology, we also rely upon
trademarks, trade secrets, copyrights and unfair competition laws and other contractual provisions, to protect our intellectual property
and other proprietary rights. Despite these measures, any of our intellectual property rights could be challenged, invalidated, circumvented
or misappropriated. In addition, we take steps to protect our intellectual property and proprietary technology by entering into confidentiality
agreements and intellectual property assignment agreements with our employees, consultants, corporate partners and, when needed, our advisors.
Our suppliers may also have access to the patented technology owned or used by us as well as other proprietary information, and these
suppliers are subject to confidentiality provisions under their agreements with us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Such agreements or provisions may not be enforceable or may not provide
meaningful protection for our trade secrets or other proprietary information in the event of unauthorized use or disclosure or other breaches
of the agreements, and we may not be able to prevent such unauthorized disclosure. Notwithstanding any such agreements, there is no assurance
that our current or former manufacturers or suppliers will not use and/or supply our competitors with our trade secrets, know-how or other
proprietary information to which these parties gained access or generated from their relationship with us. This could lead to our competitors
gaining access to patented or other proprietary information. Moreover, if a party to an agreement with us has an overlapping or conflicting
obligation to a third party, our rights in and to certain intellectual property could be undermined. Monitoring unauthorized disclosure
is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce
a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, the outcome
would be unpredictable, and any remedy may be inadequate. Courts outside the United States may be less willing to protect trade secrets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, competitors could purchase our products and technologies
and attempt to replicate some or all of the competitive advantages we derive from our development efforts, willfully infringe our intellectual
property rights, design around our protected technology or develop their own competitive technologies that fall outside of our intellectual
property rights. If our intellectual property does not adequately protect our market share against competitors’ products and technologies
and methods, our competitive position could be adversely affected, as could our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may need or may choose to obtain licenses from third parties
to advance our research or allow commercialization of our current or future products and technologies, and we cannot provide any assurances
that we would be able to obtain such licenses.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may need or may choose to obtain licenses from third parties to
advance our research or allow commercialization of our current or future products and technologies, and we cannot provide any assurances
that third-party patents do not exist that might be enforced against our current or future products and technologies in the absence of
such a license. We may fail to obtain any of these licenses on commercially reasonable terms, if at all. Even if we are able to obtain
a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we could not obtain
a license, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable
to do so, we may be unable to develop or commercialize the affected products and technologies, which could materially harm our business
and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect
to our sales, an obligation on our part to pay royalties, damages and/or other forms of compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Licensing intellectual property involves complex legal, business and
scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the scope of rights granted under the license agreement and other interpretation-related issues;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">whether and the extent to which our technology and processes infringe intellectual property of the licensor that is not subject to the licensing agreement;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our products and technologies, and what activities satisfy those diligence obligations; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and our partners.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If disputes over licensed intellectual property prevent or impair our
ability to maintain the licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected
product, or the dispute may have an adverse effect on our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition to agreements pursuant to which we in-licenses intellectual
property, we may in the future grant licenses under our intellectual property. Like in-licenses, out-licenses are complex, and disputes
may arise between us and our licensees, such as the types of disputes described above. Moreover, our licensees may breach their obligations,
or we may be exposed to liability due to our failure or alleged failure to satisfy our obligations. Any such occurrence could have an
adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The licensing and acquisition of third-party intellectual property
rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing
strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive for commercializing
our technology. More established companies may have a competitive advantage over us due to their larger size, cash resources, or commercialization
capabilities. There can be no assurance that we will be able to successfully complete such negotiations and ultimately acquire the rights
to the intellectual property that we may seek to acquire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We and our partners may be sued for infringing the intellectual
property rights of third parties. If that happens, such litigation would be costly and time consuming, and an unfavorable outcome in any
such litigation could have a material adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our success also depends on our ability to develop, manufacture, market
and sell the Vicarious System without infringing the proprietary rights of third parties. Numerous U.S. and foreign-issued patents and
pending patent applications owned by third parties exist in the fields in which we are developing the Vicarious System. As part of a business
strategy to impede our successful commercialization and entry into new markets, competitors may claim that the Vicarious System infringes
their intellectual property rights and may suggest that we enter into license agreements. Such competitors may bring litigation against
us or our partners to enforce such claims.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Such claims may or may not be meritorious, but even if such claims
are without merit, we could incur substantial costs and the attention of our management and technical personnel could be diverted in defending
us against or settling such claims. Any adverse ruling by a court or administrative body, or perception of an adverse ruling, may have
a material adverse effect on our ability to conduct our business and on our finances. Moreover, third parties making claims against us
may be able to obtain injunctive relief against us, which could block our ability to offer the Vicarious System and could result in a
substantial award of damages against us. In addition, since we could sometimes agree to indemnify customers, collaborators or licensees,
we may have additional liability in connection with any infringement or alleged infringement of third-party intellectual property. Because
patent applications can take many years to issue, there may be pending applications, some of which are unknown to us, that may result
in issued patents that the Vicarious System or proprietary technologies infringe. Moreover, we may fail to identify issued patents of
relevance or incorrectly conclude that an issued patent is invalid or not infringed by our technology or the Vicarious System. There is
a substantial amount of litigation involving patent and other intellectual property rights in the medical device space in general and
in the robotic surgery field in particular. As we face increasing competition and as our business grows, we will likely face claims of
infringement. If a third party claims that we or any of our licensors, customers or collaboration partners infringe a third party’s
intellectual property rights, we may have to do any or all of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">seek licenses that may not be available on commercially reasonable terms, if at all;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">cease commercializing any infringing product or redesign the Vicarious System or processes to avoid infringement where in some cases redesign may not be possible or may require substantial monetary expenditures and time;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">pay substantial damages, including treble damages and attorneys’ fees, which we may have to pay if a court decides that the product or proprietary technology at issue infringes upon or violates the third-party’s rights;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">pay substantial royalties or fees or grant cross-licenses to our technology; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">defend litigation or administrative proceedings that may be costly whether we win or lose, and which could result in a substantial diversion of our financial and management resources.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Some of our competitors may be able to sustain the costs of complex
patent litigation more effectively than we can, because they have substantially greater resources. In addition, any uncertainties resulting
from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary
to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition
and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may choose to challenge the patentability of claims in a third party’s
U.S. patent by requesting that the USPTO review the patent claims in an ex-parte re-exam, inter partes review or post-grant review proceedings.
These proceedings are expensive and may consume time or other resources. We may choose to challenge a third party’s patent in patent
opposition proceedings in the European Patent Office, or EPO, or other foreign patent office. The costs of these opposition proceedings
could be substantial, and may consume time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent
office, then we may be exposed to litigation by a third party alleging that the patent is infringed by our products or proprietary technologies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">During the course of any intellectual property litigation, there could
be public announcements of the initiation of the litigation, as well as results of hearings, rulings on motions and other interim proceedings
in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our products, programs
or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements
could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be involved in lawsuits to protect or enforce our patents
or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Competitors may infringe our patents or the patents that we license.
In the event of infringement or unauthorized use, we may file one or more infringement lawsuits, which can be expensive and time-consuming.
An adverse result in any such litigation proceedings could put one or more of our patents at risk of being invalidated, being found to
be unenforceable or being interpreted narrowly and could put our patent applications at risk of not issuing. An adverse result could also
require us to pay the legal fees of the opposing party. Furthermore, because of the substantial amount of discovery required in connection
with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during
this type of litigation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many of our competitors are larger than us and have substantially greater
resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation longer than we could. In addition,
the uncertainties associated with litigation could have a material adverse effect on our ability to raise any funds necessary to continue
our operations, continue our internal research programs, in-license needed technology, or enter into development partnerships that would
help us bring the Vicarious System to market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, patent litigation can be very costly and time-consuming.
An adverse outcome in any such litigation or proceedings may expose us or any of our future development partners to loss of our proprietary
position, expose us to significant liabilities, or require us to seek licenses that may not be available on commercially acceptable terms,
if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If a defendant were to prevail on a legal assertion of invalidity and/or
unenforceability, we would lose at least part, and perhaps all, of the patent protection on the technology or process claimed by the patent.
In addition, if the breadth or strength of protection provided by our patents or those of our future licensors is threatened, it could
dissuade other companies from collaborating with us to license, develop or commercialize current or future products. Such a loss of patent
protection could have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be required to protect our patents through procedures created
to attack the validity of a patent at the USPTO. The USPTO hears post-grant proceedings, including PGR, IPR and derivation proceedings.
An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights,
which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary
standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a
USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the
claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate
our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action.
Thus, the America Invents Act (the “AIA”) and its implementation could increase the uncertainties and costs surrounding the
prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse
effect on our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our issued patents could be found invalid or unenforceable if
challenged in court, which could have a material adverse effect on our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any of our intellectual property rights could be challenged or invalidated
despite measures we take to obtain patent and other intellectual property protection with respect to our products and proprietary technology.
For example, if we or any of our partners were to initiate legal proceedings against a third party to enforce a patent covering the Vicarious
System, the defendant in such litigation could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the
United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could
be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or non-enablement, or failure
to claim patent eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with
the prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement during prosecution either in
the U.S. or abroad. Third parties may also raise similar claims before the USPTO or foreign patent offices, even outside the context of
litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question,
for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware or was otherwise
not considered during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would
lose at least part, and perhaps all, of the challenged patent. Such a loss of patent protection could have a material adverse effect on
our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be subject to claims that our employees, consultants or
independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us, which
could subject us to costly litigation.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As is common in the medical device industry, we engage the services
of consultants and independent contractors to assist us in the development of the Vicarious System. Many of these consultants and independent
contractors were previously employed at, or may have previously provided or may be currently providing consulting or other services to,
universities or other technology or medical device companies, including our competitors or potential competitors. We may become subject
to claims that we, a consultant or an independent contractor, inadvertently or otherwise, used or disclosed trade secrets or other information
proprietary to their former employers or their former or current clients. We may similarly be subject to claims stemming from similar
actions of an employee, such as one who was previously employed by another company, including a competitor or potential competitor. Litigation
may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result
in substantial costs and be a distraction to our management team. If we were not successful, we could lose access or exclusive access
to valuable intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, there could be public announcements of the results of
hearings, motions or other interim proceedings or developments, and, if securities analysts or investors perceive these results to be
negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could substantially
increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other
resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation
or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the
initiation and continuation of patent litigation or other intellectual property related proceedings could adversely affect our ability
to compete in the marketplace.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may be subject to claims challenging the inventorship or ownership
of our patents and other intellectual property.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We generally enter into confidentiality and intellectual property assignment
agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party
in the course of rendering services to us will be our exclusive property. However, those agreements may not be honored and may not effectively
assign intellectual property rights to us. For example, even if we have a consulting agreement in place with an academic advisor pursuant
to which such academic advisor is required to assign any inventions developed in connection with providing services to us, such academic
advisor may not have the right to assign such inventions to us, as it may conflict with his or her obligations to assign all such intellectual
property to his or her employing institution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to claims that former employees, collaborators or
other third parties have an interest in our patents, trade secrets, or other intellectual property as an inventor or co-inventor. Also,
former employees may become employed by competitors who develop similar technology, and could assist the competitor in designing around
our patents. While it is our policy to require our employees and contractors who may be involved in the development of intellectual property
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party
who in fact develops intellectual property that we regard as our own. The assignment agreements entered into by us may not be self-executing
or may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or our ownership
of our patents, trade secrets or other intellectual property. If we fail in defending any such claims, in addition to paying monetary
damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that
is important to our products. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial
condition, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may not be able to protect our intellectual property rights
throughout the world, which could materially, negatively affect our business.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filing, prosecuting and defending patents on current and future products
and technologies in all countries throughout the world would be prohibitively expensive, and many markets outside the United States will
likely be smaller than the United States for commercializing the Vicarious System. We may therefore choose to pursue a more limited set
of patent filings outside the United States, such that our intellectual property rights in some countries outside the United States may
be less extensive than those in the United States, or may not be pursued at all in such countries. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently,
regardless of whether we are able to prevent third parties from practicing our inventions in the United States, we may not be able to
prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products
and technologies made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies
in jurisdictions where we have not pursued and obtained patent protection to develop their own products and technologies, and further,
may export otherwise infringing products and technologies to territories where we have patent protection, but enforcement is not as strong
as it is in the United States. These products and technologies may compete with our products and technologies, and our patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing. Even if we pursue and obtain issued patents
in particular jurisdictions, our patent claims or other intellectual property rights may not be effective or sufficient to prevent third
parties from competing in such jurisdictions. Patent protection must ultimately be sought on a country-by-country basis, which is an expensive
and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection in certain countries, and
we will not have the benefit of patent protection in such countries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Many companies have encountered significant problems in protecting
and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing
countries, do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to
stop the infringement of our patents or marketing of competing products and technologies in violation of our proprietary rights generally.
Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention
from other aspects of our business. These proceedings could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing. Additionally, these proceedings could provoke third parties to assert claims against us. We
may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial
advantage from the intellectual property that we develop or license and may adversely impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, we also face the risk that the Vicarious System will be
imported or reimported into markets with relatively higher prices from markets with relatively lower prices, which would result in a decrease
of sales and any payments we receive from the affected market. Recent developments in U.S. patent law have made it more difficult to stop
these and related practices based on theories of patent infringement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Patent terms may be inadequate to protect our competitive position
on technology for an adequate amount of time.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Patents have a limited lifespan. In the United States, if all maintenance
fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various
extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our products
are obtained, once the patent life has expired for a product, we may be open to competition. Given the amount of time required for the
development, testing and regulatory review of new products, patents protecting such products might expire before or shortly after such
products are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing
products similar or identical to our products for a meaningful amount of time, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Obtaining and maintaining our patent protection depends on compliance
with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent
protection could be reduced or eliminated for non-compliance with these requirements.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The USPTO and various foreign governmental patent agencies require
compliance with a number of procedural, documentary, fee payment and other provisions during the patent process. There are situations
in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of
patent rights in the relevant jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise
have been the case.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Periodic maintenance fees on any issued patent are due to be paid to
the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent
agencies also require compliance with a number of procedural, documentary, fee payment (such as annuities) and other similar provisions
during the patent application process and beyond. While an inadvertent lapse can in many cases be cured by payment of a late fee or by
other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of
the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance
events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond
to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In
some cases, our licensors may be responsible for these payments or filings, thereby decreasing our control over compliance with these
requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If we fail to comply with such procedural, documentary, payment and
other provisions for any item of intellectual property, such intellectual property may become abandoned or may lapse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><b><i>If our trademarks and trade names are not adequately protected,
then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our registered or unregistered trademarks or trade names may be challenged,
infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to
these trademarks and trade names, which we need to build name recognition by potential partners or customers in our markets of interest.
At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly
leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other
registered trademarks. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then
we may not be able to compete effectively and our business may be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, if we are unable to establish name recognition based on
our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. We may license
our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how
our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may
jeopardize our rights in, or diminish the goodwill associated with, our trademarks and trade names. Our efforts to enforce or protect
our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may
be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Numerous factors may limit any potential competitive advantage
provided by our intellectual property rights.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The degree of future protection afforded by our intellectual property
rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier
to entry against our competitors or potential competitors, or permit us to maintain our competitive advantage. Moreover, if a third party
has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from
our intellectual property rights. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology that are not covered by the claims of any patents that have issued, or may issue, from our owned or in-licensed patent applications;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we might not have been the first to make the inventions covered by a pending patent application that we own or license;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we might not have been the first to file patent applications covering an invention and therefore may not be able to obtain or maintain patent protection for the invention;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">others may independently develop similar or alternative technologies without infringing our intellectual property rights;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">pending patent applications that we own or license may not lead to issued patents;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">patents, if issued, that we own or license may not provide us with any competitive advantages, or may be interpreted narrowly or held invalid or unenforceable, as a result of legal challenges by our competitors;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may not be able to obtain and/or maintain necessary or useful licenses on reasonable terms or at all;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">third parties may be able to also license the intellectual property that we have licensed nonexclusively;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude us from exercising exclusive rights over that intellectual property;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may not be able to maintain the confidentiality of our trade secrets or other proprietary information;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">we may not develop or in-license additional proprietary technologies that are patentable; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: left; font-size: 10pt"><span style="font-size: 10pt">one or more third parties may pursue continuation patent applications with claims directed to our product offerings, and if issued such patents may have an adverse effect on our business.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Should any of these events occur, they could significantly harm our
business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Litigation Risks</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>In addition to IP litigation risks (referenced above), we face
the risk of product liability claims and may be subject to damages, fines, penalties and injunctions, among other things.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business exposes us to the risk of product liability claims that
are inherent in the testing, manufacturing and marketing of medical devices, including those which may arise from the misuse (including
system hacking or other unauthorized access by third parties to our systems) or malfunction of, or design flaws in, our products, when
or if authorized for marketing. This liability may vary based on the FDA classification associated with our devices and with state law
governing product liability standards applied to specification developers and/or manufacturers in a given negligence or strict liability
lawsuit. We may be subject to product liability claims if the Vicarious System causes, or merely appears to have caused, an injury. Claims
may be made by patients, healthcare providers or others selling the Vicarious System. The risk of product liability claims may also increase
if our products are subject to a recall or seizure. Product liability claims may be brought by individuals or by groups seeking to represent
a class.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Although we have insurance at levels that we believe to be appropriate,
this insurance is subject to deductibles and coverage limitations. Our current product liability insurance may not continue to be available
to us on acceptable terms, if at all, and, if available, the coverage may not be adequate to protect us against any future product liability
claims. If we are unable to maintain insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect
against potential product liability claims, we may be exposed to significant liabilities, which may harm our business. A product liability
claim, recall or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant
costs and significant harm to our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may be subject to claims against us even if the apparent injury
is due to the actions of others or misuse of the device or a partner device. Healthcare providers may use the Vicarious System in a manner
inconsistent with the labeling and that differs from the manner in which it was used in clinical studies and authorization for use by
the FDA. Off-label use of medical products by healthcare providers is common, and any such off-label use of the Vicarious System could
subject us to additional liability, or require design changes to limit this potential off-label use once discovered. Defending a suit,
regardless of merit, could be costly, could divert management attention and might result in adverse publicity, which could result in the
withdrawal of, or result in reduced acceptance of, the Vicarious System in the market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, we may enter into various agreements where we indemnify
third parties for certain claims relating to the Vicarious System. These indemnification obligations may require us to pay significant
sums of money for claims that are covered by these indemnification obligations. We are not currently subject to any product liability
claims; however, any future product liability claims against it, regardless of their merit, may result in negative publicity about us
that could ultimately harm our reputation and could have a material adverse effect on our business, financial condition, or results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Risks Related to Our Securities and to Being a Public Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our outstanding warrants become exercisable for our Class A common
stock 30 days after the closing of our Business Combination, which could increase the number of shares eligible for future resale in the
public market and result in dilution to our stockholders.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Business Combination, there were (i) 17,249,991 outstanding
public warrants to purchase 17,249,991 shares of our Class A common stock at an exercise price of $11.50 per share, (ii) 8,900,000 outstanding
private placement warrants issued in connection with D8’s initial public offering exercisable for 8,900,000 shares of our Class
A common stock at an exercise price of $11.50 per share, and (iii) 1,500,000 outstanding private placement warrants issued upon conversion
of working capital loans made to D8 exercisable for 1,500,000 shares of our Class A common stock at an exercise price of $11.50 per share.
The warrants became exercisable 30 days after the closing of our Business Combination, which occurred on September 17, 2021. In certain
circumstances, the warrants may be exercised on a cashless basis. To the extent such warrants are exercised, additional shares of our
Class A common stock will be issued, which will result in dilution to the holders of our Class A common stock and increase the number
of shares eligible for resale in the public market. Sales of substantial numbers of such shares in the public market could adversely affect
the market price of our Class A common stock, the impact of which is increased as the value of our stock price increases. However, there
is no guarantee that the warrants will remain in the money prior to their expiration, and as such, the warrants may expire worthless.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our warrants are accounted for as liabilities and changes in
the value of our warrants could have a material effect on our financial results.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On April 12, 2021, the Acting Director of the Division of Corporation
Finance and Acting Chief Accountant of the SEC together issued a statement regarding the accounting and reporting considerations for warrants
issued by special purpose acquisition companies entitled “<i>Staff Statement on Accounting and Reporting Considerations for Warrants
Issued by Special Purpose Acquisition Companies (“SPACs”)</i>” (the “SEC Statement”). Specifically, the
SEC Statement focused on certain settlement terms and provisions related to certain tender offers following a business combination, which
terms are similar to those contained in the warrant agreement governing our warrants. As a result of the SEC Statement, D8 reevaluated
the accounting treatment of its public warrants and private placement warrants, and determined to classify the warrants as derivative
liabilities measured at fair value, with changes in fair value each period reported in earnings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result, included on D8’s balance sheet as of December 31,
2020 are derivative liabilities related to D8’s warrants. Accounting Standards Codification 815, Derivatives and Hedging (“ASC
815”), provides for the remeasurement of the fair value of such derivatives at each balance sheet date, with a resulting non-cash
gain or loss related to the change in the fair value being recognized in earnings in the statement of operations. As a result of the recurring
fair value measurement, our financial statements and results of operations may fluctuate quarterly, based on factors that are outside
of our control. Due to the recurring fair value measurement, it is expected that we will recognize non-cash gains or losses on the warrants
each reporting period and that the amount of such gains or losses could be material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We may face litigation and other risks as a result of the material
weakness in our internal control over financial reporting.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the issuance of the SEC Statement, after consultation with
its independent registered public accounting firm, D8’s management and its audit committee concluded that it was appropriate to
restate its previously issued audited financial statements as of and for the period ended December 31, 2021. See “— <i>Our
warrants are accounted for as liabilities and changes in the value of our warrants could have a material effect on our financial results.</i>”
As part of the Restatement, D8 identified a material weakness in its internal controls over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of such material weakness, the Restatement, the change
in accounting for the warrants, and other matters raised or that may in the future be raised by the SEC, we face potential for litigation
or other disputes which may include, among others, claims invoking the federal and state securities laws, contractual claims or other
claims arising from the Restatement and material weaknesses in our internal control over financial reporting and the preparation of our
financial statements. We can provide no assurance that such litigation or dispute will not arise in the future. Any such litigation or
dispute, whether successful or not, could have a material adverse effect on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We are an emerging growth company and a smaller reporting company
within the meaning of the Securities Act, and if we take advantage of certain exemptions from disclosure requirements available to “emerging
growth companies” or “smaller reporting companies,” this could make our securities less attractive to investors and
may make it more difficult to compare our performance with other public companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are an “emerging growth company” within the meaning
of the Securities Act, as modified by the JOBS Act, and we may take advantage of certain exemptions from various reporting requirements
that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not
being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations
regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding
advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. As a result,
our stockholders may not have access to certain information they may deem important. We could be an emerging growth company for up to
five years, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held
by non-affiliates exceeds $700 million as of the end of any second quarter of a fiscal year, in which case we would no longer be an emerging
growth company as of the last day of such fiscal year. We cannot predict whether investors will find our securities less attractive because
we will rely on these exemptions. If some investors find our securities less attractive as a result of our reliance on these exemptions,
the trading prices of our securities may be lower than they otherwise would be, there may be a less active trading market for our securities
and the trading prices of our securities may be more volatile.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Further, Section 102(b)(1) of the JOBS Act exempts emerging growth
companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that
have not had a registration statement under the Securities Act declared effective or do not have a class of securities registered under
the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company
can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but
any such election to opt out is irrevocable. We have elected not to opt out of such extended transition period, which means that when
a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company,
can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our
financial statements with another public company that is not an emerging growth company or is an emerging growth company which has opted
out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Additionally, we are a “smaller reporting company” as defined
in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including,
among other things, providing only two years of audited financial statements. We will remain a smaller reporting company until the last
day of the fiscal year in which (i) the market value of our common stock held by non-affiliates is greater than or equal to $250 million
as of the end of that fiscal year’s second fiscal quarter, and (ii) our annual revenues are greater than or equal to $100 million
during the last completed fiscal year and the market value of our common stock held by non-affiliates exceeds $700 million as of the end
of that fiscal year’s second fiscal quarter. To the extent we take advantage of such reduced disclosure obligations, it may also
make comparison of our financial statements with other public companies difficult or impossible.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>We cannot predict the impact our dual class structure may have
on the stock price of our Class A common stock.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We cannot predict whether our dual class structure will result in a
lower or more volatile market price of our Class A common stock or in adverse publicity or other adverse consequences. For example, certain
index providers have announced restrictions on including companies with multiple-class share structures in certain of their indexes. Under
these policies, our dual class capital structure would make us ineligible for inclusion in certain indices, and as a result, mutual funds,
exchange-traded funds and other investment vehicles that attempt to passively track those indices will not be investing in our stock.
It is unclear what effect, if any, these policies will have on the valuations of publicly traded companies excluded from such indices,
but it is possible that they may depress valuations, as compared to similar companies that are included. As a result, the market price
of shares of our Class A common stock could be adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>If securities or industry analysts do not publish research or
reports about our business or if they issue an adverse or misleading opinion regarding our securities, our stock price and trading volume
could decline.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The trading market for our securities is influenced by the research
and reports that industry or securities analysts publish about us or our business. If one or more of these analysts ceases coverage of
us or fails to publish reports on us regularly, we could lose visibility in the financial markets, which could cause the price and trading
volume of our securities to decline. Further, if any of these analysts issues an adverse or misleading opinion regarding us, our business
model, our industry or our stock performance or if our operating results fail to meet analyst expectations, the price of our securities
could also decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Delaware law and our organizational documents contain certain
provisions, including anti-takeover provisions that limit the ability of stockholders to take certain actions and could delay or discourage
takeover attempts that stockholders may consider favorable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The provisions of the General Corporation Law of the State of Delaware
(“DGCL”) and our organizational documents contain provisions that could have the effect of rendering more difficult, delaying,
or preventing an acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive
a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares
of our common stock, and therefore depress the trading price of our common stock. Additionally, these provisions could also make it difficult
for stockholders to take certain actions, including electing directors who are not nominated by the current members of our board of directors
or taking other corporate actions, including effecting changes in our management. Among other things, our organizational documents include
provisions regarding:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the ability of our board of directors to issue one or more series of preferred stock;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the ability of our board of directors to issue shares of preferred stock, including “blank check” preferred stock and to determine the price and other terms of those shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquirer;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">limitations on the liability of, and the indemnification of, our directors and officers;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the right of our board of directors to elect a director to fill a vacancy created by the expansion of our board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; &nbsp;&nbsp;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the requirement that directors may only be removed from our board of directors for cause and upon the affirmative vote of the holders of at least 66 2/3% of the total voting power of then outstanding shares of our common stock; &nbsp;&nbsp;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">a prohibition on stockholder action by written consent (except for actions by the holders of our Class&nbsp;B common stock or as required for holders of future series of our preferred stock), which forces stockholder action to be taken at an annual or special meeting of stockholders and could delay the ability of stockholders to force consideration of a stockholder proposal or to take action, including the removal of directors;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the requirement that a special meeting of stockholders may be called only by our board of directors, the chairman of our board of directors, or our chief executive officer, which could delay the ability of stockholders to force consideration of a proposal or to take action, including the removal of directors;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">controlling the procedures for the conduct and scheduling of our board of directors and stockholder meetings;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the requirement for the affirmative vote of holders of at least 66 2/3% of the total voting power of all of the then outstanding shares of the voting stock, voting together as a single class, to amend, alter, change or repeal certain provisions in our certificate of incorporation (the “Charter”) which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our board of directors and also may inhibit the ability of an acquirer to effect such amendments to facilitate an unsolicited takeover attempt;</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">the ability of our board of directors to amend our amended and restated bylaws (the “Bylaws”), which may allow our board of directors to take additional actions to prevent an unsolicited takeover and inhibit the ability of an acquirer to amend the Bylaws to facilitate an unsolicited takeover attempt; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">advance notice procedures with which stockholders must comply to nominate candidates to our board of directors or to propose matters to be acted upon at a stockholders’ meeting, which could preclude stockholders from bringing matters before annual or special meetings of stockholders and delay changes in our board of directors and also may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These anti-takeover provisions as well as certain provisions of Delaware
law could make it more difficult for a third party to acquire us, even if the third party’s offer may be considered beneficial by
many of our stockholders. As a result, our stockholders may be limited in their ability to obtain a premium for their shares. If prospective
takeovers are not consummated for any reason, we may experience negative reactions from the financial markets, including negative impacts
on the price of our common stock. These provisions could also discourage proxy contests and make it more difficult for our stockholders
to elect directors of their choosing and to cause us to take other corporate actions that our stockholders desire.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the provisions of the Director Nomination Agreement entered
into on September 17, 2021 (the “Director Nomination Agreement”) with D8 Sponsor LLC (the “Sponsor”) provide the
Sponsor with certain board nomination rights which could also have the effect of delaying or preventing a change in control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>The provisions of our certificate of incorporation requiring
exclusive forum in the Court of Chancery of the State of Delaware and the federal district courts of the United States for certain types
of lawsuits may have the effect of discouraging certain lawsuits, including derivative lawsuits and lawsuits against us or our directors,
officers or other employees, by limiting plaintiffs’ ability to bring a claim in a judicial forum that they find favorable.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our certificate of incorporation provides that, unless we consent in
writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, in the event that such court does
not have subject matter jurisdiction, any other court located in the State of Delaware with subject matter jurisdiction), will be the
sole and exclusive forum for (a) any derivative action or proceeding brought on behalf of us, (b) any action asserting a claim of breach
of a fiduciary duty owed by any current or former director, officer, other employee or stockholder of ours to us or our stockholders,
(c) any action asserting a claim against us or our officers or directors arising pursuant to any provision of the DGCL or the Charter
or Bylaws or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, (d) any action to interpret,
apply, enforce or determine the validity of the Charter or the Bylaws or any provision thereof, (e) any action asserting a claim against
us or any current or former director, officer, employee, stockholder or agent of ours governed by the internal affairs doctrine of the
law of the State of Delaware or (f) any action asserting an “internal corporate claim” as defined in Section 115 of the DGCL.
The Charter also provides that, unless we consent in writing to the selection of an alternative forum, to the fullest extent permitted
by law, the federal district courts of the United States will be the exclusive forum for the resolutions of any complaint asserting a
cause of action arising under the Securities Act. This provision in the Charter does not address or apply to claims that arise under the
Exchange Act. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability
created by the Exchange Act or the rules and regulations thereunder; to the extent these provisions could be construed to apply to such
claims, there is uncertainty as to whether a court would enforce such provisions in connection with such claims, and our stockholders
cannot waive compliance with the federal securities laws and the rules and regulations thereunder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Any person or entity purchasing or otherwise acquiring any interest
in any of our securities will be deemed to have notice of and consented to the provisions of the Charter described in the preceding paragraph.
These provisions may have the effect of discouraging certain lawsuits, including derivative lawsuits and lawsuits against us and our directors
and officers, by limiting plaintiffs’ ability to bring a claim in a judicial forum that they find favorable. The enforceability
of similar choice of forum provisions in other companies’ certificates of incorporation or bylaws has been challenged in legal proceedings,
and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions
contained in the Charter to be inapplicable or unenforceable in such action. Furthermore, if a court were to find these provisions of
our certificate of incorporation inapplicable or unenforceable with respect to one or more of the specified types of actions or proceedings,
we may incur additional costs associated with resolving such matters in other jurisdictions, which could materially adversely affect our
business, financial condition and results of operations and result in a diversion of the time and resources of our management and board
of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Although we are not a “controlled company” within
the meaning of the NYSE rules, we might become a “controlled company” in the future, and, as a result, our stockholders may
not have certain corporate governance protections that are available to stockholders of companies that are not controlled companies.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If more than 50% of the voting power for the election of our directors
is held by an individual, a group or another company, we will become a “controlled company” within the meaning of the NYSE
corporate governance standards. Following the completion of the Business Combination, <span style="font-family: Times New Roman, Times, Serif">Adam
Sachs, Sammy Khalifa, and Barry Greene</span> held approximately 80.0% of the voting power of our outstanding capital stock. Messrs. Sachs,
Khalifa and Greene have no agreement or arrangement to act together with respect to voting of the Class B common stock, and thus they
have not formed a “group” for purposes of controlled company status. Although no individual, group or other company will have
more than 50% of our voting power, Messrs. Sachs, Khalifa and Greene may in the future decide to act as a group, and this concentration
of voting power would cause us to become a “controlled company” within the meaning of the NYSE corporate governance standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result, if we become a “controlled company” within
the meaning of the NYSE corporate governance standards, then we will not be subject to the requirements that would otherwise require it
to have: (i) a majority of independent directors; (ii) a nominating committee comprised solely of independent directors; (iii) compensation
of our executive officers determined by a majority of the independent directors or a compensation committee comprised solely of independent
directors; and (iv) director nominees selected, or recommended for our board of directors’ selection, either by a majority of the
independent directors or a nominating committee comprised solely of independent directors. Each share of Class A common stock initially
entitles its holders to one vote on all matters presented to stockholders generally and each share of Class B common stock initially entitles
its holders to twenty votes on all matters presented to stockholders generally. Accordingly, Messrs. Sachs, Khalifa and Greene, by virtue
of their Class B common stock, hold approximately 80.0% of the voting power of our outstanding capital stock. Accordingly, those owners,
if voting in the same manner, will be able to control the election and removal of the directors of our board of directors (subject to
the Director Nomination Agreement) and thereby determine corporate and management policies, including potential mergers or acquisitions,
payment of dividends, asset sales, amendment of the Charter and Bylaws and other significant corporate transactions of ours for so long
as they retain significant ownership of Class B common stock. This concentration of ownership may delay or deter possible changes in control
of us, which may adversely affect the market price of shares of our Class A common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Our principal stockholders and management will exert significant
influence over us and their interests may conflict with yours in the future.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each share of Class A common stock initially entitles its holders to
one vote on all matters presented to stockholders generally and each share of Class B common stock initially entitles its holders to twenty
votes on all matters presented to stockholders generally. Accordingly, Messrs. Sachs, Khalifa and Greene, by virtue of their Class B common
stock, hold approximately 80.0% of the voting power of our outstanding capital stock. Accordingly, those owners, if voting in the same
manner, will be able to control the election and removal of the directors of our board of directors (subject to the Director Nomination
Agreement) and thereby determine corporate and management policies, including potential mergers or acquisitions, payment of dividends,
asset sales, amendment of the Charter and Bylaws and other significant corporate transactions of ours for so long as they retain significant
ownership of Class B common stock. This concentration of ownership may delay or deter possible changes in control of us, which may adversely
affect the market price of shares of our Class A common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM IB. UNRESOLVED STAFF COMMENTS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 2. PROPERTIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We currently maintain our executive offices at
78 Fourth Avenue, Waltham, Massachusetts 02451. We also occupy manufacturing and laboratory space located at 62 Fourth Avenue Waltham,
MA 02451. We lease office space under operating leases. We consider our current office space adequate for our current operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 3. LEGAL PROCEEDINGS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">As of the date of this Annual Report on Form 10-K,
to our knowledge, we are not party to and our property is not subject to any material pending legal proceedings. However, from time to
time, we may become involved in legal proceedings or subject to claims that arise in the ordinary course of our business activities. Regardless
of the outcome, such legal proceedings or claims could have an adverse impact on us because of defense and settlement costs, diversion
of management resources, negative publicity and reputational harm, and other factors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_008"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 4. MINE SAFETY DISCLOSURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><div><a id="a_009"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
II</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_010"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Market Information </b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our Class&nbsp;A common stock and public warrants
are currently listed on the NYSE under the symbols “RBOT,” and “RBOT WS,” respectively. We do not intend to list
the private placement warrants on any securities exchange.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Holders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">As
of March 1, 2022, there were approximately 77 holders of record of our Class&nbsp;A common stock, three holders of record of our Class&nbsp;B
common stock, </span>one <span style="font-family: Times New Roman, Times, Serif">holder of record of the public warrants and two holders
of record of the private placement warrants.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Such numbers do not include beneficial owners holding
our securities through nominee names. There is no public market for our Class&nbsp;B common stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Dividends</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have not paid any cash dividends on our Class&nbsp;A
common stock or Class&nbsp;B common stock to date. The payment of cash dividends in the future will be dependent upon our revenues and
earnings, if any, capital requirements and general financial condition. The payment of any cash dividends will be within the discretion
of our board of directors at such time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Unregistered Sales of Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Issuer Purchases of Equity Securities</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_011"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 6. [RESERVED]</b></p><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><div><a id="a_012"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.</b>&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><i>The following discussion and analysis provides
information which management believes is relevant to an assessment and understanding of our condensed consolidated results of operations
and financial condition. This discussion contains forward-looking statements and involves numerous risks and uncertainties, including,
but not limited to, those described in the “Risk Factors” section of this Annual Report on Form 10-K. Actual results may differ
materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”,
“us”, “our”, and “the Company” are intended to mean the business and operations of Vicarious Surgical
Inc. and its consolidated subsidiaries. </i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Overview</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are combining advanced miniaturized robotics, computer science and
3D visualization to build a new category of intelligent and affordable, single-incision surgical robot that virtually transports surgeons
inside the patient to perform minimally invasive surgery, or MIS. With our next-generation robotics technology and proprietary human-like
surgical robots, we are seeking to improve patient outcomes, as well as the cost and efficacy of surgical procedures. Led by a visionary
team of engineers from the Massachusetts Institute of Technology, or MIT, we intend to deliver the next generation in robotic surgery,
designed to solve the shortcomings of both open surgery, as well as current manual and robot-assisted MIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We estimate there are over 39 million soft tissue surgical procedures
addressable by our technology. Of these procedures, it is estimated that more than 50% are performed using open surgery, and less than
5% are performed by current robot-assisted MIS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We believe this slow adoption of robot-assisted surgery has occurred
because of several factors, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Significant Capital Investment. Existing robotic systems require a high upfront cost and burdensome annual service contracts that are often prohibitively expensive, especially in outpatient settings. These capital costs are estimated to be up to $2.0 million per system upfront, plus an additional 10-20% annually for maintenance and service contracts.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Low Utilization. In addition to the significant acquisition costs, existing robotic systems create inefficiencies and increase costs to medical facilities considering adoption. Due to their large size and limited portability, existing robotic systems require the construction of a dedicated operating room, occupying valuable real estate within the hospital. Once in place, these robotic systems require extensive set-up and operating room turnover times, which limits the number of procedures that can be performed with the robotic system.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Limited Capabilities. Existing robotic systems have limited capabilities and are ill-suited for many outpatient procedures. Due to their limited degrees of freedom inside the abdomen, they depend on significant, complicated, robotic motion outside the body, and they have limited ability to operate in multiple quadrants, difficulty operating on the “ceiling” of the abdomen, create collisions inside and outside of the patient’s abdomen, and restrict overall access of the operating team to the patient.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-size: 10pt">●</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">Difficult to Use. Existing robotic systems necessitate device-specific training requiring the surgeon to “design the robotic motion” for each procedure. In choosing the incision sites, the surgeon must effectively design the kinematic motion of the robot for every procedure to operate well and avoid collisions inside and outside of the patient’s abdomen. They must design this kinematic motion with fewer degrees of freedom than they would employ using open surgery, restricting their natural movements. To become proficient at manipulating these legacy robotic systems to perform the procedures they otherwise were trained to perform via open surgery requires extensive training and several dozen procedures on live patients. As these systems are maintained in dedicated, expensive, operating rooms, obtaining access to train on the system becomes a significant impediment to adoption, resulting in more open surgeries.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our single-port system with advanced, miniaturized robotics and advanced
visualization is designed to address the significant limitations of open surgery and existing single- and multi-port robotic surgical
approaches to improve patient outcomes and enhance adoption by hospitals and other medical facilities. The Vicarious System is designed
with a fundamentally different architecture, and proprietary “de-coupled actuators,” to overcome many of the limitations of
open surgery or existing robot-assisted surgical procedures with a minimally invasive and more capable robotic system. This architecture
enables unprecedented dexterity inside the abdomen through an ultra-thin support tube, providing significant improvement over existing
legacy robotic systems and minimizing the complications and trauma associated with open surgery.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Financial Highlights</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are pre-revenue generating as of December 31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We incurred a net loss of $35.2 million and $12.9 million for the years
ended December 31, 2021 and 2020, respectively, representing a period-over-period loss of 173%. The 2021 net loss is inclusive of a gain
of $3.1 million related to the decrease in the fair value of our warrant obligations due to our stock price decrease during Q4. Our loss
from operations prior to the warrant gain and other income and expense items was $38.2 million and $13.0 million for the years ended December
31, 2021 and 2020, respectively, representing a period-over-period loss of 194%, which was primarily due to a 70% increase in our average
headcount and a 467% increase in our G&amp;A expenses which was primarily related to expenses associated with our becoming a public company
during 2021. Our increase in average headcount was driven almost entirely by our ramp up in R&amp;D personnel for which our average headcount
increased by 65% from an average of 51 people in the year ended December 31, 2020 to an average of 84 people for the year ended December
31, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>COVID-19</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In March 2020, the World Health Organization declared the global outbreak
of COVID-19 to be a pandemic. We continue to closely monitor the recent developments surrounding the continued spread and potential resurgence
of COVID-19. The COVID-19 pandemic has had, and is expected to continue to have, an adverse impact on our operations, particularly as
a result of preventive and precautionary measures that we, other businesses, and governments are taking. Refer to “Risk Factors”
included elsewhere in this Annual Report on Form 10-K for more information. We are unable to predict the full impact that the COVID-19
pandemic will have on our future results of operations, liquidity and financial condition due to numerous uncertainties, including the
duration of the pandemic, the actions that may be taken by government authorities across the United States. However, COVID-19 is not expected
to result in any significant changes in costs going forward. We will continue to monitor the performance of our business and reassess
the impacts of COVID-19.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Business Combination</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 17, 2021, we completed the Business Combination. The Business
Combination was approved by D8’s stockholders at its special meeting held on September 15, 2021. The transaction resulted in the
combined company being renamed “Vicarious Surgical Inc.,” Legacy Vicarious being renamed “Vicarious Surgical Operating
Co.” and the combined company’s Class A common stock and warrants to purchase Class A common stock commencing trading on the
NYSE on September 20, 2021 under the symbol “RBOT” and “RBOT WS”, respectively. As a result of the Business Combination,
we received gross proceeds of approximately $142.0 million. On October 6, 2021, Legacy Vicarious changed its name from “Vicarious
Surgical Operating Co.” to “Vicarious Surgical US Inc.”</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Factors Affecting Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following factors have been important to our business and we expect
them to impact our results of operations and financial condition in future periods:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Revenue</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, we have not generated any revenue. We do not expect to generate
revenue until at least 2023 and only if it receives FDA approval of our product. Any revenue from initial sales of a new product is difficult
to predict and in any event will initially only modestly reduce our continued net losses resulting from our increasing research and development
and marketing activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Research and Development Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Research and development, or R&amp;D, expenses consist primarily of
engineering, product development, clinical studies to develop and support our products, regulatory expenses, medical affairs, and other
costs associated with products and technologies that are in development. These expenses include employee compensation, including stock-based
compensation, supplies, consulting, prototyping, testing, materials, travel expenses, depreciation and an allocation of facility overhead
expenses. Additionally, R&amp;D expenses include costs associated with our clinical studies, including clinical trial design, clinical
trial site initiation and study costs, data management, related travel expenses and the cost of products used for clinical trials, internal
and external costs associated with our regulatory compliance and quality assurance functions and overhead costs. We expect R&amp;D expenses
as a percentage of revenue to vary over time depending on the level and timing of our new product development efforts, as well as our
clinical development, clinical trial and other related activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>General and Administrative Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">General and administrative, or G&amp;A, expenses consist primarily
of compensation for personnel, including stock-based compensation, related to executive, finance and accounting, information technology
and human resource functions. Other G&amp;A expenses include travel expenses, professional services fees (including legal, audit and tax
fees), insurance costs, general corporate expenses and allocated facilities-related expenses. We expect G&amp;A expenses to continue to
increase in absolute dollars as we expand our infrastructure to both drive and support the anticipated growth due to additional legal,
accounting, insurance and other expenses associated with being a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sales and Marketing Expenses</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Sales and marketing, or S&amp;M, expenses consist primarily of compensation
for personnel, including stock-based compensation, related to selling and marketing functions and physician education programs. Other
S&amp;M expenses include training, travel expenses, promotional activities, marketing initiatives, market research and analysis, conferences
and trade shows, professional services fees and allocated facilities-related expenses. We expect S&amp;M expenses to continue to increase
in absolute dollars as we increase potential customers’ awareness of our presence and prepares our sales and marketing function
for our product launch at a future, yet undetermined date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Change in Fair Value of Warrant Liabilities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Change in fair value of warrant liability represents the mark-to-market
fair value adjustments to the outstanding public and private placement warrants assumed as part of the consummation of the Business Combination
on September 17, 2021. The change in fair value of our Private Warrants is primarily the result of the change in the underlying stock
price of our stock used in the Black-Scholes Option Pricing Model while the Public Warrants are marked to market based on their price
on the NYSE. The warrant liability was measured at fair value initially on September 17, 2021 and is remeasured at exercise, and for warrants
that remain outstanding at the end of the reporting period.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interest Income</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest income consists primarily of interest income earned on our
cash and cash equivalents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Interest Expense</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Interest expense consists primarily of interest incurred on our outstanding
term and equipment loans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Results of Operations</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table sets forth our historical operating results for
the periods indicated:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="text-align: center">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands, except for per share amounts)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">% Change</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Operating expenses:</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; width: 52%; text-align: left">Research and development</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">22,059</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">9,796</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">12,263</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">125</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Sales and marketing</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,961</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">861</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,100</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">244</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13,203</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,328</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">10,875</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: right">467</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">38,223</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,985</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,238</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: right">194</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss from operations</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(38,223</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,985</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(25,238</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">194</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Other income (expense):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Change in fair value of warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,085</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,085</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">N/M</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left">Interest income</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">113</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(93</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(82</td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Interest expense</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(89</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(86</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: right">2,867</td><td style="padding-bottom: 1.5pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Loss before income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(35,207</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(12,875</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(22,332</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">173</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: right"><span style="font-size: 10pt">N/M</span></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss and comprehensive loss</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(35,207</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(12,875</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(22,332</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt; text-align: right">173</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net loss per common share, basic and diluted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.36</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.16</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(0.20</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt; text-align: right">125</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Comparison of the years ended December 31, 2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Research and Development Expenses</i>. Research and development
expenses increased $12.3 million, or 125%, to $22.1 million during the year ended December 31, 2021, compared to $9.8 million during the
year ended December 31, 2020. The increase in research and development expenses was primarily due to increases of $7.9 million of personnel-related
expenses, $1.4 million in professional services, $1.3 million in facility expenses, $1.0 million in materials and supplies, $0.3 million
in equipment and depreciation costs, $0.1 million for travel and $0.3 million of other operating expense. The increase in personnel-related
expense was due primarily to an increase in average headcount of 65%, from an average of 51 people in 2020 to an average of 84 people
in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Sales and Marketing Expenses</i>. Sales and marketing expenses increased
$2.1 million, or 244%, from $0.9 million in the year ended 2020 to $3.0 million during the year ended December 31, 2021. The increase
in sales and marketing costs was primarily due to increases of $1.6 million in personnel-related expenses, $0.3 million in advertising,
$0.1 million in facility expense, and $0.1 million in travel expense. The increase in personnel-related expense was due to an average
headcount increase of 50%, from an average of 4 people in 2020 to an average of 6 people in 2021 with the remainder of the increase attributable
to increases in wages and benefits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>General and Administrative Expenses</i>. General and administrative
expenses increased $10.9 million, or 467%, to $13.2 million during the year ended December 31, 2021, compared to $2.3 million during the
year ended December 31, 2020. The increase in general and administrative costs was due to an increase of $4.5 million in personnel-related
expenses, an increase of $2.7 million in professional fees, $1.8 million in insurance as a result of becoming a public company, $1.0 million
of facilities expenses associated with our expansion and new lease, $0.2 million in computer equipment, $0.1 million in travel and $0.6
million of other expense. The increase in professional fees resulted from consulting, audit and legal fees associated with work performed
in the year ended December 31, 2021 to produce public company financial statements for the past two years and with becoming a public company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Change in Fair Value of Warrant Liabilities</i>. The change in fair
value of warrant liabilities during the year ended December 31, 2021 was a $3.1 million gain. The change in fair value of warrant liability
resulted from the remeasurement of the public and private placement warrant liabilities between September 17, 2021 and the end of the
reporting period, December 31, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interest Income</i>. Interest income decreased by $0.1 million,
or 82% during the year ended December 31, 2021, compared to the year ended December 31, 2020. The decrease in interest income was primarily
due to a decrease in average short-term investments during the year ended December 31, 2021, compared to the year ended December 31, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Interest Expense</i>. Interest expense increased by $0.1 million
during the year ended December 31, 2021, compared to the year ended December 31, 2020. This was primarily due to having the $1.5 million
term loan outstanding for nine months in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Income Taxes</i>. Our income tax provision consists of an estimate
for U.S. federal and state income taxes based on enacted rates, as adjusted for allowable credits, deductions, uncertain tax positions,
changes in deferred tax assets and liabilities and changes in tax law. Due to cumulative losses, we maintain a valuation allowance against
our U.S. and state deferred tax assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Liquidity and Capital Resources</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To date, our primary sources of capital had been private placements
of preferred stock prior to the Business Combination and recapitalization with D8. We have incurred a net loss in each of our annual periods
since our inception. We incurred net losses of $35.2 million and $12.9 million during the years ended December 31, 2021 and 2020, respectively.
As of December 31, 2021, we held cash and cash equivalents of $173.5 million and had an accumulated deficit of $66.8 million.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We expect net losses to continue in connection with our ongoing activities,
particularly as we continue to invest in commercialization and new product development. We believe our current cash balance of $173.5
million will be sufficient to support our operations beyond the next twelve months.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We may seek to sell additional common or preferred equity or convertible
debt securities, enter into an additional credit facility or another form of third-party funding or seek other debt financing. The sale
of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or
convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. The terms
of debt securities issued or borrowings pursuant to a credit agreement could impose significant restrictions on our operations. If we
raise funds through collaborations and licensing arrangements, we might be required to relinquish significant rights to our platform technologies
or products or grant licenses on terms that are not favorable to us. Additional capital may not be available on reasonable terms, or at
all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our cash and cash equivalents balance as of December 31, 2021 was $173.5
million. Our future capital requirements may vary from those currently planned and will depend on various factors, including the timing
and extent of R&amp;D spending and spending on other strategic business initiatives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash Flows Summary</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Comparison of the Years Ended December 31, 2021 and December 31,
2020</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">(in thousands)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Statement of Cash Flows Data:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Net cash used in operating activities</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(33.3</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(12.0</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 10pt">Net cash provided by (used in) investing activities</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(1.3</td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.2</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Net cash provided by financing activities</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">192.2</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13.5</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Cash flows for the Years Ended December 31, 2021 and 2020</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Operating Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash used in operating activities for the year ended December 31,
2021 was $33.3 million, attributable to a net loss of $35.2 million and a net change in our net operating assets and liabilities of $1.0
million and non-cash items that generated a change of $0.9 million. Non-cash items consisted of $3.7 million in stock-based compensation
and $0.3 million of depreciation and amortization, partially offset by a $3.1 million gain due to the change in fair value of our warrant
liabilities. The $1.0 million change in our net operating assets and liabilities was primarily due to a $3.7 million increase in accrued
expenses, a $1.1 million increase in accounts payable, and a $0.8 million increase in deferred rent partially offset by a $4.6 million
increase in prepaid and other assets.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash used in operating activities for the year ended December 31,
2020 was $12.0 million, attributable to a net loss of $12.9 million and a net change in our net operating assets and liabilities of $0.3
million and non-cash items of $0.6 million. Non-cash items consisted of $0.4 million in stock-based compensation and $0.2 million in depreciation.
The $0.3 million change in our net operating assets and liabilities was primarily due to a $0.2 million increase in accounts payable and
a $0.1 million increase in accrued expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash flows used in Investing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by investing activities for the year ended December
31, 2021 was $1.3 million for equipment purchases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by investing activities for the year ended December
31, 2020 was $13.2 million and related to the sales and maturities of short-term investments of $13.3 million, offset by purchases of
property and equipment of $0.1 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Cash flows provided by Financing Activities</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities for the year ended December
31, 2021 was $192.2 million resulting from $190.4 million of proceeds from the reverse recapitalization and $1.5 million related to proceeds
from a term loan, $0.4 million of proceeds from the exercise of stock options and warrants, partially offset by $0.2 million of cash used
to pay back a portion of the outstanding term and equipment loans and $0.1 million for other items.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Net cash provided by financing activities for the year ended December
31, 2020 was $13.5 million and related to proceeds of $13.5 million from the issuance of our Series A3 convertible preferred stock.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Critical Accounting Policies and Estimates</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our consolidated financial statements have been prepared in accordance
with U.S. GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the
reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the consolidated balance sheet
date, as well as the reported expenses incurred during the reporting periods. Our management bases its estimates on historical experience
and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying
values of assets and liabilities. Actual results could differ from those estimates, and such differences could be material to our consolidated
financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While our significant accounting policies are described in the notes
to our historical financial statements (see Note 2 of the accompanying financial statements), we believe the following critical accounting
policy requires significant judgment and estimates in the preparation of our financial statements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Stock-Based Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We account for all stock-based compensation, including stock options
and warrants, at fair value and recognize stock-based compensation expense for those equity awards, net of actual forfeitures, over the
requisite service period, which is generally the vesting period of the respective award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The fair value of our stock options and warrants on the date of grant
is determined by a Black-Scholes pricing model utilizing key assumptions such as the fair value of the common stock, expected volatility
and expected term. Our estimates of these assumptions are primarily based on the fair value of our stock, historical data, peer company
data and judgment regarding future trends. The fair value of our common stock has been determined by our board of directors at each award
grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, our financial position
and historical financial performance, the status of technological developments within our proposed products, the illiquid nature of the
common stock, arm’s length sales of our capital stock, including convertible preferred stock, the effect of the rights and preferences
of the preferred shareholders, and the prospects of a liquidity event, among others, as our common stock is not actively traded. We use
the simplified method when calculating the expected term due to insufficient historical exercise data. Our stock is currently publicly
traded, the volatility is based on a benchmark of comparable companies within the automotive and energy storage industries. The dividend
yield used is zero, as we have never paid any cash dividends and does not anticipate doing so in the foreseeable future.&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Recently Adopted Accounting Pronouncements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">A description of recently issued accounting pronouncements that may
potentially impact our financial position and results of operations is disclosed in Note 2 “Summary of Significant Accounting Policies
– Recently Issued Accounting Pronouncements” in our condensed financial statements contained in this Annual Report on Form
10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Emerging Growth Company</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Following the Business Combination, we became an “emerging growth
company,” as defined in the JOBS Act. Pursuant to the JOBS Act, an emerging growth company is provided the option to adopt new or
revised accounting standards that may be issued by FASB or the SEC either (i) within the same periods as those otherwise applicable to
non-emerging growth companies or (ii) within the same time periods as private companies. We intend to take advantage of the exemption
for complying with new or revised accounting standards within the same time periods as private companies. Accordingly, the information
contained herein may be different than the information you receive from other public companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We also intend to take advantage of some of the reduced regulatory
and reporting requirements of emerging growth companies pursuant to the JOBS Act so long as we qualify as an emerging growth company,
including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation, and exemptions from the requirements of holding non-binding advisory
votes on executive compensation and golden parachute payments.&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_013"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.</b>&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_014"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Audited Consolidated Financial Statements of Vicarious
Surgical Inc. (formerly D8 Holdings Corp.)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tbody><tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; padding-left: 0.125in; text-indent: -0.125in; width: 90%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Index
    to Financial Statements and Financial Statement Schedules</b></span></td>
    <td style="width: 1%"><b>&nbsp;</b></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Number</b></span></td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No. 34)</span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-2</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt"><a href="#f_002">Consolidated Balance Sheet as of December 31, 2021 and 2020</a></span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</a></span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-size: 10pt"><a href="#f_004">Consolidated Statements of
    Convertible Preferred Stock, Common Stock and Stockholders’ Equity/(Deficit) for the years ended December 31, 2021 and
    2020</a> </span></td>
    <td>&nbsp;</td>
    <td style="text-align: center">F-5</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-size: 10pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td>
    <td>&nbsp;</td>
    <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 31.5pt">&nbsp;</p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_015"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_016"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9A. CONTROLS AND PROCEDURES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Background and Material Weakness</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with our evaluation of disclosure controls and procedures
covering our consolidated financial statements as of December 31, 2020 and 2021, we identified material weaknesses in our internal control
over financial reporting. We have concluded that material weaknesses exist in our evaluation of disclosure controls and procedures, including
internal control over financial reporting, as we do not have the necessary business processes, personnel and related internal controls
to operate in a manner to satisfy the accounting and financial reporting requirements of a public company. These material weaknesses manifested
themselves in ways that included the improper segregation of duties relating to the recording of journal entries and the reconciliation
of key accounts, as well as the analysis of accounting for certain transactions and accounts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are focused on designing and implementing effective internal controls
measures to improve our evaluation of disclosure controls and procedures, including internal control over financial reporting, and remediate
the material weaknesses. In order to remediate these material weaknesses, we have taken and plan to take the following actions:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">the hiring and continued hiring of additional accounting, finance and legal resources with public company experience; and</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 24px">&nbsp;</td>
    <td style="width: 24px"><span style="font-size: 10pt">●</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">implementation of additional review controls and processes requiring timely account reconciliation and analyses of certain transactions and accounts.</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">These actions and planned actions are subject
to ongoing evaluation by management and will require testing and validation of design and operating effectiveness of internal controls
over financial reporting over future periods. We are committed to the continuous improvement of our internal control over financial reporting
and will continue to review the internal controls over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Evaluation of Disclosure Controls and Procedures</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the supervision and with the participation of our management,
including our principal executive officer and principal financial and accounting officer, we conducted an evaluation of the effectiveness
of our disclosure controls and procedures as of the end of the fiscal year ended December 31, 2021, as such term is defined in Rules 13a-15(e)
and 15d-15(e) under the Exchange Act. Based upon their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that
our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were not effective as of December
31, 2021 to provide reasonable assurance that information required to be disclosed in the reports we file and submit under the Securities
and Exchange Act is recorded, processed, summarized and reported as and when required.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Disclosure controls and procedures are designed to ensure that information
required to be disclosed by us in our Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified
in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal
executive officer and principal financial officer or persons performing similar functions, as appropriate to allow timely decisions regarding
required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Changes in Internal Control over Financial Reporting</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Other than the material weakness described above, and the acquisition
of D8, there have been no changes in our internal control over financial reporting identified in connection with the evaluation of such
internal control required by Rules 13a-15(d) and 15d-15(d) under the Exchange Act that occurred during the fiscal year ended December
31, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_017"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9B. OTHER INFORMATION.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.3in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p><div>

</div><div><a id="a_018"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT
INSPECTIONS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_019"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
III</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_020"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board of Directors and Management</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">The
following table sets forth certain information concerning our executive officers and directors as of March </span>1<span style="font-family: Times New Roman, Times, Serif">,
2022:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Age</b></span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 42%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Position</b></span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Executive Officers:</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Sachs</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">30</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer, President and Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sammy Khalifa</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Technology Officer and Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Kelly</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer and Treasurer</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June Morris</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">72</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Legal Officer, General Counsel and Secretary</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Non-Employee Directors:</b></span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Styka</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">63</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman of the Board</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samir Kaul</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">48</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Liang</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">40</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ric Fulop</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">47</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dror Berman</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">43</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald Tang</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Ho</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">69</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Executive Officers</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Adam Sachs</i></b> has served as our President
and Chief Executive Officer and as a member of our board of directors since the Closing of the Business Combination in September&nbsp;2021,
and had served as Legacy Vicarious’ President and Chief Executive Officer and a member of Legacy Vicarious’ board of directors,
or the Legacy Vicarious Board, since 2014. Mr.&nbsp;Sachs received his B.S. in Engineering from the Massachusetts Institute of Technology
in 2014. Prior to founding Legacy Vicarious in 2014, from June&nbsp;2012 to January&nbsp;2013, Mr.&nbsp;Sachs worked in Manufacturing
Design at Apple. Mr.&nbsp;Sachs’ qualifications to serve on our board of directors include his previous board experience serving
on the Legacy Vicarious Board, his deep experience founding, managing and directing all aspects of Legacy Vicarious operations for over
six&nbsp;years and his extensive experience in robotics, engineering, manufacturing and product development.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24pt">&nbsp;</p><div>
</div><p style="margin: 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sammy Khalifa </i></b>has served as our Chief
Technology Officer and as a member of our board of directors since the Closing of the Business Combination in September&nbsp;2021, and
had served as Legacy Vicarious’ Chief Technology Officer since 2015 and as a member of the Legacy Vicarious Board since 2018. Prior
to working full time at Legacy Vicarious, Mr.&nbsp;Khalifa worked at Apple as a Product Design Engineer from December&nbsp;2013 to May&nbsp;2015.
Prior to that, Mr.&nbsp;Khalifa worked as a Biomedical Design Engineer at Hemedex, Inc. Mr.&nbsp;Khalifa received his B.S. in Mechanical
Engineering from the Massachusetts Institute of Technology in 2012. Mr.&nbsp;Khalifa’s qualifications to serve on our board of directors
include his previous board experience serving on the Legacy Vicarious Board as well as his extensive experience in robotics, product development
and engineering.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>William Kelly </i></b>has served as our Chief
Financial Officer and Treasurer since the Closing of the Business Combination in September&nbsp;2021, and had served as Legacy Vicarious’
Chief Financial Officer since January&nbsp;2021. Prior to joining Legacy Vicarious, Mr.&nbsp;Kelly served as Chief Financial Officer at
Exosome Diagnostics, a privately held life science company focused on developing and commercializing revolutionary biofluid-based diagnostics,
from 2014 to 2018. Before joining Exosome Diagnostics, Inc., Mr.&nbsp;Kelly served as Chief Financial Officer of Repligen Corporation
from 2008 to 2014, a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems.
Mr.&nbsp;Kelly received a B.A. from the College of the Holy Cross and an M.B.A. and M.S. in Accounting from the Graduate School of Professional
Accounting at Northeastern University.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>June Morris </i></b>has served as our Chief
Legal Officer, General Counsel and Secretary since the Closing of the Business Combination in September&nbsp;2021, and had served as Legacy
Vicarious’ Chief Legal Officer and General Counsel since February&nbsp;2021. Prior to joining Legacy Vicarious, Ms.&nbsp;Morris
served as Managing Partner and General Counsel of FT Management&nbsp;&amp; Associates, a private consulting firm, from March&nbsp;2017
until February&nbsp;2021 and as VP&nbsp;&amp; General Counsel of Northern Power Systems from 2016 to February&nbsp;2017. Ms.&nbsp;Morris
has also served as General Counsel and Chief Legal Officer at Picis Inc., Pegasystems, Sequoia Systems and LISP Machine. Ms.&nbsp;Morris
holds an M.P.A. from the Sawyer Graduate School of Management at Suffolk University and a Juris Doctorate from Suffolk University School
of Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Non-Employee Directors</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>David Styka </i></b>has served as the chairman
and a member of our board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as member
of the Legacy Vicarious Board since October&nbsp;2020. Mr.&nbsp;Styka served as the Chief Financial Officer for Auris Health, a company
specializing in robotic medical platform development, from August&nbsp;2014 till June&nbsp;2019. In addition to the responsibilities associated
with his role of Chief Financial Officer at Auris Health, Mr.&nbsp;Styka was also responsible for investor relations and securing financing
for the company. Mr.&nbsp;Styka received his B.A. in Business Economics from the University of California, Santa Barbara in 1991. Mr.&nbsp;Styka’s
qualifications to serve on our board of directors include his previous board experience serving as a member of the Legacy Vicarious Board,
his experience managing companies and his extensive business and finance experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Dror Berman </i></b>has served a member of
our board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as member of the Legacy Vicarious
Board since January&nbsp;2018. In 2010, Mr.&nbsp;Berman co-founded Innovation Endeavors, a venture fund focused on transformational technologies.
At Innovation Endeavors, Mr.&nbsp;Berman oversees investment activities and personnel. Mr.&nbsp;Berman also currently serves on the board
of several private companies in connection with his role at Innovation Endeavors. Mr.&nbsp;Berman received his M.B.A. from the Stanford
Graduate School of Business in 2009 and his B.S. in Computer Science from Ben-Gurion University in 2005. Mr.&nbsp;Berman’s qualifications
to serve on our board of directors include his previous board experience serving as a member of the Legacy Vicarious Board and his extensive
business and finance experience at Innovation Endeavors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>


</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Samir Kaul</i></b> has served a member of
our board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as member of the Legacy Vicarious
Board since January&nbsp;2018. Mr.&nbsp;Kaul has been a General Partner at Khosla Ventures, a venture capital firm focusing on technology
investing, since February&nbsp;2006. He has served on the board of directors of Guardant Health, Inc. since April&nbsp;2014 and currently
serves on the boards of directors of several private companies. Previously, Mr.&nbsp;Kaul served as a member of the board of directors
of Gevo, Inc. from March&nbsp;2013 to May&nbsp;2014 and Amyris, Inc. from May&nbsp;2006 to May&nbsp;2012. Mr.&nbsp;Kaul holds a B.S. degree
in Biology from the University of Michigan, an M.S. degree in Biochemistry from the University of Maryland and an M.B.A. degree from Harvard
Business School. Mr.&nbsp;Kaul’s qualifications to serve on our board of directors include his previous board experience serving
as a member of the Legacy Vicarious Board, his wide-ranging experience in technology companies and insight in the management of startup
companies and the building of companies from early stage to commercial scale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Philip Liang </i></b>has served a member of
our board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as member of the Legacy Vicarious
Board since July&nbsp;2020. Since December&nbsp;2016, Mr.&nbsp;Liang has been a managing partner of E15VC, a global technology venture
fund. At E15VC, Mr.&nbsp;Liang’s responsibilities include assisting emerging growth companies and investors through the venture
capital life cycle. Mr.&nbsp;Liang sits on the board of directors for several of the companies affiliated with E15VC.&nbsp;Mr.&nbsp;Liang
received his Master of Science in Media Laboratory from the Massachusetts Institute of Technology in 2006. Mr.&nbsp;Liang’s qualifications
to serve on our board of directors include his previous board experience serving as a member of the Legacy Vicarious Board as well as
his business and finance experience at E15VC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Ric Fulop</i></b> has served a member of our
board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as member of the Legacy Vicarious
Board since June&nbsp;2020. Mr.&nbsp;Fulop has also served as the Chief Executive Officer and Chairman of the board of directors of Desktop
Metal, Inc. since December&nbsp;2020. Prior to that, Mr.&nbsp;Fulop served as the Chief Executive Officer of Legacy Desktop Metal from
its incorporation in 2015. Prior to the founding of Legacy Desktop Metal, Mr.&nbsp;Fulop was a general partner at North Bridge Venture
Partners from 2010 to 2015 and served as a founder of A123 Systems, Inc. from 2001 to 2010. Mr.&nbsp;Fulop currently serves on the board
of governors of World Economic Forum Advanced Manufacturing Initiative (nonprofit). Mr.&nbsp;Fulop holds an M.B.A. from the MIT Sloan
School of Management. Mr.&nbsp;Fulop’s qualifications to serve on our board of directors include his previous board experience serving
as a member of the Legacy Vicarious Board, his experience managing public companies and his extensive business and finance experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Donald Tang</i></b> has served a member of
our board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as D8’s President and
as a member of D8’s board of directors since June&nbsp;2020. In 2018, he founded Celadon Partners, a private equity firm focused
on mispriced opportunities ready for operational or strategic transformation. From 2004 to 2017, Mr.&nbsp;Tang worked at D.E.&nbsp;Shaw&nbsp;&amp;
Co., most recently as chief executive officer of D.E.&nbsp;Shaw&nbsp;&amp; Co. (Asia-Pacific). He was the sole D.E.&nbsp;Shaw&nbsp;&amp;
Co. partner on the investment side in Asia, and a founding member of the firm’s Asian private equity business. Mr.&nbsp;Tang started
his career at Citadel Investment Group in 2003. He is a member of the Harvard Kennedy School Mossavar-Rahmani Center for Business and
Government Advisory Council, Special Advisor (China) to the Milken Institute and a member of the Aspen Global Leadership Network. Mr.&nbsp;Tang
graduated from Carnegie Mellon University with a degree in computer science and business administration, and a minor in computational
finance. Mr.&nbsp;Tang’s qualifications to serve on our board of directors include his previous board experience serving as a member
of D8’s board of directors, his experience managing public companies and his extensive business, finance and private equity experience.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>David Ho</i></b> has served a member of our
board of directors since the Closing of the Business Combination in September&nbsp;2021, and had served as a member of D8’s board
of directors since April&nbsp;2021. Dr.&nbsp;Ho has been employed and has served on the board of directors of Columbia University since
January&nbsp;2020. Dr.&nbsp;Ho is the Founding Scientific Director of the Aaron Diamond AIDS Research Center, where he previously served
as the CEO, a director and professor at the ADARC from 1990 to December&nbsp;2019. Dr.&nbsp;Ho is the Clyde and Helen Wu Professor of
Medicine at Columbia University Irving Medical Center. Dr.&nbsp;Ho serves as a member of the Trustees of Caltech, and was previously a
board member of the MIT Corporation for 12&nbsp;years and Harvard Board of Overseers for 6&nbsp;years. Dr.&nbsp;Ho has been at the forefront
of AIDS research for 40&nbsp;years, publishing over 450 papers. Dr.&nbsp;Ho’s studies unraveled the nature of HIV replication in
vivo and revolutionized society’s basic understanding of the AIDS disease. This knowledge led Dr.&nbsp;Ho to champion combination
antiretroviral therapy that resulted in unprecedented control of HIV in patients. Dr.&nbsp;Ho’s research team is now devoting considerable
efforts on vaccine and antibody research in order to halt or slow the spread of the AIDS epidemic. Recently, Dr.&nbsp;Ho has been devoting
a considerable effort to develop novel strategies to diagnose, treat and prevent Covid-19 infection. Dr.&nbsp;Ho received his degrees
from California Institute of Technology and Harvard Medical School (Harvard-MIT Health Science and Technology program). Dr.&nbsp;Ho’s
qualifications to serve on our board of directors include his previous board experience serving as a member of D8’s board of directors
and his extensive research experience and medical background.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">There are no family relationships between or among
any of our directors or executive officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Role of Board in Risk Oversight</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors will have extensive involvement
in the oversight of risk management related to us and our business and will accomplish this oversight through the regular reporting to
the board of directors by the audit committee. The audit committee will represent our board of directors by periodically reviewing our
accounting, reporting and financial practices, including the integrity of our financial statements, the surveillance of administrative
and financial controls and our compliance with legal and regulatory requirements. Through its regular meetings with management, including
the finance, legal, internal audit and information technology functions, the audit committee will review and discuss all significant areas
of our business and summarize for our board of directors all areas of risk and the appropriate mitigating factors. In addition, our board
of directors will receive periodic detailed operating performance reviews from management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Composition of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our business and affairs will be managed under the
direction of our board of directors. Our board of directors is declassified, and the directors will be elected annually.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Independence of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NYSE rules generally require that independent directors
must comprise a majority of a listed company’s board of directors. Based upon information requested from and provided by each proposed
director concerning his or her background, employment and affiliations, including family relationships, we have determined that Messrs.
Kaul, Berman, Fulop, Liang and Styka and Dr.&nbsp;Ho, representing six of our directors, are “independent” as that term is
defined under the applicable rules and regulations of the SEC and the listing requirements and rules of the NYSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Board Committees</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The standing committees of our board of directors
consist of an audit committee, a compensation committee and a nominating and corporate governance committee. Our board of directors may
from time to time establish other committees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our chief executive officer and other executive
officers will regularly report to the non-executive directors and the audit, the compensation and the nominating and corporate governance
committees to ensure effective and efficient oversight of our activities and to assist in proper risk management and the ongoing evaluation
of management controls. We believe that the leadership structure of our board of directors will provide appropriate risk oversight of
our activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Audit Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our audit committee consists of Mr.&nbsp;Styka,
who serves as the chairperson, and Messrs. Fulop and Berman. Each proposed member of the audit committee qualifies as an independent director
under the NYSE corporate governance standards and the independence requirements of Rule&nbsp;10A-3 under the Exchange&nbsp;Act. Our board
of directors has determined that Mr.&nbsp;Styka qualifies as an “audit committee financial expert” as such term is defined
in Item&nbsp;407(d)(5)&nbsp;of Regulation&nbsp;S-K and possesses financial sophistication, as defined under the rules of the NYSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of the audit committee is to prepare
the audit committee report required by the SEC to be included in our proxy statement and to assist our board of directors in overseeing
and monitoring (1)&nbsp;the quality and integrity of the financial statements, (2)&nbsp;compliance with legal and regulatory requirements,
(3)&nbsp;our independent registered public accounting firm’s qualifications and independence, (4)&nbsp;the performance of our internal
audit function and (5)&nbsp;the performance of our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Our board of directors has adopted a written charter
for the audit committee, which is available on our website at <i>https://www.vicarioussurgical.com</i> under Investors&nbsp;—&nbsp;Governance&nbsp;—&nbsp;Governance
Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Compensation Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our compensation committee consists of Mr.&nbsp;Kaul,
who serves as the chairperson, Mr.&nbsp;Liang and Dr.&nbsp;Ho.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purpose of the compensation committee is to
assist our board of directors in discharging its responsibilities relating to (1)&nbsp;setting our compensation program and compensation
of our executive officers and directors, (2)&nbsp;monitoring our incentive and equity-based compensation plans and (3)&nbsp;preparing
the compensation committee report required to be included in our proxy statement under the rules and regulations of the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors has adopted a written charter
for the compensation committee, which is available on our website at <i>https://www.vicarioussurgical.com</i> under Investors&nbsp;—&nbsp;Governance&nbsp;—&nbsp;Governance
Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Nominating and Corporate Governance Committee</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our nominating and corporate governance committee
consists of Mr.&nbsp;Styka, who serves as the chairperson, and Mr.&nbsp;Liang. The purpose of the nominating and corporate governance
committee is to assist our board of directors in discharging its responsibilities relating to (1)&nbsp;identifying individuals qualified
to become new board of directors members, consistent with criteria approved by our board of directors, (2)&nbsp;reviewing the qualifications
of incumbent directors to determine whether to recommend them for reelection and selecting, or recommending that our board of directors
select, the director nominees for the next annual meeting of stockholders, (3)&nbsp;identifying members of the board of directors qualified
to fill vacancies on any committee of our board of directors and recommending that our board of directors appoint the identified member
or members to the applicable committee, (4)&nbsp;reviewing and recommending to our board of directors corporate governance principles
applicable to us, (5)&nbsp;overseeing the evaluation of our board of directors and management and (6)&nbsp;handling such other matters
that are specifically delegated to the committee by our board of directors from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors have adopted a written charter
for the nominating and corporate governance committee, which is available on our website at <i>https://www.vicarioussurgical.com</i> under
Investors&nbsp;—&nbsp;Governance&nbsp;—&nbsp;Governance Documents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Code of Business Conduct and Ethics</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We have adopted a code of business conduct and ethics
that applies to all of our directors, officers and employees, including our principal executive officer, principal financial officer and
principal accounting officer, which is available on our website at <i>https://www.vicarioussurgical.com</i> under Investors&nbsp;—&nbsp;Governance&nbsp;—&nbsp;Governance
Documents. Our code of business conduct is a “code of ethics,” as defined in Item&nbsp;406(b)&nbsp;of Regulation&nbsp;S-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our Internet website address is provided as an inactive
textual reference only. We will make any legally required disclosures regarding amendments to, or waivers of, provisions of our code of
ethics on our Internet website.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Compensation Committee Interlocks and Insider Participation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None of our officers currently serves, and in the
past year has not served, (i)&nbsp;as a member of the compensation committee or the board of directors of another entity, one of whose
officers served on the compensation committee, or (ii)&nbsp;as a member of the compensation committee of another entity, one of whose
officers served on the board of directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Corporate Governance Guidelines</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Our board of directors has adopted corporate governance
guidelines in accordance with the corporate governance rules of the NYSE that serve as a flexible framework within which our board of
directors and its committees operate. These guidelines cover a number of areas including board membership criteria and director qualifications,
director responsibilities, board agenda, meetings of non-management directors, committee responsibilities and assignments, board member
access to management and independent advisors, director communications with third parties, director compensation, director orientation
and continuing education, evaluation of our chief executive officer, and management succession planning. A copy of our corporate governance
guidelines is posted on our website at <i>https://www.vicarioussurgical.com</i> under Investors&nbsp;—&nbsp;Governance&nbsp;—&nbsp;Governance
Documents.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Delinquent Section 16(a) Reports</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Section 16(a) of the Exchange Act requires our officers,
directors and persons who own more than ten percent of a registered class of our equity securities to file reports of ownership and changes
in ownership with the SEC. <span style="font-family: Times New Roman, Times, Serif">These reporting persons are also required to furnish
us with copies of all Section 16(a) forms they file.</span></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based solely upon a review of such forms, we believe
that, during the year ended December 31, 2021, all filing requirements applicable to our officers, directors and greater than ten percent
beneficial owners were complied with, except that each of Adam Sachs, William Kelly, June Morris, David Styka, Philip Liang, Dror Berman,
Barry Greene, Khosla Ventures Seed C, L.P., Innovation Endeavors III LP, Chelvey International Ltd, and Gates Frontier, LLC filed a late
Form 3 and/or Form 4 upon the Closing of the Business Combination due to inadvertent administrative delays with respect to the Closing
of the Business Combination.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><div><a id="a_021"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 11. EXECUTIVE COMPENSATION.</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This section provides an overview of our executive
compensation programs, including a narrative description of the material factors necessary to understand the information disclosed in
the summary compensation table below.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As of December&nbsp;31, 2021, our named executive
officers, which we refer to as Named Executive Officers, or NEOs, were:</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Adam Sachs, <i>Chief Executive Officer and President</i>,</td>
</tr></tbody></table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">Sammy Khalifa, <i>Chief Technology Officer, </i>and</td>
</tr></tbody></table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: justify">William Kelly, <i>Chief Financial Officer and Treasurer.</i></td>
</tr></tbody></table><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The objective of our compensation program is to
provide a total compensation package to each NEO that will enable us to attract, motivate and retain outstanding individuals, align the
interests of our executive team with those of our equity holders, encourage individual and collective contributions to the successful
execution of our short- and long-term business strategies and reward NEOs for performance. Our board of directors has historically determined
the compensation for the NEOs.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Summary Compensation Table</b></p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows information concerning
the annual compensation for services provided to Legacy Vicarious prior to the Business Combination in September 2021 and to us for the
period thereafter by our NEOs for the years ended December&nbsp;31, 2020 and December 31, 2021.</p><div>

</div><p style="font: 7pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-indent: -0.125in; padding-left: 0.125in; border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Name and Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary <br>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus <br>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Stock Awards <br>
($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Option Awards <br>
($)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">All Other Compensation <br>
($)(3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total <br>
($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; width: 16%; text-align: left">Adam Sachs,</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: center">2021</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">267,753</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">158,999</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">2,426,343</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">3,030,414</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">10,710</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">5,894,219</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left">Chief Executive Officer and President</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">180,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,200</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">187,200</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Sammy Khalifa,</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">226,203</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">131,276</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,940,955</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,424,330</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">7,741</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,730,505</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left">Chief Technology Officer</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">160,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,400</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">166,400</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">William Kelly,</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">2021</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">279,038</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">108,698</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">648,172</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,026,454</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,070,362</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-style: italic; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Chief Financial Officer and Treasurer </i><sup>(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: center">2020</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 23.75pt">(1)</td><td>The amounts represent the aggregate grant date fair value for restricted stock unit (“RSU”) awards, computed in accordance
with Financial Accounting Standards Board Accounting Standards Codification Topic 718 (“ASC 718”). A discussion of our methodology
for determining grant date fair value may be found in Note 10 “Stockholders’ Equity” in our consolidated financial statements
included elsewhere in this Annual Report on Form 10-K.</td></tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 23.75pt">(2)</td><td>The amounts represent the aggregate grant date fair value for option awards, computed in accordance with ASC 718. A discussion of
our methodology for determining grant date fair value may be found in Note 10 “Stockholders’ Equity” in our consolidated
financial statements included elsewhere in this Annual Report on Form 10-K.</td></tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 23.75pt">(3)</td><td>The amounts represent 401(k) matching contributions by us for the periods presented unless described otherwise.</td></tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tbody><tr style="vertical-align: top">
<td style="width: 23.75pt">(4)</td><td>Mr. Kelly commenced employment with us on January 29, 2021.</td></tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Outstanding Equity Awards at 2021 Fiscal Year-End</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following table shows information regarding
outstanding equity awards held by the NEOs as of December&nbsp;31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="15" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option Awards</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock Awards</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Name    </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Grant<br>
 Date    </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of<br>
 Securities<br>
 Underlying<br>
 Unexercised<br>
 Options<br>
 Exercisable<br>
 (#)  </td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">  Number of<br>
 Securities<br>
 Underlying<br>
 Unexercised<br>
 Options<br>
 Unexercisable<br>
 (#)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">  Option<br>
 Exercise<br>
 Price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Option<br>
 Expiration<br>
 Date</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of<br>
 Shares or<br>
 Units That<br>
 Have<br>
 Not Vested</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">    Market<br>
 Value of<br>
 Shares or<br>
 Units of<br>
 Stock That<br>
 Have Not<br>
 Vested</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">&nbsp;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adam Sachs    </td><td>&nbsp;</td>
    <td style="text-align: center">    11/23/2021</td><td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">    24,360</span></td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"> 365,414</span></td><td style="text-align: left"><sup>(1)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 12.45</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"> 11/22/2031</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 18%">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="text-align: center; width: 11%">11/23/2021</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">&nbsp;</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">182,707</td><td style="width: 1%; text-align: left"><sup>(2)</sup></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,940,348</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sammy Khalifa</td><td>&nbsp;</td>
    <td style="text-align: center">11/23/2021</td><td>&nbsp;</td>
    <td style="text-align: right">19,488</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">292,331</td><td style="text-align: left"><sup>(3)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span style="font-size: 10pt"> 12.45</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">11/22/2031</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">11/23/2021</td><td>&nbsp;</td>
    <td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">146,157</td><td style="text-align: left"><sup>(4)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1,552,187</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">William Kelly</td><td>&nbsp;</td>
    <td style="text-align: center">02/25/2021</td><td>&nbsp;</td>
    <td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,024,263</td><td style="text-align: left"><sup>(5)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">1.90</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">02/24/2031</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: center">11/23/2021</td><td>&nbsp;</td>
    <td style="text-align: right">6,507</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">97,618</td><td style="text-align: left"><sup>(6)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12.45</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt">11/22/2031</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"> </td><td>&nbsp;</td>
    <td style="text-align: center">11/23/2021</td><td>&nbsp;</td>
    <td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">48,809</td><td style="text-align: left"><sup>(7)</sup></td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">518,352</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt">&nbsp;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 20pt"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Represents an option to purchase 389,774 shares of Class A common
stock granted on November 23, 2021. The shares underlying this option vest, subject to continued service, as follows: 24,360 shares vested
on December 20, 2021, with the remainder vesting in equal monthly installments over the following 48-month period.</td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Represents 194,887 RSUs granted on November 23, 2021. The RSUs
vest, subject to continued service, as follows: 12,180 of the shares vested on December 20, 2021, with the remainder vesting in equal
quarterly installments over the following four-year period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Represents an option to purchase 311,819 shares of Class A common
stock granted on November 23, 2021. The shares underlying this option vest, subject to continued service, as follows: 19,488 shares vested
on December 20, 2021, with the remainder vesting in equal monthly installments over the following 48-month period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Represents 155,900 RSUs granted on November 23, 2021. The RSUs
vest, subject to continued service, as follows: 9,743 of the shares vested on December 20, 2021, with the remainder vesting in equal
quarterly installments over the following four-year period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Represents an option to purchase 1,024,263 shares of Class A
common stock granted on February 25, 2021. The shares underlying this option vest, subject to continued service, as follows: 256,065
shares vest on January 29, 2022, with the remainder vesting in equal monthly installments over the following 36-month period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Represents an option to purchase 104,125 shares of Class A common
stock granted on November 23, 2021. The shares underlying this option vest, subject to continued service, as follows: 6,507 shares vested
on December 20, 2021, with the remainder vesting in equal monthly installments over the following 48-month period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(7)</td><td style="text-align: justify">Represents 52,062 RSUs granted on November 23, 2021. The RSUs
vest, subject to continued service, as follows: 3,253 of the shares vested on December 20, 2021, with the remainder vesting in equal
quarterly installments over the following four-year period.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employment Arrangements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In July&nbsp;2021, Legacy Vicarious entered into
employment agreements with our executive officers, including our NEOs, which was assumed by us effective as of the Closing of the Business
Combination, the material terms of which are described below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Adam Sachs</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Legacy Vicarious entered into an employment agreement
with Mr.&nbsp;Sachs on July&nbsp;13, 2021, pursuant to which Mr.&nbsp;Sachs will serve as our President and Chief Executive Officer and
will report directly to our board of directors or our board of directors’ designee. Mr.&nbsp;Sachs’s service pursuant to the
employment agreement will continue until terminated in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Under the employment agreement, Mr.&nbsp;Sachs will
receive an initial annual base salary of $531,234, which will be subject to increase at the discretion of our board of directors or a
subcommittee thereof and will be eligible to receive an annual performance bonus targeted at 75% of Mr.&nbsp;Sachs’s then-current
annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable company and/or
individual performance objectives, as determined by our board of directors or a subcommittee thereof. Pursuant to the employment agreement,
Mr.&nbsp;Sachs will also be eligible to participate in customary welfare and fringe benefit plans, provided by us to our employees at
the same level as Mr.&nbsp;Sachs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Pursuant to the terms of the 2021 Equity Incentive
Plan, and subject to the approval of our board of directors or a subcommittee thereof, in May of each calendar year that Mr.&nbsp;Sachs
remains employed by us, Mr.&nbsp;Sachs shall be eligible to receive an annual equity award. Beginning in May&nbsp;2022, the value of such
annual equity award shall be $5,502,700, awarded 50% in restricted stock units (“Annual RSU Award”) with a value of $2,751,350
(the number of restricted stock units determined by reference to the closing market price of a share of our common stock on the&nbsp;day
immediately preceding the date of grant) and 50%, or a fair value of $2,751,350, in our stock options to purchase a number of shares of
our common stock (“Annual Option Award”) calculated by dividing the fair value of the stock option award by the then current
Black-Scholes value of our stock options, at a per share exercise price equal to the Fair Market Value (as defined in the 2021 Equity
Incentive Plan) of our common stock on the date of grant. On November 23, 2021, our board of directors granted Mr.&nbsp;Sachs a restricted
stock unit award consisting of 194,887 RSUs (“Initial RSU Award”) and a stock option award to purchase 389,774 shares of our
common stock (“Initial Option Award”). Provided that Mr.&nbsp;Sachs remains employed by us on the vesting date (except as
otherwise provided in such agreement or the 2021 Equity Incentive Plan), (i) the shares and RSUs subject to the Annual RSU Awards and
Annual Option Awards shall vest in equal installments on the last&nbsp;day of each successive month thereafter for a period of 48&nbsp;months,
(ii) the RSUs subject to the Initial RSU Award shall vest in 16 equal quarterly installments beginning on September 20, 2021, provided
that the initial quarterly vesting installment shall not occur until December 20, 2021, and (iii) the shares subject to the Initial Option
Award shall vest in 48 equal monthly installments beginning on September 20, 2021, provided that the initial three months of vesting shall
not occur until December 20, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In the event that Mr.&nbsp;Sachs is terminated without
cause or resigns from his position for good reason, he would be entitled to receive a severance payment equal to one year of his then
in-effect base salary plus the pro-rata portion of his target bonus, as well as any earned but unpaid annual bonus and payment of an amount
equal to COBRA premiums for 12&nbsp;months. In the event that Mr.&nbsp;Sachs is terminated without cause or resigns from his position
for good reason within three&nbsp;months prior to or 12&nbsp;months following a change in control, he would be entitled to receive a severance
payment equal to two times the sum of his then in-effect base salary for 12&nbsp;months plus the pro-rata portion of his target bonus,
as well as any earned but unpaid annual bonus and payment of an amount equal to COBRA premiums for 24&nbsp;months. In addition, his outstanding
equity awards with time-based vesting will be vested in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We will reimburse Mr.&nbsp;Sachs for all ordinary
and reasonable out-of-pocket business expenses incurred by Mr.&nbsp;Sachs in furtherance of our business in accordance with its policies
with respect thereto as in effect from time to time. Mr.&nbsp;Sachs will be subject to our Non-Competition, Non-Solicitation, Non-Disclosure,
and Intellectual Property Agreement, which includes a one year post-employment covenant not to compete with us subject to certain limitations,
a one year post-employment covenant not to solicit, interfere with or service our customers, clients, vendors or partners or prospective
customers, clients, vendors or partners to or for a competing business, and a one year post-employment covenant not to solicit or hire
our employees or contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sammy Khalifa</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Legacy Vicarious entered into an employment agreement
with Mr.&nbsp;Khalifa on July&nbsp;13, 2021, pursuant to which Mr.&nbsp;Khalifa will serve as our Chief Technology Officer and will report
directly to our Chief Executive Officer. Mr.&nbsp;Khalifa’s service pursuant to the employment agreement will continue until terminated
in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Under the employment agreement, Mr.&nbsp;Khalifa
will receive an initial annual base salary of $425,000, which will be subject to increase at the discretion of our board of directors
or a subcommittee thereof and will be eligible to receive an annual performance bonus targeted at 75% of Mr.&nbsp;Khalifa’s then-current
annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable company and/or
individual performance objectives, as determined by our board of directors or a subcommittee thereof. Pursuant to the employment agreement,
Mr.&nbsp;Khalifa will also be eligible to participate in customary welfare and fringe benefit plans, provided us to our employees at the
same level as Mr.&nbsp;Khalifa.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Pursuant to the terms of the 2021 Equity Incentive
Plan, and subject to the approval of our board of directors or a subcommittee thereof, in May of each calendar year that Mr.&nbsp;Khalifa
remains employed by us, Mr.&nbsp;Khalifa shall be eligible to receive an annual equity award. Beginning in May&nbsp;2022, the value of
such annual equity award shall be $4,402,160, awarded 50% in restricted stock units (“Annual RSU Award”) with a value of $2,201,080
(the number of restricted stock units determined by reference to the closing market price of a share of our common stock on the&nbsp;day
immediately preceding the date of grant) and 50%, or a fair value of $2,201,080, in our stock options to purchase a number of shares of
our common stock (“Annual Option Award”) calculated by dividing the fair value of the stock option award by the then current
Black-Scholes value of our stock options, at a per share exercise price equal to the Fair Market Value (as defined in the 2021 Equity
Incentive Plan) of our common stock on the date of grant. On November 23, 2021, our board of directors granted Mr.&nbsp;Khalifa a restricted
stock unit award consisting of 155,900 RSUs (“Initial RSU Award”) and a stock option award to purchase 311,819 shares of our
common stock (“Initial Option Award”). Provided that Mr.&nbsp;Khalifa remains employed by us on the vesting date (except as
otherwise provided in such agreement or the 2021 Equity Incentive Plan), (i) the shares and RSUs subject to the Annual RSU Awards and
Annual Option Awards shall vest in equal installments on the last&nbsp;day of each successive month thereafter for a period of 48&nbsp;months,
(ii) the RSUs subject to the Initial RSU Award shall vest in 16 equal quarterly installments beginning on September 20, 2021, provided
that the initial quarterly vesting installment shall not occur until December 20, 2021, and (iii) the shares subject to the Initial Option
Award shall vest in 48 equal monthly installments beginning on September 20, 2021, provided that the initial three months of vesting shall
not occur until December 20, 2021.</p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In the event that Mr.&nbsp;Khalifa is terminated
without cause or resigns from his position for good reason, he would be entitled to receive a severance payment equal to 75% of his then
in-effect base salary for 12&nbsp;months plus the pro-rata portion of his target bonus, as well as any earned but unpaid annual bonus
and payment of an amount equal to COBRA premiums for 9&nbsp;months. In the event that Mr.&nbsp;Khalifa is terminated without cause or
resigns from his position for good reason within three&nbsp;months prior to or 12&nbsp;months following a change in control, he would
be entitled to receive a severance payment equal to the sum of his then in-effect base salary for 12&nbsp;months plus the pro-rata portion
of his target bonus, as well as any earned but unpaid annual bonus and payment of an amount equal to COBRA premiums for 12&nbsp;months.
In addition, his outstanding equity awards with time-based vesting will be vested in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We will reimburse Mr.&nbsp;Khalifa for all ordinary
and reasonable out-of-pocket business expenses incurred by Mr.&nbsp;Khalifa in furtherance of our business in accordance with its policies
with respect thereto as in effect from time to time. Mr.&nbsp;Khalifa will be subject to our Non-Competition, Non-Solicitation, Non-Disclosure,
and Intellectual Property Agreement, which includes a one year post-employment covenant not to compete with us subject to certain limitations,
a one year post-employment covenant not to solicit, interfere with or service our customers, clients, vendors or partners or prospective
customers, clients, vendors or partners to or for a competing business, and a one year post-employment covenant not to solicit or hire
our employees or contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>William Kelly</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Legacy Vicarious entered into an employment agreement
with Mr.&nbsp;Kelly on July&nbsp;13, 2021, pursuant to which Mr.&nbsp;Kelly will serve as our Chief Financial Officer and Treasurer and
will report directly to our Chief Executive Officer and our board of directors. Mr.&nbsp;Kelly’s service pursuant to the employment
agreement will continue until terminated in accordance with its terms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Under the employment agreement, Mr.&nbsp;Kelly will
receive an initial annual base salary of $350,000, which will be subject to increase at the discretion of our board of directors or a
subcommittee thereof and will be eligible to receive an annual performance bonus targeted at 50% of Mr.&nbsp;Kelly’s then-current
annual base salary. The actual amount of any such bonus will be determined by reference to the attainment of applicable company and/or
individual performance objectives, as determined by our board of directors or a subcommittee thereof. Pursuant to the employment agreement,
Mr.&nbsp;Kelly will also be eligible to participate in customary welfare and fringe benefit plans, provided by us to our employees at
the same level as Mr.&nbsp;Kelly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Pursuant to the terms of the 2021 Equity Incentive
Plan, and subject to the approval of our board of directors or a subcommittee thereof, in May of each calendar year that Mr.&nbsp;Kelly
remains employed by us, Mr.&nbsp;Kelly shall be eligible to receive an annual equity award. Beginning in May&nbsp;2022, the value of such
annual equity award shall be $1,470,000, awarded 50% in restricted stock units (“Annual RSU Award”) with a value of $735,000
(the number of restricted stock units determined by reference to the closing market price of a share of our common stock on the&nbsp;day
immediately preceding the date of grant) and 50%, or a fair value of $735,000, in our stock options to purchase a number of shares of
our common stock (“Annual Option Award”) calculated by dividing the fair value of the stock option award by the then current
Black-Scholes value of our stock options, at a per share exercise price equal to the Fair Market Value (as defined in the 2021 Equity
Incentive Plan) of our common stock on the date of grant. On November 23, 2021, our board of directors granted Mr.&nbsp;Kelly a restricted
stock unit award consisting of 52,062 RSUs (“Initial RSU Award”) and a stock option award to purchase 104,125 shares of our
common stock (“Initial Option Award”). Provided that Mr.&nbsp;Kelly remains employed by us on the vesting date (except as
otherwise provided in such agreement or the 2021 Equity Incentive Plan), (i) the shares and RSUs subject to the Annual RSU Awards and
Annual Option Awards shall vest in equal installments on the last&nbsp;day of each successive month thereafter for a period of 48&nbsp;months,
(ii) the RSUs subject to the Initial RSU Award shall vest in 16 equal quarterly installments beginning on September 20, 2021, provided
that the initial quarterly vesting installment shall not occur until December 20, 2021, and (iii) the shares subject to the Initial Option
Award shall vest in 48 equal monthly installments beginning on September 20, 2021, provided that the initial three months of vesting shall
not occur until December 20, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In the event that Mr.&nbsp;Kelly is terminated without
cause or resigns from his position for good reason, he would be entitled to receive a severance payment equal to 75% of his then in-effect
base salary for 12&nbsp;months plus the pro-rata portion of his target bonus, as well as any earned but unpaid annual bonus and payment
of an amount equal to COBRA premiums for 9&nbsp;months. In the event that Mr.&nbsp;Kelly is terminated without cause or resigns from his
position for good reason within three&nbsp;months prior to or 12&nbsp;months following a change in control, he would be entitled to receive
a severance payment equal to the sum of his then in-effect base salary for 12&nbsp;months plus the pro-rata portion of his target bonus,
as well as any earned but unpaid annual bonus and payment of an amount equal to COBRA premiums for 12&nbsp;months. In addition, his outstanding
equity awards with time-based vesting will be vested in full.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">We will reimburse Mr.&nbsp;Kelly for all ordinary
and reasonable out-of-pocket business expenses incurred by Mr.&nbsp;Kelly in furtherance of our business in accordance with its policies
with respect thereto as in effect from time to time. Mr.&nbsp;Kelly will be subject to our Non-Competition, Non-Solicitation, Non-Disclosure,
and Intellectual Property Agreement, which includes a one year post-employment covenant not to compete with us subject to certain limitations,
a one year post-employment covenant not to solicit, interfere with or service our customers, clients, vendors or partners or prospective
customers, clients, vendors or partners to or for a competing business, and a one year post-employment covenant not to solicit or hire
our employees or contractors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Employee Benefits</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Our NEOs participate in employee benefit programs
available to our employees generally, including a tax-qualified 401(k)&nbsp;plan. We do not maintain any executive-specific benefit or
perquisite programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Legacy Vicarious’ directors classified as
employees received no additional compensation for services as directors on the Legacy Vicarious Board. The following table summarizes
the compensation paid to our non-employee directors during the fiscal year ended December&nbsp;31, 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fees Earned <br> or Paid in <br> Cash <br> ($)(1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Stock <br> Awards <br> ($)(2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Option <br> Awards<br> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">All Other Compensation ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total <br> ($)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-align: left; text-indent: -10pt; padding-left: 10pt">Dror Berman</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">12,549</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">444,577</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">—</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">457,126</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Samir Kaul</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">14,555</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">444,577</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">459,132</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Philip Liang</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13,237</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">444,577</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">457,814</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ric Fulop <sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12,549</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">119,819</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">477,790</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">610,158</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Styka <sup>(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">27,849</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">119,819</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">63,250</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">210,918</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">David Ho</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">12,177</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">444,577</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">456,754</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Donald Tang</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,744</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">444,577</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">455,321</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">The amounts represent fees earned during 2021 under our Non-Employee
Director Compensation Policy.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: left">The amounts represent the aggregate grant date fair value
of RSU awards granted to each director in 2021, computed in accordance with ASC 718. A discussion of the assumptions used in determining
grant date fair value may be found in Note 10 “Stockholders’ Equity” in our consolidated financial statements included
elsewhere in this Annual Report on Form 10-K. Each non-employee director was granted 9,624 RSUs for their service on our board of directors
following the Business Combination (the “Annual Director RSU Grants”). The Annual Director RSU Grants vest in equal monthly
installments over 12 months beginning on September 20, 2021, subject to continued service through the applicable vesting date. Messrs.
Berman, Kaul, Liang, Ho and Tang were each granted 26,085 RSUs upon their appointment as our directors following the Business Combination
(the “Initial Director RSU Grants”). The Initial Director RSU Grants vest in equal monthly installments over 36 months beginning
on September 20, 2021, subject to continued service through the applicable vesting date.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: left">The amount represents the aggregate grant date fair value
of options granted to Mr. Fulop in 2021, computed in accordance with ASC 718. A discussion of the assumptions used in determining grant
date fair value may be found in Note 10 “Stockholders’ Equity” in our consolidated financial statements included elsewhere
in this Annual Report on Form 10-K. The amount also represents an option to purchase 409,702 of Class A common stock granted on January
25, 2021. The shares underlying this option vest in equal monthly installments over 48 months beginning on January 25, 2021, subject
to Mr. Fulop’s continued service through the applicable vesting date.</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: left">On June 2, 2021, Mr. Styka entered into a letter agreement
with Legacy Vicarious, which formalized Mr. Styka’s prior agreement to serve as executive chairman of the Legacy Vicarious Board,
which commenced on October 18, 2020. Under the terms of the letter agreement, Mr. Styka was eligible to receive an annual director fee
of $66,000, payable in equal monthly installments of $5,500. The amount included in the table represents cash payments paid in 2021 pursuant
to the letter agreement.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Director Compensation</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The non-employee director compensation policy provides
annual retainers for members serving on our board of directors and committees as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Position</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Retainer</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Chairperson of the Board</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">72,500</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Member of the Board</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">37,500</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Chairperson of the Audit Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,500</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Member of the Audit Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">6,300</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Chairperson of the Compensation Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">13,300</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Member of the Compensation Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">5,000</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Chairperson of the Nominating and Corporate Governance Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9,200</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Member of the Nominating and Corporate Governance Committee</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3,700</td><td style="text-align: left">&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">These fees are payable in arrears in quarterly installments
no later than the fifteenth&nbsp;day following the end of each calendar quarter, provided that the amount of such payment will be prorated
for any portion of such quarter that a director is not serving on our board of directors, on such committee or in such position. Non-employee
directors may elect to receive a restricted stock unit award with a grant date fair value of the retainer amounts in lieu of receiving
cash in such amounts. Non-employee directors are also reimbursed for reasonable out-of-pocket business expenses incurred in connection
with attending meetings of our board of directors and any committee of the board on which they serve and in connection with other business
related to the board. Directors may also be reimbursed for reasonable out-of-pocket business expenses in accordance with our travel and
other expense policies, as may be in effect from time to time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">In addition, we grant to new non-employee directors
upon their initial election to our board of directors a number of restricted stock units (each restricted stock unit relating to one share
of Class&nbsp;A common stock) having an aggregate fair market value equal to $301,800, determined by dividing (A)&nbsp;$301,800 by (B)&nbsp;the
closing price of Class&nbsp;A common stock on the NYSE on the date of the grant (rounded down to the nearest whole share), on the first
business&nbsp;day after the date that the non-employee director is first appointed or elected to our board of directors. Each of these
grants shall vest in equal monthly installments over 36&nbsp;months from the date of the grant, subject to the non-employee director’s
continued service as a director on the applicable vesting dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Furthermore, each non-employee director, who has
been serving on our board of directors for six&nbsp;months as of the date of any annual meetings of stockholders, shall automatically
receive a restricted stock unit award having an aggregate grant date fair value of $157,200, determined by dividing (A)&nbsp;$157,200
by (B)&nbsp;the closing price of Class&nbsp;A common stock on the NYSE on the date of the grant (rounded down to the nearest whole share),
each year on the first business&nbsp;day after our annual meeting of stockholders. Each of these restricted stock unit awards shall vest
in equal monthly installments over 12&nbsp;months from the date of the grant, subject to the non-employee director’s continued service
as a director on the applicable vesting dates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_022"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The following table sets forth information known
to us regarding the beneficial ownership of our common stock as of March 1, 2022 by:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">each person known to us to be the beneficial owner of more
than 5% of our outstanding common stock;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">each of our executive officers and directors; and</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">all of our executive officers and directors as a group.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Beneficial ownership is determined according to
the rules of the SEC, which generally provide that a person has beneficial ownership of a security if he, she or it possesses sole or
shared voting or investment power over that security, including options and warrants that are currently exercisable or exercisable within
60 days and restricted stock units that vest within 60 days. Shares of Class A common stock issuable upon exercise of options and warrants
currently exercisable within 60 days and restricted stock units that vest within 60 days are deemed outstanding solely for purposes of
calculating the percentage of total ownership and total voting power of the beneficial owner thereof.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">The beneficial ownership of our common stock is
based on 100,548,007 shares of our Class&nbsp;A common stock and 19,789,860 shares of our Class B common stock issued and outstanding
as of March 1, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Unless otherwise indicated, we believe that each
person named in the table below has sole voting and investment power with respect to all shares of our common stock beneficially owned
by them.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left; border-bottom: Black 1.5pt solid; font-weight: bold">Name and Address of Beneficial Owner</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number&nbsp;of <br> shares&nbsp;of <br> Class&nbsp;A <br> Common&nbsp;Stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of <br> shares <br> Class&nbsp;B <br> Common&nbsp;stock</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; font-weight: bold">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">% of <br> Total <br> Voting <br> Power**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; font-style: italic">Directors and Executive Officers:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Sachs<sup>(1)(2)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">69,022</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">11,329,695</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">57.3</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">45.7</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sammy Khalifa<sup>(1)(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">55,217</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,551,668</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23.0</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">William Kelly<sup>(1)(4)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">338,520</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">June Morris<sup>(1)(5)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">181,776</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dror Berman<sup>(6)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13,780,828</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13.7</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Samir Kaul<sup>(7)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20,966,807</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20.9</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philip Liang<sup>(8)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2,700,329</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.7</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ric Fulop<sup>(1)(9)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">133,645</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Styka<sup>(1)(10)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">483,062</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Donald Tang<sup>(11)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,545,685</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8.5</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Ho<sup>(12)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,685</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>All Current Directors and Executive Officers as a Group (11 Individuals)<sup>(9)</sup></b></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">47,265,576</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">47.0</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">15,881,363</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">80.3</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">73.5</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; font-style: italic; text-align: left">Five Percent Holders:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adam Sachs<sup>(1)(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">69,022</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">11,329,695</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">57.3</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">45.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sammy Khalifa<sup>(1)(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">55,217</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4,551,668</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">23.0</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">D8 Sponsor LLC<sup>(11)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8,535,000</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">8.5</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.7</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khosla Ventures, LLC<sup>(7)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20,956,122</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">20.8</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">4.2</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovation Endeavors III LP<sup>(6)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13,770,143</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">13.7</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sun Hung Kai Strategic Capital Ltd.<sup>(13)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5,148,970</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.1</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gates&nbsp;Frontier,&nbsp;LLC<sup>(14)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10,096,043</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">10.0</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">2.0</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cadin Limited<sup>(15)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">6,336,190</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">5.9</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1.3</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Barry Greene, M.D.<sup>(1)(16)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">18,283</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">3,908,497</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">19.7</td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">15.8</td><td style="text-align: left">%</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.27in; text-align: left">*</td><td style="text-align: justify">Indicates beneficial ownership of less than 1%.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.27in; text-align: left">**</td><td style="text-align: left">Percentage of total voting power represents voting power with
respect to all shares of our Class A common stock and our Class B common stock as a single class. Each share of our Class B common stock
is entitled to 20 votes per share and each share of our Class A common stock is entitled to 1 vote per share.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.27in; text-align: left">(1)</td><td style="text-align: left">Unless otherwise indicated, the business address of each of
these individuals is c/o Vicarious Surgical Inc., 78 Fourth Avenue, Waltham, Massachusetts 02451.</td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.27in; text-align: left">(2)</td><td style="text-align: left">Consists of (i) options to purchase 56,842 shares of our Class
A common stock exercisable within 60 days of March 1, 2022 held by Mr. Sachs, (ii) 12,180 shares of our Class A common stock issuable
upon vesting of RSUs within 60 days of March 1, 2022 held by Mr. Sachs, and (iii) 11,329,695 shares of our Class B common stock held
by Mr. Sachs.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.27in; text-align: left">(3)</td><td style="text-align: left">Consists of (i) options to purchase 45,474 shares of our Class
A common stock exercisable within 60 days of March 1, 2022 held by Mr. Khalifa, (ii) 9,743 shares of our Class A common stock issuable
upon vesting of RSUs within 60 days of March 1, 2022 held by Mr. Khalifa, and (iii) 4,551,668 shares of our Class B common stock held
by Mr. Khalifa.</td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(4)</td><td style="text-align: left">Consists of (i) options to purchase 335,267 shares of our
Class A common stock exercisable within 60 days of March 1, 2022 held by Mr. Kelly and (ii) 3,253 shares of our Class A common stock
issuable upon vesting of RSUs within 60 days of March 1, 2022 held by Mr. Kelly.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(5)</td><td style="text-align: left">Consists of (i) options to purchase 178,558 shares of our
Class A common stock exercisable within 60 days of March 1, 2022 held by Ms. Morris and (ii) 3,218 shares of our Class A common stock
issuable upon vesting of RSUs within 60 days of March 1, 2022 held by Ms. Morris.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(6)</td><td style="text-align: left">Consists of (i) 7,632 shares of our Class A common stock
held by Mr. Berman, (ii) 3,053 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held
by Mr. Berman, and (iii) 13,770,143 shares of our Class A common stock held by Innovation Endeavors III LP (“Innovation Endeavors”).
Mr. Berman is a managing partner at Innovation Endeavors, and as such may be deemed to have voting and investment control over the shares
held by Innovation Endeavors. The business address of Innovation Endeavors is 1845 El Camino Real, Palo Alto, CA 94306.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(7)</td><td style="text-align: left">Consists of (i) 7,632 shares of our Class A common stock
held by Mr. Kaul, (ii) 3,053 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Kaul, (iii) 7,896,787 shares of our Class A common stock held by Khosla Ventures Seed C, LP (“Khosla Ventures Seed C”),
and (iv) 13,059,335 shares of our Class A common stock held by Khosla Ventures V, LP (“Khosla Ventures V”). Khosla Ventures
Seed Associates C, LLC (“KVA Seed C”) is the general partner of Khosla Ventures Seed C. Khosla Ventures Associates V, LLC
(“KVA V”) is the general partner of Khosla Ventures V, LP. Vinod Khosla is the managing member of VK Services, LLC (“VK
Services”), which is the sole manager of KVA Seed C and KVA V. Each of KVA Seed C, VK Services and Vinod Khosla may be deemed to
possess voting and investment control over such securities held by Khosla Ventures Seed C, and each of KVA Seed C, VK Services and Vinod
Khosla may be deemed to have indirect beneficial ownership of such securities held by Khosla Ventures Seed C. Each of KVA&nbsp;V, VK&nbsp;Services
and Vinod Khosla may be deemed to possess voting and investment control over such securities held by Khosla Ventures V, and each of KVA
V, VK Services and Vinod Khosla may be deemed to have indirect beneficial ownership of such securities held by Khosla Ventures V. Each
of KVA Seed C, KVA V, VK Services and Vinod Khosla disclaims beneficial ownership of such shares except to the extent of his or its respective
pecuniary interests therein. Mr. Kaul is a General Partner and Managing Director of Khosla Ventures, LLC. Mr. Kaul disclaims any beneficial
ownership of the securities held by Khosla Ventures Seed C and Khosla Ventures V other than to the extent of any pecuniary interest he
may have therein, directly or indirectly. The business address of each of the reporting persons is 2121 Sand Hill Road, Menlo Park, CA
94025.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(8)</td><td style="text-align: left">Consists of (i) 7,632 shares of our Class A common stock
held by Mr. Liang, (ii) 3,053 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Liang, (iii) 2,389,644 shares of our Class A common stock held by Chelvey International Limited (“Chelvey”), and (iv)
300,000 shares of our Class A common stock held by E15 Fund Advisors (HK) Limited (“E15 Fund Advisors”). Chelvey is an entity
affiliated with E15 Fund II, LP (“E15”). Mr. Liang is the managing partner for E15. Shrikant Patnaik is a principal for E15.
Each of Messrs. Liang and Patnaik share voting and investment discretion with respect to the shares of our Class A common stock held
of record by E15, and as such may be deemed to have voting and investment control over the shares held by E15 and the entities affiliated
with E15. Mr. Liang is the managing partner for E15 Fund Advisors, and as such may be deemed to have voting and investment control over
the shares held by E15 Fund Advisors and the entities affiliated with E15 Fund Advisors. The business address of E15 is Ogier Global
(Cayman) Limited, 89 Nexus way, Camana Bay, Grand Cayman, KY1 — 9009, Cayman Islands. The business address of E15 Fund Advisors
is RMS2102 — 03 China Insurance Group Bldg., 141 Des Voeux Rd., Central, Hong Kong.</td>
</tr>
</tbody></table><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
<tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(9)</td><td style="text-align: left">Consists of (i) options to purchase 128,031 shares of our
Class A common stock exercisable within 60 days of March 1, 2022 held by Mr. Fulop, (ii) 4,010 shares of our Class A common stock held
by Mr. Fulop, and (iii) 1,604 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Fulop.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(10)</td><td style="text-align: left">Consists of (i) options to purchase 477,448 shares of our
Class A common stock exercisable within 60 days of March 1, 2022 held by Mr. Styka, (ii) 4,010 shares of our Class A common stock held
by Mr. Styka, and (iii) 1,604 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Styka.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(11)</td><td style="text-align: left">Consists of (i) 7,632 shares of our Class A common stock
held by Mr. Tang, (ii) 3,053 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Tang, and (iii) 8,535,000 shares of our Class A common stock held by D8 Sponsor LLC (“D8 Sponsor”). David Chu and Mr.
Tang are the managers of D8 Sponsor and share voting and investment discretion with respect to the shares of common stock held of record
by the D8 Sponsor. Each of the Messrs. Chu and Tang disclaims any beneficial ownership of the securities held by D8 Sponsor other than
to the extent of any pecuniary interest he may have therein, directly or indirectly. The business address of D8 Sponsor is Unit 1008,
10/F, Champion Tower, 3 Garden Road, Central, Hong Kong.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(12)</td><td style="text-align: left">Consists of (i) 7,632 shares of our Class A common stock
held by Mr. Ho and (ii) 3,053 shares of our Class A common stock issuable upon vesting of RSUs within 60 days of March 1, 2022 held by
Mr. Ho.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(13)</td><td style="text-align: left">Based on Schedule 13G filed by Sun Hung Kai &amp; Co Ltd.
(“SHK”), a publicly traded company on the Hong Kong Stock Exchange (SEHK: 86), on February 17, 2022. Consists of 5,148,970
shares of our Class A common stock held for the account of Sun Hung Kai Strategic Capital Ltd. (“SHK Strategic Capital”).
SHK is the sole shareholder of Shipshape Investments Ltd. (“Shipshape”), which is the sole shareholder of SHK Strategic Capital.
As a result of these relationships, each of SHK, Shipshape and SHK Strategic Capital may be deemed to share beneficial ownership of the
securities reported herein. The business address of each of SHK, Shipshape and SHK Strategic Capital is 42/F Lee Garden One, 33 Hysan
Avenue, Causeway Bay, Hong Kong.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(14)</td><td style="text-align: left">Based on Schedule 13G filed by Gates Frontier, LLC on September
24, 2021. Consists of 10,096,043 shares of our Class A common stock held by Gates Frontier, LLC. William H. Gates III is the sole member
of Gates Frontier, LLC, and as such may be deemed to have sole voting and dispositive power over the shares held by Gates Frontier, LLC.
The business address of Gates Frontier, LLC is 2365 Carillon Point, Kirkland, WA 98033.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left">(15)</td><td style="text-align: left">Consists of 6,336,190 private placement warrants and 6,336,190
shares of our Class A common stock issuable upon exercise of such private placement warrants. Voting and dispositive power over the shares
held by Cadin Limited is exercised by an investment committee consisting of Donald Tang, George Ho and Yunhan Shi. Each member has one
vote, and the approval of a majority is required to approve an action. Under the so-called “rule of three,” if voting and
dispositive decisions regarding an entity’s securities are made by three or more individuals, and voting or dispositive decisions
require the approval of a majority of those individuals, then none of the individuals is deemed a beneficial owner of the entity’s
securities. The business address of Cadin Limited is Appleby Global Services (Cayman) Limited, PO Box 500, 71 Fort Street, Grand Cayman,
KY1-1106, Cayman Islands.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.27in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">(16)</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">Consists
of (i) 18,283 shares of our Class A common stock held by Dr. Greene and (ii) 3,908,497 shares of our Class B common stock held by Dr.
Greene.</span></td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 23.75pt; text-indent: -23.75pt">&nbsp;</p><div>

</div><div><a id="a_023"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR
INDEPENDENCE.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>D8</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Relationship with Sponsor</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Prior to the consummation of D8’s initial
public offering, on May&nbsp;14, 2020, the Sponsor, paid $25,000, or approximately $0.003 per share, to cover certain offering costs in
consideration for 7,187,500 Class&nbsp;B ordinary shares, par value $0.0001 (the “D8 Founder Shares”). On June&nbsp;25, 2020,
the Sponsor transferred 15,000 D8 Founder Shares to Robert Kirby and 25,000 D8 Founder Shares to each of Michael Kives, Fred Langhammer
and Terry Lundgren, resulting in the Sponsor holding 7,097,500 D8&nbsp;Founder Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Pursuant to letter agreements dated as of July&nbsp;14,
2020 and April&nbsp;9, 2021, (the “Letter Agreements”), the Sponsor, Michael Kives, Fred Langhammer, Terry Lundgren, Robert
Kirby and each other director and officer of D8 (the “Insiders”) agreed, subject to limited exceptions, not to transfer, assign
or sell any of their D8 Founder Shares and any D8 Class&nbsp;A ordinary shares issuable upon conversion thereof (collectively, the “Subject
Securities”) until the earlier to occur of: (i)&nbsp;one year after the completion of D8’s initial business combination, or
(ii)&nbsp;the date on which D8 completes a liquidation, merger, share exchange or other similar transaction after the initial business
combination that results in all of D8’s shareholders having the right to exchange their Class&nbsp;A ordinary shares for cash, securities
or other property; except to certain permitted transferees and under certain circumstances (the “lock-up”). The Letter Agreements
further provided that, if (1)&nbsp;the closing price of Class&nbsp;A ordinary shares equaled or exceeded $12.00 per share (as adjusted
for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like) for any 20&nbsp;trading days within any
30-trading&nbsp;day period commencing at least 150&nbsp;days after the initial business combination or (2)&nbsp;if D8 consummated a transaction
after the initial business combination which resulted in its shareholders having the right to exchange their Class&nbsp;A ordinary shares
for cash, securities or other property, the D8 Founder Shares would be released from the lock-up.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the execution of the Business
Combination Agreement, D8 entered into a support agreement (the “Sponsor Support Agreement”) with the Sponsor, Michael Kives,
Fred Langhammer, Terry Lundgren, Robert Kirby and each other director and officer of D8, pursuant to which, among other things, the Letter
Agreements and the lock-up were amended so that the Lock-Up Period (as defined in the Sponsor Support Agreement) applicable to the Subject
Securities held by the Insiders will end on the earlier of (a)&nbsp;180&nbsp;days after the Closing Date and (b)&nbsp;the date on which
the volume weighted average closing sale price of one share of Class&nbsp;A common stock as reported on the NYSE (or the exchange on which
the shares of Class&nbsp;A common stock are then listed) is greater than or equal to $12.00 for a period of at least 20&nbsp;trading days
out of 30 consecutive&nbsp;trading days ending on the&nbsp;trading day immediately prior to the date of determination (which shall be
equitably adjusted for stock splits, reverse stock splits, stock dividends, reorganizations, recapitalizations, reclassifications, combination,
exchange of shares or other like change or transaction with respect to Class&nbsp;A common stock occurring on or after the Closing); provided
that, the 30&nbsp;day consecutive&nbsp;trading day period referenced above shall have commenced no earlier than 90&nbsp;days after the
Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Private Placement Warrants</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Simultaneously with the closing of D8’s initial
public offering on July&nbsp;17, 2020, D8 consummated the private placement of 8,000,000 private placement warrants to the Sponsor (the
“private placement warrants”), at a price of $1.00 per private placement warrant, generating gross proceeds of $8.0&nbsp;million.
As a result of the underwriters’ election to fully exercise their over-allotment option in full on July&nbsp;24, 2020, D8 consummated
a private sale of an additional 900,000 private placement warrants to the Sponsor, generating additional gross proceeds of $900,000. Each
whole private placement warrant is exercisable to purchase one share of Class&nbsp;A common stock at a price of $11.50 per share, subject
to adjustment. A portion of the proceeds from the private placement warrants was added to the proceeds from D8’s initial public
offering held in D8’s Trust Account. The private placement warrants are identical to the public warrants included in the D8&nbsp;Units&nbsp;sold
in D8’s initial public offering, except that the private placement warrants and the Class&nbsp;A common stock issuable upon exercise
of the private placement warrants, so long as they are held by their initial purchasers or their permitted transferees, (i)&nbsp;will
not be redeemable by us, (ii)&nbsp;may not (including the Class&nbsp;A common stock issuable upon exercise of these warrants), subject
to certain limited exceptions, be transferred, assigned or sold until 30&nbsp;days after the Closing of the Business Combination, (iii)&nbsp;may
be exercised by the holders on a cashless basis and (iv)&nbsp;are entitled to registration rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On December&nbsp;28, 2020, the Sponsor transferred
3,465,160 private placement warrants to Bright Insight Holdings Limited and 5,434,840 private placement warrants to Cadin Limited, resulting
in the Sponsor holding no private placement warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Sponsor Loan</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On May&nbsp;14, 2020, the Sponsor agreed to loan
D8 up to $300,000 to cover expenses related to the initial public offering pursuant to a promissory note (the “Sponsor Note”).
D8 borrowed approximately $127,000 under the Sponsor Note and fully repaid this note on July&nbsp;17, 2020.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Working Capital Loans</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On August&nbsp;23, 2021, D8 issued a convertible
promissory note (the “Bright Insight Note”) in the principal amount of $598,650 to Bright Insight Holdings Limited (the “Bright
Insight”) and a convertible promissory note (the “Cadin Note” and together with the Bright Insight Note, the “Notes”)
in the principal amount of $901,350 to Cadin Limited (“Cadin”). The Notes did not bear interest and were repayable in full
on the earlier of (i)&nbsp;July&nbsp;17, 2022 and (ii)&nbsp;the effective date of the initial business combination (such earlier date,
the “Maturity Date”). Bright Insight and Cadin each had the option, at any time on or prior to the Maturity Date, to convert
any amounts outstanding under their respective Note into private placement warrants at a conversion price equal to $1.00 per warrant.
We had the right to prepay any outstanding principal amount under the Notes at any time at its election and without penalty; <i>provided,
however</i>, that Bright Insight and Cadin would each have a right to first convert such principal balance upon notice of such payment.
The Notes were subject to customary events of default, the occurrence of which automatically trigger the unpaid principal balance of the
Notes and all other sums payable with regard to the Notes becoming immediately due and payable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the Closing of the Business Combination,
Bright Insight elected to convert the full principal outstanding of $598,650 on the Bright Insight Note into 598,650 private placement
warrants and Cadin elected to convert the full principal outstanding of $901,350 on the Cadin Note into 901,350 private placement warrants.
Each whole private placement warrant is exercisable to purchase one share of Class&nbsp;A common stock at a price of $11.50 per share,
subject to adjustment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Administrative Support Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Commencing upon consummation of its initial public
offering, D8 reimbursed the affiliate of the Sponsor $10,000 per month for office space, utilities, and secretarial and administrative
support services provided to members of its management team. D8 incurred and paid approximately $145,000 in these fees for the period
from May&nbsp;8, 2020 through the Closing of the Business Combination. Upon completion of the Business Combination, D8 ceased paying these
monthly fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">D8’s executive offices were located at Unit
1008, 10/F Champion Tower, 3 Garden Road, Central, Hong&nbsp;Kong, which office space was leased by an affiliate of the Sponsor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Underwriting Discount</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">UBS, as the underwriter of D8’s initial public
offering, which provided certain advice to D8 in connection with the Business Combination, received an underwriting commission of $6,037,500
in connection with the Closing of the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>PIPE Financing</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the execution of the Business
Combination Agreement, D8 entered into subscription agreements on April 15, 2021 and September 9, 2021 with certain qualified institutional
buyers and accredited investors (the “PIPE Investors”), pursuant to which, among other things, D8 issued and sold in the financing
an aggregate of 14,200,000 shares of Class&nbsp;A common stock to the PIPE Investors, for $10.00 per share immediately prior to the Closing,
for aggregate gross proceeds of $142.0&nbsp;million (the “PIPE Financing”). E15 Fund Advisors (HK) Limited (of which (i)&nbsp;Philip
Liang has shared voting and investment control over the entity’s shares and (ii)&nbsp;Donald Tang has pecuniary interest but disclaims
any beneficial ownership over the entity’s shares) purchased 300,000 shares of Class&nbsp;A common stock, Khosla Ventures&nbsp;V,
LP (of which Samir Kaul has shared voting and investment control over the entity’s shares) purchased 333,334 shares of Class&nbsp;A
common stock, and Innovation Endeavors&nbsp;III LP (of which Dror Berman has shared voting and investment control over the entity’s
shares) purchased 333,333 shares of Class&nbsp;A common stock in the PIPE Financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Legacy Vicarious</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Series&nbsp;A3 Financing</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">On July&nbsp;2, 2020, Legacy Vicarious entered into
a Series&nbsp;A3 preferred stock purchase agreement, as amended on November&nbsp;5, 2020 and December&nbsp;11, 2020, pursuant to which,
from July&nbsp;2, 2020 through December&nbsp;11, 2020, Legacy Vicarious issued an aggregate of 4,143,304 shares of Legacy Vicarious Series&nbsp;A3
preferred stock at a purchase price of $3.2862 per share for aggregate consideration of approximately $13.6&nbsp;million. The outstanding
shares of Legacy Vicarious Series&nbsp;A3 preferred stock were exchanged for shares of Class&nbsp;A common stock in connection with the
Closing of the Business Combination.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The participants in this preferred stock financing
include certain holders of more than 5% of Legacy Vicarious capital stock and entities related to Legacy Vicarious’ directors. The
following table sets forth the aggregate number of shares of Legacy Vicarious Series&nbsp;A3 preferred stock issued to these related persons
in this preferred stock financing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Aggregate Purchase Price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Date of Issuance</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Khosla Ventures<sup>(1)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right">304,302</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">999,997</td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 11%; text-align: right">July&nbsp;2,&nbsp;2020</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Innovation Endeavors<sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">304,302</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">999,997</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">July&nbsp;2,&nbsp;2020</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gates Frontier, LLC<sup>(3)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">304,302</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right">999,997</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: right">July&nbsp;2,&nbsp;2020</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt">&nbsp;&nbsp;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">Consists of 304,302 shares of Legacy Vicarious Series&nbsp;A3
preferred stock purchased by Khosla Ventures,&nbsp;V, LP.&nbsp;Samir Kaul, General Partner of Khosla Ventures, is a member of our board
directors.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: left">Consists of 304,302 shares of Legacy Vicarious Series&nbsp;A3
preferred stock purchased by Innovation Endeavors&nbsp;III, LP.&nbsp;Dror Berman, Partner of Innovation Endeavors, is a member of our
board directors.</td>
</tr></tbody></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: left">Consists of 304,302 shares of Legacy Vicarious Series&nbsp;A3
preferred stock purchased by Gates Frontier, LLC.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Investors’ Rights, Voting and Right of First Refusal Agreements</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with Legacy Vicarious’ Series&nbsp;A3
preferred stock financing, Legacy Vicarious entered into investors’ rights, voting and right of first refusal and co-sale agreements
containing registration rights, information rights, voting rights and rights of first refusal, among other things, with holders of Legacy
Vicarious preferred stock. In connection with the Closing of the Business Combination, these agreements were terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Agreements with Vicarious Surgical Stockholders</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Amended and Restated Registration Rights Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">At the Closing of the Business Combination, we entered
into the Amended and Restated Registration Rights Agreement with the Sponsor, D8’s independent directors and certain Legacy Vicarious
stockholders, pursuant to which, among other things, the parties to the Amended and Restated Registration Rights Agreement agreed, subject
to certain exceptions, not to effect any sale or distribution of any of our equity securities held by any of them (except with respect
to shares of Class&nbsp;A common stock acquired in open market transactions or by the Sponsor or D8’s independent directors pursuant
to the PIPE Financing) during the lock-up period described therein and were granted certain registration rights with respect to their
respective shares of our common stock, in each case, on the terms and subject to the conditions therein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Director Nomination Agreement</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">At the Closing of the Business Combination, we entered
into the Director Nomination Agreement with the Sponsor, pursuant to which, the Sponsor is entitled to certain rights to nominate two
members to serve on our board of directors effective as of the Closing Date, subject to the conditions set forth in the Director Nomination
Agreement. The Sponsor’s initial nominees to our board of directors were Donald Tang and David Ho. The Sponsor’s right to
nominate one such member to our board of directors shall expire at our 2022 annual meeting of stockholders and the right to nominate the
other member to our board of directors shall expire upon the earlier of (i)&nbsp;the first date on which the Sponsor ceases to beneficially
own at least 2.5% of our issued and outstanding common stock and (ii)&nbsp;the termination of the Director Nomination Agreement as of
the date that is 36&nbsp;months after the Closing Date.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Indemnification Agreements with Officers and Directors and Directors’
and Officers’ Liability Insurance</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">In connection with the Closing of the Business Combination,
we entered into indemnification agreements with each of our executive officers and directors. The indemnification agreements, the Charter
and the Bylaws require us to indemnify our directors to the fullest extent not prohibited by Delaware law. Subject to certain limitations,
the Bylaws also require us to advance expenses incurred by our directors and officers. We will also maintain a general liability insurance
policy, which covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities
as directors or officers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>&nbsp;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Policies and Procedures for Related Party Transactions</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have adopted a written related person transaction
policy that sets forth the following policies and procedures for the review and approval or ratification of related person transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">A “Related Person Transaction” is a
transaction, arrangement or relationship in which we or any of our subsidiaries was, is or will be a participant, the amount of which
involved exceeds $120,000, and in which any related person had, has or will have a direct or indirect material interest. Transactions
involving compensation for services provided to us or any of our subsidiaries as an employee, consultant or director will not be considered
related person transactions under this policy. A “Related Person” is:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">any person who is or was an executive officer, director,
or director nominee of our at any time since the beginning of our last fiscal year;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">a person who is or was an Immediate Family Member (as defined
below) of an executive officer, director, director nominee at any time since the beginning of our last fiscal year;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">any person who, at the time of the occurrence or existence
of the transaction, is the beneficial owner of more than 5% of any class of our voting securities (a “Significant Stockholder”);
or</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">any person who, at the time of the occurrence or existence
of the transaction, is an Immediate Family Member of a Significant Stockholder of ours.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">An “Immediate Family Member” of a person
is any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law
or sister-in-law of such person, or any other person sharing the household of such person, other than a tenant or employee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">We have implemented policies and procedures designed
to minimize potential conflicts of interest arising from any dealings we may have with our affiliates and to provide appropriate procedures
for the disclosure of any real or potential conflicts of interest that may exist from time to time. Specifically, pursuant to our charter,
the audit committee has the responsibility to review related party transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Under the related person transaction policy, the
related person in question or, in the case of transactions with a beneficial holder of more than 5% of our voting stock, an officer with
knowledge of a proposed transaction, will be required to present information regarding the proposed related person transaction to the
audit committee (or to another independent body of the board of directors) for review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">To identify related person transactions in advance,
we expect to rely on information supplied by our executive officers, directors and certain significant stockholders. In considering related
person transactions, our audit committee is expected to take into account the relevant available facts and circumstances, which may include,
but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the related person’s interest in the transaction;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the approximate dollar value of the amount involved in the
transaction;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the approximate dollar value of the amount of the related
person’s interest in the transaction without regard to the amount of any profit or loss;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">whether the transaction was undertaken in the ordinary course
of our business;</td>
</tr></tbody></table><div>

</div><p style="margin-top: 0; margin-bottom: 0">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">whether the transaction with the related person is proposed
to be, or was, entered into on terms no less favorable to us than terms that could have been reached with an unrelated third party;</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">the purpose of, and the potential benefits to us of, the
transaction; and</td>
</tr></tbody></table><div>

</div><p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-indent: -24pt">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="text-align: left; width: 0.25in"></td><td style="width: 0.25in; text-align: left">●</td><td style="text-align: left">any other information regarding the transaction or the related
person in the context of the proposed transaction that would be material to investors in light of the circumstances of the particular
transaction.</td>
</tr></tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The audit committee will approve only those transactions
that it determines are fair to us and in our best interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Independence of the Board of Directors</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">NYSE rules generally require that independent directors
must comprise a majority of a listed company’s board of dire<b>c</b>tors. Based upon information requested from and provided by
each director concerning his or her background, employment and affiliations, including family relationships, we have determined that Messrs.&nbsp;Kaul,
Berman, Fulop, Liang and Styka and Dr.&nbsp;Ho, representing six of our nine directors, are “independent” as that term is
defined under the applicable rules and regulations of the SEC and the listing requirements and rules of the NYSE.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&nbsp;</i></p><div>

</div><div><a id="a_024"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">At the completion of the Business Combination, on September 17, 2021,
our board of directors engaged Deloitte &amp; Touche LLP (“Deloitte”) as the independent registered public accounting firm
to audit our consolidated financial statements for the fiscal year ending December 31, 2021. The following is a summary of fees paid to
Deloitte for services rendered for the fiscal year ended December 31, 2021.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left"><span style="font-size: 10pt">Audit fees <sup>(1)</sup></span></td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">595,631</td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left"><span style="font-size: 10pt">Audit-related fees <sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">1,587,471</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 10pt">Tax fees <sup>(2)</sup></span></td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">—</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt"><span style="font-size: 10pt">All other fees <sup>(2)</sup></span></td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">—</td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,183,102</td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; text-align: justify">&nbsp;&nbsp;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-indent: -24pt"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: left">Audit fees consisted of audit work performed in the preparation
of consolidated financial statements, as well as work generally only the independent registered public accounting firm can reasonably
be expected to provide, such as quarterly review procedures and the provision of consents in connection with the filing of registration
statements and related amendments, as well as other filings.</td>
</tr></tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; "></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%">
  <tbody><tr style="vertical-align: top">
    <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(2)</span></td>
    <td style="font-size: 10pt"><span style="font-size: 10pt">There were no tax and other related fees in 2021.</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Our
audit committee was formed upon the consummation of our initial public offering. As a result, the audit committee did not pre-approve
all of the foregoing services, although any services rendered prior to the formation of our audit committee were approved by our board
of directors. Since the formation of our audit committee, the audit committee has pre-approved all auditing services and permitted non-audit
services to be performed for us by our auditors, including the fees and terms thereof (subject to the de minimis exceptions for non-audit
services described in the Exchange Act which are approved by the audit committee prior to the completion of the audit).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; "></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Policy on Audit Committee
Pre-Approval of Audit and Permissible Non-Audit Services of Independent Public Accountant</b></p><div>




</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Consistent
with SEC policies regarding auditor independence, the audit committee has responsibility for appointing, setting compensation and overseeing
the work of our independent registered public accounting firm. In recognition of this responsibility, the audit committee has established
a policy to pre-approve all audit and permissible non-audit services provided by our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Prior
to engagement of an independent registered public accounting firm for the next year’s audit, management will submit an aggregate
of services expected to be rendered during that year for each of four categories of services to the audit committee for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">1. <b><i>Audit</i></b>
services include audit work performed in the preparation of financial statements, as well as work that generally only an independent registered
public accounting firm can reasonably be expected to provide, including comfort letters, statutory audits, and attest services and consultation
regarding financial accounting or reporting standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">2. <b><i>Audit-Related</i></b>
services are for assurance and related services that are traditionally performed by an independent registered public accounting firm,
including due diligence related to mergers and acquisitions, employee benefit plan audits, and special procedures required to meet certain
regulatory requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">3. <b><i>Tax</i></b>
services include all services performed by an independent registered public accounting firm’s tax personnel except those services
specifically related to the audit of the financial statements, and includes fees in the areas of tax compliance, tax planning, and tax
advice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; ">4. <b><i>Other Fees</i></b>
are those associated with services not captured in the other categories. The Company generally does not request such services from our
independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Prior
to engagement, the audit committee pre-approves these services by category of service. The fees are budgeted and the audit committee requires
our independent registered public accounting firm and management to report actual fees versus the budget periodically throughout the year
by category of service. During the year, circumstances may arise when it may become necessary to engage our independent registered public
accounting firm for additional services not contemplated in the original pre-approval. In those instances, the audit committee requires
specific pre-approval before engaging our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">The
audit committee may delegate pre-approval authority to one or more of its members. The member to whom such authority is delegated must
report, for informational purposes only, any pre-approval decisions to the audit committee at its next scheduled meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; "></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; ">&nbsp;</p><div>

</div><div><a id="a_025"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="text-transform: uppercase"><b>PART
IV</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><div><a id="a_026"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 15(a).</b> The following documents are filed as part of this annual report on Form 10-K:</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-left: 0in; text-indent: 0in; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 15(a)(1) and (2)</b> See
“Index to Consolidated Financial Statements and Financial Statement Schedules” at Item 8 to this Annual Report on Form
10-K. Other financial statement schedules have not been included because they are not  applicable or the information is
included in the financial statements or notes thereto.</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <b>Item 15(a)(3)</b> <span style="text-decoration:underline">Exhibits</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The following is a list of exhibits filed as part of this Annual Report
on Form 10-K.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; width: 8%; padding-right: 3pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br>
Number</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 45%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit Description</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 8%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filed<span style="text-decoration:underline"><br>
</span>Herewith</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 14%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporated<span style="text-decoration:underline"><br>
</span>by Reference<span style="text-decoration:underline"><br>
</span>Herein from<span style="text-decoration:underline"><br>
</span>Form or<span style="text-decoration:underline"><br>
</span>Schedule</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 10%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Filing<span style="text-decoration:underline"><br>
</span>Date</b></span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 12%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SEC File/<span style="text-decoration:underline"><br>
</span>Reg.<span style="text-decoration:underline"><br>
</span>Number</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1†</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021021631/ea139500ex2-1_d8holdings.htm">Agreement and Plan of Merger, dated as of April&nbsp;15, 2021, by and among Vicarious Surgical Inc. (formerly D8 Holdings Corp.), Snowball Merger Sub, Inc., and Vicarious Surgical Operating Co. (formerly Vicarious Surgical Inc.).</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 2.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex3-1_vicarious.htm">Certificate of Incorporation of Vicarious Surgical Inc.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K<br>
(Exhibit 3.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex3-2_vicarious.htm">Amended and Restated Bylaws of Vicarious Surgical Inc.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 3.2)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex4-1_vicarious.htm">Description of Securities</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex4-1_vicarious.htm">Specimen Class&nbsp;A Common Stock Certificate</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 4.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390020017781/ea124277ex4-1_d8holdings.htm">Warrant Agreement, dated as of July&nbsp;14, 2020, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.) and Continental Stock Transfer&nbsp;&amp; Trust Company.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 4.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/17/2020</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021021631/ea139500ex10-1_d8holdings.htm">Form of Subscription Agreement, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.), and the subscriber parties thereto.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 10.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.1†</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021039875/fs42021a2ex10-12_d8holdings.htm">Building Lease for the premises located at 78 Fourth Avenue, Waltham, Massachusetts, dated as of January&nbsp;25, 2021, by and among Vicarious Surgical Inc. and Fourth Avenue LLC.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A (Exhibit&nbsp;10.12)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8/2/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.2†</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021053746/ea149098ex10-1_vicarious.htm">Amendment to Lease, dated as of October 14, 2021, by and between Vicarious Surgical US Inc. and Fourth Avenue LLC</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 10.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/20/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
</tbody></table><div>
</div><p style="margin: 0">&nbsp;</p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; width: 8%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2.3†</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; width: 1%">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; width: 45%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021053746/ea149098ex10-2_vicarious.htm">Guaranty of Lease between Vicarious Surgical US Inc. and Fourth Avenue LLC dated as of October 14, 2021</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; width: 1%">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; width: 8%">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; width: 1%">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center; width: 14%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit 10.2)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; width: 1%">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center; width: 10%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/20/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt; width: 1%">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center; width: 12%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-13_d8holdings.htm">Executive Employment Agreement, dated as of July&nbsp;13, 2021, by and between Vicarious Surgical Inc. and Adam Sachs.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit&nbsp;10.13)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-14_d8holdings.htm">Executive Employment Agreement, dated as of July&nbsp;13, 2021, by and between Vicarious Surgical Inc. and Sammy Khalifa.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit&nbsp;10.14)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-15_d8holdings.htm">Executive Employment Agreement, dated as of July&nbsp;13, 2021, by and between Vicarious Surgical Inc. and William Kelly.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit&nbsp;10.15)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-16_d8holdings.htm">Executive Employment Agreement, dated as of July&nbsp;13, 2021, by and between Vicarious Surgical Inc. and June Morris.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit 10.16)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-17_d8holdings.htm">Letter Agreement, dated as of June&nbsp;2, 2021, by and between Vicarious Surgical and David Styka.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit&nbsp;10.17)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021037090/fs42021a1ex10-18_d8holdings.htm">Nonemployee Director Compensation Policy.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-4/A<br>
(Exhibit&nbsp;10.18)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-257055</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex10-9_vicarious.htm">Vicarious Surgical Inc. 2014 Stock Incentive Plan, as amended.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K (Exhibit&nbsp;10.9)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex10-10_vicarious.htm">Vicarious Surgical Inc. 2021 Equity Incentive Plan, and forms of agreement thereunder, as amended.</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex10-11_vicarious.htm">Amended and Restated Registration Rights Agreement, dated as of September&nbsp;17, 2021, by and among Vicarious Surgical Inc. (formerly D8 Holdings Corp.), Vicarious Surgical Operating Co. (formerly Vicarious Surgical Inc.) and certain of their securityholders.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K<br>
(Exhibit&nbsp;10.11)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex10-12_vicarious.htm">Form of Indemnification Agreement.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K<br>
(Exhibit&nbsp;10.12)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021049537/ea147795ex10-13_vicarious.htm">Director Nomination Agreement, dated as of September&nbsp;17, 2021, by and between Vicarious Surgical Inc. (formerly D8 Holdings Corp.) and D8 Sponsor LLC.</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;8-K<br>
(Exhibit&nbsp;10.13)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">09/23/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">001-39384</span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration:underline"><a href="http://www.sec.gov/Archives/edgar/data/1812173/000121390021053039/fs12021ex21-1_vicarioussurg.htm">List of Subsidiaries</a></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form&nbsp;S-1<br>
(Exhibit 21.1)</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10/15/2021</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">333-260281</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex23-1_vicarious.htm">Consent of Deloitte&nbsp;&amp; Touche LLP</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex31-1_vicarious.htm">Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td></tr>
  <tr style="vertical-align: top; ">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex31-2_vicarious.htm">Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">32*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10k2021ex32_vicarious.htm">Certifications of the Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&nbsp;</td>
    <td style="padding-bottom: 2.25pt">&nbsp;</td></tr>


<tr style="vertical-align: top; ">
    <td style="width: 7%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document</span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="width: 13%">&nbsp;</td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="width: 9%">&nbsp;</td>
    <td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="width: 11%">&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase
Document</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase
Document</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: top; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (formatted as Inline
XBRL and contained in Exhibit 101)</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</span></td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="white-space: nowrap">&nbsp;</td>
    <td>&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="margin: 0">&nbsp;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 3pt; margin-bottom: 3pt; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="margin: 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">*</span></td><td style="text-align: justify"><span style="font-size: 10pt">The certifications furnished in
Exhibit 32 attached hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates
it by reference.</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">†</span></td><td style="text-align: justify"><span style="font-size: 10pt">Certain of the exhibits and schedules
to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted
exhibits and schedules to the SEC upon its request.</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><tbody><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><span style="font-size: 10pt">+</span></td><td style="text-align: justify"><span style="font-size: 10pt">Management contract or compensatory
plan or arrangement.</span></td>
</tr></tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 31.5pt; text-indent: -31.5pt"><b>&nbsp;</b></p><div>

</div><div><a id="a_027"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>ITEM 16. FORM 10-K SUMMARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>


</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of Section 13 or 15(d)
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized<b>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td colspan="2"><b>VICARIOUS SURGICAL INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%"><span style="font-size: 10pt">Date: March 31, 2022</span></td>
    <td style="width: 4%"><span style="font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 36%"><span style="font-size: 10pt">/s/ Adam Sachs</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Adam Sachs</span></td></tr>
  <tr style="vertical-align: top">
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td><span style="font-size: 10pt">Chief Executive Officer and President</span></td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated
below and on the dates indicated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&nbsp;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: top">
    <td style="width: 40%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Signature</b></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 38%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Title</b></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 20%; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Adam Sachs</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Chief Executive Officer, President and Director</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Principal Executive Officer)</p></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Adam Sachs</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ William Kelly</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Chief Financial Officer and Treasurer (Principal Financial and Accounting Officer)</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">William Kelly</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ David Styka</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Chairman</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">David Styka</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Sammy Khalifa</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Sammy Khalifa</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Samir Kaul</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Samir Kaul</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Philip Liang</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Philip Liang</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Ric Fulop</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Ric Fulop</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Dror Berman</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Dror Berman</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ Donald Tang</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">Donald Tang</span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td style="vertical-align: top; text-align: center">&nbsp;</td></tr>
  <tr>
    <td style="vertical-align: top; border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt">/s/ David Ho</span></td>
    <td rowspan="2" style="vertical-align: top">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">Director</span></td>
    <td rowspan="2">&nbsp;</td>
    <td rowspan="2" style="text-align: center"><span style="font-size: 10pt">March 31, 2022</span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center"><span style="font-size: 10pt">David Ho</span></td></tr>
  </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tbody><tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="width: 93%"><span style="font-size: 10pt"><a href="#f_001">Report of Independent Registered Public Accounting Firm</a> (PCAOB ID No. <ix:nonnumeric contextref="c0" name="dei:AuditorFirmId">34</ix:nonnumeric>)</span></td> <td style="width: 7%; text-align: center"><span style="font-size: 10pt">F-2</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-size: 10pt"><a href="#f_002">Consolidated Balance Sheets as of December 31, 2021 and 2020</a></span></td> <td style="text-align: center"><span style="font-size: 10pt">F-3</span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt"><a href="#f_003">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</a></span></td> <td style="text-align: center"><span style="font-size: 10pt">F-4</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-size: 10pt"><a href="#f_004">Consolidated Statements of Convertible Preferred Stock, Common Stock and Stockholders’ Equity/(Deficit) for the years ended December 31, 2021 and 2020</a> </span></td> <td style="text-align: center">F-5</td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td><span style="font-size: 10pt"><a href="#f_005">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</a></span></td> <td style="text-align: center"><span style="font-size: 10pt">F-6</span></td></tr> <tr style="vertical-align: top; "> <td><span style="font-size: 10pt"><a href="#f_006">Notes to Consolidated Financial Statements</a></span></td> <td style="text-align: center"><span style="font-size: 10pt">F-7</span></td></tr> </tbody></table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 97; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>Report
of Independent Registered Public Accounting Firm</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">To the stockholders and the Board of Directors
of Vicarious Surgical Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Opinion
on the Financial Statements</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">We have audited the accompanying consolidated
balance sheets of Vicarious Surgical Inc. and its subsidiaries (the “Company”) as of December 31, 2021 and 2020, the related
consolidated statements of operations, convertible preferred stock, common stock, and stockholders’ equity/(deficit), and cash flows,
for each of the two years in the period ended December 31, 2021, and the related notes (collectively referred to as the “financial
statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company
as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the two years in the period ended December
31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
for Opinion</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board
(United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities
laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company
is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits,
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion
on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error
or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding
the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
<ix:nonnumeric contextref="c0" name="dei:AuditorName">Deloitte &amp; Touche LLP</ix:nonnumeric></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonnumeric contextref="c0" name="dei:AuditorLocation"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Boston,
Massachusetts</span></ix:nonnumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
31, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company’s auditor since 2020.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VICARIOUS
SURGICAL INC.<br>
CONSOLIDATED BALANCE SHEETS<br>
AS OF DECEMBER 31, 2021 and 2020<br>
(in thousands, except share and per sha</b>re <b>data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
    and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitref="usd">173,507</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitref="usd">16,867</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
    expenses and other current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitref="usd">4,867</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitref="usd">258</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitref="usd">178,374</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitref="usd">17,125</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
    cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitref="usd">1,055</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCash" scale="3" unitref="usd">118</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd">2,250</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd">445</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
    long-term assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitref="usd">100</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitref="usd">181,679</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitref="usd">17,788</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities,
    Convertible Preferred Stock and Stockholders’ Equity</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts
    payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitref="usd">1,500</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitref="usd">373</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
    expenses</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitref="usd">4,098</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" unitref="usd">394</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of equipment loans</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" unitref="usd">47</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeaseObligationsCurrent" scale="3" unitref="usd">47</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
    portion of term loan</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CurrentPortionOfTermLoan" scale="3" unitref="usd">600</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    current liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitref="usd">6,245</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitref="usd">814</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred
    rent</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" unitref="usd">1,631</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRentCreditNoncurrent" scale="3" unitref="usd">58</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equipment
    loans, net of current portion</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:NotesPayableEquipmentLoansOfNetCurrent" scale="3" unitref="usd">16</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="rbot:NotesPayableEquipmentLoansOfNetCurrent" scale="3" unitref="usd">63</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Term
    loan, net of current portion and issuance costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" unitref="usd">675</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" unitref="usd">90,021</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitref="usd">98,588</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" unitref="usd">935</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments
    and Contingencies (Note 8)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    convertible preferred stock (Note 10)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stockholders’
    Equity:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred stock, $<ix:nonfraction contextref="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitref="usdPershares"><ix:nonfraction contextref="c5" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction></ix:nonfraction>&nbsp;par value;&nbsp;<ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitref="shares"><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitref="shares">1,000,000</ix:nonfraction></ix:nonfraction>&nbsp;shares authorized;&nbsp;<span style="-sec-ix-hidden: hidden-fact-7"><span style="-sec-ix-hidden: hidden-fact-8"><span style="-sec-ix-hidden: hidden-fact-9"><span style="-sec-ix-hidden: hidden-fact-10">no</span></span></span></span>&nbsp;shares issued or outstanding at December 31, 2021 and 2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class&nbsp;A Common stock, $<ix:nonfraction contextref="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares"><ix:nonfraction contextref="c7" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction></ix:nonfraction> par value; <ix:nonfraction contextref="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares">300,000,000</ix:nonfraction> and <ix:nonfraction contextref="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares">200,000,000</ix:nonfraction> shares authorized at December 31, 2021 and 2020, respectively; <ix:nonfraction contextref="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c6" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares">99,979,207</ix:nonfraction></ix:nonfraction> and <ix:nonfraction contextref="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c7" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares">67,640,740</ix:nonfraction></ix:nonfraction> issued and outstanding at December 31, 2021 and&nbsp;2020, respectively</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitref="usd">12</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitref="usd">7</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Class&nbsp;B Common stock, $<ix:nonfraction contextref="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares"><ix:nonfraction contextref="c9" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction></ix:nonfraction> par value; <ix:nonfraction contextref="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares">22,000,000</ix:nonfraction> and <ix:nonfraction contextref="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitref="shares">20,000,000</ix:nonfraction> shares&nbsp;authorized at December 31, 2021 and 2020, respectively; <ix:nonfraction contextref="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c8" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares">19,789,860</ix:nonfraction></ix:nonfraction> and <ix:nonfraction contextref="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitref="shares">19,572,257</ix:nonfraction></ix:nonfraction> shares issued and outstanding at December 31, 2021 and&nbsp;2020</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CommonStockValueOne" scale="3" unitref="usd">2</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additional
    paid-in capital</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitref="usd">149,877</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitref="usd">48,435</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accumulated
    deficit</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitref="usd">66,798</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitref="usd">31,591</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    stockholders’ equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">83,091</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">16,853</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities and stockholders’ equity</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitref="usd">181,679</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitref="usd">17,788</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VICARIOUS
SURGICAL INC.<br>
CONSOLIDATED STATEMENTS OF OPERATIONS<br>
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020<br>
(in thousands except, per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended <br> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Operating expenses:</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2" style="text-align: right">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 0.25in">Research and development</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitref="usd">22,059</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitref="usd">9,796</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Sales and marketing</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitref="usd">2,961</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingAndMarketingExpense" scale="3" unitref="usd">861</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">General and administrative</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitref="usd">13,203</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitref="usd">2,328</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Total operating expenses</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitref="usd">38,223</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" unitref="usd">12,985</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Loss from operations</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitref="usd">38,223</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitref="usd">12,985</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Other income (expense):</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Change in fair value of warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" sign="-" unitref="usd">3,085</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Interest income</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitref="usd">20</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentIncomeInterest" scale="3" unitref="usd">113</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in">Interest expense</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitref="usd">89</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" unitref="usd">3</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Loss before income taxes</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Provision for income taxes</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">—</div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">—</div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Net loss per share of Class A and Class B common stock, basic and diluted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitref="usdPershares">0.36</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" sign="-" unitref="usdPershares">0.16</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </tbody></table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VICARIOUS
SURGICAL INC.<br>
CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK, COMMON STOCK AND<br>
STOCKHOLDERS’ EQUITY/(DEFICIT)<br>
FOR THE YEARS ENDED DECEMBER 31, 2021 AND 2020<br>
(In thousands, except share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>


</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tbody><tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Convertible<br>
Preferred Stock</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; border-left: black 1.5pt solid; text-align: center">&nbsp;</td>
    <td colspan="5" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Class&nbsp;A&nbsp;&amp; B <br>
Common Stock</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Additional<br>
Paid-In</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Accumulated</b></span></td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Total<br>
Stockholders’</b></span></td>
    <td>&nbsp;</td></tr>
  <tr>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; border-left: black 1.5pt solid; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shares</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Amount</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Capital</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Deficit</b></span></td>
    <td style="padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&nbsp;</td>
    <td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Equity/(Deficit</b></span></td>
    <td><b>)</b></td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 47%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, January 1, 2020</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c11" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares">52,885,027</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">33,150</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-left: black 1.5pt solid">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares">17,613,962</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">2</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">1,196</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitref="usd">18,716</ix:nonfraction></span></td>
    <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 5%; border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitref="usd">17,518</ix:nonfraction></span></td>
    <td style="width: 1%">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Retroactive application of recapitalization (Note 1)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" sign="-" unitref="shares">52,885,027</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" sign="-" unitref="usd">33,150</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfUnits" scale="0" unitref="shares">52,885,027</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitref="usd">5</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitref="usd">33,145</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitref="usd">33,150</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted balance, beginning of period</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="0" unitref="shares">70,498,989</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" unitref="usd">7</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" unitref="usd">34,341</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" sign="-" unitref="usd">18,716</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodValue" scale="3" unitref="usd">15,632</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A-3 financing, net issuance cost of $<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitref="usd">95</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitref="shares">13,665,901</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd">1</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd">13,519</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-15"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitref="usd">13,520</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of common stock options</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptionsinShares" scale="0" unitref="shares">436,950</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptions" scale="3" unitref="usd">43</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptions" scale="3" unitref="usd">43</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitref="usd">448</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitref="usd">448</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting of restricted stock</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitref="shares">2,611,157</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" unitref="usd">1</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" sign="-" unitref="usd">1</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issuance of common stock warrants</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c18" decimals="-3" format="ixt:num-dot-decimal" name="rbot:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrants" scale="3" unitref="usd">85</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:StockIssuedDuringPeriodValueIssuanceOfCommonStockWarrants" scale="3" unitref="usd">85</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></span></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2020</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c20" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares">87,212,997</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">9</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">48,435</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitref="usd">31,591</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">16,853</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reverse recapitalization, net of transaction costs (Note 1)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitref="shares">30,579,972</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitref="usd">3</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitref="usd">97,311</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="3" unitref="usd">97,314</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cashless exercise of warrants</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitref="shares">146,577</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of common stock options</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptionsinShares" scale="0" unitref="shares">1,558,908</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c24" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptions" scale="3" unitref="usd">421</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ExerciseOfCommonStockOptions" scale="3" unitref="usd">421</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise of public warrants</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="INF" format="ixt:num-dot-decimal" name="rbot:StockIssuedDuringPeriodSharesExerciseOfPublicWarrants" scale="0" unitref="shares">1,370</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitref="usd">16</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" scale="3" unitref="usd">16</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock-based compensation</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3, 694 </span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitref="usd">3,694</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vesting of restricted stock</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitref="shares">269,243</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-27"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-28"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-30"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></span></td>
    <td>)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Balance, December 31, 2021</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">&nbsp;</div></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">$</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">&nbsp;</div></td>
    <td>&nbsp;</td>
    <td style="border-left: black 1.5pt solid">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c27" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitref="shares">119,769,067</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">12</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">149,877</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitref="usd">66,798</ix:nonfraction></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitref="usd">83,091</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VICARIOUS
SURGICAL INC.<br>
CONSOLIDATED STATEMENTS OF CASH FLOWS<br>
FOR THE YEARS ENDED DECEMBER 31, 2021 and 2020<br>
(in thousands)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Years Ended<br> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cash flows from operating activities:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net loss</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Adjustments to reconcile net loss to net cash used in operating</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.25in">Operating activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 27pt">Depreciation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd">316</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd">157</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Loss on disposal of fixed assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" sign="-" unitref="usd">8</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitref="usd">3,694</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitref="usd">448</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Amortization of debt issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitref="usd">21</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 27pt">Change in fair value of warrant liabilities</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ChangeInFairValuesOfWarrantLiabilities" scale="3" sign="-" unitref="usd">3,085</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 27pt">Changes in operating assets and liabilities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.5in">Prepaid expenses and other current assets</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" unitref="usd">4,609</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" unitref="usd">3</ix:nonfraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.5in">Accounts payable</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:OfferingCostsIncludedInNotePayable" scale="3" sign="-" unitref="usd">1,127</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:OfferingCostsIncludedInNotePayable" scale="3" sign="-" unitref="usd">170</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.5in">Accrued expenses</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:OfferingCostsIncludedInAccruedExpenses" scale="3" sign="-" unitref="usd">3,704</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:OfferingCostsIncludedInAccruedExpenses" scale="3" sign="-" unitref="usd">80</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.5in">Deferred rent</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:IncreaseDecreaseInDeferredRent" scale="3" sign="-" unitref="usd">733</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.5in">Other noncurrent assets</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">—</div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" unitref="usd">15</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 45pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitref="usd">33,298</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitref="usd">12,038</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Purchases of property and equipment</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitref="usd">1,289</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitref="usd">120</ix:nonfraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Proceeds from short term investments</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">—</div></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" scale="3" sign="-" unitref="usd">13,324</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 45pt">Net cash provided by/(used in) investing activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitref="usd">1,289</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitref="usd">13,204</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Repayment of equipment loans</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConstructionLoansPayable" scale="3" unitref="usd">47</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfConstructionLoansPayable" scale="3" unitref="usd">48</ix:nonfraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from issuance of common stock, net of issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">—</div></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" unitref="usd">13,520</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from term loan</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromBankDebt" scale="3" unitref="usd">1,500</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Repayment of term loan</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RepaymentsOfBankDebt" scale="3" unitref="usd">150</ix:nonfraction></td><td style="text-align: left">)</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Proceeds from reverse recapitalization, net of issuance costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ProceedsFromReverseRecapitalizationNetOfIssuanceCosts" scale="3" unitref="usd">190,424</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Proceeds from exercise of public warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" unitref="usd">16</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">—</div></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Proceeds from exercise of stock options</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitref="usd">421</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitref="usd">43</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 45pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitref="usd">192,164</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitref="usd">13,515</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 45pt">Change in cash, cash equivalents and restricted cash</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitref="usd">157,577</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitref="usd">14,681</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash, cash equivalents and restricted cash, beginning of year</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd">16,985</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd">2,304</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash, cash equivalents and restricted cash, end of year</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd">174,562</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" unitref="usd">16,985</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Reconciliation of restricted cash:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash and cash equivalents</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CashAndCashEquivalentsRestricted" scale="3" unitref="usd">173,507</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CashAndCashEquivalentsRestricted" scale="3" unitref="usd">16,867</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Restricted cash</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalents" scale="3" unitref="usd">1,055</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashEquivalents" scale="3" unitref="usd">118</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitref="usd">174,562</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedCashAndCashEquivalents" scale="3" unitref="usd">16,985</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: left">Supplemental cash flow information:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Interest paid</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitref="usd">36</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitref="usd">3</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: left">Non-cash investing and financing activities:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Leasehold improvements funded by the landlord</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:LeaseholdImprovementsAcquiredInConnectionWithWalthamLease" scale="3" unitref="usd">840</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Warrants assumed in acquisition</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:WarrantsAssumedInAcquisition" scale="3" unitref="usd">93,110</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 9pt">Issuance of warrants recorded as deferred financing costs</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ReverseRecapitalizationCostsInAccountsPayableAndAccruedExpenses" scale="3" unitref="usd">85</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
accompanying notes to these consolidated financial statements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>


</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>VICARIOUS
SURGICAL INC.<br>
<span style="text-transform: uppercase">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS<br>
aS OF AND FOR THE YEARs ENDED DECEMBER 31, 2021 AND 2020<br>
</span>(in thousands, except for share and per share data)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>1.
NATURE OF BUSINESS AND BASIS OF PRESENTATION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Nature
of Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vicarious
Surgical Inc. (“Vicarious” or the “Company”) was incorporated in the state of Delaware on May 1, 2014, and is
headquartered in Waltham, Massachusetts. The Company is currently developing its virtual reality surgical system using proprietary human-like
surgical robots and virtual reality to transport surgeons inside the patient to perform minimally invasive surgical procedures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
accompanying financial statements are prepared in conformity with accounting principles generally accepted in the United States of America
(“US GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative US GAAP</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless
otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to the “Company” and
“Vicarious Surgical” refer to the consolidated operations of Vicarious Surgical Inc. References to “D8” refer
to the company prior to the consummation of the Business Combination and references to “Legacy Vicarious Surgical” refer
to Vicarious Surgical Inc. prior to the consummation of the Business Combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span><ix:nonnumeric contextref="c30" name="us-gaap:BusinessCombinationIndemnificationAssetsDescription">On April
15, 2021, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with D8 Holdings Corp (“D8”)
to effect a business combination between D8 and the Company with the Company surviving the merger as a wholly owned subsidiary of D8 (the
“Business Combination”). On September 17, 2021 the Merger Agreement was effected, and each share of Vicarious Surgical Inc.
stock was exchanged for 3.29831 shares of D8 common stock. The Company received total proceeds of $77,993 after redemptions. In connection
with the Business Combination, D8 entered into subscription agreements with subscribers who agreed to purchase an aggregate of 14,200,000
shares of Class&nbsp;A common stock for a purchase price of $142,000 (the “PIPE”), all of which were issued on the effective
date.</ix:nonnumeric>&nbsp;In total, this provided the Company cash of $<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" unitref="usd">190,424</ix:nonfraction>, which is net of transaction costs of $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetAcquisitionConsiderationTransferredTransactionCost" scale="3" unitref="usd">29,569</ix:nonfraction>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>Legacy Vicarious
Surgical was deemed to be the accounting acquirer in the Business Combination. The determination was primarily based on Legacy Vicarious
Surgical’s stockholders having a majority of the voting power in the combined Company, Legacy Vicarious Surgical having the ability
to appoint a majority of the Board of Directors of the Company, Legacy Vicarious Surgical’s existing management team comprising
the senior management of the combined Company, Legacy Vicarious Surgical comprising the ongoing operations of the combined Company and
the combined Company assuming Vicarious Surgical’s name. Accordingly, for accounting purposes, the Business Combination was treated
as the equivalent of Legacy Vicarious Surgical issuing stock for the net assets of D8, accompanied by a recapitalization. The net assets
of D8 are stated at historical cost, with no goodwill or other intangible assets recorded.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>&nbsp;While
D8 was the legal acquirer in the Business Combination, because Legacy Vicarious Surgical was deemed the accounting acquirer, the historical
financial statements of Legacy Vicarious Surgical became the historical financial statements of the combined Company upon the consummation
of the Business Combination. As a result, the financial statements included in this report reflect (i) the historical operating results
of Legacy Vicarious Surgical prior to the Business Combination; (ii) the combined results of D8 and Legacy Vicarious Surgical following
the close of the Business Combination; (iii) the assets and liabilities of Legacy Vicarious Surgical at their historical cost; and (iv)
the Legacy Vicarious Surgical’s equity structure for all periods presented, as affected by the recapitalization presentation.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span><ix:nonnumeric contextref="c31" name="us-gaap:BusinessCombinationAcquiredReceivablesDescription">In accordance
with guidance applicable to these circumstances, the equity structure has been restated in all comparable periods up to September 17,
2021, to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to Legacy Vicarious Surgical’s
stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share
related to Legacy Vicarious Surgical’s outstanding convertible preferred stock and Legacy Vicarious Surgical’s common stock
prior to the Business Combination have been retroactively restated as shares reflecting the exchange ratio of 3.29831 established in the
Business Combination.</ix:nonnumeric>&nbsp;Legacy Vicarious Surgical’s convertible preferred stock previously classified as mezzanine was retroactively
adjusted, converted into common stock and reclassified to permanent as a result of the reverse recapitalization.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Basis
of Presentation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
consolidated financial statements of the Company are prepared in conformity with accounting principles generally accepted in the United
States of America (“US&nbsp;GAAP”) and pursuant to the regulations of the U.S Securities and Exchange Commission (“SEC”).
Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (“ASC”)
and Accounting Standards Updates (“ASU”) promulgated by the Financial Accounting Standards Board (“FASB”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Principles
of Consolidation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany
transactions and balances have been eliminated in consolidation.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying financial statements reflect the application of certain significant accounting policies as described in this note and elsewhere
in the accompanying consolidated financial statements and notes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonnumeric contextref="c0" continuedat="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use
of Estimates</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation continuedat="_UseOfEstimates-c0_cont_2" id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions
that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of expenses during the reporting periods presented.&nbsp;Estimates are used for, but are not limited
to, the Company’s ability to continue as a going concern, depreciation of property and equipment, fair value of financial instruments,
and contingencies. Actual results may differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_UseOfEstimates-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. Management
has evaluated whether there are conditions and events that raise substantial doubt about the Company’s ability to continue as a
going concern within <ix:nonnumeric contextref="c0" format="ixt-sec:durwordsen" name="us-gaap:DebtInstrumentTerm">one year</ix:nonnumeric> after the date the financial statements are issued. Since its inception, the Company has incurred net losses
and negative cash flows from operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonnumeric contextref="c0" continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair
Value of Financial Instruments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">US&nbsp;GAAP requires disclosure of fair value
information about financial instruments, whether or not recognized in the balance sheet, for which it is practicable to estimate that
value. US&nbsp;GAAP provides a fair value hierarchy that prioritizes the inputs for the valuation techniques. The hierarchy gives the
highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level&nbsp;1 measurements)&nbsp;and
the lowest priority to unobservable inputs (Level&nbsp;3 measurements)&nbsp;and minimizes the use of unobservable inputs. The most observable
inputs are used, when available. The three levels of the fair value hierarchy are described as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
1 </i></b>— Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets
that the Company has the ability to access.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
2 </i></b>— Inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets; quoted
prices for identical or similar assets and liabilities in markets that are not active; inputs other than quoted prices that are observable
for the asset or liability; and inputs that are derived from, or corroborated by, observable market data by correlation or other means.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Level
3 </i></b>— Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation continuedat="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying values of prepaid expenses, accounts payable, and accrued expenses approximate their fair values due to the short-term nature
of the instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The fair value of Public Warrants, was determined
from their trading value on public markets. The fair value of Private Warrants was calculated using the Black-Scholes Option Pricing Model
since these instruments do not have the early redemption feature.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:nonnumeric contextref="c0" continuedat="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Cash
and Cash Equivalents</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
and cash equivalents consist of checking accounts and money market funds. The Company considers all highly liquid investments with an
original maturity of 90&nbsp;days or less at the date of purchase to be cash equivalents.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:nonnumeric contextref="c0" continuedat="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Restricted
Cash</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:continuation id="_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company has an agreement to maintain a cash balance of $<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitref="usd">1,055</ix:nonfraction>&nbsp;and $<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" unitref="usd">118</ix:nonfraction>&nbsp;at </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
31, 2021 and 2020<span>, respectively as collateral for letters of credit related to the Company’s
leases. The balance is classified as long-term on the Company’s balance sheets as the lease periods end beginning in December 2023
through February 2029.</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:nonnumeric contextref="c0" continuedat="_InvestmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Short-Term
Investments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_InvestmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
of the Company’s investments, which consist of certificates of deposit, are classified as available for sale and are carried at
fair value. There were no unrealized gains for the years ended December 31, 2021 and 2020. The Company held no other investments as of
December 31, 2021 and 2020<span>. </span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonnumeric contextref="c0" continuedat="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations
of Credit Risk and Off-Balance-Sheet Risk</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company has no significant off-balance-sheet risk, such as foreign exchange contracts, option contracts, or other foreign hedging arrangements.
Financial instruments that potentially expose the Company to concentrations of credit risk consist mainly of cash and cash equivalents.
The Company maintains its cash and cash equivalents principally with accredited financial institutions of high-credit standing</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonnumeric contextref="c0" continuedat="_DerivativesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DerivativesPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Warrant
Liabilities</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation continuedat="_DerivativesPolicyTextBlock-c0_cont_2" id="_DerivativesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company does not use derivative instruments to hedge its exposures to cash flow, market or foreign currency risks. Management evaluates
all of the Company’s financial instruments, including issued Warrants to purchase its Class A common stock, to determine if such
instruments are derivatives or contain features that qualify as embedded derivatives, pursuant to ASC 480 and ASC 815-15. The classification
of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end
of each reporting period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:continuation id="_DerivativesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>As part
of the Business Combination, the Company assumed <ix:nonfraction contextref="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitref="shares">17,249,991</ix:nonfraction> Public Warrants that are exercisable to purchase shares of Class A common
stock to investors as well as&nbsp;<ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitref="shares">10,400,000</ix:nonfraction>&nbsp;Private Placement Warrants. All of the Company’s outstanding Warrants are recognized
as derivative liabilities in accordance with ASC 815-40. Accordingly, the Company recognizes the warrants as liabilities at fair value
and adjusts the warrant liability to fair value at each reporting period. The liabilities are subject to re-measurement at each balance
sheet date until exercised, and any change in fair value is recognized in the statement of operations. The fair value of Public Warrants
was determined from their trading value on public markets.&nbsp;The fair value of Private Warrants was calculated using the Black-Scholes
Option Pricing Model since these instruments do not have the early redemption feature.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&nbsp;</span></p></ix:continuation></ix:continuation><div>
</div><div>


</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:nonnumeric contextref="c0" continuedat="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Property
and Equipment</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Property and equipment are recorded at cost. Expenditures
for repairs and maintenance are expensed as incurred. When assets are retired or disposed of, the assets and related accumulated depreciation
are eliminated from the accounts, and any resulting gain or loss is included in the determination of net loss. Depreciation is calculated
using the straight-line method over the estimated useful lives of the related assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:nonnumeric contextref="c0" continuedat="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Impairment
of Long-Lived Assets</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually evaluates whether events or circumstances have occurred that indicate that the estimated remaining useful life of
its long-lived assets may warrant revision or that the carrying value of these assets may be impaired. During 2021, in connection with
a lease termination, the Company disposed of $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:FixedAssets" scale="3" unitref="usd">24</ix:nonfraction> of fixed assets with accumulated depreciation of $<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FlightEquipmentAccumulatedDepreciation" scale="3" unitref="usd">16</ix:nonfraction> incurring an $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="3" unitref="usd">8</ix:nonfraction> loss on the disposal.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:nonnumeric contextref="c0" continuedat="_GuaranteesAndIndemnificationsPolicyTableTextBlock-c0_cont_1" escape="true" name="rbot:GuaranteesAndIndemnificationsPolicyTableTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Guarantees
and Indemnifications</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation id="_GuaranteesAndIndemnificationsPolicyTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">As
permitted under Delaware law, the Company indemnifies its officers, directors, consultants and employees for certain events or occurrences
that happen by reason of the relationship with, or position held at, the Company. Through December 31, 2021, the Company had not experienced
any losses related to these indemnification obligations, and no claims were outstanding. The Company does not expect significant claims
related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and
no related liabilities have been established.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:nonnumeric contextref="c0" continuedat="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Research
and Development</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development costs are expensed in the period incurred.&nbsp;Research and development costs include payroll and personnel expenses,
consulting costs, software and webservices, legal, raw materials and allocated overhead such as depreciation and amortization, rent and
utilities. Advance payments for goods and services to be used in future research and development activities are recorded as prepaid expenses
and are expensed over the service period as the services are provided or when the goods are consumed.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:nonnumeric contextref="c0" continuedat="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Stock-Based
Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedat="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company accounts for all stock-based compensation, including stock options and warrants issued as compensation for services, at fair
value and recognizes stock-based compensation expense for those equity awards, net of actual forfeitures, over the requisite service
period, which is generally the vesting period of the respective award</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
fair value of the Company’s stock options and warrants on the date of grant is determined by a Black-Scholes pricing model utilizing
key assumptions such as stock price, expected volatility and expected term. The Company’s estimates of these assumptions are primarily
based on the fair value of the Company’s stock, historical data, peer company data and judgment regarding future trends. Prior
to becoming a publicly traded company, the fair value of the Company’s common stock was determined by the Board of Directors at
each award grant date based upon a variety of factors, including the results obtained from an independent third-party valuation, the
Company’s financial position and historical financial performance, the status of technological developments within the Company’s
proposed products, the illiquid nature of the common stock, arm’s length sales of the Company’s capital stock, including
convertible preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity
event, among others, as the Company’s common stock is was not actively traded. Since becoming a publicly traded company, the Company
uses its publicly traded stock price as the fair value of its common stock</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:nonnumeric contextref="c0" continuedat="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Income
Taxes</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedat="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company accounts for income taxes under the asset and liability method pursuant to ASC 740,&nbsp;<i>Accounting for Income Taxes</i>,
which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been
included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the
differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year
in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized
in income in the period that includes the enactment date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedat="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company recognizes deferred tax assets to the extent that management believes that these assets are more likely than not to be realized
in the future. In making such a determination, management considers all available positive and negative evidence, including future reversals
of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company provides reserves for potential payments of taxes to various tax authorities related to uncertain tax positions. Amounts recognized
are based on a determination of whether a tax benefit taken by the Company in its tax filings or positions is “more likely than
not” to be sustained on audit. The amount recognized is equal to the largest amount that is more than&nbsp;<ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:RevenueRemainingPerformanceObligationPercentage" scale="-2" unitref="pure">50</ix:nonfraction>% likely to be sustained.
Interest and penalties associated with uncertain tax positions are recorded as a component of income tax expense.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:nonnumeric contextref="c0" continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Net
Loss Per share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedat="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Basic
net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the
weighted average number of common shares outstanding for the period. Diluted net loss attributable to common stockholders is computed
by adjusting net loss attributable to common stockholders to reallocate undistributed earnings based on the potential impact of dilutive
securities. Diluted loss per share attributable to common stockholders is computed by dividing the diluted net loss attributable to common
stockholders by the weighted average number of common shares outstanding for the period, including potential dilutive common stock. For
purpose of this calculation, outstanding stock options, stock warrants and convertible preferred stock are considered potential dilutive
common stock and are excluded from the computation of net loss per share as their effect is anti-dilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
in periods in which the Company reports a net loss, such losses are not allocated to such participating securities. In periods in which
the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is
the same as basic net loss per share attributable to common stockholders, since dilutive common shares are not assumed to be outstanding
if their effect is anti-dilutive.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:nonnumeric contextref="c0" continuedat="_ComprehensiveLossPolicyTextBlock-c0_cont_1" escape="true" name="rbot:ComprehensiveLossPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Comprehensive
Loss</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation id="_ComprehensiveLossPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
were no differences between net loss and comprehensive loss presented in the statements of operations for 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:nonnumeric contextref="c0" continuedat="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:SegmentReportingPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Segments</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation id="_SegmentReportingPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Operating
segments are identified as components of an enterprise about which separate discrete financial information is made available for evaluation
by the chief operating decision maker (“CODM”) in making decisions regarding resource allocation and assessing performance.
The CODM is the Company’s chief executive officer. The Company manages its operations as a single segment for the purposes of assessing
performance and making operating decisions. The Company’s singular concentration is focused on the development of its virtual reality
surgical system</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:nonnumeric contextref="c0" continuedat="_EmergingGrowthCompanyPolicyTextBlock-c0_cont_1" escape="true" name="rbot:EmergingGrowthCompanyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Emerging
Growth Company Status</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation id="_EmergingGrowthCompanyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is an “emerging growth company,” (“EGC”) as defined in the Jumpstart Our Business Startups Act, (the
“JOBS Act”), and may take advantage of certain exemptions from various reporting requirements that are applicable to other
public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&nbsp;107
of the JOBS Act and has elected to use the extended transition period for complying with new or revised accounting standards. As a result
of this election, the Company’s financial statements may not be comparable to companies that comply with public company Financial
Accounting Standards Board (“FASB”) standards’ effective dates. The Company may take advantage of these exemptions
up until the last day of the fiscal year following the fifth anniversary of an offering or such earlier time that it is no longer an
EGC.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:nonnumeric contextref="c0" continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Recently
Issued Accounting Standards</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued Accounting Standards Updates (“ASU”)&nbsp;No.&nbsp;2016-02,<i>&nbsp;Leases&nbsp;(Topic 842)</i>,
as amended, with guidance regarding the accounting for and disclosure of leases. The update requires lessees to recognize the liabilities
related to all leases, including operating leases on the balance sheet. This update also requires lessees and lessors to disclose key
information about their leasing transactions. This update is effective for entities other than public business entities, including emerging
growth companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer
is required to comply with such standards, for annual reporting periods beginning after December&nbsp;15, 2021. Early adoption is permitted.
The Company is currently evaluating the impact of adopting ASU&nbsp;No.&nbsp;2016-02&nbsp;on&nbsp;the financial statements and related
disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation continuedat="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3" id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2016, the FASB issued ASU&nbsp;No.&nbsp;2016-13,<i>&nbsp;Financial Instruments-Credit Losses: Measurement of Credit Losses on Financial
Instruments&nbsp;(Topic 326)</i>. ASU&nbsp;No.&nbsp;2016-13&nbsp;requires measurement and recognition of expected credit losses for financial
assets. In April 2019, the FASB issued clarification to ASU&nbsp;No.&nbsp;2016-13&nbsp;within ASU&nbsp;No.&nbsp;2019-04,<i>&nbsp;Codification&nbsp;Improvements
to Topic 326, Financial Instruments-Credit Losses, Topic 815, Derivatives and Hedging,&nbsp;and Topic 825, Financial Instruments</i>.
This update is effective for entities other than public business entities, including emerging growth companies that elected to defer
compliance with new or revised financial accounting standards until a company that is not an issuer is required to comply with such standards,
for annual reporting periods beginning after December&nbsp;15, 2022. The Company is currently evaluating the impact that ASU&nbsp;No.&nbsp;2016-13&nbsp;will
have on the financial statements and related disclosures.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
December 2019, the FASB issued ASU&nbsp;No.&nbsp;2019-12,<i>&nbsp;Simplifying the Accounting for Income Taxes</i>. ASU&nbsp;No.&nbsp;2019-12&nbsp;eliminates
certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim
period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects
of the accounting for income taxes. This update is effective for entities other than public business entities, including emerging growth
companies that elected to defer compliance with new or revised financial accounting standards until a company that is not an issuer is
required to comply with such standards, for annual reporting periods beginning after December&nbsp;15, 2021. The Company is currently
evaluating the impact that ASU&nbsp;No.&nbsp;2019-12&nbsp;will&nbsp;have on the financial statements and related disclosure</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:BusinessCombinationDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>3.
ACQUISITION</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_2" id="_BusinessCombinationDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>On September
17, 2021, the Company and D8 consummated the Business Combination with Legacy Vicarious Surgical surviving the merger as a wholly-owned
subsidiary of D8. Upon the consummation of the Business Combination, each share of Legacy Vicarious Surgical issued and outstanding was
exchanged for&nbsp;<ix:nonnumeric contextref="c33" name="rbot:DebtInstrumentConvertibleConversionShares">3.29831</ix:nonnumeric>&nbsp;shares (the “Exchange Ratio”) of the Company’s common stock (the “Merger Consideration”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_3" id="_BusinessCombinationDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>Upon the
closing of the Business Combination, D8’s certificate of incorporation was amended and restated to, among other things, increase
the total number of authorized shares of all classes of capital stock to&nbsp;<ix:nonfraction contextref="c33" decimals="0" format="ixt:num-dot-decimal" name="rbot:IncreasedNumberOfSharesAuthorizedOfCaptialStock" scale="0" unitref="shares">143,931,076</ix:nonfraction>&nbsp;shares, of which&nbsp;<ix:nonfraction contextref="c34" decimals="0" format="ixt:num-dot-decimal" name="rbot:DesignatedSharesOfCommonStock" scale="0" unitref="shares">124,141,216</ix:nonfraction>&nbsp;were
designated as Class A common stock and&nbsp;<ix:nonfraction contextref="c35" decimals="0" format="ixt:num-dot-decimal" name="rbot:DesignatedSharesOfCommonStock" scale="0" unitref="shares">19,789,860</ix:nonfraction>&nbsp;were designated as Class B common stock both having a par value of $<ix:nonfraction contextref="c36" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction>&nbsp;per
share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_4" id="_BusinessCombinationDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>In connection
with the execution of the definitive agreement for the Business Combination, D8 entered into separate subscription agreements (each a
“Subscription Agreement”) with a number of investors (each a “Subscriber”), pursuant to which the Subscribers
agreed to purchase, and D8 agreed to sell to the Subscribers, an aggregate of&nbsp;<ix:nonfraction contextref="c33" decimals="0" format="ixt:num-dot-decimal" name="rbot:AggregateSharesOfCommonStock" scale="0" unitref="shares">14,200,000</ix:nonfraction>&nbsp;shares of the Company’s common
stock, for a purchase price of $<ix:nonfraction contextref="c37" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" unitref="usdPershares">10.00</ix:nonfraction>&nbsp;per share and an aggregate purchase price of $<ix:nonfraction contextref="c33" decimals="0" format="ixt:num-dot-decimal" name="rbot:ValueOfAggregatePurchasepriceCommonStock" scale="0" unitref="usd">142,000</ix:nonfraction>, in a private placement pursuant to the
Subscription Agreements (the “PIPE” financing). The PIPE financing closed simultaneously with the consummation of the Business
Combination.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_5" id="_BusinessCombinationDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The Business
Combination is accounted for as a reverse recapitalization in accordance with US GAAP. Under this method of accounting, D8 was treated
as the “acquired” company for financial accounting purposes. See Note 1, “Nature of Business and Basis of Presentation”
for further details. Accordingly, for accounting purposes, the Business Combination was treated as the equivalent of Vicarious Surgical
issuing stock for the net assets of D8, accompanied by a recapitalization. The net assets of D8 are stated at historical cost, with no
goodwill or other intangible assets recorded.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_6" id="_BusinessCombinationDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The following
table reconciles the elements of the Business Combination to the statement of cash flows and the statement of changes in equity for the
year ended December 31, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 1.25pt"></p><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_7" id="_BusinessCombinationDisclosureTextBlock-c0_cont_6"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Recapitalization</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Cash - D8’s trust and cash (net of redemptions)</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CashTrustAndCashNetOfRedemptions" scale="3" unitref="usd">77,993</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Cash - PIPE Financing</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:CashPIPEFinancing" scale="3" unitref="usd">142,000</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Transaction costs and advisory fees</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:TransactionCostsAndAdvisoryFees" scale="3" unitref="usd">29,569</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net proceeds from reverse recapitalization</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:NetProceedsFromReverseRecapitalization" scale="3" unitref="usd">190,424</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Less: Warrant liabilities assumed</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:LessWarrantLiabilitiesAssumed" scale="3" unitref="usd">93,110</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net assets and liabilities assumed in reverse recapitalization</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:NetProceedsFromReverseRecapitalizations" scale="3" unitref="usd">97,314</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-indent: 1.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_8" id="_BusinessCombinationDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The number
of shares of common stock issued immediately following the consummation of the Business Combination was as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><ix:continuation continuedat="_BusinessCombinationDisclosureTextBlock-c0_cont_9" id="_BusinessCombinationDisclosureTextBlock-c0_cont_8"><ix:nonnumeric contextref="c0" escape="true" name="rbot:BusinessAcquisitionNumberOfSharesOfCommonStockIssuedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br> Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Common stock, outstanding prior to the Business Combination</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:CommonStockOutstandingPriorToTheBusinessCombinationinDollars" scale="0" unitref="shares">34,500,000</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Less: Redemption of D8 shares</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment" scale="0" sign="-" unitref="usd">26,745,028</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>D8 Public Shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:D8PublicShares" scale="0" unitref="shares">7,754,972</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>D8 Sponsor Shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:D8SponsorShares" scale="0" unitref="shares">8,625,000</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Shares issued in PIPE financing</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:SharesIssuedInPIPEFinancing" scale="0" unitref="shares">14,200,000</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Business combination and PIPE financing shares</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:BusinessCombinationAndPIPEFinancingShares" scale="0" unitref="shares">30,579,972</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Legacy Vicarious Surgical shares (1)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" id="ix_0_fact" name="rbot:LegacyVicariousSurgicalShares" scale="0" unitref="shares">88,042,340</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total shares of common stock immediately after Business Combination</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:TotalSharesOfCommonStockImmediatelyAfterBusinessCombination" scale="0" unitref="shares">118,622,312</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_BusinessCombinationDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"> <tbody><tr style="vertical-align: top"> <td style="width: 0in"></td> <td style="width: 0.25in; font-size: 10pt"><span style="font-size: 10pt">(1)</span></td> <td style="font-size: 10pt"><span style="font-size: 10pt">The number of Legacy Vicarious Surgical shares was determined from the shares of Legacy Vicarious Surgical shares outstanding immediately prior to the closing of the Business Combination converted at the Exchange Ratio of <ix:nonnumeric contextref="c0" name="rbot:DebtInstrumentConvertibleConversionShares">3.29831</ix:nonnumeric>. All fractional shares were rounded down.</span></td></tr> </tbody></table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in">&nbsp;</p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>4.
PROPERTY AND EQUIPMENT, NET</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and equipment, net consist of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated</span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31,</span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Useful
    Lives</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 55%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Machinery
    and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonnumeric contextref="c40" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonnumeric> to <ix:nonnumeric contextref="c41" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonnumeric>&nbsp;years</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c42" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">957</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c43" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">535</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture
    and fixed assets</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonnumeric contextref="c44" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonnumeric> to <ix:nonnumeric contextref="c45" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">7</ix:nonnumeric>&nbsp;years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c46" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">186</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c47" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">103</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer
    hardware and software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonnumeric contextref="c48" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonnumeric>&nbsp;years</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">259</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">67</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold
    improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;Lesser&nbsp;of&nbsp;lease&nbsp;term&nbsp;or&nbsp;asset&nbsp;life</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">1,432</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">24</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 20pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    property and equipment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">2,834</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitref="usd">729</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Less
    accumulated depreciation</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitref="usd">584</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitref="usd">284</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
    and equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd">2,250</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitref="usd">445</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>During 2021,
the Company received $<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LandImprovements" scale="3" unitref="usd">840</ix:nonfraction>&nbsp;related to leasehold improvements funded by its landlord. These leasehold improvements are being depreciated
over the shorter of the lesser of the lease term or each asset’s life. The $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:noncashAllowance" scale="3" unitref="usd">840</ix:nonfraction>&nbsp;amount paid to vendors by the landlord has
been included in deferred rent and leasehold improvements and is being amortized as a reduction to rent expense on a straight-line basis
over the life of the lease.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2021, in connection with a lease termination, the Company disposed of $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:DisposedOfFixedAssets" scale="3" unitref="usd">24</ix:nonfraction> of fixed assets with accumulated depreciation of $<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SaleLeasebackTransactionAccumulatedDepreciation" scale="3" unitref="usd">16</ix:nonfraction> incurring
an $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="3" unitref="usd">8</ix:nonfraction> loss on the disposal which was included in general and administrative expense.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense for the years ended December 31, 2021 and 2020 was $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd">316</ix:nonfraction> and $<ix:nonfraction contextref="c38" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitref="usd">157</ix:nonfraction>, respectively. Machinery with a gross value of $<ix:nonfraction contextref="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MachineryAndEquipmentGross" scale="3" unitref="usd">232</ix:nonfraction> was acquired
for cash of $<ix:nonfraction contextref="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndDueFromBanks" scale="3" unitref="usd">47</ix:nonfraction> and equipment loans of $<ix:nonfraction contextref="c39" decimals="-3" format="ixt:num-dot-decimal" name="rbot:equipmentLoans" scale="3" unitref="usd">185</ix:nonfraction> in 2019. This machinery had accumulated amortization of $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitref="usd">155</ix:nonfraction> and $<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationSaleOfPropertyPlantAndEquipment1" scale="3" unitref="usd">97</ix:nonfraction> at December 31, 2021
and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>5.
FAIR VALUE MEASUREMENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following fair value hierarchy table presents information about the Company’s financial assets measured at fair value on a recurring
basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><ix:nonnumeric contextref="c0" continuedat="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="14" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December
    31, 2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Quoted
    Prices <br> in Active <br> Markets for <br> Identical Items <br> (Level 1)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    <br> Other <br> Observable <br> Inputs <br> (Level 2)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
    <br> Unobservable <br> Inputs <br> (Level 3)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; width: 52%; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Money
    market funds</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" unitref="usd">171,196</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">&nbsp;&nbsp;&nbsp;<span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" unitref="usd">171,196</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    assets</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitref="usd">171,196</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitref="usd">171,196</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities - public warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c54" decimals="0" format="ixt:num-dot-decimal" name="rbot:WarrantLiabilitiesPublicWarrants" scale="0" unitref="usd">37,085</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="rbot:WarrantLiabilitiesPublicWarrants" scale="0" unitref="usd">37,085</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Warrant
    liabilities - private warrants</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c56" decimals="0" format="ixt:num-dot-decimal" name="rbot:WarrantLiabilitiesPrivateWarrants" scale="0" unitref="usd">52,936</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="rbot:WarrantLiabilitiesPrivateWarrants" scale="0" unitref="usd">52,936</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    liabilities</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c54" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" unitref="usd">37,085</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">—</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c56" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" unitref="usd">52,936</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueDisclosure" scale="0" unitref="usd">90,021</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Quoted Prices <br> in Active <br> Markets for <br> Identical Items <br> (Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant <br> Other <br> Observable <br> Inputs <br> (Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Significant <br> Unobservable <br> Inputs <br> (Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Assets:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Money market funds</td><td style="width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" unitref="usd">15,768</ix:nonfraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;—</div></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 1.5pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="0" unitref="usd">15,768</ix:nonfraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total assets</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c57" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitref="usd">15,768</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AssetsFairValueDisclosure" scale="0" unitref="usd">15,768</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_5" id="_FairValueDisclosuresTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Money market funds are classified as cash and
cash equivalents and short term investments, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_6" id="_FairValueDisclosuresTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The fair
value of the Public Warrants was determined from their value trading on the public markets.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_7" id="_FairValueDisclosuresTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
fair value of Private Warrants was calculated using the Black-Scholes Option Pricing Model. The significant assumptions used in the model
were the Company’s stock price, exercise price, expected term, volatility, interest rate, and dividend yield.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_8" id="_FairValueDisclosuresTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>For the
year ended December 31, 2021, the Company recognized a gain to the statement of operations resulting from a decrease in the fair value
of liabilities of approximately $<ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesFairValueAdjustment" scale="6" unitref="usd">3.1</ix:nonfraction> million presented as change in fair value of warrant liabilities on the accompanying statement of
operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_9" id="_FairValueDisclosuresTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The Company
estimates the volatility of its warrants based on implied volatility from the Company’s publicly traded Warrants and from historical
volatility of select peer companies’ common stock that matches the expected remaining life of the Warrants. The risk-free interest
rate is based on the U.S. Treasury zero-coupon yield curve on the grant date for a maturity similar to the expected remaining life of
the Warrants. The expected life of the Warrants is assumed to be equivalent to their remaining contractual term. The dividend rate is
based on the historical rate, which the Company anticipates remaining at zero.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_10" id="_FairValueDisclosuresTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The following
table provides quantitative information regarding Level 3 fair value measurement inputs at their measurement:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_11" id="_FairValueDisclosuresTextBlock-c0_cont_10"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="font-weight: bold; border-bottom: Black 1.5pt solid">Private Warrants</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&nbsp;17, <br> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of September&nbsp;30, <br> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">As of December 31,<br> 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%">Volatility</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c60" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">62.5</ix:nonfraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c61" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">62.5</ix:nonfraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">60.0</ix:nonfraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Stock price</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonfraction contextref="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitref="usdPershares">11.57</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonfraction contextref="c62" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitref="usdPershares">14.96</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitref="usdPershares">10.62</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected life</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonnumeric contextref="c60" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonnumeric> years</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonnumeric contextref="c61" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.0</ix:nonnumeric> years</span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-size: 10pt"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">4.7</ix:nonnumeric>&nbsp;years</span></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Risk-free rate</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c60" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">0.90</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">1.00</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">1.2</ix:nonfraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c60" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitref="pure">0.00</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c61" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitref="pure">0.00</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitref="pure">0.00</ix:nonfraction></td><td style="text-align: left">%</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>


</div><div>

</div><ix:continuation continuedat="_FairValueDisclosuresTextBlock-c0_cont_12" id="_FairValueDisclosuresTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The following
table shows the change in number and value of the Warrants since September 17, 2021, the date they were assumed:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_12"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Public</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Private</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Shares</b></span></td>
    <td style="text-align: center">&nbsp;</td>
    <td style="text-align: center">&nbsp;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Value</b></span></td>
    <td style="text-align: center">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%"><span style="font-size: 10pt">September 17, 2021</span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c63" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">17,249,991</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c63" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">29,670</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c64" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">10,400,000</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c64" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">63,440</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c36" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">27,649,991</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%">&nbsp;</td>
    <td style="width: 1%"><span style="font-size: 10pt">$</span></td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c36" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">93,110</ix:nonfraction></span></td>
    <td style="width: 1%">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Exercised</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c65" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" scale="0" unitref="shares">1,370</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c65" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitref="usd">4</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60"><span style="font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-61"><span style="font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c67" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" scale="0" unitref="shares">1,370</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c67" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" unitref="usd">4</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in"><span style="font-size: 10pt">Change in value</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62"><span style="font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c65" decimals="0" format="ixt:num-dot-decimal" name="rbot:ChangeInValue" scale="0" sign="-" unitref="usd">7,419</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63"><span style="font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c66" decimals="0" format="ixt:num-dot-decimal" name="rbot:ChangeInValue" scale="0" unitref="usd">10,504</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-64"><span style="font-size: 10pt">—</span></div></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 1.5pt solid"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">(<ix:nonfraction contextref="c67" decimals="0" format="ixt:num-dot-decimal" name="rbot:ChangeInValue" scale="0" unitref="usd">3,085</ix:nonfraction></span></td>
    <td><span style="font-size: 10pt">)</span></td></tr>
  <tr style="vertical-align: bottom; ">
    <td><span style="font-size: 10pt">December 31, 2021</span></td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c68" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">17,248,621</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c68" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">37,085</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c69" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">10,400,000</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c69" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">52,936</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right">&nbsp;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitref="shares">27,648,621</ix:nonfraction></span></td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td style="border-bottom: black 4.5pt double"><span style="font-size: 10pt">$</span></td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WarrantsAndRightsOutstanding" scale="0" unitref="usd">90,021</ix:nonfraction></span></td>
    <td>&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>6. ACCRUED EXPENSES </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2" id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following table summarizes the Company’s
components of accrued expenses (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><ix:continuation id="_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-c0_cont_2"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Compensation and benefits related</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitref="usd">3,233</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitref="usd">291</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Professional services and other</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="3" unitref="usd">865</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" scale="3" unitref="usd">103</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total accrued expenses</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:AccruedExpenses" scale="3" unitref="usd">4,098</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="rbot:AccruedExpenses" scale="3" unitref="usd">394</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><b>&nbsp;</b></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_DebtDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>7.
DEBT</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_2" id="_DebtDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Term
Loan</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_3" id="_DebtDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
October 2020, the Company entered into a term loan that provides the Company with borrowings up to $<ix:nonfraction contextref="c70" decimals="-5" format="ixt:num-dot-decimal" name="rbot:CompanyBorrowing" scale="6" unitref="usd">3.5</ix:nonfraction>&nbsp;million that becomes due
on&nbsp;April 1, 2024.&nbsp;<ix:nonnumeric contextref="c0" name="us-gaap:CertainLoansAndDebtSecuritiesAcquiredInTransferDescriptionOfHowPrepaymentsAreConsideredInDeterminationOfContractualCashFlowsAndCashFlowsExpectedToBeCollected">The loan consists of two tranches; a $1.5 million tranche which became available to the Company upon the
close of the loan agreement in October 2020 and was available to the Company to draw through March 31, 2021. The second tranche of $2.0
million becomes available to the Company through September 30, 2021, upon the Company’s successful achievement of a milestone related
to the development of the Company’s surgical robot. Although the milestone was achieved, the Company chose not to draw down the
$2.0 million tranche.</ix:nonnumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_4" id="_DebtDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><ix:nonnumeric contextref="c0" name="us-gaap:DebtInstrumentMaturityDateDescription">The
term loan is interest-only through September 30, 2021, at which time the Company made the first of 30 equal monthly payments of principal
plus interest. Upon receipt of the second tranche, the interest-only window will be extended by six months to March 30, 2022, then followed
by twenty-four equal monthly payments of principal plus interest.&nbsp;&nbsp;The term loan bears interest at a floating rate equal to
the&nbsp;Prime Rate, but not less than a minimum rate of 3.25%. In addition, the final payment made at the earlier of the maturity of
the loan or its termination is to include a deferred interest payment of 7.5% of the amount borrowed, resulting in a minimum annual rate
of 5.98% to be paid to the lender. In the event the Company chooses to repay the term loan prior to the first anniversary of the term
loan closing, a prepayment fee of 3% of the outstanding principal balance will apply. The prepayment fee is reduced to 2% if paid after
the first anniversary date but before the second anniversary date and then is 1% thereafter. The prepayment fee does not apply if the
Company and the bank agree to refinance the loan prior to maturity</ix:nonnumeric>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_5" id="_DebtDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt"><span>The loan has
no financial covenants but does contain monthly reporting requirements and gives the lender a first priority lien on all Company assets.
No amounts were outstanding as of December 31, 2020. In March of 2021, the Company borrowed the first tranche of $<ix:nonfraction contextref="c71" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="6" unitref="usd">1.5</ix:nonfraction>&nbsp;million. As
of December 31, 2021, </span>$<ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShorttermDebtAverageOutstandingAmount" scale="6" unitref="usd">1.4</ix:nonfraction> <span>million was outstanding on the term loan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_6" id="_DebtDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Deferred
Financing Costs</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_7" id="_DebtDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
connection with the term loan, the Company incurred $<ix:nonfraction contextref="c10" decimals="-5" format="ixt:num-dot-decimal" name="rbot:IncurredExpenses" scale="6" unitref="usd">0.1</ix:nonfraction>&nbsp;million in expenses, inclusive of the warrant expense, which are included
in other long-term assets at December 31, 2020 and were then netted against the loan proceeds drawn in March 2021. The Company is amortizing
these costs over the life of the borrowing. The Company amortized </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$21
<span>of deferred financing costs for the year ended December 31, 2021</span>.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_8" id="_DebtDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Common
Stock Warrant</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_9" id="_DebtDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>In connection
with the term loan, the Company issued the lender a warrant to purchase&nbsp;<ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="rbot:WarrantToPurchaseShares" scale="0" unitref="shares">254,794</ix:nonfraction>&nbsp;shares of common stock at $<ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="usdPershares">0.41</ix:nonfraction>&nbsp;per share.&nbsp;&nbsp;The
common stock warrant was exercisable for&nbsp;<ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:ExerciseOfWarrant">10</ix:nonnumeric>&nbsp;years from the date of issuance, was structured to survive a merger or acquisition
(except all-cash and/or public stock acquisitions) and allowed for cashless exercise in whole or part.&nbsp;&nbsp;The fair value of the
common stock warrant was $<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:FairValueOfCommonStockWarrantPerShare" scale="0" unitref="shares">0.33</ix:nonfraction>&nbsp;per share at the grant date, and the Company recorded a total of $<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredCosts" scale="3" unitref="usd">85</ix:nonfraction>&nbsp;in deferred financing costs
associated with the warrant issuances which are included in other long-term assets at December 31, 2020. At the time of the Company’s
recapitalization, the lender elected to cashless exercise the warrants resulting in the net issuance of&nbsp;<ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="rbot:ExcerciseOfWarrant" scale="0" unitref="shares">146,577</ix:nonfraction>&nbsp;shares of common
stock. The remaining warrants were cancelled due to the Company’s decision not to borrow the second tranche. </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>&nbsp;</i></b></span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_10" id="_DebtDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Equipment
Loan</i></b><i>s</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_11" id="_DebtDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
March 2019, the Company entered into two equipment loans with a vendor for the purchase of manufacturing machinery.&nbsp;<ix:nonnumeric contextref="c0" continuedat="_EquipmentLoansDescription-c0_cont_1" name="rbot:EquipmentLoansDescription">The equipment
loans had an aggregate principal balance of $185 at inception, with forty-eight equal monthly payments of principal and interest due
beginning ninety days after taking possession of the machinery. The equipment loans are collateralized by the underlying machinery. As
of December 31, 2021 and 2020, the aggregate outstanding principal balance of the equipment loans was </ix:nonnumeric></span><ix:continuation id="_EquipmentLoansDescription-c0_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$16
<span>and $63, respectively, net of current portion of $47.</span></span></ix:continuation></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DebtDisclosureTextBlock-c0_cont_12" id="_DebtDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
following table represents the future payments required under the noncancellable equipment agreements and includes interest of </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$4<span>:</span></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DebtDisclosureTextBlock-c0_cont_12"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfDebtTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years
    Ended December 31,</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" unitref="usd">50</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: bold 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitref="usd">17</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
    future equipment payments</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitref="usd">67</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table></ix:nonnumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>8.
COMMITMENTS and CONTINGENCIES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company leases its office facility under noncancelable operating lease agreements expiring in March of 2032</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.
Rent expense for the years ended December 31, 2021 and 2020 was $1,447 and $447, respectively. </span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>On January
25, 2021, the Company entered into a twelve-year lease agreement that commences on April 1, 2021 and ends on February 28, 2029, for its
new corporate headquarters. Rental payments due over the period of the lease total $<ix:nonfraction contextref="c72" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesContingentRentalPaymentsDue" scale="6" unitref="usd">9.7</ix:nonfraction>&nbsp;million. On October 14, 2021, the lease was
amended to add additional space and was simultaneously extended to end on March 31, 2032. Rental payments due over the period of the lease
were amended from $<ix:nonfraction contextref="c73" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesContingentRentalPaymentsDue" scale="6" unitref="usd">9.7</ix:nonfraction> million to $<ix:nonfraction contextref="c74" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CapitalLeasesContingentRentalPaymentsDue" scale="6" unitref="usd">25.0</ix:nonfraction> million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
November of 2021, the landlord of the Company’s lease for its previous corporate headquarters, terminated the agreement and the
Company and the landlord were disputing amounts due to the parties, if any, in accordance with the terms of the lease agreement. Subsequent
to year end, the Company and landlord have agreed to settle their dispute for a payment to the landlord of $<ix:nonfraction contextref="c75" decimals="-3" format="ixt:num-dot-decimal" name="rbot:PaymentToLandlord" scale="3" unitref="usd">118</ix:nonfraction>. The Company has recorded
this settlement by accruing $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherSellingGeneralAndAdministrativeExpense" scale="3" unitref="usd">118</ix:nonfraction> to general and administrative expense as of December 31, 2021. As the lease has been terminated, the
minimum lease payments that would have been due under the agreement have been excluded from the future minimum lease payments table presented
below.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
following table presents the future minimum lease payments required under the Company’s noncancellable operating leases at December
31, 2021:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: left; font-weight: bold; border-bottom: Black 1.5pt solid">Years Ended December 31,</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">2022</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" scale="3" unitref="usd">1,644</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">2023</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwo" scale="3" unitref="usd">2,162</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">2024</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" scale="3" unitref="usd">2,286</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">2025</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" unitref="usd">2,358</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: -10pt; padding-left: 10pt">2026</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" unitref="usd">2,430</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; font-weight: bold; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Thereafter</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" scale="3" unitref="usd">13,936</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total future minimum lease payments</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="rbot:TotalFutureMinimumLeasePayment" scale="3" unitref="usd">24,816</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal
Proceedings — From time to time, the Company may face legal claims or actions in the normal course of business. At each reporting
date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the
provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses as incurred the costs related
to its legal proceedings.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>9.
INCOME TAXES</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company’s entire pretax loss for the years ended December 31, 2021 and 2020 was from its U.S. domestic operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded a tax loss for the years ended December 31, 2021 and 2020. Therefore, the Company recorded no current or deferred income
tax expense or benefit for the years ended December 31, 2021 and 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
reconciliation of the Company’s statutory income tax rate to the Company’s effective income tax rate is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Income at US Statutory Rate</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitref="pure">21</ix:nonfraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" unitref="pure">21</ix:nonfraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">State taxes, net of Federal benefit</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitref="pure">8</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" unitref="pure">6</ix:nonfraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Permanent differences</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:PermanentDifferences" scale="-2" unitref="pure">0</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="rbot:PermanentDifferences" scale="-2" sign="-" unitref="pure">1</ix:nonfraction></td><td style="text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Change in fair value of warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:ChangeInFairValueOfWarrants" scale="-2" unitref="pure">2</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-65"><span style="font-size: 10pt">⸻</span></div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Transaction costs</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:TransactionCosts" scale="-2" unitref="pure">5</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-66"><span style="font-size: 10pt">⸻</span></div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Stock-based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">(<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" sign="-" unitref="pure">1</ix:nonfraction></td><td style="text-align: left">)%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-67"><span style="font-size: 10pt">⸻</span></div></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax credits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitref="pure">4</ix:nonfraction></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" unitref="pure">4</ix:nonfraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitref="pure">39</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" sign="-" unitref="pure">30</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="pure">0</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitref="pure">0</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:nonnumeric></ix:continuation><div>




</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company’s deferred tax assets and (liabilities)
are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&nbsp;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred Tax Assets:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 9pt">Net operating loss carryforwards</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitref="usd">18,269</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitref="usd">7,602</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Tax credits</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" unitref="usd">2,727</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="3" unitref="usd">1,244</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 9pt">Stock based compensation</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitref="usd">657</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" unitref="usd">23</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">Accruals and reserves</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" unitref="usd">1,065</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves" scale="3" unitref="usd">23</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Depreciation and amortization</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitref="usd">56</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOther" scale="3" unitref="usd">104</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.25in">Total deferred tax assets before valuation allowance</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitref="usd">22,774</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitref="usd">8,996</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitref="usd">22,774</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitref="usd">8,996</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 27pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-68">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-69">—</div></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021 and 2020 the Company is in a net deferred tax asset position. The deferred tax assets consist principally of net
operating loss carryforwards and research and development tax credits. The future realization of the tax benefits from existing temporary
differences and tax attributes, ultimately depends on the existence of sufficient taxable income. In assessing the realization of the
deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will
not be realized. Management considers the scheduled reversal of projected future taxable income, and tax planning strategies in making
this assessment. After consideration of all available evidence, both positive and negative, the Company has determined that it was more
likely than not that the Company would not recognize the benefits of its federal and state net deferred tax assets. Accordingly, the
Company has a full valuation allowance against the deferred tax assets as of December 31, 2021 and 2020. The change in the valuation
allowance for the years ended December 31, 2021 and 2020 was an increase of $<ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" unitref="usd">13.8</ix:nonfraction> million and $<ix:nonfraction contextref="c10" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" unitref="usd">3.9</ix:nonfraction> million, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has incurred losses since inception that would generally be available to reduce future taxable income. As of December 31, 2021,
the Company had U.S. federal net operating loss carryforwards of $<ix:nonfraction contextref="c76" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" unitref="usd">67.3</ix:nonfraction> million which includes $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" scale="6" unitref="usd">2.8</ix:nonfraction> million that expire at various dates
from 2034 through 2037, and $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="rbot:DeferredTaxSssetsOperatingLossUnlimitedCarryforwards" scale="6" unitref="usd">64.5</ix:nonfraction> million that have an unlimited carryforward period. As of December 31, 2021, the Company had state
net operating loss carryforwards of $<ix:nonfraction contextref="c77" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" unitref="usd">65.2</ix:nonfraction> million which includes $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" unitref="usd">65.0</ix:nonfraction> million that expire at various dates from 2035 through 2041, and
$<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="rbot:DeferredTaxAssetsOperatingLossUnlimitedCarryforwardsStateAndLocal" scale="6" unitref="usd">0.2</ix:nonfraction> million that have an unlimited carryforward period.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2021, the Company had U.S. federal and state research and development tax credits of $<ix:nonfraction contextref="c76" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" unitref="usd">1.6</ix:nonfraction> million and $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" scale="6" unitref="usd">1.4</ix:nonfraction> million respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
future realization of the Company’s net operating loss carryforwards and other tax attributes may also be limited by the change
in ownership rules under Code Section&nbsp;382. Under Section&nbsp;382 of the Code, if a corporation undergoes an “ownership change”
(as defined in Section 382 of the Code), the corporation’s ability to utilize its net operating loss carryforwards and other tax
attributes to offset income may be limited. The Company has not completed a study to assess whether an ownership change has occurred
or whether there have been multiple ownership changes.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company files income tax returns in the U.S. federal jurisdiction and in any state and local jurisdiction in which it operates. The Company
is subject to tax examination by various taxing authorities. The Company is not currently under examination and is not aware of any issues
under review that could result in significant payments, accruals or material deviation from its tax positions. To the extent the Company
has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal
Revenue Service and state and local tax authorities to the extent utilized in a future period. As of December 31, 2021, the tax years
from 2018 to present remain open to examination by relevant taxing jurisdictions to which the Company is subject. However, to the extent
the Company utilizes net operating losses from years prior to 2018, the statute remains open to the extent of the net operating losses
or other credits that are utilized.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">The calculation and assessment of the Company’s
tax exposures generally involve the uncertainties in the application of complex tax laws and regulations for federal, state and local
jurisdictions. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be
sustained upon examination, including resolutions of any related appeals or litigation, on the basis of the technical merits. As of December
31, 2021, the Company has not recorded any liabilities related to uncertain tax positions in its financial statements. Similarly, the
Company has not accrued any interest and penalties related to uncertain tax positions as of December 31, 2021. The Company recognizes
accrued interest and penalties, if any, related to uncertain tax positions in tax expense in its financial statements.</p></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>10.
STOCKHOLDERS’ EQUITY</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Authorized
Shares</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">At
December&nbsp;31, 2021, the Company’s authorized shares consisted of&nbsp;<ix:nonfraction contextref="c6" decimals="0" format="ixt:num-dot-decimal" name="rbot:CommonStockShareAuthorized" scale="0" unitref="shares">300,000,000</ix:nonfraction>&nbsp;shares of Class A common stock, $<ix:nonfraction contextref="c6" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction>&nbsp;par
value; and&nbsp;<ix:nonfraction contextref="c8" decimals="0" format="ixt:num-dot-decimal" name="rbot:CommonStockShareAuthorized" scale="0" unitref="shares">22,000,000</ix:nonfraction>&nbsp;shares of Class B common stock, $<ix:nonfraction contextref="c8" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction>&nbsp;par value; and&nbsp;<ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" unitref="shares">1,000,000</ix:nonfraction>&nbsp;shares of preferred stock,
par value of $<ix:nonfraction contextref="c4" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction>&nbsp;per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Legacy
Vicarious Surgical Preferred Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
connection with the Business Combination, Legacy Vicarious Surgical’s Convertible Preferred Stock (“Legacy Convertible Preferred
Stock”), previously classified as mezzanine was retroactively adjusted, converted into Common Stock, and reclassified to permanent
equity as a result of the reverse recapitalization. As of December 31, 2021, there were no Legacy Convertible Preferred Stock authorized,
issued or outstanding. The following table summarizes details of Legacy Convertible Preferred Stock authorized, issued and outstanding
immediately prior to the Business Combination:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><ix:nonnumeric contextref="c0" escape="true" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="10" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior
    to Business Combination</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="6" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Shares</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legacy
    Convertible Preferred Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Authorized</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued
    and Outstanding</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Preferred
    Stock</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A Legacy
    Convertible Preferred Stock, $0.0001 par value</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c78" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareAuthorized" scale="0" unitref="shares">16,740,853</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c78" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c78" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareOutstanding" scale="0" unitref="shares">16,740,853</ix:nonfraction></ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c78" decimals="0" format="ixt:num-dot-decimal" name="rbot:PreferredStockValues" scale="0" unitref="usd">6,477</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A1 Legacy Convertible
    Preferred Stock, $0.0001 par value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c79" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareAuthorized" scale="0" unitref="shares">26,107,321</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c79" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c79" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareOutstanding" scale="0" unitref="shares">26,107,321</ix:nonfraction></ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c79" decimals="0" format="ixt:num-dot-decimal" name="rbot:PreferredStockValues" scale="0" unitref="usd">16,678</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series A2 Legacy Convertible
    Preferred Stock, $0.0001 par value</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c80" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareAuthorized" scale="0" unitref="shares">10,036,853</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c80" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c80" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareOutstanding" scale="0" unitref="shares">10,036,853</ix:nonfraction></ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c80" decimals="0" format="ixt:num-dot-decimal" name="rbot:PreferredStockValues" scale="0" unitref="usd">9,995</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Series
    A3 Legacy Convertible Preferred Stock, $0.0001 par value</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c81" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareAuthorized" scale="0" unitref="shares">18,267,057</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c81" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c81" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareOutstanding" scale="0" unitref="shares">13,665,901</ix:nonfraction></ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c81" decimals="0" format="ixt:num-dot-decimal" name="rbot:PreferredStockValues" scale="0" unitref="usd">13,520</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: bold 10pt Times New Roman, Times, Serif; padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareAuthorized" scale="0" unitref="shares">71,152,084</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareIssued" scale="0" unitref="shares"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareOutstanding" scale="0" unitref="shares">66,550,928</ix:nonfraction></ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="rbot:PreferredStockValues" scale="0" unitref="usd">46,670</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
following describes the rights and preferences of the Company’s Legacy Convertible Preferred Stock prior to the conversion in the
Business Combination:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Voting</i>&nbsp;—
The holders of Legacy Series Preferred Stock vote together with all other classes and series of stock as a single class on an as-converted
basis. Each share of Legacy Series Preferred Stock entitles the holder to such number of votes per share as shall equal the number of
shares of common stock into which the share is then convertible. The holders of the Legacy Series&nbsp;A1 and A2 Preferred Stock, collectively,
are entitled to elect two directors to the Company’s Board of Directors and holders of the Legacy Series&nbsp;A3 Preferred Stock
are entitled to elect two directors to the Company’s Board of Directors.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Dividends</i>&nbsp;—
Dividends may be declared and paid on Legacy Series Preferred Stock from funds lawfully available as and when determined by the Company’s
Board of Directors. Through the date of the conversion and through December&nbsp;31, 2021, no dividends have been declared.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Liquidation</i>&nbsp;—
Upon any liquidation, dissolution, or winding up of the Company, whether voluntary or involuntary, the holders of the Legacy Series Preferred
Stock are entitled to first be paid out of assets available for distribution, prior and in preference to any distribution to the holders
of the Company’s common stock, the greater of (a)&nbsp;an amount equal to $<ix:nonfraction contextref="c78" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitref="usdPershares">0.3926</ix:nonfraction>&nbsp;per share for Series&nbsp;A Preferred Stock,
$<ix:nonfraction contextref="c79" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitref="usdPershares">0.6420</ix:nonfraction>&nbsp;per share for Legacy Series&nbsp;A1 Preferred Stock, plus declared but unpaid dividends, $<ix:nonfraction contextref="c80" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitref="usdPershares">0.9963</ix:nonfraction>&nbsp;per share for Legacy
Series&nbsp;A2 Preferred Stock, plus declared but unpaid dividends, $<ix:nonfraction contextref="c81" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockLiquidationPreference" scale="0" unitref="usdPershares">0.9963</ix:nonfraction>&nbsp;per share for Legacy Series&nbsp;A3 Preferred Stock,
plus declared but unpaid dividends (b)&nbsp;an amount per share that would have been payable had all shares of the Legacy Series Preferred
Stock been converted to shares of Class B common stock immediately prior to any liquidation, dissolution, or winding up of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Conversion</i>&nbsp;—
Each holder of Legacy Series Preferred Stock has the right, at their option at any time, to convert any such shares of Legacy Series
Preferred Stock into fully paid and nonassessable shares of Class B common stock. The conversion ratio is determined by dividing the
purchase price by the conversion price, which is equal to $<ix:nonfraction contextref="c78" decimals="4" format="ixt:num-dot-decimal" name="rbot:PreferredStockConversionPricePerShare" scale="0" unitref="usdPershares">0.3926</ix:nonfraction>, $<ix:nonfraction contextref="c79" decimals="4" format="ixt:num-dot-decimal" name="rbot:PreferredStockConversionPricePerShare" scale="0" unitref="usdPershares">0.6420</ix:nonfraction>, $<ix:nonfraction contextref="c80" decimals="4" format="ixt:num-dot-decimal" name="rbot:PreferredStockConversionPricePerShare" scale="0" unitref="usdPershares">0.9963</ix:nonfraction>&nbsp;and $<ix:nonfraction contextref="c81" decimals="4" format="ixt:num-dot-decimal" name="rbot:PreferredStockConversionPricePerShare" scale="0" unitref="usdPershares">0.9963</ix:nonfraction>&nbsp;per share for Legacy Series&nbsp;A,
A1, A2 and A3 Preferred Stock, respectively. The conversion price is subject to change if certain dilutive events occur. Conversion is
mandatory with an initial public offering of the Company’s common stock with a value of at least $<ix:nonfraction contextref="c4" decimals="-6" format="ixt:num-dot-decimal" name="rbot:CommonStockGrossProceeds" scale="6" unitref="usd">40</ix:nonfraction>&nbsp;million of gross proceeds
to the Company or upon the election of greater than&nbsp;<ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="rbot:PreferredStockShareHoldersPercentage" scale="-2" unitref="pure">50</ix:nonfraction>% of the holders of Series Preferred Stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Redemption</i>&nbsp;—
The Legacy Series&nbsp;Preferred Stock is not subject to mandatory or optional redemption other than in connection with a liquidation,
dissolution, or winding-up of the Company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Classes
of Common Stock</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Class
A common stock receive 1 vote per share. Subject to preferences that may be applicable to any outstanding preferred stock, the holders
of shares of Class A common stock are entitled to receive ratably such dividends, if any, as may be declared from time to time by the
board of directors out of funds legally available for such purposes. In the event of any voluntary or involuntary liquidation, dissolution
or winding up of our affairs, the holders of Class A common stock are entitled to share ratably in all assets remaining after payment
of our debts and other liabilities, subject to prior distribution rights of preferred stock or any class or series of stock having a
preference over the Class A common stock, then outstanding, if any.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>




</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Class
B common stock receives 20 votes per share and converts into Class A at a one-to-one conversion rate per share. Holders of Class B common
stock will share ratably together with each holder of Class A common stock, if and when any dividend is declared by the board of directors.
Holders of Class B common stock have the right to convert shares of their Class B common stock into fully paid and non-assessable shares
of Class A common stock, on a one-to-one basis, at the option of the holder at any time. Upon the occurrence of certain events, holders
of Class B common stock automatically convert into Class A common stock, on a one-to-one basis. In the event of any voluntary or involuntary
liquidation, dissolution or winding up of our affairs, the holders of Class B common stock are entitled to share ratably in all assets
remaining after payment of our debts and other liabilities, subject to prior distribution rights of preferred stock or any class or series
of stock having a preference over the Class B common stock, then outstanding, if any.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Restricted
Stock Agreements</i>&nbsp;—&nbsp;<ix:nonnumeric contextref="c0" name="rbot:RestrictedStockAgreementDescription">In 2014, the Company issued 19,789,860&nbsp;shares of Legacy Class A common stock to the initial
founders of the Company at par that contained a repurchase right by the Company at the lesser of the original purchase price of $0.0001
per share or the then current fair value of the share, which lapsed over a four-year period. In 2016 and 2018 these shares were amended
with respect to the lapse of the repurchase rights, such that beginning as of January 2018 60% percent of the shares were vested and
the remaining shares vest over a thirty-six month period.</ix:nonnumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">As
of January 30, 2021 the shares were fully vested and on September 17, 2021, in connection with the recapitalization the shares were converted
to Class B common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
2021, subsequent to the recapitalization, the Company issued <ix:nonfraction contextref="c82" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockSplits" scale="0" unitref="shares">749,691</ix:nonfraction> restricted stock units (“RSUs”) of Class A common stock
to employees and members of the board of directors. The RSUs vest over a four-year period. The activity for common stock subject to vesting
for the years ended December 31, 2021 and 2020, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Shares Subject to Vesting</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted Average Grant Date Fair Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-bottom: 4pt">Balance of unvested shares - January 1, 2020</td><td style="width: 1%; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="width: 9%; padding-bottom: 4pt; text-align: right"><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitref="shares">217,602</ix:nonfraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="width: 1%; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="2" format="ixt:num-dot-decimal" name="rbot:UnvestedSharesWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares">0.05</ix:nonfraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Granted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares">749,692</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:GrantedWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares">12.53</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; padding-left: 9pt">Vested</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" unitref="shares">269,243</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:VestedWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares">2.42</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Balance of unvested shares - December 31, 2021</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitref="shares">698,051</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="2" format="ixt:num-dot-decimal" name="rbot:UnvestedSharesWeightedAverageGrantDateFairValue" scale="0" unitref="usdPershares">12.54</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
total stock-based compensation related to the RSUs during the years ended December 31, 2021, was $<ix:nonfraction contextref="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationRestrictedStockUnitsRequisiteServicePeriodRecognition" scale="6" unitref="usd">0.8</ix:nonfraction> million. As of December 31, 2021,
the total unrecognized stock-based compensation expense related to unvested RSUs aggregated $<ix:nonfraction contextref="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" scale="6" unitref="usd">8.4</ix:nonfraction> million and is expected to be recognized
over a weighted average period of <ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">3.3</ix:nonnumeric> years. The aggregate intrinsic value of the awards granted and vested during the year ended December
31, 2021 was $<ix:nonfraction contextref="c83" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested" scale="6" unitref="usd">6.4</ix:nonfraction> million and $<ix:nonfraction contextref="c82" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" scale="6" unitref="usd">0.5</ix:nonfraction> million, respectively. The aggregate intrinsic value of RSUs outstanding at December 31, 2021 was
$<ix:nonfraction contextref="c83" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" scale="6" unitref="usd">6.0</ix:nonfraction> million.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>Preferred
Stock</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Preferred
stock shares authorized may be issued from time to time in one or more series, with each series terms, voting, dividend, conversion,
redemption, liquidation and other rights to be determined by the Board of Directors at the time of&nbsp;issuance.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><b>Warrants</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>




</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">In
D8’s initial public offering, on July 17, 2020 it sold units at a price of $<ix:nonfraction contextref="c84" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="usdPershares">10.00</ix:nonfraction>&nbsp;per unit, which consisted of one D8 Class
A ordinary share, $<ix:nonfraction contextref="c84" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitref="usdPershares">0.0001</ix:nonfraction>&nbsp;par value, and one-half of a redeemable warrant (each a “Public Warrant”). On July 17, 2020,
simultaneously with the closing of its initial public offering, D8 consummated the Private Placement of&nbsp;<ix:nonfraction contextref="c85" decimals="0" format="ixt:num-dot-decimal" name="rbot:PrivatePlacementWarrants" scale="0" unitref="shares">8,000,000</ix:nonfraction>&nbsp;Private Placement
Warrants, each exercisable to purchase one D8 Class A ordinary share at $<ix:nonfraction contextref="c86" decimals="2" format="ixt:num-dot-decimal" name="rbot:ErcisableToPurchasePricePerShare" scale="0" unitref="usdPershares">11.50</ix:nonfraction>&nbsp;per share, at a price of $<ix:nonfraction contextref="c87" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="usdPershares">1.00</ix:nonfraction>&nbsp;per Private Placement
Warrant. On July 24, 2020, simultaneously with the sale of D8’s over-allotment units, D8 consummated a private sale of an additional&nbsp;<ix:nonfraction contextref="c88" decimals="0" format="ixt:num-dot-decimal" name="rbot:AdditionalShares" scale="0" unitref="shares">900,000</ix:nonfraction>&nbsp;Private
Placement Warrants. In connection with the Business Combination,&nbsp;<ix:nonfraction contextref="c89" decimals="0" format="ixt:num-dot-decimal" name="rbot:AdditionalShares" scale="0" unitref="shares">1,500,000</ix:nonfraction>&nbsp;additional Private Placement Warrants were issued
upon conversion of D8 working capital loans. In connection with the Business Combination, each issued and outstanding D8 Class A ordinary
share automatically converted into one share of Class A common stock. Each warrant is exercisable to purchase one share of Class A common
stock at $<ix:nonfraction contextref="c90" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitref="usdPershares">11.50</ix:nonfraction>&nbsp;per share.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_25"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">As
of December&nbsp;31, 2021, the Company had&nbsp;<ix:nonfraction contextref="c91" decimals="0" format="ixt:num-dot-decimal" name="rbot:PublicWarrants" scale="0" unitref="shares">17,248,621</ix:nonfraction>&nbsp;Public Warrants and&nbsp;<ix:nonfraction contextref="c4" decimals="0" format="ixt:num-dot-decimal" name="rbot:PrivatePlacementWarrantsOutstanding" scale="0" unitref="shares">10,400,000</ix:nonfraction>&nbsp;Private Placement Warrants outstanding.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_26"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Public Warrants became exercisable at $<ix:nonfraction contextref="c33" decimals="2" format="ixt:num-dot-decimal" name="rbot:ExercisablePricePerShare" scale="0" unitref="usdPershares">11.50</ix:nonfraction>&nbsp;per share 30 days after the completion of the September 17, 2021 Business Combination.
When the warrants became redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or
qualify the underlying securities for sale under all applicable state securities laws. The Company filed a registration statement with
the SEC that was declared effective as of October 22, 2021 covering the shares of Class A common stock issuable upon exercise of the
warrants and is maintaining a current prospectus relating to those shares of Class A common stock until the warrants expire, are exercised
or redeemed, as specified in the warrant agreement.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_27"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>The warrants
will expire five years after the completion of a Business Combination or earlier upon redemption or liquidation.&nbsp;<ix:nonnumeric contextref="c92" name="us-gaap:BusinessCombinationReasonForBusinessCombination">If (x) the Company
issues additional shares of Class A common stock or equity-linked securities for capital raising purposes in connection with the closing
of its initial Business Combination at an issue price or effective issue price of less than $9.20 per share of Class A common stock (with
such issue price or effective issue price to be determined in good faith by the Company’s board of directors and, in the case of
any such issuance to the initial shareholders or their affiliates, without taking into account any Founder Shares held by the initial
shareholders or such affiliates, as applicable, prior to such issuance) (the “Newly Issued Price”), (y) the aggregate gross
proceeds from such issuances represent more than 60% of the total equity proceeds, and interest thereon, available for the funding of
the initial Business Combination on the date of the consummation of our initial Business Combination (net of redemptions), and (z) the
volume weighted average trading price of Class A common stock during the 10 trading day period starting on the trading day prior to the
day on which the Company consummates the initial Business Combination (such price, the “Market Value”) is below $9.20 per
share, the exercise price of the Warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of the Market Value
and the Newly Issued Price, and the $18.00 per share redemption trigger prices described below under “Redemption of Warrants when
the price per share of Class A common stock equals or exceeds $18.00” will be adjusted (to the nearest cent) to be equal to 180%
of the higher of the Market Value and the Newly Issued Price, and the $10.00 per share redemption trigger price described below under
“Redemption of Warrants when the price per share of Class A common stock equals or exceeds $10.00” will be adjusted (to the
nearest cent) to be equal to the higher of the Market Value and the Newly Issued Price.</ix:nonnumeric></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_28"><ix:nonnumeric contextref="c0" continuedat="_WarrantDescription-c0_cont_1" name="rbot:WarrantDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Redemption
of Warrants when the price per share of Class A common stock equals or exceeds $18.00.</i>&nbsp;The Company may call the Public Warrants
for redemption:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_29"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><ix:continuation continuedat="_WarrantDescription-c0_cont_2" id="_WarrantDescription-c0_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><ix:continuation continuedat="_WarrantDescription-c0_cont_3" id="_WarrantDescription-c0_cont_2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_4" id="_WarrantDescription-c0_cont_3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_5" id="_WarrantDescription-c0_cont_4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_6" id="_WarrantDescription-c0_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_7" id="_WarrantDescription-c0_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_8" id="_WarrantDescription-c0_cont_7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_9" id="_WarrantDescription-c0_cont_8"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_10" id="_WarrantDescription-c0_cont_9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $0.01 per warrant;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_11" id="_WarrantDescription-c0_cont_10"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_12" id="_WarrantDescription-c0_cont_11"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_13" id="_WarrantDescription-c0_cont_12"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_14" id="_WarrantDescription-c0_cont_13"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_15" id="_WarrantDescription-c0_cont_14"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_16" id="_WarrantDescription-c0_cont_15"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon a minimum of 30 days’ prior written notice of redemption; and</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_17" id="_WarrantDescription-c0_cont_16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_18" id="_WarrantDescription-c0_cont_17"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_19" id="_WarrantDescription-c0_cont_18"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_20" id="_WarrantDescription-c0_cont_19"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c0_cont_21" id="_WarrantDescription-c0_cont_20"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation id="_WarrantDescription-c0_cont_21"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the last reported sale price of Class A common stock equals or exceeds $18.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.</span></ix:continuation></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_30"><ix:nonnumeric contextref="c93" continuedat="_WarrantDescription-c93_cont_1" name="rbot:WarrantDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; "><i>Redemption
of Warrants when the price per share of Class A common stock equals or exceeds $10.00</i>. The Company may call the Public Warrants for
redemption:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_31"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><ix:continuation continuedat="_WarrantDescription-c93_cont_2" id="_WarrantDescription-c93_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><ix:continuation continuedat="_WarrantDescription-c93_cont_3" id="_WarrantDescription-c93_cont_2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_4" id="_WarrantDescription-c93_cont_3"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in whole and not in part;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_5" id="_WarrantDescription-c93_cont_4"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_6" id="_WarrantDescription-c93_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_7" id="_WarrantDescription-c93_cont_6"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_8" id="_WarrantDescription-c93_cont_7"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_9" id="_WarrantDescription-c93_cont_8"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_10" id="_WarrantDescription-c93_cont_9"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">at a price of $0.10 per warrant;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_11" id="_WarrantDescription-c93_cont_10"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_12" id="_WarrantDescription-c93_cont_11"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_13" id="_WarrantDescription-c93_cont_12"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_14" id="_WarrantDescription-c93_cont_13"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation continuedat="_WarrantDescription-c93_cont_15" id="_WarrantDescription-c93_cont_14"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></ix:continuation></td> <td style="font: 10pt Times New Roman, Times, Serif"><ix:continuation id="_WarrantDescription-c93_cont_15"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">upon a minimum of 30 days’ prior written notice of redemption;&nbsp;<i>provided</i>&nbsp;that holders will be able to exercise their warrants on a cashless basis prior to redemption and receive that number of shares based on the redemption date and the “fair market value” of the Company’s Class A common stock; and</span></ix:continuation></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">if, and only if, the last reported sale price of Class A common stock shares equals or exceeds $10.00 per share (as adjusted) for any 20 trading days within a 30-trading day period ending three trading days before the Company sends the notice of redemption to the warrant holders.</span></td></tr> </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_32"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Private Placement Warrants are identical to the Public Warrants except that the Private Placement Warrants and the shares of Class A
common stock issuable upon exercise of the Private Placement Warrants, so long as they are held by the Sponsor or its permitted transferees,
(i) will not be redeemable by the Company, (ii) may not (including the shares of Class A common stock issuable upon exercise of these
warrants), subject to certain limited exceptions, be transferred, assigned or sold by the holders until 30 days after the completion
of the initial Business Combination, (iii) may be exercised by the holders on a cashless basis and (iv) will be entitled to registration
rights. If the Private Placement Warrants are held by holders other than the Sponsor or its permitted transferees, the Private Placement
Warrants will be redeemable by the Company and exercisable by the holders on the same basis as the Public Warrants.&nbsp;</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>11.
Stock-based Compensation</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>&nbsp;</i></span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2014
Plan</i>&nbsp;— In 2014, the Board of Directors approved the adoption of the 2014 Stock Incentive Plan (the “2014 Plan”).
The 2014 Plan allows for the award of incentive and nonqualified stock options, restricted stock, and other stock-based awards to employees,
officers, directors, consultants, and advisors of the Company. Awards may be made under the Plan for up to&nbsp;<ix:nonfraction contextref="c94" decimals="0" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAward" scale="0" unitref="shares">19,914,315</ix:nonfraction>&nbsp;shares
of Class A common stock. The Board of Directors administers the 2014 Plan and determines the exercise price of options, purchase price
for restricted stock, the rates at which awards vest, and the other terms and conditions of the awards. Options and restricted stock
generally vest&nbsp;<ix:nonfraction contextref="c95" decimals="2" format="ixt:num-dot-decimal" name="rbot:StockbasedCompensationOptionsAndRestrictedStockVest" scale="-2" unitref="pure">25</ix:nonfraction>% upon the first anniversary of the grant date and at the rate of&nbsp;<ix:nonfraction contextref="c95" decimals="4" format="ixt:num-dot-decimal" name="rbot:GrantRate" scale="-2" unitref="pure">6.25</ix:nonfraction>% per quarter thereafter over a three-year
period for employees or over the service period for nonemployees and expire&nbsp;<ix:nonnumeric contextref="c95" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonnumeric>&nbsp;years from the date of grant. The 2021 Plan
replaced the 2014 Plan.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021
Plan</i>&nbsp;— In 2021, the Board of Directors approved the adoption of the 2021 Equity Incentive Plan (the “2021 Plan”).
The 2021 Plan allows for the award of incentive and nonqualified stock options, restricted stock, and other stock-based awards to employees,
officers, directors, consultants, and advisors of the Company. Awards may be made under the Plan for up to&nbsp;<ix:nonfraction contextref="c96" decimals="0" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAward" scale="0" unitref="shares">18,384,074</ix:nonfraction>&nbsp;shares
of common stock (either Class A or Class B). The Board of Directors administers the 2021 Plan and determines the exercise price of options,
purchase price for restricted stock, the rates at which awards vest, and the other terms and conditions of the awards. Options and restricted
stock generally vest&nbsp;<ix:nonfraction contextref="c97" decimals="2" format="ixt:num-dot-decimal" name="rbot:StockbasedCompensationOptionsAndRestrictedStockVest" scale="-2" unitref="pure">25</ix:nonfraction>% upon the first anniversary of the grant date and at the rate of&nbsp;<ix:nonfraction contextref="c97" decimals="4" format="ixt:num-dot-decimal" name="rbot:GrantRate" scale="-2" unitref="pure">6.25</ix:nonfraction>% per quarter thereafter over
a three-year period for employees or over the service period for nonemployees and expire&nbsp;<ix:nonnumeric contextref="c97" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">10</ix:nonnumeric>&nbsp;years from the date of grant.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The Company grants stock options to employees
at exercise prices deemed by the Board of Directors to be equal to the fair value of the common stock at the time of grant. The fair value
of the Company’s stock options and warrants on the date of grant is determined by a Black-Scholes pricing model utilizing key assumptions
such as common stock price, risk-free interest rate, dividend yield, expected volatility and expected life. The Company’s estimates
of these assumptions are primarily based on the fair value of the Company’s stock, historical data, peer company data and judgement
regarding future trends. Prior to the Business Combination, the fair value of the Company’s common stock was determined by the Board
of Directors at each award grant date based upon a variety of factors, including the results obtained from a third-party valuation, the
Company’s financial position and historical financial performance, the status of technological development within the Company’s
proposed products, the illiquid nature of the common stock, arm’s-length sales of the Company’s capital stock, including convertible
preferred stock, the effect of the rights and preferences of the preferred shareholders, and the prospects of a liquidity event, among
others, as the Company’s common stock was not actively traded. <span>Since becoming a publicly traded
company, the Company uses its publicly traded stock price as the fair value of its common stock</span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the years ended December 31, 2021 and 2020, the Company granted options to purchase <ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="rbot:GrantedOptionsToPurchase" scale="0" unitref="shares">5,870,433</ix:nonfraction> and <ix:nonfraction contextref="c10" decimals="0" format="ixt:num-dot-decimal" name="rbot:GrantedOptionsToPurchase" scale="0" unitref="shares">3,415,779</ix:nonfraction> shares, respectively of common
stock, to employees and consultants with a fair value of $<ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" unitref="usd">21.3</ix:nonfraction> million and $<ix:nonfraction contextref="c10" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" unitref="usd">0.8</ix:nonfraction> million, respectively, calculated using the Black-Scholes
option-pricing model with the following assumptions:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="text-align: right; padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; text-align: left">Risk-free interest rate</td><td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c98" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">0.45</ix:nonfraction>% - <ix:nonfraction contextref="c99" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">1.45</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c100" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">0.26</ix:nonfraction>%&nbsp;-&nbsp;<ix:nonfraction contextref="c101" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitref="pure">0.53</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: right">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Expected lives, in years</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonnumeric contextref="c98" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharesbasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.20</ix:nonnumeric> - <ix:nonnumeric contextref="c99" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharesbasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.11</ix:nonnumeric></span></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonnumeric contextref="c100" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharesbasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.00</ix:nonnumeric>&nbsp;-&nbsp;<ix:nonnumeric contextref="c101" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharesbasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.08</ix:nonnumeric></span></td><td style="text-align: right">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-70">—</span></span></td><td style="text-align: left">%</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: hidden-fact-71">—</span></span></td><td style="text-align: right">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: left">Expected volatility</td><td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c98" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">69.66</ix:nonfraction>% - <ix:nonfraction contextref="c99" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">71.02</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&nbsp;</td>
    <td style="white-space: nowrap; text-align: left">&nbsp;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c100" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">67.45</ix:nonfraction>%&nbsp;-&nbsp;<ix:nonfraction contextref="c101" decimals="4" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitref="pure">70.36</ix:nonfraction></span></td><td style="white-space: nowrap; text-align: right">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="white-space: nowrap; width: 76%">Fair value of Common Stock</td><td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td style="white-space: nowrap; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c98" decimals="2" format="ixt:num-dot-decimal" name="rbot:FairValueOfCommonStock" scale="0" unitref="usd">1.90</ix:nonfraction>
- $<ix:nonfraction contextref="c99" decimals="2" format="ixt:num-dot-decimal" name="rbot:FairValueOfCommonStock" scale="0" unitref="usd">13.05</ix:nonfraction></span></td><td style="white-space: nowrap; width: 1%; text-align: left">&nbsp;</td><td style="white-space: nowrap; width: 1%">&nbsp;</td>
    <td style="white-space: nowrap; width: 1%; text-align: left">$</td><td style="white-space: nowrap; width: 9%; text-align: right"><ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="rbot:FairValueOfCommonStock" scale="0" unitref="usd">1.34</ix:nonfraction></td><td style="white-space: nowrap; width: 1%; text-align: right">&nbsp;</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>



</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
risk-free interest rate assumption is based upon observed interest rates appropriate for the term of the related stock options. The expected
life of employee and non-employee stock options was calculated using the average of the contractual term of the option and the weighted-average
vesting period of the option, as the Company does not have sufficient history to use an alternative method to calculate an expected life
for employees. The Company does not pay a dividend and is not expected to pay a dividend in the foreseeable future. Expected volatility
for the Company’s common stock was determined based on an average of the historical volatility of a peer group of similar public
companies.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2021 and 2020, the total gross unrecognized stock-based compensation expense related to unvested stock options aggregated
$<ix:nonfraction contextref="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitref="usd">18.8</ix:nonfraction> million and $<ix:nonfraction contextref="c10" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockOptionPlanExpense" scale="6" unitref="usd">1.1</ix:nonfraction> million, respectively. The costs remaining as of December 31, 2021 and 2020 are expected to be recognized over
a weighted-average period of <ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">3.01</ix:nonnumeric> and <ix:nonnumeric contextref="c10" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharebasedPaymentAwardNonvestweightedAveragePeriodExpectedTerm">3.18</ix:nonnumeric>&nbsp;years, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Total stock-based compensation expense related
to all of the Company’s stock-based awards granted is reported in the statements of operations as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 77%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitref="usd">975</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="3" unitref="usd">335</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales and marketing</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:SalesAndMarketingExpense" scale="3" unitref="usd">621</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:SalesAndMarketingExpense" scale="3" sign="-" unitref="usd">6</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
    and administrative</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitref="usd">2,098</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitref="usd">119</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensations" scale="3" unitref="usd">3,694</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensations" scale="3" unitref="usd">448</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company plans to generally issue previously unissued shares of common stock for the exercise of stock options.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span>There were&nbsp;<ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="rbot:SharesAvailableAwardUnderPlan" scale="0" unitref="shares">4,506,133</ix:nonfraction>&nbsp;shares
available for award under the Plan at December&nbsp;31, 2021</span>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt">&nbsp;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 18pt"><span>The option
activity of the Plan for the year ended December&nbsp;31, 2021, is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tbody><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Weighted
                                            Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Remaining</b></span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercise</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contractual
    Life</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Price</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in
    Years)</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at January 1, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" scale="0" unitref="shares">8,890,535</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare" scale="0" unitref="usdPershares">0.31</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.89</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Granted</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitref="shares">5,870,433</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares">5.82</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.41</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Exercised</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" scale="0" unitref="shares">1,558,908</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitref="usdPershares">0.28</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:StockIssuedDuringPeriodSharesStockOptionsExercise"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.05</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cancelled,
    forfeited, or expired</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardRepurchasedCancelledForfeitedOrExpiredOptions" scale="0" sign="-" unitref="shares">1,192,292</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsRepurchasedCancelledForfeitedOrExpiredExercisePrice" scale="0" unitref="usdPershares">1.14</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><div style="-sec-ix-hidden: hidden-fact-72"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-</span></div></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Outstanding at December
    31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptions" scale="0" unitref="shares">12,009,768</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingExercisePricePerShare" scale="0" unitref="usdPershares">2.92</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.76</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options vested December
    31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionVestedOptions" scale="0" unitref="shares">4,280,515</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedExercisePrice" scale="0" unitref="usdPershares">0.50</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:StockIssuedDuringPeriodSharesStockOptionsVestedWeightedAverageRemainingContractualLife"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.28</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; ">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Options
    vested and expected to vest at December 31, 2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOptions" scale="0" unitref="shares">12,009,768</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="rbot:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisePrice" scale="0" unitref="usdPershares">2.92</ix:nonfraction></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: right"><ix:nonnumeric contextref="c0" format="ixt-sec:duryear" name="rbot:StockIssuedDuringPeriodSharesStockOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualLife"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.76</span></ix:nonnumeric></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>


</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&nbsp;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted-average grant date fair value for options granted during 2021 and 2020 was $<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="rbot:WeightedAverageFairValuesOfOptionsGranted" scale="0" unitref="usdPershares">3.62</ix:nonfraction> and $<ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="rbot:WeightedAverageFairValuesOfOptionsGranted" scale="0" unitref="usdPershares">0.25</ix:nonfraction>, respectively. The aggregate intrinsic
value of options exercised during the years ended December 31, 2021 and 2020, was $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="rbot:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedIntrinsicValue1" scale="6" unitref="usd">13.0</ix:nonfraction> million and $<ix:nonfraction contextref="c5" decimals="-3" format="ixt:num-dot-decimal" name="rbot:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedIntrinsicValue1" scale="3" unitref="usd">33</ix:nonfraction> thousand respectively. The aggregate
intrinsic value of options exercisable at December 31, 2021 and 2020, was $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" unitref="usd">34.7</ix:nonfraction> million and $<ix:nonfraction contextref="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="6" unitref="usd">0.8</ix:nonfraction> million respectively. The aggregate
intrinsic value of options outstanding at December 31, 2021 and 2020, was $<ix:nonfraction contextref="c4" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" unitref="usd">76.4</ix:nonfraction> million and $<ix:nonfraction contextref="c5" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" unitref="usd">0.9</ix:nonfraction> million respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Common
Stock Reserved for Future Issuance</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedat="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As of December 31, 2021 and 2020, the Company
has reserved the following shares of Class A Common Stock for future issuance (in thousands):</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"></p><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Common Stock options outstanding</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c102" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">12,010</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 1%">&nbsp;</td>
    <td style="width: 1%; text-align: left">&nbsp;</td><td style="width: 9%; text-align: right"><ix:nonfraction contextref="c103" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">8,891</ix:nonfraction></td><td style="width: 1%; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Shares available for issuance under the Plan</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c104" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">4,506</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c105" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">5,699</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Bank warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">-</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c106" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">254</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Public warrants</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c107" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">17,249</ix:nonfraction></td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right"><ix:nonfraction contextref="c108" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">17,250</ix:nonfraction></td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Private warrants</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c109" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">10,400</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td><td style="padding-bottom: 1.5pt">&nbsp;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonfraction contextref="c110" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">10,400</ix:nonfraction></td><td style="padding-bottom: 1.5pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total shares of authorized Common Stock reserved for future issuance</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">44,165</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitref="shares">42,494</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  </tbody></table></ix:nonnumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.25in"><span style="text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>12.
EMPLOYEE RETIREMENT PLAN</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation id="_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company maintains the Vicarious Surgical Inc. 401(k)&nbsp;plan, under Section&nbsp;401(k)&nbsp;of the Internal Revenue Code, covering
all eligible employees. Employees of the Company may participate in the 401(k)&nbsp;Plan after three months of service and must be 21
years of age</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. The Company offers a company-funded matching
contribution which totaled $<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" unitref="usd">424</ix:nonfraction> and $<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeBenefitPlan" scale="3" unitref="usd">223</ix:nonfraction> for each of the years ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>&nbsp;</b></span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>13.
Net Loss Per Share</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation continuedat="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">The
Company computes basic loss per share using net loss attributable to Vicarious Surgical&nbsp;Inc. common shareholders and the weighted-average
number of common shares outstanding during each period. Diluted earnings per share include shares issuable upon exercise of outstanding
stock options and stock-based awards where the conversion of such instruments would be dilutive</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"></p><div>

</div><ix:continuation continuedat="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><ix:nonnumeric contextref="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tbody><tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Year Ended <br> December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Numerator for basic and diluted net loss per share:</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td>
    <td colspan="2">&nbsp;</td><td>&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 4pt">Net loss</td><td style="width: 1%; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" sign="-" unitref="usd">35,207</ix:nonfraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td><td style="width: 1%; padding-bottom: 4pt">&nbsp;</td>
    <td style="width: 1%; border-bottom: Black 4pt double; text-align: left">$</td><td style="width: 9%; border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="3" sign="-" unitref="usd">12,875</ix:nonfraction></td><td style="width: 1%; padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Denominator for basic and diluted net loss per share:</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td><td>&nbsp;</td>
    <td style="text-align: left">&nbsp;</td><td style="text-align: right">&nbsp;</td><td style="text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; padding-bottom: 4pt">Weighted average shares</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitref="shares">96,690,716</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&nbsp;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonfraction contextref="c10" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" unitref="shares">78,736,661</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">&nbsp;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net loss per Class A and Class B common stock&nbsp;– basic and diluted</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitref="usdPershares">0.36</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&nbsp;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonfraction contextref="c10" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareDiluted" scale="0" sign="-" unitref="usdPershares">0.16</ix:nonfraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </tbody></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the years ended December 31, 2021 and 2020 the effect of dilutive securities, including non-vested stock options, restricted stock awards,
and common stock warrants was excluded from the denominator for the calculation of diluted net loss per share because the Company recognized
a net loss for the periods and their inclusion would be antidilutive. Dilutive securities excluded were <ix:nonfraction contextref="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitref="shares">39,658,398</ix:nonfraction> and <ix:nonfraction contextref="c10" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitref="shares">52,456,129</ix:nonfraction> shares
for the years ended December 31, 2021 and 2020, respectively.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><ix:nonnumeric contextref="c0" continuedat="_SubsequentEventsTextBlock-c0_cont_1" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><b>14.
SUBSEQUENT EVENTS</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p></ix:nonnumeric><div>

</div><div>

</div><ix:continuation id="_SubsequentEventsTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Management
has evaluated subsequent events occurring through the date that these financial statements were issued and determined that no subsequent
events other than that disclosed above or in the notes to these financial statements have occurred that would require recognition or
disclosure in these financial statements.</span></p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">******<b>&nbsp;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-24&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&nbsp;</b></span></p><div>



</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonfraction contextref="c3" decimals="0" id="hidden-fact-0" name="dei:EntityPublicFloat" unitref="usd">337600000</ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-3" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-4" name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-5" name="us-gaap:PreferredStockValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-6" name="us-gaap:PreferredStockValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-7" name="us-gaap:PreferredStockSharesIssued" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-8" name="us-gaap:PreferredStockSharesIssued" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-9" name="us-gaap:PreferredStockSharesOutstanding" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-10" name="us-gaap:PreferredStockSharesOutstanding" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-11" name="us-gaap:FairValueAdjustmentOfWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-12" name="us-gaap:IncomeTaxExpenseBenefit" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-13" name="us-gaap:IncomeTaxExpenseBenefit" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c19" id="hidden-fact-14" name="us-gaap:StockIssuedDuringPeriodValueOther" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c19" id="hidden-fact-15" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c19" id="hidden-fact-16" name="rbot:ExerciseOfCommonStockOptions" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c19" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c19" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c23" id="hidden-fact-20" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c24" id="hidden-fact-21" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c25" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c24" decimals="-3" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitref="usd">3694000</ix:nonfraction>
<ix:nonfraction contextref="c23" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c24" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c25" id="hidden-fact-27" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-28" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c23" id="hidden-fact-29" name="us-gaap:ProfitLoss" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c24" id="hidden-fact-30" name="us-gaap:ProfitLoss" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c26" id="hidden-fact-31" name="us-gaap:SharesOutstanding" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c26" id="hidden-fact-32" name="us-gaap:StockholdersEquity" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-33" name="us-gaap:GainLossOnDispositionOfAssets1" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-34" name="us-gaap:AmortizationOfFinancingCosts" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-35" name="rbot:ChangeInFairValuesOfWarrantLiabilities" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-36" name="rbot:IncreaseDecreaseInDeferredRent" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-37" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-38" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-39" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-40" name="us-gaap:ProceedsFromBankDebt" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-41" name="us-gaap:RepaymentsOfBankDebt" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-42" name="rbot:ProceedsFromReverseRecapitalizationNetOfIssuanceCosts" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-43" name="us-gaap:ProceedsFromIssuanceOfWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-44" name="rbot:LeaseholdImprovementsAcquiredInConnectionWithWalthamLease" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-45" name="rbot:WarrantsAssumedInAcquisition" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-46" name="rbot:ReverseRecapitalizationCostsInAccountsPayableAndAccruedExpenses" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:footnote id="ix_0_footnote" xml:lang="en-US">The number of Legacy Vicarious Surgical shares was determined from the shares of Legacy Vicarious Surgical shares outstanding immediately prior to the closing of the business combination converted at the Exchange Ratio of 3.29831. All fractional shares were rounded down.</ix:footnote><!--Text not found in footnote sections assigned to Schedule of number of shares of common stock issued -->
<ix:nonfraction contextref="c55" id="hidden-fact-47" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c56" id="hidden-fact-48" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c55" id="hidden-fact-49" name="us-gaap:AssetsFairValueDisclosure" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c56" id="hidden-fact-50" name="us-gaap:AssetsFairValueDisclosure" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c55" id="hidden-fact-51" name="rbot:WarrantLiabilitiesPublicWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c56" id="hidden-fact-52" name="rbot:WarrantLiabilitiesPublicWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c54" id="hidden-fact-53" name="rbot:WarrantLiabilitiesPrivateWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c55" id="hidden-fact-54" name="rbot:WarrantLiabilitiesPrivateWarrants" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c55" id="hidden-fact-55" name="us-gaap:LiabilitiesFairValueDisclosure" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c58" id="hidden-fact-56" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c59" id="hidden-fact-57" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c58" id="hidden-fact-58" name="us-gaap:AssetsFairValueDisclosure" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c59" id="hidden-fact-59" name="us-gaap:AssetsFairValueDisclosure" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c66" id="hidden-fact-60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOther" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c66" id="hidden-fact-61" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c65" id="hidden-fact-62" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c66" id="hidden-fact-63" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c67" id="hidden-fact-64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPeriodIncreaseDecrease" unitref="shares" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-65" name="rbot:ChangeInFairValueOfWarrants" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-66" name="rbot:TransactionCosts" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-67" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c4" id="hidden-fact-68" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c5" id="hidden-fact-69" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitref="usd" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c0" id="hidden-fact-70" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonfraction contextref="c10" id="hidden-fact-71" name="rbot:ShareBasedCompensationArrangementBySharesBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitref="pure" xsi:nil="true"></ix:nonfraction>
<ix:nonnumeric contextref="c0" id="hidden-fact-72" name="rbot:StockIssuedDuringPeriodSharesStockOptionsRepurchasedCancelledForfeitedOrExpiredRemainingContractualLife" xsi:nil="true"></ix:nonnumeric>
<ix:nonnumeric contextref="c0" name="dei:AmendmentFlag">false</ix:nonnumeric>
<ix:nonnumeric contextref="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonnumeric>
<ix:nonnumeric contextref="c0" name="dei:EntityCentralIndexKey">0001812173</ix:nonnumeric>
<ix:nonnumeric contextref="c51" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives">Lesser of lease term or asset life</ix:nonnumeric><!--From Schedule of property and equipment, net with text 'Lesser of lease term or asset life'-->
</ix:hidden>
<ix:references><link:schemaref xlink:href="rbot-20211231.xsd" xlink:type="simple"></link:schemaref></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromrefs="ix_0_fact" torefs="ix_0_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-06-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">rbot:BusinessCombinationMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-04-01</xbrli:startdate>
    <xbrli:enddate>2021-04-15</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">rbot:BusinessCombinationMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">rbot:PublicWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-01</xbrli:startdate>
    <xbrli:enddate>2021-09-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-01</xbrli:startdate>
    <xbrli:enddate>2021-09-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-01</xbrli:startdate>
    <xbrli:enddate>2021-09-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-05-06</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2019-01-01</xbrli:startdate>
    <xbrli:enddate>2019-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSra8s8zL6ZW1MmCv9x/lK+QwXaG7VWTBSWfRmjtONu4BCl8w1A1hbaKVczlw7zOuiiXswlFf+nCt9Z3Xk+8oJX+e1VfUo4u2A78cV0Um8EkLna7VpW1jobToJQmJqgxC+uyOgHDgkh9eezk55+k1SVMDrolR5bnIh5p2dbm4NzvhBnGVrvHWULU0PSgZS7VV2V6X63fCZydUtlMJEhc2s3ZxqbTIzBk4oiiziCI9rLCczKpE/yd/gdIa] CSR-->
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-17</xbrli:startdate>
    <xbrli:enddate>2021-09-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-09-30</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-30</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-09-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-18</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-18</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-09-18</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:NoteWarrantMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-10-01</xbrli:startdate>
    <xbrli:enddate>2020-10-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-03-01</xbrli:startdate>
    <xbrli:enddate>2021-03-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-01-25</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-11-01</xbrli:startdate>
    <xbrli:enddate>2021-11-30</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">rbot:SeriesA1PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">rbot:SeriesA2PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">rbot:SeriesA3PreferredStockMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-07-10</xbrli:startdate>
    <xbrli:enddate>2020-07-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-07-10</xbrli:startdate>
    <xbrli:enddate>2020-07-17</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-07-20</xbrli:startdate>
    <xbrli:enddate>2020-07-24</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-07-20</xbrli:startdate>
    <xbrli:enddate>2020-07-24</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-17</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rbot:TwoThosandFourteenPlanMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rbot:TwoThosandFourteenPlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rbot:TwoThousandTwentyOnePlanMember</xbrldi:explicitmember>
      <xbrldi:explicitmember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:PlanNameAxis">rbot:TwoThousandTwentyOnePlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2021-01-01</xbrli:startdate>
    <xbrli:enddate>2021-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startdate>2020-01-01</xbrli:startdate>
    <xbrli:enddate>2020-12-31</xbrli:enddate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">rbot:CommonStockOptionsOutstandingMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">rbot:CommonStockOptionsOutstandingMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">rbot:SharesAvailableForIssuanceUnderThePlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:StatementEquityComponentsAxis">rbot:SharesAvailableForIssuanceUnderThePlanMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rbot:BankWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rbot:PublicWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rbot:PublicWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rbot:PrivateWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001812173</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitmember dimension="us-gaap:ClassOfWarrantOrRightAxis">rbot:PrivateWarrantsMember</xbrldi:explicitmember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitnumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitnumerator>
    <xbrli:unitdenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitdenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div>

</body>
</html>